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Summary  
 
Hyperelongation of glycosaminoglycan (GAG) chains on proteoglycans 
synthesized by the vascular smooth muscle cells (VSMC) increases lipoprotein 
binding in the blood vessel wall and in the development of atherosclerotic plaque. 
GAG chain synthesis occurs via post-translational modification of the proteoglycan 
core protein driven by the concerted action of a wide range of GAG synthesizing 
enzymes. An in vivo study showed that elevated GAG synthesizing enzyme gene 
expression contributes to the development of atherosclerosis. In human VSMC, 
transforming growth factor-β (TGF-β) regulates GAG chain hyperelongation via 
serine/threonine kinases ERK and p38 as well as Smad2 linker region (Smad2L) 
phosphorylation. In this study, the involvement of TGF-β receptor, intracellular 
serine/threonine kinases and specific residues on transcription factor Smad2L that 
regulate GAG synthesizing enzymes to mediate their effects on proteoglycans was 
investigated. Experiments were conducted on cultured human VSMC in the 
presence of TGF-β. Quantitative RT-PCR analysis demonstrated the upregulation 
of xylosyltransferase-1 (XT-1), chondroitin sulfate synthase-1 (ChSy-1), 
chondroitin polymerising factor (ChPF) and chondroitin sulfotransferase-1 
(C4ST-1) mRNA expression. Elevated mRNA expression correlated with the 
increased protein expression for ChSy-1 and C4ST-1, which was determined by 
Western blot analysis. Proteoglycan synthesis was assessed by measuring [35S]-SO4 
incorporation into proteoglycans via the cetylpyridinium chloride precipitation 
assay. Proteoglycan and GAG chain size were determined by SDS-PAGE and size 
exclusion chromatography. TGF-β stimulation increased proteoglycan synthesis 
and size indicating GAG chain hyperelongation in VSMC. Investigation on the 
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TGF-β signalling pathways using pharmacological experiments revealed that ERK, 
p38, PI3K and CDK differentially regulated mRNA expression of the enzymes 
XT-1, ChSy-1 and C4ST-1. Four individual residues (Thr220, Ser245, Ser250 and 
Ser255) in the TGF-β receptor mediator Smad2L can be phosphorylated by these 
kinases and in turn regulate the synthesis and activity of GAG synthesizing 
enzymes. Western blot analysis of phospho-Smad2L for each residue suggests that 
TGF-β-mediated phosphorylation of Thr220 occurs via CDK whilst Ser245 by 
ERK, p38, PI3K and CDK. Ser250 phosphorylation occurs through ERK whereas 
Ser255 phosphorylation involves ERK, PI3K and CDK. Further investigation to 
identify the involvement of multiple CDK isoforms in proteoglycan modification 
demonstrated that CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9 are present in 
human VSMC. Studies utilising CDK inhibitors CVT313 (CDK1 and CDK2 
inhibitor), PD0332991 (CDK4 and CDK6 inhibitor), roscovitine (CDK2, CDK7, 
and CDK9 inhibitor) and flavopiridol (CDK1, CDK2, CDK4, CDK6, CDK7 and 
CDK9 inhibitor) suggested the involvement of these CDKs in biglycan, XT-1, 
ChSy-1 and C4ST-1 mRNA expression ultimately affecting proteoglycan size. 
Results also suggest that CDK4 and CDK6 signals exclusively through the Thr220 
residue in the Smad2 linker region while the other CDKs (CDK1, CDK2, CDK7 
and CDK9) phosphorylate serine residues (Ser245/255) in the TGF-β signalling 
pathway. This study shows that CDKs play a role beyond cell cycling events 
particulary in proteoglycan GAG chain synthesis and as such they are potential 
therapeutic targets to prevent atherosclerosis. In conclusion, the current study has 
identified that the mRNA regulation of three GAG synthesizing enzymes XT-1, 
ChSy-1 and C4ST-1 in VSMC to involve the signalling pathway from TGF-β to 
Smad2 linker region phosphorylation, exists in these cells. Together, these findings 
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provide a better understanding of the complex signalling pathway that contribute to 
GAG chain hyperelongation and may facilitate the identification of a specific 
therapeutic target(s) for events important in the early development of 
atherosclerosis. 
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1.1 Cardiovascular disease 
Cardiovascular disease (CVD) is the largest cause of mortality in developed as well 
as developing countries. CVD is a collective term to represent diseases involving the 
heart and blood vessels. These diseases include coronary heart disease, heart failure, 
cardiomyopathy, congenital heart disease, peripheral vascular disease and stroke (1). 
The World Health Organization reported that in 2008, 30% of all deaths 
(17.3 million) globally were due to CVD (2). This number of CVD deaths had 
greatly increased from 14.4 million recorded in 1990. In Australia, CVD is among 
the major causes of death with 44,000 deaths attributed to CVD in 2012 (3). The 
high incidence of CVD imposes an enormous burden on the healthcare system (4). In 
2008, more than 84 million prescriptions for CVD medicines were supplied to the 
community with a total cost burden of $3 billion to the Australian government (5). 
The trend of increased death due to CVD is also seen in developing countries in 
Eastern Europe, Central Asia, Middle East and North Africa (6). This trend will 
continue to escalate due to the global shift from infectious to non-communicable 
diseases over the next few decades (7). High rates of CVD are due to tobacco 
smoking, alcohol abuse, obesity, lack of physical activity, dietary habits and type 2 
diabetes (8,9). Researchers predict that by 2030, non-communicable diseases will 
account for more than three-quarters of deaths worldwide. In low income countries, 
CVD alone will be responsible for more deaths in comparison to infectious diseases 
(including HIV/AIDS, tuberculosis and malaria) (7). 
Atherosclerosis is the main cause of CVD which leads to myocardial 
infarction and stroke (10). It is a pathological condition where accumulation of lipid 
and inflammatory products in the arterial wall leads to formation of atherosclerotic 
plaques (11). Currently available therapeutics for treatment of atherosclerosis are 
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largely restricted to targeting risk factors such as alleviating hyperlipidaemia, 
hypertension and/or controlling hemostasis to prevent thrombotic complications 
(11). Historically, lipid-lowering drugs are the most effective pharmaceutical 
treatment for CVD and ongoing therapeutic improvements include more aggressive 
lowering of circulating lipoproteins and earlier treatment initiation. Among the most 
common drugs used are the lipid lowering 3-hydroxy-3-methylglutaryl-coenzyme A 
(HMG-CoA) reductase inhibitors also known as statins (12). This therapy is aimed to 
reduce the blood cholesterol level as well as creating other pleiotropic actions that 
positively impact on the development of CVD. Statins are highly efficacious drugs, 
but in clinical trials they only prevent < 30% of cardiovascular events (13). Data 
collected from a cross sectional, retrospective study of three sources: electronic 
medical records (2003–2010), administrative claims data (2003–2010) and National 
Health and Nutrition Examination Survey data (2007–2008) demonstrated that 
among patients undergoing statin therapy, only 20–26% of high-risk patients were 
able to reduce LDL cholesterol levels to < 70 mg/dL (optimal level for patients 
high-risk of a heart attack) (14). Because of that reason, even with multiple therapies, 
the rate of CVD is still high and warrants a better understanding of the major 
underlying causes of atherosclerosis eventually leading to the development of new 
targets and ultimately new treatment modalities for atherosclerosis.  
1.2 Structure of normal artery 
The normal arterial wall is made up of three concentric layers that surround the 
arterial lumen, each composed of distinct cells and extracellular matrix (ECM). The 
layer immediately adjacent to the lumen is known as the intima, the middle layer 
comprises the media, and the outermost layer is called the adventitia. These three 
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layers are demarcated by layers of elastin (15). The intima is separated from the 
media by a layer called internal elastic lamina while the media is separated from the 
adventitia by the external elastic lamina (16) (Fig. 1.1). 
The intima is lined by a monolayer of endothelial cells that form a physical 
and functional barrier between flowing blood and the arterial wall surface, regulating 
a wide array of processes including thrombosis, vascular tone and leukocyte 
trafficking. Endothelial cells adhere to a basement membrane of ECM containing 
proteoglycans and collagen (17). In contrast to animal species used for 
atherosclerosis experiments, the human neointima contains resident vascular smooth 
muscle cells (VSMC) (18). 
The media is composed principally of VSMC arranged in layers, with the 
number of layers varying according to the size of arteries. These VSMC are held 
together by an ECM consisting largely of elastic fibers and collagen with a lesser 
content of proteoglycans. In larger arteries, an increasing content of elastin is found 
to provide for considerable elastic recoil during diastole, the time period between 
ejections of blood from the heart (19). 
The adventitia is the outermost layer of the artery and consists of a loose 
matrix of elastin, smooth muscle cells (SMC), fibroblasts and collagen. It also 
contains nerve endings that allow neural input to traverse through the adventitia into 
blood vessels (20). 
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Figure 1.1: Diagrammatic model for a cross sectional view of a non-diseased 
artery  
The artery is composed of three layers: intima, media and adventitia. Intima is the 
innermost layer closest to the lumen and lined by endothelial cells. Thickness of the 
subendothelial layer is influenced by age and disease state. Media layer is composed 
of smooth muscle cells, a network of elastic and collagen fibrils with elastic laminae 
separating media into several fiber reinforced layers. Adventitia is the outermost 
layer surrounded by loose connective tissue. Reproduced from Holzapfel et al. (21). 
<Image removed due to copyright restrictions> 
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1.3 Atherosclerosis 
Atherosclerosis derives its name from the Greek words ‘athere’ that means gruel and 
‘sclerosis’ meaning hardening (accumulation of lipid) describing the association 
between fatty degeneration and vessel stiffening. It is a progressive disease of the 
arterial wall which occurs most commonly in coronary arteries (22).  
 Pathology of atherosclerosis 
Atherogenesis refers to the development of atheromatous plaques in the inner lining 
of the arteries. The initiation of atherosclerosis occurs when endothelial cells become 
activated and secrete adhesion molecules. Parallel changes both in the permeability 
of the endothelium as well as the composition of ECM inside the subendothelial 
layers induce the entry and retention of cholesterol-containing low density 
lipoprotein (LDL) particles inside the arterial wall (23). Arterial endothelial cells 
normally resist attachment of leukocytes that stream pass the endothelium. However, 
due to atherogenic stimuli such as dyslipidemia, hypertension and pro-inflammatory 
mediators, endothelial cells express surface selective adhesion molecules that bind 
multiple classes of leukocytes particularly the vascular adhesion molecule-1 (24) 
(Fig. 1.2). 
LDL retained in the intima is then subjected to modification. Biochemically 
modified LDL (hydroperoxides, lysophospholipid and carbonyl compounds) can 
undergo endocytosis by monocyte-derived macrophages that leads to intracellular 
cholesterol accumulation. Monocyte chemmoattractant protein-1 (MCP-1) is then 
responsible for directing the migration of adherent leukocytes into the intima (25).  
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Figure 1.2: Pathology of atherosclerosis 
Modified proteoglycans and abundance of LDL lead to the entrapment of positively 
charged LDL in the subendothelial space. Retained LDL particles are prone to 
oxidation. Oxidized LDL has a lower affinity for proteoglycans compared to 
non-oxidized LDL, and therefore is released from the proteoglycan 
glycosaminoglycan chains. The presence of oxidized LDL activates an inflammatory 
response. Monocytes pass through the endothelium and differentiate into 
macrophages that entrap and attempt to remove the LDL. The presence of LDL 
overwhelms the macrophages, which could not phagocytose these molecules and the 
lipid-laden macrophages or foam cells are deposited in the subendothelial space. 
Reproduced from Nigro et al. (26). 
<Image removed due to copyright restrictions> 
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Once inside the subendothelial space, monocytes (the most numerous 
leukocytes in plaques) orchestrate the development of atherosclerosis through 
cytokine release. Monocytes undergo differentiation into tissue macrophages that 
scavenge modified LDL particles producing foam cells, a term that describes the 
microscopic appearance of these lipid-laden macrophages (27). This process is 
enhanced by the local release of macrophage colony–stimulating factor activating the 
monocyte proliferation leading to both cytokine mediated progression of 
atherosclerosis and oxidation of LDL (28). Macrophages in the atheroma would 
secrete high levels of inflammatory cytokines including tumour necrosis factor 
(TNF) and interleukin-1β (IL-β) which stimulate macrophages as well as vascular 
endothelial cells and VSMC (29).  
Progression of atheroma formation is apparent with the recruitment of VSMC 
from the tunica media adding to the existing resident population of these cells in the 
intima. In response to growth factors including platelet-derived growth factor 
(PDGF) and transforming growth factor beta (TGF-β) secreted by VSMC, the cells 
undergoes a phenotypic change that leads to cell proliferation and secretion of ECM 
components including proteoglycans, collagen, elastin, fibronectin, laminin, 
vitronectin and thrombospondin (30). Gradual accumulation of LDL within foam 
cells, proliferation of VSMC and elaboration of ECM create the definitive fibrous 
cap that covers the plaque (31) (Fig. 1.3C). The inefficient clearance of cells that 
undergo apoptosis leads on to accumulation of cellular debris and extracellular lipids 
(released by macrophage-derived foam cells) that form into a lipid-rich pool defined 
as necrotic core of plaque (32). The enlarging necrotic core dominates the central 
part of the intima ultimately occupying 30–50% of the arterial wall layer (33,34).  
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(A) Healthy right coronary artery showing normal intima. (B) Intermediate lesion of 
the right coronary artery demonstrating presence of lipid pool in the thickened 
intima. (C) Formation of lipid core inside a developing atheromatous plaque covered 
by fibrous cap (left anterior descending coronary artery). IEL indicates internal 
elastic lamina. Reproduced from Dalager et al. (35). 
Figure 1.3: Histological examples of human lesion types (H&E staining) 
<Image removed due to copyright restrictions> 
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Calcifications may occur as microscopic calcium granules deposit into the 
necrotic core material subsequently expanding to form larger lumps and plates of 
calcium deposits (36). 
Complications of atherosclerosis mainly depend on the development and 
rupture of plaques. Some plaques develop at higher rates by simple LDL 
accumulation and expansion of the fibrous plaque components. Accumulation of 
cholesterol within these plaques is due to both ‘passive’ transfer of circulatory LDL 
and scavenging of red blood cell membranes deposited during intra-plaque 
haemorrhage (37). Most plaques remain asymptomatic (subclinical disease). 
Nevertheless some become obstructive (chronic stable angina) that can lead to flow 
limiting stenosis resulting in tissue ischemia (38). Others elicit acute thrombosis and 
may lead to an acute myocardial infarction due to thrombotic occlusion of an 
epicardial blood vessel. This occurs after rupture of plaques especially those with 
thin, collagen-poor fibrous caps with few VSMC but abundant macrophages. The 
inflammatory cells accelerate the plaque disruption by elevating the production of 
collagenolytic enzymes that degrade collagen (39). When the atherosclerotic plaque 
is exposed to high shear stress especially at sites of stenosis and arterial branching, 
spontaneous fissuring leads to sudden disruption of the atherosclerotic plaque (38). 
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 Theories of atherogenesis 
Many reviews on atherogenesis have appeared over the years, each emphasizing a 
particular aspect of the process. Among these, published theories that were most 
prominent and received widest coverage include the response to injury hypothesis 
(40), the oxidative modification hypothesis (41) and the response to retention 
hypothesis (42). 
The common theme of the response to injury hypothesis is endothelial 
denudation leading to compensatory responses that alter the normal vascular 
homeostatic properties. Injury enhances endothelial layer adhesiveness for 
leukocytes and platelets, and changes the local vascular environment from 
anti-coagulant to pro-coagulant. Recruited leukocytes and platelets then produce 
cytokines, vasoactive agents and growth factors that induce an inflammatory 
response manifested by migration of VSMC into the intima and their proliferation to 
form an intermediate lesion. The ‘secretory’ form of VSMC as opposed to the 
‘contractile’ phenotype contributes to the major cellular components of the 
neointima (43). The subsequent recruitment of macrophages into the arterial wall 
enables the engulfment of deposited LDL to form lipid-laden foam cells, which is the 
hallmark of an early atherosclerotic lesion (44,45).  
The oxidative modification hypothesis focuses on the concept that LDL in its 
native state is not atherogenic whilst following biochemical modification, it is 
readily internalized by macrophages through a scavenger receptor pathway (46). 
Oxidation of LDL, resulting in modification of the apolipoprotein (apo) B-100 
creates a substrate susceptible to uptake by scavenger receptor pathway macrophages 
producing lipid-laden foam cells (47).  
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The response to retention hypothesis proposes that subendothelial lipoprotein 
retention is the initiating event for atherosclerosis. It is estimated that > 85% of 
subendothelial lipoprotein delivery is the consequence of transcytosis. The 
subendothelial retention of lipoproteins within the arterial wall is tightly associated 
to components of the ECM. ApoB-100, the single protein associated with LDL is 
retained within the arterial wall by arterial proteoglycans (48,49). 
The three hypotheses compliment each other to a certain extent. 
Nevertheless, the response to retention hypothesis covers the key initiating step in 
atherogenesis. The emphasis on retained lipoproteins is crucial because 
understanding the root cause of a disease provides the foundation for the most 
effective therapy (23). 
 The response to retention hypothesis 
The response to retention hypothesis (42) provides a clear illustration of the initiation 
of atherosclerosis and this has gained substantial support from recent findings, 
suggesting that intimal thickenings associated with intimal proteoglycans are 
important precursors leading to more advanced atherosclerotic lesions (50-54). In 
1995, William and Tabas (42) proposed the response to retention hypothesis which 
described that atherogenic lipoprotein retention associated with ECM in the arterial 
neointima is the key event that initiates early atherogenesis (42). In the non-diseased 
state, lipoproteins penetrate the endothelial layer via transcytosis and subsequently 
efflux through the artery wall. They are then transported through the lymphatic 
vasculature and may return to the artery lumen to re-enter the circulation (26). 
Retention of lipoproteins within the vessel wall and efflux to the lymph are 
rate-limiting steps (55). Nakashima et al. (50) reported that the initial deposition of 
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extracellular lipid occurs in the outer area of diffuse intimal thickenings. Deposited 
lipids in the diffuse intimal thickenings colocalize with proteoglycans, specifically 
biglycan and decorin, forming a permissive environment for the initiation and 
progression of atherosclerosis (43,56). Retention of proteoglycans can be 
exacerbated by predisposing stimuli including mechanical strain and cytokines that 
enhance local synthesis of proteoglycans with high binding affinity for lipoproteins 
(23,57). Increase in wall stress activates production of proteoglycans that can bind 
and retain LDL, further facilitating the oxidative modification and promoting 
inflammatory response at the site of lesions (58) (Fig. 1.4). 
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The figure depicts the development of atherosclerosis inside the intimal space of the arterial layer. (A) The pre-inflammatory stage involves 
initiation of atherosclerosis via the response to retention hypothesis. Modified proteoglycans (biglycan) produced by VSMC retain LDL creating 
oxidized LDL (Ox-LDL) activating the inflammatory response. (B) The inflammatory stage depicts the progression of atheroma formation 
largely due to the inflammatory response. (C) The complication stage: stable plaque can become obstructive (chronic stable angina) 
whilst rupture of thin plaques elicit acute thrombosis. Adapted from Libby et al. (24) and Nigro et al. (26).
(A) Pre-inflammatory (initial)  (B) Inflammatory (progression)  (C) Complication (final)  
Figure 1.4: The three major stages in the development of atherosclerosis 
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 Current therapy for atherosclerosis 
 Treatment of risk factors for atherosclerosis 
The established risk factors of atherosclerosis include type 2 diabetes, hypertension, 
dyslipidemia, cigarette smoking, gender and age (59,60). Current medical therapies 
to treat atherosclerosis are mainly based on lowering associated risk factors. Reports 
from intravascular ultrasound of plaque progression in people with diabetes show 
that increased hyperglycemia is associated with accelerated atherosclerosis (61). 
Chronically elevated glucose levels may contribute to the development of intima 
thickness during atherosclerosis progression in individuals with diabetes (59).  
Angiotensin-converting enzyme (ACE) inhibitors are well known for their 
benefits in treating hypertension and congestive heart failure. The anti-atherogenic 
properties of ACE inhibitors may derive from inhibition of angiotensin II which is 
recognized as an agent that increases oxidative stress (62). Angiotensin II is a central 
component of the oxidative signalling that contributes to vascular inflammation and 
endothelial dysfunction. Therefore, ACE inhibitors that block angiotensin formation 
are used to modulate atherosclerosis (63). 
The HMG-CoA reductase is the rate controlling enzyme of the mevalonate 
pathway, the metabolic pathway that produces cholesterol (64). The HMG-CoA 
reductase inhibitors, also known as statins, are the most effective class of drugs for 
lowering plasma LDL cholesterol concentrations. Nevertheless, strategies to reduce 
hypercholesterolemia using statins still leave a considerable residual burden of 
cardiovascular risk (65). Despite receiving high-dose statin treatment, > 20% of 
patients will experience a recurrent event within 30 months of an acute coronary 
syndrome (66). Thus, even with multiple therapies, the rate of cardiovascular events 
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is still high and warrants better understanding of the major underlying causes of 
atherosclerosis, eventually leading to the development of new targets and ultimately 
new treatment modalities of atherosclerosis.  
A recent therapy that has entered phase 3 clinical trials is the use of the 
proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor to reduce LDL 
cholesterol level. PCSK9 breaks down the LDL-receptor in the liver that removes 
LDL cholesterol from the blood, to be destroyed and recycled (67). Thus the PCSK9 
inhibitor acts by inactivating the PCSK9 resulting in decreased LDL-receptor 
degradation, increased recirculation of the receptor to the surface of hepatocytes, and 
consequent lowering of LDL cholesterol levels in the bloodstream (68).  
Lifestyle changes were also shown to facilitate the prevention of CVD. 
Approximately 80% of CVD-related mortality and morbidity is preventable by 
healthy dietary habits, exercise, maintaining a healthy body weight and not smoking 
(69). Regular moderate physical activity (30 min/day) is highly beneficial in 
lowering blood pressure, decreasing blood coagulation, improving fibrinolytic 
capacity and helping in vascular remodelling (70). 
 Surgical intervention to relieve atherosclerotic obstruction 
Coronary artery bypass graft (CABG) surgeries are among the most commonly 
performed surgical operations for treatment of atherosclerosis. CABG surgery is 
suitable for patients with significant narrowing and blockages of the main coronary 
artery or multiple larger arteries. In a CABG procedure, a portion of a healthy vessel 
for example the saphenous vein is used to create a bypass around the blocked portion 
of the coronary artery and hence this is effective in the relief of angina and heart 
failure and may prolong life (71,72).  
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Percutaneous Transluminal Angioplasty is a procedure in which a small 
balloon is inserted into the blocked or narrowed area of the artery. A balloon-tipped 
catheter is inflated to a predetermined diameter dilating the artery and pushing the 
plaque back to allow for improved blood flow in the artery (73). Another angioplasty 
technique involves coronary stenting procedure. Stents are small wire-mesh metal 
tubes that provide scaffolding to support the damaged arterial wall, reducing the rate 
of restenosis after angioplasty with controlled release of anti-proliferative drugs (74). 
 Proposed interventions for treatment of atherosclerosis 
It has been twenty years since the introduction of statins and there has been no major 
new therapeutic agent arising from the existing strategy of targeting risk factors. The 
focus has now moved to the vessel wall and great advances in imaging technology 
may well be timely in facilitating this new but obvious direction. The major 
pathological mechanisms currently under investigation as causes of atherosclerosis 
are the retention of lipoproteins (42), endothelial dysfunction (75), oxidative 
stress (76) and inflammation (77,78). 
Evidence of the important role of the proteoglycan biglycan in blood vessel 
wall and its interaction with LDL as the primary events of atherosclerosis preceding 
inflammatory response suggests investigation of alternative therapies that target the 
involvement of the vessel wall. This includes targeting the proteoglycan 
modifications as a strategy to prevent atherogenesis (50,79,80). No therapy directed 
at the vessel currently exists, but it is believed that a vessel wall-directed therapy 
may complement a risk factor-directed strategy to reduce atherosclerotic 
development (81). These evidence suggests the importance of targeting 
proteoglycans of the vascular wall as treatment of CVD (82). On the basis of the 
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response to retention hypothesis and atherogenesis, there are three different 
approaches to the therapeutic intervention on the interaction between proteoglycans 
and lipoproteins: first, modification of the lipoproteins, second, modification of the 
proteoglycans structure, especially the glycosaminoglycan (GAG) chains on 
proteoglycans, and third, modification of the interaction between proteoglycans and 
lipoproteins through GAG mimetics that may bind to lipoproteins (83). The major 
focus of this study is addressing the changes in proteoglycan structure that can 
directly influence the ionic interaction with apoB on normal human LDL (84). 
1.4 Proteoglycans  
 Proteoglycans of the vascular extracellular matrix 
The ECM is a highly-ordered supra macromolecular structure with various 
physiological and pathophysiological roles. The cells which produce matrix 
molecules are important in determining matrix function and metabolism. Conversely, 
matrix components are also able to influence cell functions. The biochemical 
properties of a tissue are thus closely related to the architecture of its matrix (85,86). 
The vascular ECM is composed of two main classes of macromolecules: fibrous 
proteins and proteoglycans. The main fibrous ECM proteins are elastins, 
fibronectins, collagens and laminins (87). Proteoglycans fill the majority of the 
extracellular interstitial space within the tissue in the form of a hydrated gel, 
synthesized primarily by VSMC (88,89). Proteoglycans are made up of GAG chains 
covalently linked to a protein core (with the exception of hyaluronan). As an 
example, a chondroitin sulfate/dermatan sulfate (CS/DS) proteoglycan is composed 
of a CS/DS GAG chain attached to a core protein backbone (Fig. 1.5). 
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Figure 1.5: CS/DS proteoglycan structure. Proteoglycans consist of a GAG chain attached to the core protein backbone by a linkage region 
consisting of a xylose (Xyl), two galactose (Gal) and a glucuronic acid (GlcA) residue. CS/DS GAG synthesizing enzymes (shown in yellow 
boxes) work in a concerted manner to synthesize the linkage region and GAG chain. CS/DS GAG chains are made up of repeating disaccharide 
unit consisting of GlcA/idorunic acid (IdoA) and N-acetylgalactosamine (GalNAc). Pathological conditions could stimulate hyperelongation 
(abnormal increase in GAG chain length) of these GAG chain structure. Ser indicates Serine residue. Adapted from Little et al. (43).  
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Proteoglycans have been classified based on their core proteins, localization 
and composition of the GAG chain. The three main families of proteoglycans 
include: cell-surface proteoglycans, modular proteoglycans and small leucine-rich 
proteoglycans (SLRP) (89). SLRP are involved in various signalling pathways 
including binding to and activation of TGF-β receptor, epidermal growth factor 
(EGF) receptor, insulin-like growth factor 1 receptor and LDL-receptor-related 
protein 1 (90,91). Modular proteoglycans (versican, perlecan and agrin) can 
modulate cell adhesion, migration and proliferation. Basement membrane modular 
proteoglycans (perlecan and agrin) have a dual function as pro- and anti-angiogenic 
factors (92). Cell surface proteoglycans (syndecans and glypicans) can act as 
co-receptors facilitating ligand encounters with signalling receptors (89). In the 
human coronary artery, the proteoglycans predominantly secreted by VSMC include 
the SLRP biglycan and decorin, while the modular proteoglycans versican and 
perlecan are secreted in lesser amounts (82).  
 Proteoglycans and atherosclerosis 
Biglycan, decorin and versican are most closely associated with lipoprotein binding 
in the vessel wall (79,93). This current study will focus more on biglycan due to its 
significance in human atherosclerosis. Biglycan is the major proteoglycan often 
associated with atherosclerosis, particularly due to its importance in lipoprotein 
retention in human blood vessel (42). Histological studies of human arteries show 
evidence of strong colocalization between apoB-100 lipoproteins with biglycan 
(50,54). Biglycan is a member of CS/DS proteoglycans that has the binding ability to 
apoB containing lipoproteins (94) such as LDL, very-low-density lipoprotein 
(VLDL), and intermediate density lipoprotein (95). Studies have shown that 
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overexpression of biglycan by rat SMC lead to production of ECM with higher 
binding affinity to lipoproteins (96). Biglycan is well known to be present in the 
intima of normal human saphenous veins, coronary arteries and other muscular 
arteries (97,98). In human coronary arteries biglycan is localized in the outer layer of 
the diffuse intimal thickening. The presence of this pre-lesional distribution of 
biglycan was shown to be similar to the distribution of lipids in the early phases of 
atherogenesis. This supports that the existence of biglycan in the intima occurs 
before deposition of lipids, which plays an essential role in initial deposition of lipids 
in the arterial intima. The colocalization of biglycan with apoB and apoE are found 
in early as well as advanced human and murine lesions (50,54,99). The existence of 
apoE indicates the binding of biglycan to high density lipoprotein (HDL) suggesting 
that biglycan not only retains apoB-containing lipoproteins but also apoE-containing 
HDL (100). 
 Proteoglycan core protein synthesis 
The nascent proteoglycan core protein biosynthesis is initiated by translation carried 
out on ribosomes in the cytosol, followed by translocation of the nascent polypeptide 
into the lumen of the rough endoplasmic reticulum (ER) (101). Inside the ER lumen, 
post-translational modifications occur including addition of N-linked 
oligosaccharides to asparagine (Asn) residues from dolichol phosphate 
intermediates. Before the modified core protein exits the ER, chaperone-mediated 
folding, formation of disulfide bonds as well as initial trimming of the N-linked 
oligosaccharides takes place. Additionally, aberrant proteins that are not properly 
folded are degraded inside the ER (102). The product is a core protein ranging in size 
between 10 and 500 kDa (103). 
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 Biochemistry of glycosaminoglycan (GAG) chain 
GAG chains are long-chain polysaccharides made up of repeated disaccharide units 
consisting either N-acetyl-D-glucosamine (D-GlcNAc) or N-acetyl-D-galactosamine 
(D-GalNAc), and a uronic acid, either D-glucuronic (D-GlcA) or L-iduronic acid 
(L-IdoA) except for keratan sulfate, which consists of a galactose instead of the 
uronic acid. The absolute configurations of the amino sugars and uronic acids as 
mentioned above will be abbreviated as GlcNAc, GalNAc, GlcA, and IdoA 
throughout this thesis. In mammals, there are five different subgroups of GAG; they 
are (i) hyaluronic acid or hyaluronan (HA), the only non-sulfated GAG, (ii) keratan 
sulfate (KS), (iii) chondroitin sulfate (CS), (iv) dermatan sulfate (DS) and 
(v) heparin⁄heparan sulfate (HS) (104,105) (Fig. 1.6). The disaccharide component of 
GAG chains is intrinsically carboxylated and is prone to further sulfation, which 
makes them negatively charged at physiological pH (83). 
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Figure 1.6: Disaccharide composition of five subgroups of GAG chain 
(i) Heparan sulfate (HS), (ii) Keratan sulfate (KS), (iii) Chondroitin sulfate (CS), (iv) 
Dermatan sulfate (DS) and (v) Hyaluronic acid (HA). Dotted red boxes indicate the 
theoretical sulfation positions in the GAG chain. Reproduced from Pyrdz et al. (101). 
<Image removed due to copyright restrictions> 
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HA is synthesized as an anionic linear polymer (106). Unlike other GAG, 
HA is unique as it is non-sulfated, not produced in the Golgi but in the plasma 
membrane by a family of transmembrane proteins called hyaluronan synthases. HA 
can be very large in size, with a molecular weight often between 1-10 million 
Daltons (106). Even though HA is not covalently bound to a protein core, it can 
interact with numerous proteins, including the hyaladherins. Interactions of 
hyaladherins and HA stabilizes the ECM structure as well as modifying cell 
behaviour through binding with cell receptors. Because of its hydrodynamic 
properties, various physiological functions have been assigned to HA, including 
lubrication, water homeostasis, filtering effects and the regulation of plasma protein 
distribution (106,107). Elevated concentrations of HA are accompanied with an 
upregulation of the HA receptor CD44 associated with increased VSMC migration 
and proliferation observed in the early stages of neointimal formation of 
balloon-injured rat carotid arteries (108-110). 
KS is mostly found in the cornea, which is where the name “keratan” was 
derived from (111). Nevertheless, similar polysaccharides were also identified in 
cartilage. KS from these two tissues differ in the oligosaccharides linking the GAG 
chain to the core protein, and are called KSI and KSII(111). Corneal keratan sulfate 
(KSI) is attached to the Asn residue in core proteins whereas cartilage keratan sulfate 
(KSII) is linked to either serine (Ser) or threonine (Thr) residues. A third type of KS 
was found in the brain and has been called KSIII. This type of KS is different in its 
structure of the linkage region with a mannose O-linked to Ser residues in core 
proteins (111). As a result of its water-binding properties, in the cornea KS helps 
maintain the level of tissue hydration critical for corneal transparency. In the central 
nervous system KS functions as a regulator of neuronal regeneration (112). 
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HS and CS/DS have many similar features, including their initial 
tetrasaccharide linkage sequence that links between GAG chain and proteoglycan 
core protein. GAG chain synthesis on a proteoglycan occurs at a Ser residue on the 
core protein. The tetrasaccharide region consists of a xylose, two galactose (Gal) and 
a GlcA residue (102). At this point, there is no distinguishing whether this chain will 
become a HS or CS/DS GAG chain. The identity of the GAG chain is subsequently 
determined by the addition of the next sugar residue; the addition of a GlcNAc 
delineates the chain to be of the HS family, but addition of a GalNAc distinguishes 
the chain as a member of the CS/DS family (102,113). Despite the fact that no 
definitive code has been identified to dictate the type of GAG chain that will be 
produced, it is proposed that modifications including sulfation or phosphorylation 
within the linkage region may earlier influence the final production of this chain 
(114). 
While slight differences exist in the basic sugar of the GAG chain, 
subsequent sulfation, deacetylation and epimerization modifications distinguish 
individual GAG chains and are critical for their specific activity. Sulfation plays a 
particularly important role in HS and CS/DS activity. In contrast, HA is not modified 
by sulfation or epimerization. Due to the way GAG chains are constructed and 
modified, incredible diversity in GAG chains can be achieved contributing to a wide 
range of disease process (115,116).  
The involvement of HS in development and growth factor signalling has been 
extensively studied. Studies have established its roles in a wide area of 
developmental processes and signalling pathways including growth of new blood 
vessels from pre-existing vasculature (angiogenesis). Growth factors such as VEGF 
are able to bind to specific sites on HS chain to induce angiogenesis (117-119).  
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On the other hand the biological function and involvement of CS is less well 
understood and has received increasing attention (120,121). This is due to its 
significant impact in a wide variety of biological processes including cell adhesion, 
morphogenesis, cell division and neural network formation (122). Defects in CS 
biosynthesis have also been seen to affect pathological conditions of osteoarthritis 
(123), atherosclerosis (124), cancer (125) and neuropathies (126). This current study 
will focus on understanding the signalling pathways that regulate CS chain 
modification due to its importance as a therapeutic target of atherosclerosis (124).  
 Biosynthesis of CS/DS GAG chain  
The process of CS/DS chain assembly on proteoglycans is mediated by a multitude 
of membrane bound enzymes located in the ER/Golgi compartment (102). This 
process occurs via a concerted action of several GAG synthesizing enzymes, which 
are under extensive investigation (127-129) (Fig. 1.5). The overall process of CS/DS 
GAG chain synthesis involves the actions of glycosyltransferases and 
sulfotransferases (102). Glycosyltransferases are a large group of enzymes 
responsible for the biosynthesis of highly variable sugar structures present in 
bacteria, plants and animal cells. This group of enzymes transfer activated uridine 
diphosphate sugars to specific acceptor molecules consisting of proteins, sugars or 
lipids (130,131).  
Four glycosyltransferases, which are xylosyltransferase-1 (XT-1), 
β1,4-galactosyltransferase-1 (GalT-1), β1,3-galactosyltransferase-2 (GalT-2) and 
β1,3-glucuronyltransferase-1 (GlcAT-1) are involved in the synthesis of a linkage 
region that links the CS/DS GAG chain to the core protein. On the contrary, six 
homologous glycosyltransferases; chondroitin synthases (ChSy)-1, ChSy-2, ChSy-3, 
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chondroitin polymerizing factor (ChPF), chondroitin N-acetylgalactosamine 
transferase (ChGn)-1 and ChGn-2 are involved in the synthesis of the CS GAG 
chain (Fig. 1.5). 
Sulfotransferases catalyze the transfer of a sulfo group from a donor 
molecule to the acceptor (132). Seven sulfotransferases are responsible for the 
sulfation of CS/DS including chondroitin 4-O-sulfotransferase (C4ST)-1, C4ST-2, 
C4ST-3, dermatan 4-O-sulfotransferase (D4ST)-1, chondroitin 6-O-sulfotransferase 
(C6ST)-1, uronyl 2-O-sulfotransferase and GalNAc 4-sulfate 6-O-sulfotransferase 
(GalNAc4S-6ST) (Table. 1.1). 
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Table 1.1: Enzymes involved in human CS/DS synthesis. Adapted from (127). 
Enzymes  
(activity) 
Abbreviation 
Gene symbols 
 (synonym) 
Chromosomal  
location 
    Glycosyltransferases involved in synthesis of the tetrasaccharide linkage region 
    Xylosyltransferase XT-1 XYLT1 16p12.3 
 
XT-2 
 
17q21.33 
β1,4-Galactosyltransferase-I GalT-1 B4GALT7 5q35.2–q35.3 
β1,3-Galactosyltransferase-II GalT-2 B3GALT6 1p36.33 
β1,3-Glucuronyltransferase-I GlcAT-1 B3GAT3 11q12.3 
    Glycosyltransferases involved in synthesis of the repeating disaccharide region of CS 
chains 
    Chondroitin synthase ChSy-1 CHSY1 15q26.3 
(GalNAcT-II, GlcAT-II) 
   
 
ChSy-2 CHSY2 (CSS3) 5q23.3 
 
ChSy-3 CHSY3 (CHPF2) 7q36.1 
    Chondroitin polymerizing factor ChPF CHPF (CSS2) 2q35 
(GalNAcT-II, GlcAT-II)    
Chondroitin GalNAc transferase ChGn-1 CSGALNACT1 8p21.3 
(GalNAcT-I, GalNAcT-II)    
 
ChGn-2 CSGALNACT2 10q11.21 
    Sulfotransferases and epimerases 
  
    Chondroitin 4-O-sulfotransferase C4ST-1 C4ST1 (CHST11) 12q 
 
C4ST-2 C4ST2 (CHST12) 7p22 
 
C4ST-3 C4ST3 (CHST13) 3q21.3 
Dermatan 4-O-sulfotransferase D4ST-1 D4ST1 (CHST14) 15q15.1 
Chondroitin 6-O-sulfotransferase C6ST-1 C6ST1 (CHST3) 10q22.1 
Uronyl 2-O-sulfotransferase UST UST 6q25.1 
GalNAc 4-sulfate 6-O 
-sulfotransferase 
GalNAc4S-6ST GALNAC4S-6ST  
(CHST15) 
10q26 
    Glucuronyl C-5 epimerase DS-epi1 DSE (SART2) 6q22 
 
DS-epi2 DSEL 18q22.1 
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CS/DS GAG chain synthesis commences with the synthesis of the linkage 
region by the addition of a xylose sugar covalently attached to a serine residue on the 
core protein. This is followed by sequential addition of individual monosacharide 
units, two Gal and single GlcA residues making up the tetrasaccharide linkage 
structure (105). This occurs by the sequential action of the specific 
glycosyltransferases; XT-1 (131), GalT-1 (133), GalT-2 (134) and GlcAT-1 (135), 
respectively. After completion of the linkage region, synthesis of the chondroitin 
chain is initiated by polymerization of repetitive disaccharide units through alternate 
additions of GlcA and GalNAc (102). Chondroitin polymerization occurs with the 
action of glycosyltransferases ChSy-1, ChSy-2, ChSy-3, ChPF, ChGn-1 and 
ChGn-2. Co-expression of any two of these enzymes allows polymerization to occur 
(121,136,137). 
Further GAG chain modification may occur with addition of sulfate at 
hydroxy group positions 4 and 6 of the GalNAc residues, position 2 of the GlcA 
residue and creates a structural diversity of the CS GAG chain (132). The importance 
of sulfotransferases was highlighted by Izumikawa et al. (129) who demonstrated 
that they can directly facilitate elongation of the CS chain. Immediately after transfer 
of newly synthesized GalNAc residue by ChGn-2, sulfation of the non-reducing 
terminal 4-O-sulfation of GalNAc residues by C4ST-1 facilitates the elongation of 
CS chains by the chondroitin polymerases, ChSy-1 and ChPF (129). Fig. 1.7 shows 
the cell biology of CS chain synthesis on a proteoglycan core protein. In the current 
literature, the sulfotransferase that specifically transfers a sulfo residue to the 
4-hydroxl group of GalNAc residue on the CS GAG is called either C4ST-1 or 
carbohydrate sulfotransferase (CHST)-11 (104). 
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Figure 1.7: Cell biology of CS/DS chain synthesis. Nuclear transcription of mRNA for GAG synthesizing enzyme and proteoglycan core 
protein enters the ER for protein synthesis. Upon exit from the ER, the XT-1 enzyme attaches a xylose unit onto the serine residue of the newly 
synthesized core protein. This enables the synthesis of the rest of the linkage region that occurs inside the Cis Golgi. Synthesis of the repeated 
disaccharide GAG chain occurs and further modification by addition of sulfotransferase proceeds in the trans Golgi region. 2S, 4S & 6S indicate 
sulfation position on the GAG chain.
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Biglycan GAG chains, synthesized initially as CS proteoglycans can be 
converted to its stereoisomers by DS epimerases. This occurs at the 5th position of 
the GlcA moiety that generates an IdoA by the action of two glucuronyl C-5 
epimerases, DS-epi1 and DS-epi2 (138,139). All of these highly variable 
modifications serve a fundamental purpose for a wide range of biological events 
involving GAGs (140).  
Despite the identification and cloning of glycosyltransferases, epimerases and 
sulfotransferase involved in CS GAG synthesis (137,141,142), their regulatory 
mechanisms are not well understood. The precise mechanism of CS GAG 
polymerization is still unclear and under extensive investigation 
(43,128,129,143,144). Thus, there is considerable interest in understanding the 
development of atherosclerosis associated with CS GAG chain synthesis by 
regulation of these synthesizing enzymes. The present study focuses on the CS GAG 
chain synthesis and structure because of its direct involvement with lipid binding 
(48). Lipoproteins are found to bind with GAG chains and not core proteins, which 
acts merely as a scaffold (105,140). Due to this reason, the changes in GAG chain 
structure are most likely responsible for lipid binding and retention thus deserves a 
greater amount of investigation. 
 Increased GAG synthesizing enzymes contributes to 
development of cardiovascular disease 
In 2011 it was demonstrated that two Golgi enzymes, C4ST-1 and ChGn-2 play a 
critical role in the regulation of the GAG chain length and amount of GAG of 
proteoglycans in vivo (129). Anggraeni et al. (145) showed that the synthesis of 
longer CS chains during the development of atherosclerosis is accompanied by 
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increased mRNA expression of C4ST-1 and ChGn-2 GAG synthesizing enzymes. 
Knowledge of the signalling pathways that relate to the expression of target enzymes 
including these two Golgi enzymes is lacking. Since these two enzymes may be 
involved in the retention of atherogenic lipoproteins by mediating CS chain 
elongation, information regarding the mechanisms of regulation of these 
synthesizing enzymes may provide a novel therapeutic target to prevent the initiation 
and progression of atherosclerosis (145). Another study on cardiac fibroblasts found 
that XT-1 mRNA expression was upregulated by TGF-β in vitro and this increased 
levels of enzymatic XT-1 activity corresponding to elevated GAG chain synthesis in 
cardiac tissues. Knockdown of the XT-1 mRNA with siRNA resulted in decreased 
enzymatic XT-1 activity which in turn reduced GAG synthesis (146).  
 Proteoglycans and retention of lipoproteins 
Proteoglycans are the main component of the ECM that play a major role in the 
vascular pathology of atherosclerosis (83). The lipoprotein binding capacity of 
proteoglycans contributes to retaining atherogenic lipoproteins in the intima. The 
binding between proteoglycans and lipoproteins is due to the ionic interaction of the 
negatively charged GAG chains of proteoglycans and the positively charged residues 
of apolipoproteins specifically the apoB-100 on LDL (79). A study reported in 
Nature by the Boren Laboratory in Gothenburg in 2002 supported the response to 
retention hypothesis especially the role of proteoglycans in lipoprotein binding. They 
showed that in mice possesing apoB-100 gene mutations, their apoB-100-modified 
lipoprotein bound poorly to artery wall proteoglycans resulting in significantly less 
atherosclerosis development (79).  
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Human plasma apolipoproteins encompass a wide spectrum of particles of 
varying physical and chemical properties whose metabolism is directed by their 
protein components. Lipoproteins are grouped into two classes, the 
non-exchangeable apolipoproteins, apoB-100 and apoB-48 as well as the 
exchangeable apolipoproteins (apoA-I, apoA-II, apoA-IV, apoC-I, apoC-II, apoC-III 
and apoE) (147). ApoB-100 one of the largest monomeric proteins known is highly 
insoluble in aqueous solution and is the main protein moiety on human LDL (148). 
The apoB-100-containing lipoproteins contains clusters of positively charged amino 
acids that bind to negatively charged proteoglycans which is linked to their affinity 
for artery wall proteoglycans (79). Boren et al. (149) showed that the site B (residues 
3359–3369) on apoB-100 was identified as the principal proteoglycan binding 
sequence. 
Proteoglycan-lipoprotein binding can be enhanced by cofactors such as 
lipoprotein lipase in promoting binding to proteoglycans (150). The non-catalytic 
function of lipoprotein lipase in bridging lipoprotein is suggested to be mediated by 
three continuous clusters in the N-terminal domain and a non-continuous cluster in 
the C-terminal domain of positively charged amino acids that are brought together by 
folding of the enzyme (151). The proteoglycan-lipoprotein complexes retained in the 
vessel wall are susceptible to further modifications including oxidation and 
aggregation that induce the uptake of oxidized lipoprotein by macrophages and their 
transformation into foam cells (152,153). The production of oxidized lipoprotein 
increases the production of proteoglycans with higher affinity for lipoprotein (93). 
These events increase the number of inflammatory T-cells and mediators of 
inflammation adhesion molecules, chemokines, pro-inflammatory cytokines in 
macrophages and vascular wall cells (154). Induction of inflammatory mediators 
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would then contribute towards the ongoing inflammatory response that provides the 
fundamental role in mediating all stages of atherosclerosis from initiation through 
progression and ultimately, thrombotic complications (78).  
 Structural changes of the glycosaminoglycan affecting LDL 
retention 
The retention of LDL is increased due to the increase in the negatively charged 
residues on the GAG chain, either by an increase in chain length or a greater degree 
of sulfation, or both (56,57,155). Variations in the structure of proteoglycans 
influences the binding capacity towards LDLs. Preventing these alterations in 
proteoglycan synthesis and structure has been proposed to be a therapeutic target for 
the prevention of atherosclerosis (156).  
 GAG chain hyperelongation and LDL binding 
Many agents are found to stimulate an increase in the elongation of GAG chains. 
These agents include growth factors such as PDGF (157) and TGF-β (158), 
vasoactive hormones such as the seven transmembrane G-protein-coupled receptor 
(GPCR) agonist angiotensin II (159) and metabolic factors such as oxidized LDL 
(93) and free fatty acids (160). In the vessel wall, these growth factors as well as 
vasoactive substances can be present together and the presence of multiple agents 
could produce additive effects on GAG elongation, for instance both PDGF and 
TGF-β (at maximally effective doses) increase GAG length and these effects are 
clearly additive (82). Little et al. (158) showed that stimulation of VSMC with 
growth factors increases the binding of both GAG chains chemically released from 
core proteins and of GAG chains synthesized on exogenous xyloside indicating that 
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these chains are indeed the critical site of LDL binding. However, the effects of these 
agonists on the signalling of the wide range of enzymes responsible for GAG 
synthesis requires further investigation.  
Several other investigators have studied the importance of GAG chain length 
to LDL binding through various methods. LDL affinity column chromatography was 
used to identify the relationship between GAG chain length from 
atherosclerosis-susceptible regions of human aorta and binding to LDL (161). 
Chang et al. (93) showed that treatment of arterial SMC with oxidized LDL results in 
GAG chain elongation and increased LDL binding. Likewise, gel mobility assay 
allowed the investigation of the relationship between larger proteoglycans and of 
their binding to proteoglycans (56). There is a study that looked into the activity of 
GAG synthesizing enzymes involved in GAG chain elongation. Srinivasan et al. 
(162) found that XT-1 and ChGn-1 were increased suggesting that post-translational 
processing of proteoglycans may be a critical determinant in their binding to LDL. 
They also discovered that proteoglycans from injured arteries had longer GAG chain 
than control arteries, which resulted in increased binding of proteoglycans to LDL 
(162). Despite that, not much is known on the signalling pathways related to the 
increase in GAG synthesizing enzymes that are significantly involved in 
development of atherosclerosis (145). 
 GAG chain hyperelongation involves new protein synthesis  
New protein synthesis through transcription and translation is required for natural 
GAG hyperelongation (163). Vijayagopal and colleagues (164) examined the effect 
of bovine endothelial cell conditioned medium containing TGF-β on bovine VSMC 
proteoglycan production. Their results showed an increase stimulation in the size of 
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proteoglycans and thus by implication, the hyperelongation of GAG chains produced 
by bovine VSMC. The presence of inhibitors of de novo protein synthesis, both 
actinomycin D (transcription inhibitor) and cycloheximide (translation inhibitor) 
blocked the ability of endothelial cell conditioned medium to stimulate GAG 
hyperelongation (164). Using a variety of growth factors (EGF, PDGF, TGF-β and 
thrombin) that are known to mediate GAG hyperelongation, Yang et al. (163) had 
validated that the effects occuring downstream of the cell surface receptors involves 
de novo protein synthesis. Blocking de novo protein synthesis with cycloheximide 
completely prevented the action of all four growth factors to elongate the GAG 
chains on biglycan (163). The likely downstream targets would include the GAG 
synthesizing enzymes required for GAG synthesis and polymerization (165) and this 
will be investigated further in this current study. The signalling pathway that is 
involved in this process presents a potential target that can be inhibited to block 
GAG chain hyperelongation on proteoglycans. The prevention of GAG chain 
hyperelongation reduces the affinity of proteoglycans to LDL binding consequently 
hindering the progression of CVD (82,156). 
 Sulfation pattern and LDL binding 
Growth factor signalling pathways can also alter epimerization and disaccharide 
sulfation pattern leading to functional consequences (82). In fibroblast cells, TGF-β1 
was shown to influence the copolymeric structure of the DS chains synthesized by 
embryonic skin fibroblasts (166). Sulfation pattern on the GAG chain was essential 
in contributing to the interaction between it and lipoproteins. Disaccharides derived 
from proteoglycans of atherosclerotic susceptible White Carneau Pigeon that 
displayed higher binding affinity for plasma LDL were shown to have a higher 6:4 
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sulfation pattern compared to the atherosclerotic resistant Show Pigeon (167). This 
sulfation pattern of GAGs was even shown to be common in proteoglycans located 
at aortic atherosclerotic lesion prone-regions (168). Both 4- and 6-sulfation of GAG 
chain results in increased in LDL binding, however the mechanism leading to 
increased binding differs due to differences in their structural formation. The 
6-sulfation allows a GAG chain more sterically accessible to LDL particles, whereas 
the 4-sulfation produces a rigid molecule of higher charge density (156).  
1.5 Targeting the signalling pathways that lead to 
atherogenesis 
As mentioned earlier, three potential therapeutic approaches towards prevention of 
atherogenesis are modification of the lipoproteins, modification of the structure of 
GAG chains on proteoglycans and modification of the interaction between 
proteoglycans and lipoproteins via GAG mimetics that can bind to lipoprotein (80). 
Identifying the signalling pathways that lead to the structural changes in 
proteoglycan, specifically GAG chains, is considered to be highly novel and provide 
tissue and pathological specificity (82). There is evidence that GAG synthesis is 
tightly regulated and amenable to pharmacological manipulation (156). Our 
therapeutic strategy is that preventing GAG chain hyperelongation may reduce the 
binding of proteoglycans to lipoproteins eventually decreasing the retention of 
lipoproteins in the vessel wall and ultimately resulting in less atherosclerosis.  
Thus, the test of the therapeutic implications of the response to retention 
hypothesis is to discover agents that can specifically reduce the length of GAG 
chains on proteoglycans either directly, or most likely by preventing the actions of 
atherogenic agents that can elongate GAG chains (157). This may be achieved by 
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either targeting the basic underlying processes of proteoglycan synthesis or by 
targeting the agonist signalling pathways (83,165). Targeting proteoglycan synthesis 
per se may be deleterious to all sites of proteoglycan formation, possibly creating 
unwanted side effects for example modification of cartilage and conditions such as 
chondrodysplasia and spondyloepiphyseal dysplasia (169). In contrast, targeting the 
signalling pathway with antagonists towards the growth factor signalling pathway 
would be a more successful strategy since these pathways are stimulated under the 
activated conditions existing in a pro-atherosclerotic vessel wall and are cell context 
specific (32). It is noteworthy that the biochemical mechanisms determining the 
synthesis of vascular proteoglycans, the role of pharmacological agents in regulating 
proteoglycan metabolism and later on the impact of altered proteoglycan structures 
on binding to atherogenic lipoproteins are less understood (156). Thus, 
understanding this overall signalling event would facilitate in the development of a 
therapeutic target for atherosclerosis. One of the primary growth factors that is 
linked to the development of atherosclerosis is TGF-β (170), and as a result its 
signalling pathway that induces increased GAG chain hyperelongation should be 
investigated.  
1.6 Transforming growth factor-beta (TGF-β)  
The TGF-β superfamily consists of more than 30 proteins in mammals including 
TGF-β, activins and inhibins, nodal, myostatin, bone morphogenetic proteins (BMP), 
growth differentiation factors and anti-Mullerrian hormone (171,172). In mammalian 
species there are three similar isoforms, which are TGF-β1, 2 and 3. The peptide 
structures of the TGF-β isoforms are 70–80% similar in homology. TGF-β1 contains 
390 amino acids while TGF-β2 and TGF-β3 each contain 412 amino acids. TGF-β1 
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is present at high levels in the healthy blood vessel wall, whereas TGF-β2 and 
TGF-β3 are closely related isoforms that are either absent (TGF-β2) or present only 
at low levels (TGF-β3) (173). TGF-β is a pleiotropic growth factor that regulates a 
wide variety of fundamental biological activities including cell growth, 
differentiation, ECM remodelling, migration and apoptosis (174,175). The regulation 
of such diverse cellular functions means that disruption of the TGF-β signalling 
pathways becomes associated with diverse disease states such as cancer, 
atherosclerosis, cardiac and renal fibrosis (176,177).  
 TGF-β and atherosclerosis 
TGF-β was initially discovered when it was shown to include the ability to induce 
fibroblasts to grow in soft agar. This was a feature of oncogenes, however unlike 
oncogenic transformation, the effects of TGF-β were found to be reversible (178). 
TGF-β was found to have multi-functional effects that depend on cellular context 
(171). As an example, in normal cells and early phases of tumor development, 
TGF-β frequently acts as a tumor suppressor. However in late phases of tumor 
development, these cells become resistant to TGF-β’s anti-mitogenic effects and this 
growth factor switches into a tumor promoter (179). 
The role of the anti-inflammatory cytokine TGF-β in atherosclerosis has been 
the subject of considerable debate for a decade (180). The response of the cell to 
TGF-β is complex and highly dependent on the cell type as well as its physiological 
environment (181). In the early 1990s, TGF-β was reported to have protective 
effects. In VSMC, TGF-β inhibits in vitro proliferation and migration, and maintains 
VSMC in the differentiated phenotype in vitro and in vivo (182,183). This was 
crucial for the homeostasis of the arterial wall and abnormalities in TGF-β signalling 
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are critical in the pathogenesis of vascular disease (184-186). Besides, other in vitro 
studies had shown that TGF-β could promote smooth muscle proliferation (187,188). 
The stimulatory effect seen in these studies was due to the ability of TGF-β to 
enhance ECM formation. Cells placed into culture simply adhere to the culture 
plastic better if TGF-β is present to stimulate ECM production. Therefore, TGF-β 
produces coordinated effects in vitro that would contribute to the maintenance of the 
normal blood vessel wall architecture if similar effects occurred in vivo (189). 
The TGF-β antigen, the TGF-β receptor type 1 (TGFβR1) and TGF-β 
receptor type 2 (TGFβR2) have been detected in normal human coronary and carotid 
arteries, the aorta and in atherosclerotic plaques (170,190-192). Oklu et al. (193) 
argued that whether TGF-β antigen in the vessel wall is biologically active and 
affects lesion development could be answered by investigating the TGF-β signalling 
pathway to determine the activity associated with TGF-β antigen in the vessel wall. 
Patchy distribution of TGF-β1 was found in neointima (194). TGF-β is found to be 
upregulated in the atherosclerotic tissue with chronic inflammation, supporting the 
view that it may play an important role in the events linked to chronic inflammation 
and advanced human atherosclerotic plaques (170).  
TGF-β is increased in atherogenesis and has been shown to promote 
atherosclerotic lesion formation in human arteries (190,192). In human aortic 
segments, TGF-β was found to be most active in lipid-rich aortic intimal lesions. 
This contributes primarily to the pathogenesis of lipid-rich atherosclerotic lesions by 
stimulating the production of lipoprotein-trapping proteoglycans (190). 
TGF-β1 is closely associated with the development of atherosclerosis due to 
its role as an important modifier of proteoglycan GAG chain structure (157,158). 
TGF-β was demonstrated to elongate GAG chains on VSMC-derived proteoglycans 
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in which the GAG chains either as intact proteoglycans or free GAG chains, and 
these chains showed enhanced binding to human LDL (158). In arterial SMC, 
treatment with TGF-β1 increased the production of two proteoglycans versican and 
biglycan (157,195) that are well known to accumulate in atherosclerotic lesions 
(54,98,196,197). These proteoglycans are found to localize in lipid-rich regions of 
atherosclerotic plaques along with TGF-β1 (198) suggesting an important  role for 
the latter in lipid retention.  
 TGF-β signalling  
Members of the TGF-β superfamily are produced as dimeric latent precursors which 
are activated in the extracellular environment to release the receptor-binding ligands 
that share a common motif known as the cysteine knot (199). The TGF-β cell 
signalling pathway is activated by release of active TGF-β from latent complex 
stored in ECM. Activated TGF-β then binds to their transmembrane cell surface 
receptors to form heteromeric complexes comprising dimers of TGFβR1 and 
TGFβR2. There are seven TGFβR1 (Activin receptor-like kinase (ALK, 1–7) and 
four TGFβR2 (TGFβR2, BMP receptor type 2, activin receptor type 2A/B), which 
differential affinities for individual ligands contribute to signalling specificity (200). 
Within the heteromeric signalling complex TGFβR2 trans-phosphorylate 
TGFβR1 at a glycine-serine rich motif located directly upstream of the TGFβR1 
kinase (201). Phosphorylation of this glycine-serine motif renders the TGFβR1 
kinase active simultaneously preventing the binding of the inhibitory immunophilin 
FK506 binding protein 12, which otherwise keeps this kinase in an inactive 
conformation (202).  
Smad proteins are the intracellular mediators of the TGF-β superfamily 
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signalling. Downstream intracellular signal transduction of Smad family proteins 
(201) act as transcription factors that regulate gene expression (203). Smads are 
activated following TGF-β stimulation via direct phosphorylation by TGFβR1. 
Phosphorylated Smad complexes would then move to the nucleus where they 
regulate diverse effects on gene transcription through the recruitment of transcription 
co-activators and co-repressors (204).  
Application of small specific inhibitors developed for therapeutic use can be 
a useful tool in understanding complex signal transduction pathways (205). The 
activity of the TGFβR1 specifically ALKs 4, 5 and 7 can be blocked by a small 
molecule inhibitor, SB431542 identified as a specific, potent inhibitor of ALK5 
(206). Apart from ALK5, SB431542 also inhibits the activin type I receptor ALK4 
and ALK7, and the nodal type I receptor which are highly homologous to ALK5 in 
their kinase domains. It is a highly selective inhibitor of endogenous activin and 
TGF-β signalling with no effect on other signal transduction pathways including 
BMP and mitogen activated protein kinase (MAPK) signalling pathways (206). 
In human VSMC, TGF-β signalling pathways regulate proteoglycan 
synthesis and increase proteoglycan to LDL binding. TGF-β stimulation causes 
increased [35S]-sulfate incorporation into proteoglycans as well as a 19% increase in 
GAG chain size (81). Previous studies in our laboratory have demonstrated that 
SB431542 caused a concentration-dependent decrease in TGF-β-mediated 
[35S]-sulfate incorporation with up to 92% inhibition at 3 µM showing that TGF-β 
mediates its effects on proteoglycan synthesis via TGFβR1 (81). The detailed 
signalling pathways between receptor and proteoglycan synthesis have not been 
reported. This study will use SB431542 as one of the pharmacological tools to 
explore the TGF-β signalling pathway in detail. 
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1.7 Smad transcription factors 
 Biochemistry of Smad transcription factors 
TGF-β regulates cell proliferation, differentiation and apoptosis through activation of 
Smad proteins (207). In the human genome, there are eight encoded Smad proteins 
(171). The Smad protein can be classified into three classes; receptor regulated 
Smads (R-Smads), these include five of the mammalian Smads, Smad1, Smad2, 
Smad3, Smad5 and Smad8 which are all substrates for the TGF-β family of receptors 
(208); the common mediator Smad4 (co-Smad) that interacts with the R-Smads in 
cell signalling (209); and the inhibitory Smads (I-Smad) Smad6 and Smad7 which 
are responsible for blocking the activation of R-Smad and co-Smad, and initiating 
receptor degradation (210). 
Smad proteins are 400–500 amino acids in length and contain three distinct 
regions (201). The N-terminal phosphorylation domain MAD-homology 1 (MH1) is 
a conserved domain (171) involved in nuclear translocation (211). This region binds 
to DNA and interacts with DNA-binding cofactors (208). The MH1 domains of 
Smad3 and Smad4 possess an intrinsic property which binds to specific DNA 
sequences containing 5′-AGAC-3′ sequences, termed Smad-binding elements (212). 
A complex between MH1 domain with Smad-binding elements revealed that the 
protruding β-hairpin loop (highly conserved among different R- and Co-Smads) is 
responsible for direct DNA contact (213). However, Smad2 is unable to bind directly 
to DNA as it contains an extra exon (TID domain) in the MH1 domain of the 
β-hairpin loop (213). 
The C-terminal domain MAD-homology 2 (MH2) binds to TGFβR1 at the 
L3 loop, which enables Smad homo- and hetero-oligomerization as well as 
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transactivation of nuclear Smad complexes (214). The H1 α helix in the MH2 
domain is responsible for the interaction of ALK1 with Smad1 (215). The third 
region is the non-conserved linker region rich in serine and threonine residues that 
can be phosphorylated by serine/threonine kinases (216). Phosphorylated Smad 
linker region can interact with prolyl isomerases and ubiquitin ligases (174,217) 
(Fig. 1.8).  
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(A) Smad2 and (B) Smad3 depicting the MH1, MH2 domains and the central linker 
region. This figure also shows important phosphorylation sites on Smad2 and 
Smad3. Adapted from Burch et al. (177). 
<Image removed due to copyright restrictions> 
 
Figure 1.8: Domain structure of human Smads 
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 TGF-β-mediated Smad signalling 
In TGF-β signal transduction, the R-Smads (Smad2 and Smad3) are directly 
phosphorylated by TGFβR1 at the Ser-Ser-X-Ser (where X is any amino acid) motif 
in the C-terminal sequence. In Smad2, the three serine residues are positioned at 
positions 464, 465 and 467. Of the three residues, it is only two (Ser465 and 467) 
that are directly phosphorylated while the other serine (Ser464) is involved for 
efficient phosphorylation of Smad2 (218) (Fig. 1.8). This direct receptor mediated 
C-terminal Smad phosphorylation is often referred to as the canonical TGF-β 
signalling. The phosphorylated Smad2 and Smad3 then bind to the co-Smad4 in the 
cytosol to form a complex that is translocated into the nucleus for the regulation of 
transcription of numerous target genes (219).  
Smad2 and Smad3 are very similar in structure, reflected by the 91% shared 
identity in amino acid sequence (220). However, Smad2 and Smad3 knockout mouse 
phenotypes and studies comparing expression profiles of the TGF-β target genes in 
Smad2-deficient cells with those in Smad3-deficient cells, suggest that epithelial and 
mesenchymal cells exhibit distinct but overlapping Smad2 and Smad3 signalling 
(221,222). Both Smad proteins mediate activin and TGF-β signalling however, there 
are several differences between the two. Firstly, there are two extra peptide inserts, 
named the GAG and TID regions on the Smad2 which are absent in Smad3 (223). 
The TID domain (also known as exon 3) prevents the direct binding of Smad2 to 
DNA, whereas Smad3 is able to directly bind to DNA sequence (213). Secondly, the 
stability and intracellular localization of Smad2 and Smad3 are regulated by distinct 
mechanisms resulting in functional and regulatory differences between these two 
proteins (208). An example of TGF-β-mediated Smad signalling to GAG 
synthesizing enzymes and the role of Smads, a study by Susarla et al. (224) found 
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that CS proteoglycan deposition in astrocytes is regulated by the TGF-β-mediated 
pathway selectively involving either Smad2 or Smad3 (224). They also showed that 
TGF-β induction of XT-1 mRNA expression required both Smad2 and Smad3, 
whereas induction of ChSy-1 required only Smad2. Knockdown of Smad3 was 
shown to selectively reduce the induction of C4ST-1 and the amount of 4-sulfated 
CS proteoglycan secreted by astrocytes. 
 Smad linker region phosphorylation  
In addition to the canonical TGF-β signalling involving C-terminal phosphorylation, 
experiments using linker region specific antibodies have shown that the linker region 
on Smad2/3 can also undergo phosphorylation and play an important role in 
TGF-β-mediated biological actions (225). This has led to the term Smad-independent 
or non Smad-dependent cascades that generally refer to the signalling pathway that 
occurs through phosphorylation of the linker region (177). Even though the used 
term is non-Smad pathway, linker region phosphorylation involves Smads and is 
mediated via signalling events occurring through TGF-β receptor. Cells with 
TGFβR1 deficiency (L17 cells) were shown to have inability for TGF-β induced 
Smad3 linker region phosphorylation (226). It was also observed that Smad3 linker 
region phosphorylation was dependent on the Smad3 phosphorylation at the 
C-terminal. TGF-β induced Smad3 linker region phosphorylation was abolished in 
cells with C-tail mutant of Smad3 (226). In fact, phosphorylation of the linker region 
was also found to be important from the observation that prior to the deletion of the 
Smad3 linker region, TGF-β-stimulated gene transcription activity was affected 
despite its ability to become phosphorylated at the C-terminal and form a complex 
with Smad4 (227). 
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Smad linker region can be phosphorylated by multiple kinases including 
MAPK (extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) 
and p38), phosphatidylinositide 3-kinase (PI3K), cyclin-dependent kinase (CDK), 
rho-associated protein kinase (ROCK) and glycogen synthase kinase (GSK-3) (216). 
The Proline-X-Serine-Proline (where X is any amino acid) sequence in the linker 
region provides a consensus phosphorylation site for MAPK (228). Among these 
kinases, MAPK and CDK are major groups of protein kinases showing preference 
for specific serine/threonine residues in the linker regions (216). Other vasoactive 
agents can also activate MAPK potentially leading to linker region phosphorylation. 
Thus, linker region phosphorylation may be a central integrating point through 
which many pro-atherogenic agonists stimulate changes in proteoglycan synthesis 
and as such represents a very attractive target for the development of a therapeutic 
agent to prevent atherosclerosis (177). Fig. 1.9 shows the canonical Smad signalling 
pathway and non-canonical signalling pathway involving Smad linker region 
phosphorylation resulting in increased expression of GAG synthesizing enzyme and 
proteoglycan hyperelongation. 
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Smad2 carboxy terminus can be directly phosphorylated by the activated TGFβR1. The Smad2 linker region (Thr220, Ser245, Ser250 and 
Ser255) can also be phosphorylated by the TGF-β-mediated serine/threonine kinases resulting in regulation of transcriptional activity. Increase in 
GAG synthesizing mRNA expression results in GAG chain hyperelongation and contributes to LDL retention. Adapted from Burch et al. (177).  
Figure 1.9: Representation of the TGF-β-mediated proteoglycan synthesis involving the canonical and non-canonical pathway 
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Downstream gene expression outputs of Smad linker region phosphorylation 
can have either a negative (226,229) or positive (230,231) regulatory effect on gene 
expression. Early studies on carcinogenesis had predominantly set a negative 
regulatory paradigm of linker region phosphorylation. ERK can phosphorylate serine 
residues in the linker regions of Smad2 and Smad3 and substitution of these residues 
inhibits nuclear translocation of Smads and thus signalling (228). Other reports add 
that TGF-β-induced phosphorylation of Smad3 linker sites inhibits the 
anti-proliferative activity of this Smad (via activation of a TGF-β/Smad-target gene 
for growth-inhibitory function) (226). Nevertheless, positive regulatory effects are 
also reported in the literature. Smad1 phosphorylation by TGF-β triggers 
transcriptional action required for BMP suppression of neural differentiation of 
mouse embryonic stem cells (230). As our laboratory had previously shown, in the 
context of ECM synthesis and proteoglycan modification, Smad linker region 
phosphorylation was shown to promote TGF-β signalling, regulating the synthesis 
and structure of proteoglycans (232). Smad linker region phosphorylation provides 
an important avenue for integration of multiple signalling networks to influence the 
outcome of TGF-β signalling (233). In a cell proliferation study, Smad linker region 
signalling was investigated to identify its role in modifying the outcome of 
phosphorylated Smad2/3 carboxy terminus signalling (234).  
There are at least four important phosphorylation sites on the Smad2/3 linker 
region (Smad2/3L). In human Smad2, these sites are positioned at Thr220, Ser245, 
Ser250 and Ser255. While in Smad3, phosphorylation can occur at Thr179 and 
serine residues at positions 204, 208 and 213 (216) (Fig. 1.8). According to 
Matsuzaki et al. (235), differential localization of kinases and phosphatases that can 
phosphorylate Smad linker region in the cytoplasm or nucleus leads to different 
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temporal dynamics for cytoplasmic or nuclear Smad phospho-isoforms and 
contributes to the set of signalling responses that determine cell-fate decisions.  
Previous work from our laboratory has shown that in endothelial cells, 
regulation of plasminogen activator inhibitor (PAI)-1 gene mRNA expression is 
mediated by phosphorylation of different individual serine/threonine residue on the 
Smad2 linker region (236). PAI-1 is the primary inhibitor of plasminogen activation 
and elevated levels have been proposed to promote development of intravascular 
thrombosis as well as atherosclerosis (237). As the phosphorylation of Smad2/3L is 
cell type specific, this project will emphasize on the specific TGF-β-mediated 
signalling pathways that involve downstream Smad2 linker region (Thr220, Ser245, 
Ser250 and Ser255) as well as the gene expression of specific GAG synthesizing 
enzymes for proteoglycan CS GAG chain elongation in VSMC. 
1.8 Kinases that phosphorylate the Smad linker region 
 Cyclin-dependent kinases (CDK) 
Cyclin-dependent kinases (CDK) are a family of multifunctional enzymes involved 
in the control of transcription and cell cycle progression. In bovine endothelial cells, 
CDK is able to phosphorylate Smad2 linker region and is involved in regulation of 
PAI-1 gene expression (236). In Mv1Lu mink lung epithelial cells, the Smad3 linker 
region is phosphorylated by CDK2 and CDK4 acting as a key mediator in the 
anti-proliferative effects of TGF-β (238). As their name suggests, CDKs are 
serine/threonine protein kinases that require the binding of cyclin partners to become 
active. The heterodimeric complexes would then be able to modify various protein 
substrates involved in cell cycle progression (239). CDK activity increases in 
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proliferative diseases such as cancer due to the frequent overexpression of these 
cyclins as well as frequent inactivation of CDK inhibitors (240). Abnormalities in 
CDK activity and regulation have been found in viral infections, proliferative renal 
diseases and neuro-degenerative disorders including Alzheimer’s, Parkinson’s and 
Nieman-Pick’s disease, ischemia and traumatic brain injury, leading to intensive 
research on targeting CDK for therapeutic applications (241,242). The involvement 
of CDKs in various disease conditions has led to an intensive search for selective 
pharmacological inhibitors of these kinases (243). The search for CDK inhibitors 
in the context of atherosclerosis is often associated with cell proliferative 
disorders (244). Inhibitors such as flavopiridol (245) and CVT313 (246) had been 
studied for their role in the inhibition of VSMC proliferation in vitro and 
neointimal formation in vivo. It is essential to understand the involvement of 
CDK in atherogenesis involving proteoglycans synthesis (247) to delineate the 
potential beneficial mechanisms of CDK inhibitors in the context of aiming to 
identify therapeutic targets for atherosclerosis (82). 
In humans, the CDK family is comprised of 13 members that interact with at 
least 29 cyclin or cyclin-related proteins (248). Ten CDKs (CDK1–9 and CDK11) 
have been shown to be part of heterodimeric serine/threonine kinase complexes that 
require a regulatory subunit to perform biological activity (248). Certain subsets of 
the cyclin-CDK complexes are well known for their direct involvement in the 
specific stages of the cell cycle including: CDK2, CDK4 and CDK6 involved in 
interphase, while CDK1 is involved in the mitotic process (249). These CDK 
isoforms are also known to associate with 10 cyclins that are directly involved in the 
mammalian cell cycle, belonging to four classes (three A-type, three B-type, three 
D-type and two E-type cyclins) (248,250). Others CDKs are responsible for 
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transcription (CDK7–11) and neuronal differentiation (CDK5) (248). Some of the 
CDKs including CDK4 and CDK6 are functional homologues, as well as among the 
three D-type cyclins. It is likely that the unique properties of these molecules are 
linked to their tissue specificity and/or their differential activation during 
development (251). 
The involvement of CDK and cyclin in cell cycle progression exhibits a 
coordinated signalling mechanism. In the G1 phase, mitogenic signal increases 
cyclin-D expression allowing for the formation of the CDK4/CDK6 complex. This 
results in a partial inactivation of transcriptional repressor proteins including 
retinoblastoma (Rb), p107 and p130. CDK2, CDK4 and CDK6 are involved in the 
Rb pathway by targeting the Rb tumor suppressor (250,252). In a 
non-phosphorylated state the Rb protein binds to and inhibits the E2F transcription 
factor activity. Phosphorylation of Rb releases active E2F further activating 
transcription of genes required for G1-S transition including that of cyclin-E (253-
255). Ongoing increase of phospho-Rb leads to the CDK4/CDK6 inhibitor p16 
action (254). Subsequently, in the late G1 phase, signal activation of cyclin-E allows 
cyclin-E-CDK2 complex to accumulate. Further phosphorylation of Rb by 
cyclin-E-CDK2 contributes to a complete inactivation of transcriptional repressor 
proteins.  
The S phase (DNA replication) occurs through the signal activation of 
cyclin-A through the formation of the cyclin-A-CDK2 complex. This is followed by 
the G2 phase, in which the increase in cyclin-A also activates CDK1 to enter into 
M phase leading to nuclear breakdown as well as the degradation of cyclin-A. In the 
M phase, activation of cyclin-B proceeds to create cyclin-B-CDK1 complex which 
drive those cells through mitosis (242,255). 
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 TGF-β signalling and CDKs 
TGF-β potently inhibits cell proliferation by causing cell cycle arrest at the G1 phase 
(174,256). The potent growth-inhibitory effects are due to the ultimate 
downregulation of c-myc promoter expression and the upregulation of CDK 
inhibitors p15 and p21 (257,258). Smad3 acts as a key mediator in these 
anti-proliferative effects of TGF-β and provides a target for inhibitory 
phosphorylation by CDK2 and CDK4 (238). The CDKs can phosphorylate 9 of 14 
residues on Smad3 that can be phosphorylated (four residues are on the linker 
region; Thr179, Ser204, Ser208 and Ser213) (238). All four residues are 
phosphorylated by CDK2 and CDK4 in vitro while in vivo phosphorylation only 
occurs on Thr179 and Ser213 (238). The CDK phosphorylation of Smad3 to inhibit 
Smad3 anti-proliferative function describes a negative feedback control of CDK 
activities (259). Alarcon et al. (230) reported that CDK8 and CDK9 phosphorylate 
the Smad3 linker region at Thr179, Ser208 and Ser213. Thus, there is some evidence 
for the role of CDKs in TGF-β signalling but no information is available on their role 
in TGF-β-mediated effects on proteoglycan synthesis and structure, which is thus the 
focus of this thesis. 
 Mitogen-activated protein kinases (MAPK) 
TGF-β signalling involves the interaction with MAPK pathways (204,232,260). 
MAPK include most prominently ERK1/2, JNK and p38 (261). ERK had been 
implicated in cell growth responses (262) while the p38 and JNK are traditionally 
associated with stress related signalling involving inflammatory cytokines and 
apoptosis (263,264). Research on MAPK signalling pathways has received 
significant interest among studies of cellular functions related to CVD. In VSMC, 
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TGF-β is able to phosphorylate ERK, p38 and JNK, yet only ERK and p38 are 
involved directly with proteoglycan synthesis (232). Furthermore, TGF-β-mediated 
phosphorylation of the Smad2 linker region as well as proteoglycan synthesis was 
blocked by inhibitors of ERK and p38 (UO126 and SB202190, respectively) but not 
JNK (SP600125) thus indicating that the phosphorylation of Smad linker region and 
proteoglycan synthesis is specific to ERK and p38 (232). It is noteworthy that in 
hepatic stellate cells, JNK had previously been shown to be involved in the 
TGF-β-mediated phosphorylation of the Smad linker region to increase 
transcriptional activity of PAI-1 inducing cell migration and tissue repair (265). Thus 
phosphorylation through independent Smad signalling may be cell type dependent 
and that MAPKs exhibit distinct substrate specificity that leads to differential 
activation of each kinase and downstream substrate phosphorylation. 
MAPKs are a large family of protein serine/threonine kinases that play an 
essential role in signal transduction converting extracellular stimuli into a wide range 
of cellular responses by modulating gene transcription in the nucleus. In humans, 
there are at least 11 members of the MAPK superfamily that can be divided into six 
major subfamilies: i) ERK (ERK1 and ERK2); ii) JNK (JNK1, JNK2 and JNK3); iii) 
p38s (p38α, p38β, p38γ and p38δ); iv) ERK5; v) ERK3s (ERK3, p97 MAPK and 
ERK4); and vi) ERK7s (ERK7 and ERK8) (266). TGF-β signalling of MAPK is 
activated via upstream mediators including Ras. In epithelial cells, excess or 
constitutively active Ras contributes to anti-proliferative effects resulting in lost or 
suppressed TGF-β anti-mitogenic activity (228). Massague and colleagues (267) 
showed that EGF, an activator of Ras/MAPK prevented the anti-mitogenic action of 
TGF-β through MAPK mediated phosphorylation of the cluster of sites in the linker 
region of Smads (267). They also reported that Ras acting through ERK caused 
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phosphorylation of a cluster of sites in the linker region of Smad2 and Smad3. 
Subsequently, this prevented the translocation of the Smad complex to the nucleus 
and hence inhibited TGF-β signalling from mediating its anti-mitogenic effect (267).  
Results from our laboratory which studied the effects of TGF-β-mediated 
Smad2 linker region phosphorylation on proteoglycan synthesis in VSMC, showed 
that involvement of MAPK in this signalling pathway lead to enhanced proteoglycan 
synthesis (177). This TGF-β-mediated increase in proteoglycan synthesis involved 
only phosphorylation of ERK and p38 but not JNK. 
 Phosphoinositide 3-kinases (PI3K) 
Phosphatidylinositide 3-kinase (PI3K) are a conserved family of enzymes with dual 
protein and lipid kinase activity. Members of this family share a common catalytic 
function to phosphorylate the D3 hydroxyl group of membrane phosphatidylinositols 
(PtdIns) upon receptor tyrosine kinase and GPCR stimulation or Ras activation 
(268). PI3K isoenzymes are currently grouped into three classes (I, II and III). In 
vascular biology, class I PI3Ks are the most studied isoforms, while less is known 
about class II and class III. Class I PI3Ks are heterodimers composed of a catalytic 
(p110α, β, δ and γ) and a regulatory subunit (p85 or p101 family) (269). PI3K is 
known to be a part of the inflammatory events in all stages of atherosclerosis (270). 
Among the PI3K isoforms, PI3Kγ is expressed in endothelial cells (271), 
cardiomyocytes and SMC (272) with highest expression observed in haematopoietic 
cells. Inhibition of PI3Kγ that results in loss of PI3Kγ function in the hematopoietic 
lineage of murine models of atherosclerosis was shown to alleviate atherosclerotic 
plaque development (270). 
PI3Kγ can be activated by several chemokines (IL-8, MCP-1, macrophage 
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inflammatory proteins 1α), pro-inflammatory lipids (platelet-activating factor, 
oxidized LDLs, bacterial components), and vasoactive stimuli (angiotensin II), 
downstream of GPCR. Besides that, PI3K are also known to be activated by other 
relevant pro-atherogenic stimuli which ligate different receptor types, such as 
interferon gamma, TNF-α and TGF-β (269,273).  
The regulatory subunits of PI3K are in association with TGFβR2, and the 
association with the TGFβR1 requires stimulation by TGF-β (274). Activation of 
PI3K upregulates the formation of intracellular 3-phosphorylated inositol lipids, 
which are signal transducers responsible for the regulation of cell cycle progression, 
glucose metabolism, cell motility, epithelial to mesenchymal transition, and 
apoptosis (275). A most recent study on spinal cord injury found that expression of 
CS proteoglycan by reactive astrocytes involves TGF-β-mediated activation of the 
PI3K-Akt-mTOR signalling pathway. This leads to glial scarring and regenerative 
failure, and suggests that targeting this pathway may be an effective strategy to 
prevent CS proteoglycan expression in the injured central nervous system (276). In 
mouse mammary epithelial cells (NMuMG), studies using chemical inhibitors of the 
PI3K-Akt pathways that affected the Smad-dependent transcriptional response, 
suggest the involvement of PI3K and Akt in TGF-β signal transduction (277). Akt is 
a serine/threonine kinase that is involved in multiple cellular processes including cell 
cycle regulation, cell growth and cell survival in many cell types (278). In VSMC, 
TGF-β-mediated Smad3 stimulates cell proliferation through p38 and Akt suggesting 
new targets for chemical or molecular prevention of vascular restenosis through 
inhibiting this TGF-β pathway (279). With regards to biglycan synthesis in VSMC, 
TGF-β was shown to stimulate only the synthesis of biglycan core protein but not 
GAG chain elongation via Akt phosphorylation (280). 
 
 
58 
 
 Glycogen synthase kinase-3 (GSK-3) 
Glycogen synthase kinase-3 (GSK-3) is a ubiquitously expressed serine/threonine 
kinase identified in 1980 for its role in regulating glycogen synthase, the enzyme 
involved in glycogen synthesis. The GSK-3 family includes 2 isoforms, α and β, 
sharing a 98% amino acid homology within their kinase domains but differ 
substantially in their N- and C-terminal sequences (281). GSK-3β is a known 
regulator of cell proliferation (282). In muscle cells, GSK-3α activation is 
detrimental and abrogates cardiomyocyte proliferation (283). Moreover, the genes 
involved in the cell cycle and cell proliferation were significantly downregulated by 
GSK-3α activation. This is due to the activation of GSK-3α that suppresses the E2F 
transcription factor, likely through D-type cyclins in cardiac myocytes (284).  
GSK-3β plays a role in TGF-β1 signalling by regulating myocardial fibrotic 
remodeling in the infarcted heart. GSK-3β inhibits profibrotic TGF-β1/Smad3 
signalling via dual interaction with the Smad3 linker region and carboxy terminus. 
Inhibition of GSK-3β leads to decreased phosphorylation at the linker region 
(Ser204) while increased phosphorylation of Smad3 at the carboxy terminus 
(Ser423/425) favours increased transcriptional activity (285). Millet et al. (286) 
reported that TGF-β-mediated GSK-3 phosphorylation of the Smad linker region is 
unique to Ser204 with other serine residues of the linker region remaining unaffected 
(286). These results indicate that GSK-3 is required for TGF-β-mediated 
phosphorylation of Ser204 within the Smad3 linker region (287). The involvement 
of GSK-3 in TGF-β-mediated specific Smad2 linker region phosphorylation and 
GAG synthesizing enzymes has not yet been reported and will be studied in this 
project. 
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 Calmodulin dependent protein kinase (CaMK) 
Ca2+/ Calmodulin (CaM)-dependent protein kinase (CaMK) is a family of 
serine/threonine proteins that phosphorylates a large variety of proteins in response 
to Ca2+ or CaM signals. It is activated by the variety of signal transduction pathways 
that elevate intracellular free Ca2+. CaMK regulate a broad array of functions, 
including metabolism of carbohydrates, lipids, amino acids, neurotransmitter release, 
ion channels and gene expression (288). Members of this family include 
phosphorylase kinase, myosin–light chain kinase, and CaMK I, II, III and IV. These 
kinases are grouped according to whether they are dedicated kinases having a single 
substrate (phosphorylase kinase, CaMK III and myosin–light chain kinase) or 
whether they are multifunctional and have several substrates (CaMK I, II and IV). 
Among the many CaMK discovered, the multifunctional protein kinases CaMK I, II 
and IV play pivotal roles in cell biology (289).  
Changes in cytoplasmic Ca2+ and regulation of CaMK was shown to be able to 
regulate Smad activity (290). Changes in cytoplasmic Ca2+ can occur by activation 
of intracellular CaMK II that can occur through growth factors and other 
extracellular stimuli (290,291). In human embryonic kidney fibroblast cells, Smad2 
is a target substrate for TGF-β-mediated CaMK II phosphorylation at Ser110, Ser240 
and Ser260 (285). 
In CVD, hyperactivity of CaMK II leads to heart failure contributing to disease 
progression (292). For instance, activation of the multifunctional Ca2+ and CaMK II 
causes myocardial dysfunction and cell membrane electrical instability (293). 
CaMK II can be activated by elevated levels of cellular Ca2+ that enables 
rate-dependent increases in myocardial contraction (294) and fight or flight increases 
in heart rate (295). 
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 Rho-associated protein kinase (ROCK) 
Rho-associated protein kinase (ROCK) is a member of the extended family of 
intracellular serine/threonine kinases (296). In mammals, ROCK (ROCK1 and 
ROCK2) has a molecular weight of 158 kDa and is the main downstream effector of 
Rho (296). There is evidence of the potential involvement of Rho/ROCK pathway in 
regulating Smad activity via linker region phosphorylation (297,298). Chen et al. 
(299) were the first to demonstrate Smad activity regulation by Rho/ROCK during 
differentiation of VSMC induced by TGF-β. In the process of the epithelial to 
mesenchymal transition and cytoskeletal rearrangements, TGF-β stimulation plays a 
major role in the activation of the Rho/ROCK pathway (300,301). Kamaraju et al. 
(298) demonstrated that p38 and Rho/ROCK pathways greatly influence the 
anti-proliferative effects of TGF-β. 
1.9 Project Overview 
Proteoglycans play a crucial role in atherogenesis via entrapment of LDL as 
articulated in the response to retention hypothesis (42,79). TGF-β, a growth factor 
associated with the development of human atherosclerotic lesions (190) can 
stimulate increases in GAG chain length on biglycan leading to stronger binding 
affinity to LDL (158). GAG synthesizing enzymes are responsible for elongation of 
GAG chain on biglycan in which elevated expression of GAG enzymes in animal 
models contributed to atherosclerotic development (145). Little is known regarding 
the regulation of GAG synthesizing enzymes with development of atherosclerosis. 
Elucidation of the signalling pathways involving TGF-β and GAG synthesizing 
enzyme in VSMC may contribute to the identification of a therapeutic target for the 
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prevention of atherosclerosis caused by increased LDL binding to modified GAG 
chains on biglycan. 
1.10 Aims of the study 
1. To identify the specific GAG synthesizing enzyme expression that can be 
stimulated by TGF-β in VSMC.  
 
2. To investigate the involvement of serine/threonine kinases in the 
TGF-β-mediated regulation of individual GAG synthesizing enzyme(s) that had been 
identified in the first aim. 
 
3. To extend previous studies examining the effects of TGF-β and involvement 
of Smad2 linker region phosphorylation in biglycan synthesis. In particular, to assess 
the individual residues on the Smad2 linker region that participate in the signalling 
pathway mediated by serine/threonine kinases identified in the second aim. 
 
4. To systematically determine the presence of CDK isoforms in VSMC and 
study the involvement of these isoforms in the regulation of GAG synthesizing 
enzymes identified in the first aim. 
 
5. To study the association of CDK isoforms with biglycan synthesis as well 
as the signalling pathways involving TGF-β-mediated Smad2 linker region 
phosphorylation.
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2.1 Materials 
Human recombinant TGF-β (#8915) was purchased from Cell Signaling 
Technology (MA, USA). Fetal bovine serum (FBS) was purchased from In Vitro 
Technologies Pty. Ltd. (VIC, Australia). Dulbecco’s Modified Eagle Medium 
(DMEM) (0 mM and 25 mM glucose), Trypsin-versene and antibiotics (1x104 U/ml 
penicillin, 1×104 μg/ml streptomycin) were from Gibco BRL (NE, USA). 75 cm2 
canted neck tissue culture flask with vent cap was from Corning (NY, USA). 
Dulbecco’s phosphate-buffered saline (PBS) (10×), sodium dodecyl sulfate (SDS), 
β-mercaptoethanol and dimethyl sulfoxide (DMSO) were purchased from 
Sigma-Aldrich (MO, USA). The RNeasy® Mini Kit, the QuantiTect® Reverse 
Transcription Kit, the QuantiFast™ SYBR® Green PCR kit and the Rotor-Gene® 
Q Series software were from Qiagen (VIC, Australia). Amersham ECL Prime 
chemiluminescent detection reagent was from GE Healthcare (NSW, Australia). 
Bovine Serum Albumin (BSA) was from Bovogen Biologicals Pty. Ltd. (VIC, 
Australia). Bicinchoninic acid (BCA) protein assay kit was from Thermo Scientific 
(IL, USA). Chemiluminescent molecular weight marker (MagicMark XP) and 
chromogenic molecular weight marker (BenchMark) were from Invitrogen (AK, 
New Zealand). Protease inhibitor was from Sigma (NSW, Australia). TEMED, Tris 
base and glycine were from Amresco (OH, USA). Tween-20, 30% acrylamide/bis-
acrylamide solution, ammonium persulfate, polyvinylidene fluoride (PVDF) 
membranes and Image Lab V5.0 imaging software were from BioRad Laboratories 
(CA, USA). Carrier-free [35S]-SO4 was from MP Biomedicals (CA, USA). 
Cetylpyridinium chloride (CPC) was from Uni-lab Chemicals and Pharmaceuticals 
(MUM, India).  
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2.2 Methods 
 Tissue Culture 
 Acquisition of vascular smooth muscle cells (VSMC) 
Human VSMC were prepared from discarded segments of the saphenous veins from 
patient donors undergoing cardiological procedures at The Alfred Hospital 
(Melbourne, Australia). VSMC from surgically relocated saphenous veins are known 
to undergo atherosclerotic changes (302-305). Thus, studies utilising VSCMs from 
saphenous veins were conducted to investigate atherosclerosis-related biology 
(232,280). Ethics approval was obtained from The Alfred Hospital Ethics Committee 
(Melbourne, Australia). Primary cultures of these cells were established using the 
explant technique (306). VSMC were passaged in 25 cm2 flasks containing 10% FBS 
DMEM (5 mM DMEM containing 10% (v/v) FBS and antibiotics (1×104 U/ml 
penicillin, 1×104 μg/ml streptomycin), and frozen in liquid nitrogen for long term 
storage (Section 2.2.1.2). Experiments were conducted using cells from passage 
8-19. Aseptic techniques were used throughout the whole process of tissue culture 
and experiments.  
 Freezing cells 
To each freezing vial (1.5 ml), 1 ml of cell suspension (5×106 to 2×107 cells/ml) was 
added. The freezing medium containing 1 ml of DMSO to 9 ml of 10% FBS DMEM 
was prepared and stored on ice. Cells in 75 cm2 flasks were trypsinized (2 ml of 
trypsin were added to cells for 2 min at 37oC until the cells detached from the flask), 
collected and centrifuged at 100×g for 3 min. The total number of cells was counted 
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and resuspended in the freezing medium at 5×106 to 2×107 cells/ml. The cells were 
then quickly resuspended in the freezing medium with 1 ml of total freeze 
suspension per cryogenic vial. Each vial lid was screwed tightly and placed in 
holders to store into −20°C overnight. Vials were then transferred to a −80°C freezer 
and stored for 24 h prior to being placed in liquid nitrogen for long-term storage. 
 Thawing cells  
Centrifuge tubes containing 6 ml pre-warmed 10% FBS DMEM (5 mM DMEM 
containing 10% (v/v) FBS and antibiotics (1×104 U/ml penicillin, 1×104 μg/ml 
streptomycin) were prepared. Cryogenic vials of frozen VSMC were removed from 
liquid nitrogen and immediately placed in a 37oC incubator in a controlled 5% CO2 
atmosphere. The cells were allowed to partially thaw until only a small pellet 
remained. This pellet was taken out and resuspended to completely thaw in the 
pre-warmed media prepared earlier. The cell suspension was then centrifuged at 
100×g for 3 min. The supernatant was removed and cells resuspended in fresh 10% 
FBS DMEM. Cell suspension was then transferred into 75 cm2 tissue culture flask. 
The cells were given a fresh media change 24 h later. 
 Subculturing VSMC 
Spent media was discarded, followed by addition of trypsin (2 ml) to cells for 2 min 
and the tissue culture flask was placed in the 37oC incubator until the cells were 
detached from the flask. The detached cells were then aspirated and transferred into 
30 ml of 10% FBS DMEM in a sterile 50 ml centrifugation tube, to dilute the 
trypsin. The remaining adherent cells were detached by gently flushing 10% FBS 
DMEM onto the cells and then collected with sterile pipettes. The collected cells 
were then centrifuged at 600×g for 3 min before being resuspended in fresh 10% 
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FBS DMEM. A volume of cell suspension (containing 2×106 cells/ml) was 
transferred to a new tissue culture flask (75 cm2) and additional media was added to 
a total of 12 ml volume. Flasks were returned to the incubator at 37oC and 
resuspended with fresh 10% FBS DMEM the next day. 
  Cell counting 
The ZTM series coulter counter (Beckman Coulter) was set-up and primed with 
Dulbecco’s PBS. Coulter vials with 19 ml Dulbecco’s PBS (containing calcium and 
magnesium supplements) were prepared. Cells in 75 cm2 tissue culture flasks were 
trypsinized and incubated at 37C until the cells detached. The flasks were observed 
under microscope to monitor detachment of the cells. Cells were resuspended in 20 
ml of 10% FBS DMEM. The cell suspension was resuspended by inverting the 50 ml 
centrifuge tube and then 1 ml of cell suspension was transferred into the prepared 
coulter vials. The coulter counter was set to count cells between the size of 8 and 
24 µm (diameter). Table 2.1 shows the number of cells used to seed different sized 
tissue culture vessels used in the experiments detailed in this thesis. 
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Table 2.1: Number of cells added to well/dish 
Plate/dish 
type 
Cells per 
well/dish 
(cells/ml) 
Tissue culture 
media (ml) 
24-well 4×104 1 
6-well 8×104 3 
60 mm dish 5×105 5 
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 Quantitative Real-time Polymerase Chain Reaction 
(Q-RT-PCR) analysis  
 Extraction of total RNA  
Extraction of total RNA is based on the manufacturer’s protocol (RNeasy Mini Kit 
from Qiagen). Spent culture medium from cells grown in 6-well plates was aspirated 
and discarded. Lysis buffer (350 µl RLT buffer with 0.01% β-mercaptoethanol 
per-well) was added directly into each well. Cells were scraped using a sterile cell 
scraper (Corning) and the lysates were placed into a microcentrifuge tube. The cell 
lysates were then homogenized by passing through (seven times) a 20-gauge needle 
fitted to an RNAse-free syringe. All procedures were performed on ice.  
Ethanol (70% v/v) (350 µl) was then added to the homogenized lysate and 
mixed well by pipetting. An aliquot (≤700 µl) sample was then transferred to an 
RNeasy spin column placed in a 2 ml collection tube. The spin column and 
collection tube were then centrifuged (15 sec at 8000×g) to discard the flow-through 
(eluate). The collection tube was reused and washed with 700 µl RW1 buffer 
(contains guanidine salt and ethanol) by centrifugation for 15 sec at 8000×g to 
discard the flow-through. Next, 500 µl RPE buffer was added to the column to 
remove traces of salt from RW1 buffer. The column was centrifuged for 15 sec at 
8000×g and the flow through was discarded. This step was repeated with longer 
centrifugation (2 min at 8000×g). The RNeasy spin column was removed and placed 
into a new collection tube, then centrifuged at 8000×g without any buffer for 1 min 
to remove unwanted RPE buffer.  
The RNeasy spin column was then transferred to a 1.5 ml microcentrifuge 
collection tube. RNase-free water (35 µl) was added directly to the spin column filter 
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membrane and centrifuged for 1 min at 8000×g. Eluted RNA was collected in the 
1.5 ml collection tube kept on ice. The concentration of RNA in the eluate was 
measured as described in Section 2.2.2.2. The extracted RNA was stored at −80°C 
until required for experiments. 
 Analysis of extracted RNA  
RNA quantitation and purity analysis was performed using the THERMO 
Nanodrop 2000. A blank measurement was performed by dispensing 2 μl of 
RNAse-free water onto the lower optical surface. The RNA concentrations and 
purity ratios produced by the software were recorded for calculation of RNA 
template required for cDNA synthesis. Assessment of sample purity was based on 
the ratio of absorbance at 260 nm and 280 nm. Extracted RNA samples used for 
further assessment were all within a 260/280 nm ratio of ~2.0 RNA which is pure.  
 Synthesis of cDNA  
Synthesis of cDNA was done using QIAGEN® QuantiTect® Reverse Transcription 
kit as per the manufacturer’s instructions. Calculations were done to determine the 
correct amount of RNA template needed to synthesize 1×103 ng/μl of cDNA for each 
sample. Genomic DNA elimination treatment was performed on the RNA sample by 
incubating the template RNA for 2 min at 42°C with reaction components including 
2 µl genomic DNA wipeout buffer (7×) and RNase-free water (adding up to a total 
reaction volume of 14 µl) (Table 2.2).  
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Table 2.2: Components for cDNA synthesis 
Components Volume/reaction Final concentration 
Genomic DNA Wipeout 
Buffer (7×) 
2 µl 1× 
Template RNA 1–4 µl 1×103 ng/μl 
RNase-free water 8–11 µl  
Total volume 14 µl - 
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DNAse-treated samples were then immediately kept on ice while reverse 
transcription master mix was prepared which contained 1 µl QuantiTect® Reverse 
Transcriptase, 4 µl Quantiscript Reverse Transcriptase buffer and 1 µl Reverse 
Transcriptase primer mix. DNase-treated template RNA was added to the reverse 
transcription master mix and incubated for 15 min at 42°C. After completed cDNA 
synthesis, the samples were then incubated for 3 min at 42°C to inactivate the 
reverse transcription process by QuantiTect® Reverse Transcriptase. The cDNA 
samples were stored at –20°C until required for experiments.  
 
 Amplification of cDNA samples 
A reaction mixture containing QuantiFast™ SYBR Green PCR Master Mix and 
RNase-free water was prepared as described in Table 2.3. The respective template 
cDNA (≤100 ng/reaction) was added to tubes containing the reaction mix. The 
reaction was mixed thoroughly and appropriate volume was dispensed into PCR 
reaction tubes. Primers were added to make up a total volume of 20 µl reaction 
mixture. The PCR reaction tubes were loaded into the Qiagen Rotor Gene Q thermal 
cycler. The-Rotor Gene Q Series Software 2.1.0 was then launched and the thermal 
cycler program was set up with the parameters described in Table 2.4. 
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Table 2.3: Components for the Q-RT-PCR reaction mixture 
Components Volume/reaction Final concentration 
Quantifast™ SYBR Green 
PCR Master Mix 
10 µl 1× 
Primer A 0.5–1 µl 1 µM 
Primer B 0.5–1 µl 1 µM 
Template cDNA 1–2 µl ≤100 ng/reaction 
RNase-free water 7–8 µl  
Total volume 20 µl - 
 
Table 2.4: Protocol set up for the Q-RT-PCR reaction 
Steps Temperature Time 
PCR initial activation step 95ºC 5 min 
Two Step Cycling 
Denaturation 95ºC 7 sec 
Combined 
annealing/extension                
(40 cycles) 
60ºC 15 sec                   
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 Quantitation using comparative Cycle-threshold (Ct) method 
Results from the Ct values for all samples were recorded in a spreadsheet. The 
comparative Ct method was used for quantitation of the amount of fold change in the 
level of mRNA expression (307). The Ct values of the samples of interest were 
compared with a non-treated control. The Ct values of both the control and the 
samples of interest were normalized to the 18S ribosomal gene, as an endogenous 
housekeeping gene. The formula below was used to obtain the [Δ] Ct, sample: 
 
[Δ][Δ]Ct = [Δ]Ct, sample − [Δ]Ct, reference 
 
The [Δ]Ct, sample was indicated as the Ct value for any sample normalized 
to the 18S housekeeping gene while [Δ]Ct, reference was the Ct value for the 
non-treated control also normalized to the 18S housekeeping gene. 
 Western blot analysis 
 Harvesting cells 
Tissue culture media was aspirated and the plates were washed with PBS for 1 min 
after which PBS was aspirated and lysis buffer (55 l) (Table 2.5) was added to each 
60 mm culture dish. The cells were scraped and placed into microcentrifuge tubes. 
Samples were passed through (seven times) a fine gauge needle (20G) and 
centrifuged at 9000×g for 10 min at 4°C. The supernatant was then measured for 
protein content as described in Section 2.2.3.2. The extracted protein samples were 
stored at −20°C for long-term storage. 
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Table 2.5: Components of the cell lysis buffer 
Components Final Concentration 
RIPA buffer  
  Sodium chloride 150 mM  
  Sodium deoxycholate 0.5% (w/v) 
  Sodium dodecyl sulfate 0.1% (w/v) 
  Tris-HCl, pH 8.0 50 mM  
  Nonidet P-40 (NP-40) 1.0% (v/v) 
  
10× Protease inhibitor 1 M (5 mM benzamidine in 
0.1 M 6-aminocaproic acid) 
100× Orthovanadate 1 mM 
Sodium flouride 1 mM 
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 Protein assay using the Bicinchoninic Acid (BCA) method 
The protein concentration of each sample was determined using the BCA method 
with BSA as the standard. For each unknown sample, 2.5 l protein lysate was added 
to 22.5 l H2O and 225 l BCA protein assay reagent (Pierce) into each well. For the 
known standards, 25 l of BSA and 225 l BCA protein assay reagent were added 
into each well. The plate was then incubated at 37°C for 30 min. Absorbance was 
read at 562 nm using the CLARIOstar® (BMG LABTECH) microplate reader. A 
standard curve was plotted using Microsoft Excel hence enabling the calculation for 
the volume of samples required to obtain the required protein concentration from 
30 to 40 g for Western blot experiments. 
 Protein separation by SDS-PAGE 
Separating gels were prepared based on the required gel concentration for each 
individual experiment (Table 2.6). During preparation, Ammonium Persulfate (APS) 
(10%) and TEMED were added immediately prior to pouring the gel mixture into the 
casting plates. Isopropanol was added on top to level the gel surface. After 40 min, 
the separating gel was set. Isopropanol was discarded and the gel rinsed carefully 
with water. Stacking gels were then prepared (Table 2.7) and poured on top of the 
cast separating gel. The comb (for 10 wells) was then placed and the gel was left to 
set. Meanwhile, the samples were prepared in microfuge tubes. Samples (30–40 g) 
were mixed with 10 µl loading buffer and heated at 95°C (5 min) to denature 
proteins. Gel plates were assembled onto inner cooling core with running buffer 
filled up halfway between shorter and longer plates.  
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Table 2.6: Components of the separating gel 
Components 7.5% gel 10% gel 12% gel 
ddH2O 4.85 ml 4.05 ml 3.35 ml 
1.5 M Tris-HCl pH 8.8 2.5 ml 2.5 ml 2.5 ml 
10% (w/v) SDS  100 l 100 l 100 l 
30% (w/v) Acrylamide/Bis  2.5 ml 3.3 ml 4.0 ml 
10% (w/v) APS  50 l 50 l 50 l 
TEMED 5 l 5 l 5 l 
 
Table 2.7: Components of the stacking gel 
Components 4% gel (4 gels) ½ mixture (2 gels) 
ddH2O 6.1 ml 3.05 ml 
0.5 M Tris-HCl pH 6.8 2.5 ml 1.25 ml 
10% (w/v) SDS  100 l 50 l 
30% (w/v) Acrylamide/Bis 1.3 ml 650 l 
10% (w/v) APS 50 l 50 l 
TEMED 10 l 10 l 
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Samples in loading buffer were then loaded into each dedicated lane beginning with 
the MagicMark XP Protein Standard (Thermo Fisher) 20–220 kDa molecular weight 
marker in the first lane. The supplied voltage was set at 80 V for the sample to run 
through the stacking gel. Once it had passed through, the supplied voltage was 
increased up to 120 V for the sample to run through the separating gel for 1.5 h, at 
room temperature (RT). 
 Wet transfer to PVDF membranes 
Cold (4°C) transfer buffer (25 mM Tris, 190 mM glycine, 20% methanol, 10% SDS) 
was prepared prior to use. A sheet of PVDF membrane was cut to a dimension of 
10×6 cm and pre-wetted by soaking into 100% ethanol for 1 min. The PVDF 
membrane was then rinsed with water and soaked in transfer buffer together with 
filter papers (10×7 cm) and pads for at least 10 min. The gel was then taken out of 
the cast plates. The cassette holder was then assembled following the order from top 
to bottom: clear plastic, pad, filter paper, membrane, gel, filter paper, pad, black 
plastic, respectively. The transfer was set at 100 V for 1 h at 4°C.  
 Semi dry transfer to PVDF membrane  
PVDF membranes were pre-wetted following immersion in 100% ethanol until they 
were translucent, then they were transferred into transfer buffer (Bio Rad) for 3 min. 
Transfer stacks were then equilibrated with transfer buffer for 3 min. A wetted stack 
was then placed on the bottom of the transfer cassette serving as the bottom ion 
reservoir stack. The wetted membrane was then placed on top of the bottom stack in 
the cassette. Then the gel was placed on top of the membrane. Bubbles were 
removed using a blot roller and then the second wetted transfer stack was placed on 
top of the gel. This served as the top ion reservoir stack. The assembled sandwich 
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was rolled on with blot roller to expel trapped air bubbles. The cassette lid was then 
closed and locked. The whole cassette was then inserted into the Trans Turbo Blot 
Transfer System Instrument (Bio Rad) to begin the transfer. The protocol was set at 
"Turbo" for transfer of mixed molecular weight proteins and set at 1 mini gel per 
cassette.  
 Probing with antibodes 
After transfer, the PVDF membrane was immersed in 5% (w/v) BSA in 
Tris-Buffered Saline and Tween-20 (TBST) (50 mM Tris, 150 mM NaCl, 0.05% 
Tween-20) for 1 h with shaking, to ensure the remaining binding surface is blocked 
and prevent non-specific binding of the antibodies used. The membrane was then 
washed (three times) on rocking platform in TBST for 7 min at RT then incubated in 
10 ml diluted (1:1000) primary antibody (in 5% BSA) (specific antibodies are 
detailed in Results section for each experimental chapter) overnight at 4°C on 
rocking platform. The 5% BSA was prepared in 1×TBST. The next day, the 
membranes were washed (three times) in 1×TBST (7 min) to remove the primary 
antibody after which they were incubated with the secondary antibody (1:4000, in 
5% BSA) for 1 h with shaking at RT. The membrane was then washed (three times) 
with TBST for 7 min per wash.  
 Detection of protein chemiluminescence using ECL detection kit and 
BioRad Chemidoc Imager 
An equal volume of each detection solution (Amersham) containing luminol and 
peroxidase was mixed (2 ml per membrane). The solution was spread evenly onto 
the membrane for 30 sec with agitation. Excess solution was removed using blotting 
paper prior to placing the membrane into the BioRad Chemidoc Imager. The 
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membrane was exposed in the dark to analyze the molecular weight bands. Using the 
Image Lab 5.2.1 software, chemiluminescent exposures were captured on the "Blot 
Application" protocol for: "Chemi High Resolution". Image Exposure was set 
manually using the signal accumulation setup: first image captured at 2 sec, last 
image at 40 sec for 20 images. This captures one image in 2 sec. Settings for 
saturation of pixels was set to prevent overexposure of these bands on the 
membranes. 
 Image densitometry 
Raw 16-bit TIF (tagged image files) images of membranes were opened in Image 
Lab 5.2.1 software. The image was rotated to align immunoblot bands horizontally 
in the window. The rectangle tool was then used to select the band of interest. The 
width and height of the lane’s rectangle box was drawn accurately to cover the band 
of interest without causing overlap with bands from adjacent lanes. The same 
rectangle box was then copied and used to measure the background in the respective 
lane. The amount of background for each band was subtracted from the band of 
interest. Measurement of the gel loading control (glyceraldehyde-3-phosphate 
dehydrogenase, GAPDH or α tubulin) for each experiment was also determined 
using the same protocol described above. The same membranes were reprobed using 
antibodies towards either GAPDH or α tubulin. The final intensity of the band of 
interest was obtained after normalizing it to its respective gel loading control.  
 Stripping and reprobing PVDF membrane 
Membranes that were used to reprobe with additional antibodies were stripped using 
stripping buffer (2% SDS, 1 M Tris [pH 6.7], 0.1% β-mercaptoethanol). Membranes 
were covered with stripping buffer (10 ml) and incubated at RT for 15 min with 
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gentle agitation. The stripping buffer was discarded and the membrane washed with 
TBST for 5 min (three times). This step was repeated once and checked with ECL to 
ensure antibodies were completely stripped then blocked with BSA prior to 
incubation with a new primary antibody (Section 2.2.3.6). 
 Methods to study secreted proteoglycans  
 Harvesting proteoglycans in cell media 
Cells in 24-well plates were serum deprived (cultured in 0.1% FBS DMEM) for 
48 h until quiescent. Quiescent cells were changed to fresh medium (0.1% FBS 
DMEM) containing [35S]-SO4 (50 µCi/ml) in the presence or absence of TGF-β 
(2 ng/ml) and inhibitors (as detailed in Results section for each experimental 
chapter) for 24 h. As this current study is focused on CS proteoglycans especially 
biglycan which is predominantly secreted from cells (308), analysis of the 
incorporation of radioactive [35S]-SO4 into secreted proteoglycans found in the 
media was performed (309). Secreted proteoglycans were harvested from the media 
with protease inhibitors (5 mM benzamidine in 0.1 M 6-aminocaproic acid). A 
volume of the 10× protease inhibitors solution was prepared in a fresh microfuge 
tube according to sample size in each well, so that the final concentration of 
inhibitors was 1×. All the samples and media (500 l) were then transferred from 
each well into the microfuge tube containing protease inhibitors. Each well was 
carefully rinsed with 200 l Dulbecco’s PBS at RT. The wash was then transferred 
to its corresponding microfuge tube. The solution in the tube was carefully mixed 
and then 50 l was taken for quantification of radiolabel incorporation into 
proteoglycan using the cetylpyridinium chloride (CPC) assay described in Section 
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2.2.4.2. The remaining samples were frozen (−20C) until required for 
Diethylethanolamine (DEAE) separation for proteoglycan size determination. 
 Quantification of radiolabel incorporation into proteoglycans 
Incorporation of the radiolabel into proteoglycans was measured by the CPC 
precipitation assay (310). Aliquots of the media and cell layer samples (50 l) were 
spotted in duplicate on 30×15 mm rectangles of Whatman® chromatography paper. 
Spots were carefully applied from the outside to the centre of each square to prevent 
loss of spotted samples. The paper was then left overnight to dry at RT. The papers 
were washed five times (every 30 min) in CPC solution containing 1% (w/v) CPC 
and 50 mM NaCl.  
The papers were then placed in the fume-hood overnight to dry. Once dried, 
the squares were cut into halves and each square was placed in a 20 ml scintillation 
vial to which 8 ml scintillation cocktail was added. The [35S]-SO4 was then counted 
on a Perkin Elmer Liquid Scintillation Analyzer Trib-Carb 2810 TR which was 
operated through the QuantaSmart TM software. The counts were total sulfate 
incorporation into VSMC secreted proteoglycans. 
 Isolation of proteoglycans 
Secreted proteoglycans labeled with [35S]-SO4 were prepared for sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) by isolation through 
50% (v/v) DEAE-Sephacel anionic exchange mini columns. These columns were 
equilibrated with DEAE Sepharose (500 l) and low-salt buffer (8 M urea, 0.25 M 
NaCl, 2 mM disodium EDTA, 0.5% Triton X-100) for 5 min. Samples (10 l) were 
transferred onto the pre-equilibrated columns, and then washed (three times) with 
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5 ml low-salt buffer. The proteoglycans were eluted with high-salt buffer (8 M urea, 
3 M NaCl, 2 mM Na2 EDTA, 0.5% Triton X-100). An aliquot (10 l) was then 
transferred into a small scintillation vial containing scintillation cocktail (4 ml) for 
[35S]-SO4 counting using the Perkin Elmer Liquid Scintillation Analyzer Trib-Carb 
2810 TR.  
 Concentration of isolated proteoglycans 
The counts acquired from DEAE isolation were converted to cpm/l to calculate the 
volume of sample required to separate proteoglycans by SDS-PAGE. The final 
volume of sample plus MiliQ water was set to 200 l. Equal counts of each sample 
(2.5×104 cpm) were aliquoted and the ‘cold carrier’ (chondroitin sulfate, 10 mg/mL) 
was added to a microfuge to minimise loss of sample. Samples were concentrated 
by overnight precipitation with ethanol (95% ethanol, 1.3% potassium acetate) at 
amount 3.5 times of the total volume of the sample. As the calculations were 
worked to give a final volume of 200 l, this meant that, for 200 l sample, 700 l 
of the mixture was added. The microfuge tubes were then vortexed very briefly to 
mix the contents before being placed at −20C for 60 min to precipitate the 
proteoglycans. The tubes were microcentrifuged at 4C for 10 min at 9000×g. The 
supernatant was then carefully discarded, and then 200 l of MilliQ water was 
added to the pellet. To the pellet, 700 l of wash solution (1.3% potassium acetate 
in 95% ethanol) was added to wash the proteoglycans. This method was repeated 
twice leaving as little remaining alcohol as possible. Then the tubes were left in the 
fume hood for the precipitates to dry. The pellets were then resuspended in 20 l 
buffer (8 M urea, 2 mM disodium EDTA, pH 7.5) by vortexing the microfuge tubes.  
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 SDS-PAGE of proteoglycans 
The resuspended proteoglycan mixture in Section 2.2.4.4 was then ready for 
SDS-PAGE separation based on the Laemmli system (311). Gels were prepared to 
give a 4–13% gradient separating gel (Table 2.8). This was achieved by preparing 
the solutions for a 4% gel and a 13% gel in two separate tubes. A mixing chamber 
was used to allow the formation of a gradient gel. A 3% stacking gel (Table 2.9) 
with loading wells was prepared. The running buffer was made as in (Table 2.10) 
and poured into the gel running tank chamber. Sample buffer (20 l) was added and 
mixed to: samples (in 20 l 8 M urea, 2 mM disodium EDTA, pH 7.5), 
[14C]-protein molecular weight markers (20 l), and blank (distilled water). Samples 
and marker were loaded onto the gel and radiolabeled proteoglycans were separated 
at 60 V overnight. Gels were fixed (5% methanol, 7% acetic acid) then soaked in 
drying solution (20 g/l PEG, 12.5% methanol), air dried at room temperature and 
then exposed to imaging plate (Fuji Photo Film Co, Japan) for 4-10 days. Processed 
and dried gels were scanned on a Cyclone Plus Phospho Imager (Perkin Elmer, 
USA) using the OptiQuant software. Images were saved in TIF format for further 
processing and labelling. 
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Table 2.8: Composition of gradient separating gels for SDS-PAGE 
Components 4% gel 13% gel 
ddH2O 10.24 ml 5.12 ml 
1.5 M Tris-HCl, pH8.8 4.25 ml 4.25 ml 
10%(w/v) SDS 170 l 170 l 
Acrylamide/Bis 
(30% stock) 
 
2.27 ml 7.37 ml 
10% APS 85 l 85 l 
TEMED 8.5 l 8.5 l 
Total volume 17 ml 17 ml 
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Table 2.9: Composition of stacking gel for SDS-PAGE 
Components 3% gel 
ddH2O 5.11 ml 
0.5 M Tris-HCl, pH6.8 2.0 ml 
10%(w/v) SDS 80 l 
Acrylamide/Bis 
(30% stock) 
 
800 l 
10% APS 40 l 
TEMED 8 l 
Total volume 8 ml 
 
 
Table 2.10: 5× SDS-PAGE Running buffer 
Components 3 litres 5 litres 
Tris base 45 g 75.7 g 
Glycine 216 g 360.3 g 
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 Statistics analysis 
Data are presented as mean ± Standard Error of the Mean (S.E.M.). Data were 
analyzed for statistical significance using a one-way analysis of variance 
(ANOVA), followed by least significant difference post-hoc analysis for multiple 
comparisons. Results were considered statistically significant at p<0.05 or 
p<0.01, as indicated. Microsoft Excel was used as the tool to perform statistical 
analysis. 
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Chapter 3: TFG-β mediates specific 
chondroitin sulfate 
glycosaminoglycan synthesizing 
enzyme expression in vascular 
smooth muscle 
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3.1 Introduction  
The synthesis of CS GAG chains on proteoglycans involves the concerted action of a 
wide range of GAG synthesizing enzymes (127) (Table 1.1). After the synthesized 
biglycan core protein exits the endoplasmic reticulum, post-translational 
modification of biglycan occurs inside the cis/trans Golgi (102) (Fig. 1.7). CS GAG 
chain synthesis commences with the synthesis of the linkage region 
(xylose-galactose-galactose-gluronic acid) by the action of XT-1 (131), GalT-1 
(133), GalT-2 (134) and GlcAT-1 (135), respectively. This linkage region connects 
the CS GAG chain to the biglycan core protein, composed of alternating 
disaccharide units GlcA and GalNAc (102). Chondroitin polymerization on the 
growing CS GAG chain occurs via the action of six glycosyltransferases: chondroitin 
synthase ChSy-1, ChSy-2, ChSy-3, ChPF, ChGn-1 and ChGn-2 (121,136,137). CS 
GAG chain modifications may include hyperelongation of the repeating disaccharide 
units and sulfation of hydroxy groups at positions 4 and 6 of the GalNAc residues 
and position 2 of the GlcA residue by sulfotransferases C4ST-1 and C4ST-2, thereby 
creating structural diversity of the chain (132). TGF-β-mediated structural 
modifications of the GAG chain either by elongation or sulfation pattern enhances 
the negative charge of the chain contributing to a higher affinity towards LDL 
binding (158,167). TGF-β is a pleiotropic growth factor associated with the 
development of early stages in atherosclerosis (190). Very little is known about the 
effects of TGF-β on GAG synthesizing enzyme expression in vascular smooth 
muscle.  
Biglycan, a proteoglycan secreted by VSMC in the artery wall in vivo, is 
present in early atherosclerotic lesions (50) and the GAG chain on biglycan is 
elongated by TGF-β stimulation in human VSMC in vitro (232). TGF-β-mediated 
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GAG chain hyperelongation on biglycan is dependent upon both transcription and 
translation (163). The involvement of the transcription factor Smad2 and its binding 
partners had been described in human VSMC, but the downstream gene targets, 
presumably the specific GAG synthesizing enzymes are not defined (163). In this 
chapter, the specific GAG synthesizing enzymes that are stimulated by TGF-β in 
human VSMC were investigated.  
3.2 Materials and Methods  
 Materials 
Q-RT-PCR primers (forward and reverse) for GAG synthesizing enzyme genes 
(Table 3.1) ChSy-1, C4ST-1 and C4ST-2 were purchased from GeneWorks Pty Ltd 
(SA, Australia). The primers (forward and reverse) for XT-1, ChPF, GalNacT-2 
and 18S ribosomal gene were from Qiagen (VIC, Australia). Anti-rabbit 
immunoglobulin-G (IgG) horseradish peroxidase (HRP), anti-mouse IgG HRP and 
GAPDH rabbit monoclonal IgG antibody was from Cell Signaling Technology 
(MA, USA). C4ST-1 mouse IgG monoclonal antibody was from Abcam (CBG, 
UK). ChSy-1 rabbit IgG polyclonal antibody was from Thermo Scientific (IL, 
USA).  
 Methods 
Tissue culture methods are given in detail in Chapter 2 (Section 2.2.1). Analysis of 
mRNA expression was performed using Q-RT-PCR analysis as described in 
Chapter 2 (Section 2.2.2). Protein expression was analyzed using Western blot 
technique as described in Chapter 2 (Section 2.2.3). Statistical analysis was 
conducted as described in Chapter 2 (Section 2.2.5).  
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Table 3.1: GAG synthesizing enzyme target gene and primer sequence 
Target gene Q-RT-PCR primer sequence (5'- 3') References 
XT-1 
Forward 
Reverse 
 
GTGGATCCCGTCAATGTCATC 
GTGTGTGAATTCGGCAGTGG 
 
(312) 
ChSy-1 
Forward 
Reverse 
 
CCCGCCCCAGAAGAAGTC 
TCTCATAAACCATTCATACTTGTCCAA 
 
(313) 
ChPF 
Forward 
Reverse 
 
AGATCCAGGAGTTACAGTGGGAGAT 
CCGGGCGGGATGGT 
 
(121) 
ChGn-2 
Forward 
Reverse 
 
GGGCTAATGGCATAGGCTATCA 
CTTTGTCAATTTGGGAATGAAGAA 
 
(314) 
C4ST-1 
Forward 
Reverse 
 
GGCCCTGCGCAAAG  
GGGTGTGTGGGTCGATGAG 
 
(315) 
C4ST-2 
Forward 
Reverse 
 
AACGAGGAGTTCTACCGCAAGT 
GCTTGTGTGGTTGGCGTACA 
 
(315) 
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3.3 Results  
 TGF-β stimulates mRNA expression of glycosyltransferase 
XT-1 involved in synthesis of the proteoglycan linkage region 
Initially we determined the response of VSMC to TGF-β treatment to stimulate the 
synthesis of glycosyltransferase XT-1 mRNA expression. In early atherosclerosis 
TGF-β causes elongation of CS GAG chains that in turn increases LDL binding to 
proteoglycans (158,190). However, it is not known if TGF-β regulates XT-1, the 
enzyme that attaches the first xylose residue of the linkage region to link CS GAG 
chains to the proteoglycan core protein (131). A 24 h time course of TGF-β 
treatment of human VSMC was conducted to determine whether XT-1 mRNA 
expression is stimulated by the TGF-β signalling pathway. Cells were treated in the 
presence or absence of TGF-β for 2–24 h. TGF-β stimulation increased the mRNA 
expression of XT-1 at all time points relative to non-treated basal levels. A biphasic 
mRNA expression profile was seen during this 24 h period. The first and highest 
increase (2.8-fold) was observed at 4 h (p<0.01) and 6 h (p<0.01), followed by a 
second smaller peak (2.2-fold) at 20 h (p<0.05) and 24 h (p<0.05) (Fig. 3.1). 
Findings from this study point out that in VSMC, TGF-β significantly upregulates 
XT-1 mRNA expression as early as at 4 h, which then peaks again at 20–24 h. 
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VSMC were treated with TGF-β (2 ng/ml) for different periods of time, 2–24 h and 
isolated RNA was analyzed for GAG synthesizing enzyme XT-1 mRNA expression. 
The experiment was repeated three times in duplicate and the results shown are the 
pooled data from all the experiments. Histogram represents the mean ± S.E.M. 
fold change. Experiments were analyzed using one-way ANOVA followed by least 
significant difference post-hoc analysis, ##p<0.01, #p<0.05 non-treated basal (0 h) 
versus TGF-β. 
 
 
 
Figure 3.1: TGF-β-mediated time course of GAG synthesizing enzyme XT-1 
mRNA expression 
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 TGF-β stimulates mRNA expression of glycosyltransferases 
ChSy-1, ChPF and ChGn-2 involved in synthesis of the CS 
glycosaminoglycan chains  
Chondroitin polymerization of the CS GAG chain occurs via the action of 
chondroitin synthases ChSy-1, ChSy-2, ChSy-3, ChPF, ChGn-1 and ChGn-2 (127). 
We investigated the effect of TGF-β on mRNA expression of ChSy-1, ChPF and 
ChGn-2. These enzymes were chosen as they are associated with the development of 
atherosclerosis in mice (145). TGF-β stimulation caused a large increase in mRNA 
expression of ChSy-1 at all-time points from 2-24 h (p<0.01) (Fig. 3.2). The increase 
in ChSy-1 mRNA expression ranged between 2.8 to 5-fold. ChSy-1 mRNA 
expression was elevated as early as 2 h post-TGF-β treatment and was sustained until 
16 h. A second smaller increase in ChSy-1 mRNA expression was observed at 18 h 
post-TGF-β stimulation. At 20–24 h the increase in ChSy-1 mRNA expression was 
similar to the earlier time points. The 24 h time course TGF-β stimulation of ChSy-1 
mRNA expression exhibited a biphasic time response pattern that was similar to that 
seen for XT-1 mRNA. The 24 h time course TGF-β stimulation of ChSy-1 mRNA 
expression exhibited a biphasic time response pattern that was similar to XT-1 
mRNA expression pattern, however ChSy-1 demonstrated larger increases, almost 
double in mRNA expression with identical TGF-β concentration.  
Following TGF-β treatment of VSMC, a 2.8-fold increase (p<0.01) in ChPF 
mRNA expression was observed after 4 h (Fig. 3.3). The ChPF mRNA expression 
was comparatively half of that seen for ChSy-1 at the same TGF-β treatment 
concentration. This suggests there may be a lesser demand for ChPF enzyme than 
ChSy-1 in TGF-β-stimulated GAG chain polymerization. 
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VSMC were treated with TGF-β (2 ng/ml) for different periods of time, 2–24 h and 
isolated RNA was analyzed for GAG synthesizing enzymes ChSy-1 mRNA 
expression. The experiment was repeated three times in duplicate and the results 
shown are the pooled data from all the experiments. Histogram represents the mean 
± S.E.M. fold change. Experiments were analyzed using one-way ANOVA followed 
by least significant difference post-hoc analysis, ##p<0.01, #p<0.05, non-treated 
basal (0 h) versus TGF-β. 
Figure 3.2: TGF-β-mediated time course of GAG synthesizing enzyme ChSy-1 
mRNA expression 
 
 
95 
 
VSMC were treated with TGF-β (2 ng/ml) for different periods of time, 2–24 h and 
isolated RNA was analyzed for GAG synthesizing enzyme ChPF mRNA expression. 
The experiment was repeated three times in duplicate and the results shown are the 
pooled data from all the experiments. Histogram represents the mean ± S.E.M. 
fold change. Experiments were analyzed using one-way ANOVA followed by least 
significant difference post-hoc analysis,  ##p<0.01, non-treated basal (0 h) versus 
TGF-β.  
Figure 3.3: TGF-β-mediated time course of GAG synthesizing enzyme ChPF 
mRNA expression 
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TGF-β treatment of VSMC did not stimulate the increased expression of 
ChGn-2 mRNA (Fig. 3.4). The mRNA expression of ChGn-2 at 4, 6, 16 and 20 h 
were similar or slightly lower to non-treated basal level. Therefore, there are 
differences in the regulation of glycosyltransferases ChSy-1, ChPF and ChGn-2 in 
response to TGF-β stimulation. In summary two of the three glycosyltransferases, 
ChSy-1 and ChPF, but not ChGn-2 were elevated due to TGF-β stimulation and 
suggest that they play a key role in TGF-β-mediated CS GAG chain elongation. 
Among these three glycosyltransferases, a biphasic pattern was only seen for 
ChSy-1. 
 TGF-β stimulates mRNA expression of sulfotransferases 
C4ST-1 and C4ST-2 involved in sulfation of the repeating 
disaccharide region of CS glycosaminoglycan chains  
Sulfotransferases C4ST-1 and C4ST-2 transfer a sulfo group from a donor molecule 
to GalNAc and GlcA residues on the elongating GAG chain (132). TGF-β treatment 
also stimulated an increase in C4ST-1 mRNA expression (Fig. 3.5). There was a 
biphasic pattern of mRNA expression, which was similar to that seen earlier for 
XT-1 and ChSy-1. A 2.9-fold increase in C4ST-1 mRNA expression was observed 
after 2 h, reaching a peak of 3.2-fold (p<0.05) at 6 h. C4ST-1 mRNA expression 
decreased until 16 h, after which there was a second increase in C4ST-1 mRNA 
expression which peaked at 24 h (4-fold) (p<0.05).  
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Figure 3.4: TGF-β-mediated time course of GAG synthesizing enzyme ChGn-2 
mRNA expression 
VSMC were treated with TGF-β (2 ng/ml) for different periods of time, 2–24 h and 
isolated RNA was analyzed for GAG synthesizing enzyme ChGn-2 mRNA 
expression. The experiment was repeated three times in duplicate and the results 
shown are the pooled data from all the experiments. Histogram represents the mean 
± S.E.M. fold change. Experiments were analyzed using one-way ANOVA. 
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VSMC were treated with TGF-β (2 ng/ml) for different periods of time, 2–24 h and 
isolated RNA was analyzed for GAG synthesizing enzyme C4ST-1 mRNA 
expression. The experiment was repeated three times in duplicate and the results 
shown are the pooled data from all the experiments. Histogram represents the mean 
± S.E.M. fold change. Experiments were analyzed using one-way ANOVA followed 
by least significant difference post-hoc analysis, #p<0.05, non-treated basal (0 h) 
versus TGF-β. 
Figure 3.5: TGF-β-mediated time course of GAG synthesizing enzyme C4ST-1 
mRNA expression 
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 TGF-β treatment did not increase C4ST-2 mRNA expression (Fig 3.6). In 
fact, a reduction in C4ST-2 expression was observed at 8 h (p<0.05) compared to 
non-treated controls. The results point out that at 6–8 h of TGF-β stimulation, 
C4ST-1 expression (Fig. 3.5) was elevated while that of C4ST-2 expression was at 
the lowest levels (Fig. 3.6). These findings suggest that TGF-β may upregulate 
C4ST-1 and downregulate C4ST-2 mRNA expression. This could be due to a 
counterbalance of C4ST-2 gene expression due to elevated C4ST-1 mRNA 
expression. In astrocytes, downregulation of C4ST-1 mRNAs via selective siRNA 
targeting consequently lead to a compensatory induced expression of C4ST-2 (316) 
hence showing a synergistic relation between the expression of these 
sulfotransferases. All the experiments on TGF-β-mediated GAG synthesizing 
enzymes mRNA expression were repeated three times in which XT-1 (Fig. 3.1), 
ChSy-1 (Fig. 3.2) and C4ST-1 (Fig. 3.5) showed a similar biphasic expression 
pattern. These similar temporal effects of TGF-β stimulation could suggest that the 
TGF-β signalling pathways to XT-1, ChSy-1 and C4ST-1 follows a common 
downstream pathway which includes the Smad transcription factor(s) and 
serine/threonine kinases which can act as mediators for the activation of these 
Smads (317). 
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Figure 3.6: TGF-β-mediated time course of GAG synthesizing enzyme C4ST-2 
mRNA expression 
VSMC were treated with TGF-β (2 ng/ml) for different periods of time, 2–24 h and 
isolated RNA was analyzed for GAG synthesizing enzyme C4ST-2 mRNA 
expression. The experiment was repeated three times in duplicate and the results 
shown are the pooled data from all the experiments. Histogram represents the mean 
± S.E.M. fold change. Experiments were analyzed using one-way ANOVA followed 
by least significant difference post-hoc analysis, #p<0.05 non-treated basal (0 h) 
versus TGF-β. 
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 TGF-β stimulates the synthesis of ChSy-1 protein in VSMC 
This study then investigated whether the increased mRNA expression of GAG 
synthesizing enzymes in VSMC causes an upregulation of protein synthesis of these 
respective enzymes. ChSy-1 protein was analyzed as a representative of 
glycosyltransferase enzyme directing CS GAG chain synthesis and C4ST-1 as a 
representative of sulfotransferases. A time course of TGF-β-mediated ChSy-1 and 
C4ST-1 protein levels was determined in human VSMC using Western blot analysis 
with antibodies towards these proteins. The ChSy-1 protein band intensities in 
TGF-β treated cells were significantly increased at 18, 20 and 24 h compared to 
non-treated cells (p<0.05) (Fig. 3.7A). The ChSy-1 protein expression was highest at 
24 h with 1.8-fold compared to basal (p<0.01). At 32 h the TGF-β-mediated 
expression of ChSy-1 had dropped to 1.2-fold similar to that of basal level 
(Fig. 3.7B). These results demonstrate that in human VSMC, TGF-β stimulates the 
increase in synthesis of ChSy-1 protein levels within 18 h reaching a maximum 
fold change at 24 h. The findings from this study indicates that TGF-β-stimulated 
ChSy-1 mRNA expression was sufficient to increase the ChSy-1 protein expression 
in VSMC. Elevated amount of ChSy-1 mRNA expression was associated with a rise 
in ChSy-1 enzyme activity in nucleus pulposus cells (318) hence further suggesting 
that induced ChSy-1 mRNA expression largely affects the increase in activity of 
ChSy-1 enzyme to elongate proteoglycan GAG chain. 
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Figure 3.7: TGF-β-mediated time course of GAG synthesizing enzyme ChSy-1 
protein expression 
VSMC were treated with TGF-β (2 ng/ml) and cells were harvested at time points 
(A) 16, 18, 20 and 24 h, (B) 32 h. Western blots of cell lysates were probed with 
ChSy-1 rabbit IgG polyclonal antibody followed by peroxidase labeled anti-rabbit 
IgG secondary antibody. Anti-GAPDH HRP-conjugated monoclonal antibody was 
used as loading control. The histograms show the band intensity measured by 
densitometric quantitation of (A) three replicate blots, (B) single blot and represent 
the fold change compared to non-treated basal levels. Histogram represents the mean 
± S.E.M. fold change. Experiments were analyzed using one-way ANOVA followed 
by least significant difference post-hoc analysis, ##p<0.01, #p<0.05 non-treated 
basal versus TGF-β. 
A B 
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 TGF-β stimulates the synthesis of C4ST-1 protein in VSMC 
The expression of C4ST-1 protein in the TGF-β treated human VSMC using 
Western blots was then measured. The C4ST-1 protein band intensities were 
increased at all time points, 16, 18, 20 and 24 h. A significant increase in C4ST-1 
protein expression was seen at 20 and 24 h compared to the non-treated cells 
(p<0.01) (Fig. 3.8A). At 20 h the C4ST-1 protein expression increased 1.5-fold 
(p<0.01) and peaked at 24 h with a 1.7-fold increase. At a longer time point, 32 h of 
TGF-β stimulation on C4ST-1 protein expression was similar to that of basal levels 
(Fig. 3.8B).  
These results demonstrate that in human VSMC, TGF-β significantly 
stimulates the synthesis of C4ST-1 protein after 20 h with maximum effects seen at 
24 h. It also correlates with the TGF-β-mediated increase in C4ST-1 mRNA 
expression shown earlier (Section 3.3.3). These data support the previous finding 
(Section 3.3.4), thus we suggest that VSMC treated with TGF-β increases both 
ChSy-1 and C4ST-1 mRNA expression ultimately leading to their increased protein 
expression. This also extends the observation that GAG chain hyperelongation effect 
of TGF-β is dependent upon transcription and translation (163) of ChSy-1 and 
C4ST-1 further confirming the existence of a rate limiting step in the process of 
GAG hyperelongation as a potential target to prevent this pathogenic response. 
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Figure 3.8: TGF-β-mediated time course of GAG synthesizing enzyme C4ST-1 
protein expression 
VSMC were treated with TGF-β (2 ng/ml) at time points (A) 16, 18, 20 and 24 h, (B) 
32 h. Western blots of cell lysates were probed with C4ST-1 mouse IgG monoclonal 
antibody followed by peroxidase labeled anti-mouse IgG secondary antibody. 
Anti-GAPDH HRP-conjugated monoclonal antibody was used as loading control. 
The histograms show the band intensity measured by densitometric quantitation of 
(A) three replicate blots, (B) single blot and represent the fold change compared to 
non-treated basal levels. Histogram represents the mean ± S.E.M. fold change. 
Experiments were analyzed using one-way ANOVA followed by least significant 
difference post-hoc analysis, ##p<0.01 non-treated basal versus TGF-β. 
A B 
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3.4 Summary of Results 
The results presented in this chapter demonstrate the effect of TGF-β on the mRNA 
and protein expression of GAG synthesizing enzymes in human VSMC in vitro. A 
summary of the findings from this chapter is: 
 
 TGF-β stimulates a time dependent increase in XT-1, ChSy-1, ChPF 
and C4ST-1 mRNA expression. 
 
 TGF-β treatment of VSMC did not increase ChGn-2 or C4ST-2 mRNA 
expression. 
 
  A biphasic pattern of increased mRNA expression was seen for XT-1, 
ChSy-1 and C4ST-1 throughout a 24 h time course. An early increase of 
TGF-β-mediated mRNA expression of XT-1, ChSy-1 and C4ST-1 was seen 
at the 6 h and again a later stimulation at 20 h. 
 
 The magnitude of the response to TGF-β stimulation varies for each 
GAG synthesizing enzyme with ChSy-1 showing the biggest increase in 
mRNA expression followed by C4ST-1, XT-1 and ChPF up to 4.8, 4.4 and 
2.8-fold changes, respectively. 
 
 TGF-β regulation of two sulfotransferase homologs, C4ST-1 and C4ST-2 
was found to be different. The trend of mRNA expression was found to be 
opposite between the two enzymes over a 24 h time course. 
 
 
106 
 
 
 TGF-β stimulation of both ChSy-1 and C4ST-1 enzyme protein expression 
was regulated via a time course dependent stimulation. Within a 32 h 
treatment of TGF-β, there was a maximal increase in ChSy-1 and C4ST-1 
protein expression at 24 h, which returned to basal levels by 32 h. 
3.5 Discussion 
TGF-β upregulates biglycan mRNA expression and proteoglycan core protein 
synthesis, as well as the hyperelongation of CS GAG chains. This results in 
increased binding to LDL causing increased retention of this lipoprotein and 
accelerated atherosclerosis (43,280). The LDL binding properties of 
CS proteoglycans such as biglycan are dependent on the negatively charged 
polyanionic GAG chains (56,57). Therefore, in this study we analyzed the mRNA 
expression of key enzymes that affect GAG chain biosynthesis. We investigated 
whether TGF-β upregulates GAG synthesizing enzyme mRNA expressions, which 
are responsible for CS GAG chain elongation and sulfation. Selected enzymes which 
are essential in CS GAG chain synthesis were chosen as candidates either because 
they play a critical role in the development of early atherosclerosis (C4ST-1, 
ChSy-1, ChPF and ChGn-2) (145) or they had previously been reported to be 
induced by TGF-β (XT-1) (224). We also incorporated C4ST-2 in this study to 
understand functional roles of homologous GAG enzymes. In human VSMC, XT-1, 
ChSy-1, ChPF and C4ST-1 mRNA expression was shown to be regulated by the 
TGF-β signalling pathway. Elevated mRNA expression was shown to correlate with 
increased protein expression for ChSy-1 and C4ST-1 (Figs. 3.7 and 3.8). Together 
these results indicate that TGF-β treatment increases both mRNA and protein levels 
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of ChSy-1 and C4ST-1 in these cells. TGF-β did not stimulate ChGn-2 and C4ST-2. 
A biphasic mRNA expression pattern was seen with XT-1, ChSy-1 and C4ST-1 
where there was an initial increase in levels followed by a fall before they rose again 
after 16-18 h expression, suggesting that regulation of these GAG enzymes involve a 
common signalling pathway. A time course dependent effect of TGF-β treatment is 
similarly observed in stimulation of ECM fibronectin gene expression which 
commences at 4 h and peaks at 24 h (319) whereas collagen gene expression was 
maximal after 12 to 18 h of TGF-β stimulation (320). 
Our observation of an increased XT-1 mRNA expression for up to 24 h 
(Fig. 3.1) is similar to findings in astrocytes where TGF-β was also shown to 
increase XT-1 mRNA expression (224). In astrocytes, TGF-β stimulation of XT-1 
expression sustained up to 3 days (224). Our previous study demonstrated that 
TGF-β induces an increase in proteoglycan to LDL binding (158). As the initial step 
in CS GAG chain biosynthesis is the transfer of xylose by XT-1 to the proteoglycan 
core (312), it is likely that TGF-β stimulation of the mRNA expression of this 
enzyme is key to the overall outcome of proteoglycan to LDL binding. The data 
from this current study suggests that TGF-β stimulated elevation of XT-1 mRNA 
expression could increase the level of XT-1 protein required for synthesis of the 
linkage region in proteoglycans. Consequently, TGF-β treatment of VSMC could 
induce more production of proteoglycans not limited to CS/DS PG but also HS as 
synthesis of linkage region is a common connecter to these two types of GAG 
chains. TGF-β stimulation has been shown to increase HS proteoglycan production 
in mesangial cells (321), which could possibly be contributed by increased XT-1 
mRNA expression. Therefore, TGF-β induced XT-1 mRNA expression maintains 
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the elevated amount of synthesized CS GAG chain available for hyperelongation by 
other GAG synthesizing enzymes.  
TGF-β is a pleiotropic growth factor produced as a dimeric latent precursor 
and activated in the extracellular environment to release the receptor-binding ligand 
(199). According to Yan et al. (322), increased GAG synthesizing enzyme XT-1 
mRNA expression is thought to activate an autocrine activation loop. In their study 
on vascular calcification, the CS/DS proteoglycan decorin was shown to play an 
important role as an inducer of VSMC biomineralization and that activation of 
TGF-β signalling underpins oxidized-LDL-induced mineralization of VSMC. They 
reported that increased XT-1 mRNA expression in VSMC leads to decorin GAG 
synthesis and subsequent elevated TGF-β bioavailability for the activation of 
signalling pathways such as oxidative stress without any change in total TGF-β 
protein. This is due to the ability of HS and CS/DS proteoglycan such as betaglycan 
and decorin to bind and sequester free TGF-β (323,324). This regulates the 
bioavailability and presence of active TGF-β within a local microenvironment and 
protects both diffusional and degradative loss (325). We have shown that XT-1 is 
regulated by TGF-β and this in turn may result in synthesis of GAG chain and 
thereby enhanced TGF-β activation, explaining the auto-activation loop. Therefore, a 
TGF-β autocrine activation loop by increased XT-1 mRNA levels could also induce 
the development of GAG chain hyperelongation on biglycan. This would regulate 
TGF-β bioavailability possibly by biglycan binding to TGF-β and potentially 
accelerating atherosclerosis development. 
CS GAG chain elongation occurs with the action of glycosyltransferases 
including ChSy-1, ChSy-2, ChSy-3, ChPF, ChGn-1 and ChGn-2. Co-expression of 
any two of these enzymes allows elongation to occur (121,136,137). High levels of 
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ChSy-1 mRNA expression were observed in increased plaque development in mice 
after an 8 week high fat diet (145). In ChSy-1 or ChPF knockdown mice, reduced 
levels of CS GAG synthesis were reported (326,327). This current study observed 
that only ChSy-1 and ChPF but not ChGn-2 was stimulated by TGF-β in VSMC.  
ChSy-1 has dual transferase activities, both GlcAT-2 and GalNAc 
GalNAcT-2 activity, enabling the synthesis of the repeating disaccharide units (GlcA 
and GalNAc) on CS GAG chains (136,137). In contrast, ChGn-2 catalyses chain 
initiation and elongation via GalNAcT-2 activity only, which adds GalNAc onto 
elongating CS GAG chains (129,136,328,329). A recent study had shown that 
TGF-β-stimulated a continuous increase of ChSy-1 mRNA expression from 4 h 
which peaked at 24 h (318). However Hu and co-workers (318) did not investigate 
the TGF-β effects at 16 and 18 h time points which in our study demonstrated less 
TGF-β-stimulated mRNA expression of ChSy-1, producing an overall biphasic 
pattern of mRNA expression from 2 to 24 h. We report that within 24 h treatment of 
human VSMC, TGF-β induces two phases of gene transcription regulation, which 
can be similarly observed in two other GAG enzymes XT-1 and C4ST-1. For the 
early phase of cells’ response to TGF-β stimulation, ChSy-1 mRNA expression 
contributed to a rise in ChSy-1 protein as early as 16 h (Fig. 3.7). The late phases of 
TGF-β induced GAG enzyme gene expression is suggestive of a prolonged effect of 
agonists to stimulate GAG chain synthesis. The observation of this biphasic pattern 
of mRNA expression is in keeping with the rate limiting effect of TGF-β signal 
transduction (330). 
Elevated amount of TGF-β-stimulated ChSy-1 mRNA expression was 
associated with an increase in ChSy-1 enzyme activity in nucleus pulposus cells of 
the intervertebral disc (318). It is plausible that long term stimulation by TGF-β is 
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crucial to maintain increased ChSy-1 protein levels consequently leading to an 
increase in GAG chain content (318) most likely due to elevated amount of ChSy-1 
enzyme that performs extra addition of monosaccharides to the elongating chain. 
Sulfation of CS GAG chain can be mediated by three closely related enzymes 
(C4ST-1, C4ST-2 and C4ST-3), however these isoforms are distinctive with regards 
to predominant function in specific disease conditions (331). The differential pattern 
of mRNA expression of C4ST-1 and C4ST-2 indicates a possible synergistic effect 
of the two homologs. Down-regulation of C4ST-1 mRNA via selective siRNA 
targeting in rat astrocytes lead to a compensatory induced expression of C4ST-2 
(316) hence showing a synergistic relation between the expression of the 
sulfotransferases. The C4ST-1 enzyme is crucially important in CS GAG chain 
synthesis. A C4ST-1 deficient mouse has a 90% decrease in the GalNAc (4S) 
structure and CS amount (316). This highlights the unique property of C4ST-1 which 
can sulfate GalNAc at the non-reducing termini thereby allowing the coupled 
polymerization action of ChSy-1 and ChPF to occur (129). The newly sulfated 
GalNAc enables the addition of GlcA to further elongate the CS GAG chain. In 
human VSMC C4ST-1 is the most likely critical enzyme in regulating sulfation on 
GAG chains and its expression is increased by TGF-β stimulation. Sulfation by 
C4ST-1 assists the process of GAG chain elongation at the same time producing 
sulfated disachharides with more negatively charged and higher binding affinity to 
positively charged LDL. Modification of GAG chain through sulfation by 
sulfotransferase C4ST-1 is most likely to be directly involved in the TGF-β-mediated 
pathway associated with increased proteoglycan to lipid binding. 
From our results in VSMC, we can deduce that ChSy-1, ChPF and C4ST-1 
are involved in TGF-β-stimulated GAG chain hyperelongation. These results are 
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consistent with findings from in vivo models of atherosclerotic mice (145). One 
exception is ChGn-2 which was found to increase in vivo but not observed in vitro 
with TGF-β-stimulated VSMC (145). It is possible that other growth factors relevant 
to atherogenesis in vivo are involved in producing differential regulation of GAG 
synthesizing enzyme expression. An example could be the GPCR agonist thrombin, 
which was shown to elongate the GAG chain on proteoglycans in human VSMC 
in vitro (232). Further investigation is required to elucidate thrombin effect on 
ChGn-2 in VSMC. Nevertheless, findings from this chapter support an essential role 
of TGF-β-mediated ChSy-1, ChPF and C4ST-1 in GAG chain elongation in VSMC, 
and is postulated to increase biglycan size and LDL binding (158) eventually 
progression of plaque formation and development of atherosclerosis in vivo.  
In this chapter, the treatment of human VSMC led to an upregulation of GAG 
synthesizing enzymes at the mRNA (XT-1, ChSy-1, ChPF and C4ST-1) and protein 
(ChSy-1 and C4ST-1) level. These findings highlight the important link that exists 
between TGF-β-stimulated increases in GAG synthesizing mRNA expression 
leading to the increase in length (hyperelongation) of CS GAG chain on biglycan in 
human VSMC (232). Inhibition of the TGFβR1 prevents biglycan hyperelongation 
and this signalling pathway is mediated via the Smad2 linker region, which can be 
phosphorylated by MAPK intermediates ERK and p38 but not JNK (232). Therefore, 
in the next chapter the signalling pathways for GAG synthesizing enzymes that are a 
part of the TGF-β signalling pathways in VSMC are explored. Three GAG 
synthesizing enzymes XT-1, ChSy-1 and C4ST-1 that are stimulated by TGF-β were 
chosen for further analysis.  
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4.1 Introduction 
In Chapter 3, the results have clearly shown that TGF-β stimulates the mRNA 
expression of XT-1, ChSy-1 and C4ST-1 GAG synthesizing enzymes. The effects of 
TGF-β are mediated by the cell surface receptor TGFβR1 and downstream signalling 
via Smad transcription factors (211). The canonical TGF-β signalling pathway 
involves direct carboxy-terminal phosphorylation of Smad2/3 by TGFβR1. In 
Smad2, direct phosphorylation occurs on the two serine residues Ser465 and 467 
(218). Smad2/3 then complexes with a co-Smad (Smad4) for translocation to the 
nucleus and regulation of gene expression that results in the diverse effects of TGF-β 
stimulation (81). In addition to the canonical TGF-β signalling involving 
carboxy-terminal phosphorylation, studies have shown that the linker region on 
Smad2/3 can also undergo phosphorylation and regulate TGF-β-mediated biological 
activities (225). In human Smad2, these potential phosphorylated sites are positioned 
at Thr220, Ser245, Ser250 and Ser255 whilst in Smad3, phosphorylation can occur 
at Thr179, Ser204, Ser208 and Ser213 (216). According to Matsuzaki et al. (235) 
Smad linker region phosphorylation can be activated by multiple serine/threonine 
kinases including MAPKs (ERK, p38 and JNK), PI3K, CDK, ROCK and GSK-3 
(216,232). Previous results from our laboratory had reported that TGF-β stimulates 
the elongation of GAG chain on biglycan in VSMC. The same study showed that 
Smad2 linker region phosphorylation by ERK and p38 is involved in this process 
(232). However, the individual phosphorylation sites on the Smad2 linker region that 
mediated the TGF-β signalling was not investigated in the study. The role of GAG 
synthesizing enzymes in this TGF-β signalling pathway involving Smad linker 
region is also unknown. Hence, the aim of this chapter is to elucidate the role of 
serine/threonine kinases in TGF-β-mediated phosphorylation of four individual 
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Smad2 linker region residues: Thr220, Ser245, Ser250 and Ser255. Furthermore, the 
results would also be associated with the investigation of the mRNA expression of 
GAG synthesizing enzymes in response to the TGF-β-mediated serine/threonine 
kinases.  
4.2 Materials and methods  
 Materials 
Flavopiridol, SB431542, SP600125, SB216763 and LY294002 were purchased from 
Sigma-Aldrich (MO, USA). PD98059, FR180204 and SB202190 were from 
Calbiochem (CA, USA). UO126 was from Promega (WI, USA). Human TGF-β, 
anti-rabbit immunoglobulin-G (IgG), HRP and GAPDH rabbit monoclonal IgG 
antibody was from Cell Signaling Technology (MA, USA). Phospho-Smad2/3L 
(Thr220/179) rabbit IgG polyclonal, phospho-Smad2L (Ser245) rabbit IgG 
polyclonal, phospho-Smad2L (Ser250) rabbit IgG polyclonal and phospho-Smad2L 
(Ser255) rabbit IgG polyclonal antibodies were a gift from Professor Koichi 
Matsuzaki (Kansai Medical University, Osaka, Japan) (332).  
 Methods 
Tissue culture methods are given in detail in Chapter 2 (Section 2.2.1). Analysis of 
mRNA expression was performed using Q-RT-PCR analysis as described in 
Chapter 2 (Section 2.2.2). The vehicle used for SB431542, SP600125, SB216763, 
LY294002, PD98059, FR180204 and SB202190 was DMSO. For experiments that 
utilize these inhibitors (Figs. 4.1-4.14), 1:1000 DMSO was added to the DMEM as 
vehicle control for basal and positive control (cells treated with TGF-β only). Protein 
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expression was analyzed using Western blot technique as described in Chapter 2 
(Section 2.2.3). Statistical analysis was conducted as described in Chapter 2 (Section 
2.2.5).  
4.3 Results 
 ERK and p38 MAPK regulate TGF-β-stimulated XT-1, 
ChSy-1 and C4ST-1 mRNA expression in human VSMC 
As there are similar biphasic mRNA expression profiles for XT-1, ChSy-1 and 
C4ST-1 following treatment of VSMC by TGF-β, this suggests the involvement of a 
common signalling pathway. XT-1 covalently attaches a xylose sugar to the core 
protein and initiates the linkage region, ChSy-1 synthesizes polymerization of the 
GAG chain through alternate additions of GlcA and GalNAc whereas C4ST-1 
modifies the GAG chain by transfer of a sulfo group (102). It is known from a 
previous study in our laboratory that in VSMC, TGF-β-mediated GAG chain 
hyperelongation requires ERK and p38 MAPK activity (232). To study the role of 
MAPK in mRNA levels of XT-1, ChSy-1 and C4ST-1, human VSMC were treated 
with TGF-β in the presence or absence of inhibitors towards each of the following 
kinases: MEK1/2 (UO126), p38 (SB202190) and JNK (SP600125) and TGFβR1 
(SB431542), and the mRNA levels of the three GAG synthesizing enzymes XT-1, 
ChSy-1 and C4ST-1 was measured. UO126, inhibitor of MEK1/2 is used to block its 
downstream mediator ERK (333). To ensure maximal inhibitor specificity the 
concentrations used in this study were those determined in our previous studies of 
human VSMC through dose-response curves and time-courses for the inhibitors 
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U0126 (3 µM), SB202190 (3 µM), SP600125 (1 µM) (333) and SB431542 (3 µM) 
(81). In Chapter 3, we have shown that mRNA levels of XT-1, ChSy-1 and C4ST-1 
was maximal at 6 h with TGF-β treatment at 2 ng/ml (Chap. 3, Figs. 3.1, 3.2 and 3.5, 
respectively) thus human VSMC were treated with TGF-β (2 ng/ml) for 6 h to obtain 
optimal response.  
 Cells treated with TGF-β showed an increase of approximately 2.4-fold in 
XT-1 mRNA expression compared to non-treated basal cells (Fig. 4.1). Treatment of 
VSMC with TGF-β and the presence of inhibitors to each MAPK UO126 (2.3-fold), 
SB202190 (2.3-fold) and SP600125 (2.4-fold) showed no inhibition of XT-1 mRNA 
expression. A positive control inhibitor to TGFβR1, SB431542 completely blocked 
the TGF-β-stimulated response, as the XT-1 mRNA expression was similar to the 
non-treated basal levels. These results indicate that TGF-β stimulates XT-1 mRNA 
expression and this signalling does not require ERK, p38 or JNK. 
 The effect on ChSy-1 mRNA expression was determined. Cells treated with 
TGF-β showed an increase of approximately 2.9-fold (p<0.01) in ChSy-1 mRNA 
expression compared to non-treated cells (Fig. 4.2). Treatment of cells with TGF-β 
and UO126 (3 μM) showed inhibition of ChSy-1 mRNA expression level with 24% 
less compared to cells treated with TGF-β alone (p<0.05). The presence of the p38 
inhibitor SB202190 (3 μM) resulted in a lower expression of ChSy-1 at 
1.9-fold (p<0.01). The addition of the JNK inhibitor SP600125 did not inhibit 
ChSy-1 mRNA expression. The positive control, SB431542 completely blocked 
VSMC response to TGF-β producing ChSy-1 mRNA expression similar to the 
non-treated controls.  
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Figure 4.1: MAPK ERK, p38 and JNK do not regulate TGF-β-mediated mRNA 
expression of GAG synthesizing enzyme XT-1. 
VSMC were pre-incubated with the following inhibitors: UO126, SB202190, 
SP600125 or SB431542 for 30 min before being treated with TGF-β for 6 h. 
Histogram represents the mean ± S.E.M. of three individual experiments which 
indicate the fold change of mRNA expression for XT-1 compared to non-treated 
controls. Experiments were analyzed using one-way ANOVA followed by least 
significant difference post-hoc analysis, ##p<0.01 basal versus TGF-β, **p<0.01 
inhibitor versus TGF-β.  
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Figure 4.2: MAPK ERK, p38 and JNK differentially regulate TGF-β-mediated 
mRNA expression of GAG synthesizing enzyme ChSy-1. 
VSMC were pre-incubated with the following inhibitors: UO126, SB202190, 
SP600125 or SB431542 for 30 min before being treated with TGF-β for 6 h. 
Histogram represents the mean ± S.E.M. of three individual experiments which 
indicate the fold change of mRNA expression for ChSy-1 compared to non-treated 
controls. Experiments were analyzed using one-way ANOVA followed by least 
significant difference post-hoc analysis, ##p<0.01 basal versus TGF-β, **p<0.01, 
*p<0.05 inhibitor versus TGF-β.  
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 The observation that both ERK and p38 inhibitors blocked ChSy-1 mRNA 
expression, in concordance with the findings that TGF-β receptor antagonist 
SB431542 did as well, implies that TGF-β stimulates ChSy-1 mRNA expression via 
activation of ERK and p38 but not JNK. 
The pathways regulating the mRNA expression of C4ST-1 were then 
examined. TGF-β treatment of VSMC increased C4ST-1 mRNA expression 1.8-fold 
compared to non-treated cells (Fig. 4.3). Cells treated with TGF-β in the presence of 
UO126 showed inhibition of C4ST-1 mRNA expression (1.2-fold) when compared 
to TGF-β treatment alone (p<0.01). Likewise the presence of SB202190 also 
resulted in a lower TGF-β-mediated C4ST-1 mRNA expression (1.4-fold) (p<0.05). 
The C4ST-1 mRNA expression was not blocked by SP600125, showing mRNA 
expression similar to TGF-β treatment alone (1.8-fold). The positive control, 
SB431542 completely blocked the TGF-β-stimulated C4ST-1 mRNA expression. 
These data demonstrate that TGF-β signalling to C4ST-1 mRNA expression involves 
ERK and p38 but not JNK as seen in regulation of ChSy-1 mRNA expression, but 
different to that of XT-1 mRNA expression. 
These results support findings shown in Chapter 3 that TGF-β stimulates the 
mRNA expression of three GAG synthesizing enzymes XT-1, ChSy-1 and C4ST-1. 
Furthermore, these findings demonstrate that in human VSMC, TGF-β induced 
signalling of ERK and p38 but not JNK are mediators of ChSy-1 and C4ST-1 
mRNA expression.  
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Figure 4.3: MAPK ERK, p38 and JNK differentially regulate TGF-β-mediated 
mRNA expression of GAG synthesizing enzyme C4ST-1. 
VSMC were pre-incubated with the following inhibitors: UO126, SB202190, 
SP600125 or SB431542 for 30 min before being treated with TGF-β for 6 h. 
Histogram represents the mean ± S.E.M. of three individual experiments which 
indicate the fold change of mRNA expression for C4ST-1 compared to non-treated 
controls. Experiments were analyzed using one-way ANOVA followed by least 
significant difference post-hoc analysis, ##p<0.01 basal versus TGF-β, **p<0.01, 
*p<0.05 inhibitor versus TGF-β.  
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 Interestingly, none of the MAPKs were found to be involved in the regulation 
of XT-1 mRNA expression. These findings suggest that ERK and p38 are involved 
in GAG chain elongation via ChSy-1 and C4ST-1 (232) however the synthesis of 
new GAG chains via XT-1 activity (131,312) is not via MAPKs. 
 Direct inhibition of ERK by FR180204 and inhibition of 
MEK1 by PD98059 blocks TGF-β-stimulated ChSy-1 and 
C4ST-1 mRNA expression in VSMC 
In Section 4.3.1, we used a MEK1/2 inhibitor (UO126) that blocks the downstream 
signalling of the ERK pathway. To confirm that ERK is a mediator of TGF-β 
signalling in GAG synthesizing enzyme mRNA expression in human VSMC, 
another MEK inhibitor, PD98059 that selectively blocks the activity of MEK1 by 
binding to inactive forms of MEK1 and preventing activation by upstream activators, 
such as c-Raf, consequently blocking downstream ERK activation (334) was tested. 
An adenosine triphosphate (ATP)-competitive, selective ERK inhibitor FR180204 
that directly blocks the kinase activity of ERK1 and ERK2 (335) was also used. The 
concentrations of PD98059 (30 μM) and FR180204 (10 μM) were as determined 
from our previous study in VSMC (333). Cells treated with TGF-β for 6 h had a 
3.5-fold (p<0.01) higher ChSy-1 mRNA level (Fig. 4.4). The ChSy-1 transcript 
levels following TGF-β exposure were significantly lower in samples pre-treated 
with PD98059 (30 μM) and FR180204 (10 μM) with elevation of 2.0-fold and 
2.2-fold (p<0.01), respectively. SB431542 (3 μM) abolished the TGF-β-stimulated 
increase in ChSy-1 mRNA expression (p<0.01).  
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Figure 4.4: MEK1 and ERK differentially regulate TGF-β-mediated mRNA 
expression of GAG synthesizing enzyme ChSy-1. 
VSMC were pre-incubated with the following inhibitors: PD98059, FR180204 or 
SB431542 for 30 min before being treated with TGF-β for 6 h. Histogram represents 
the mean ± S.E.M. of three individual experiments which indicate the fold change of 
mRNA expression for ChSy-1 compared to non-treated basal. Experiments were 
analyzed using one-way ANOVA followed by least significant difference post-hoc 
analysis, ##p<0.01 basal versus TGF-β, **p<0.01 inhibitor versus TGF-β.  
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These results show that MEK1 and ERK1/2 are directly involved in the TGF-β 
signalling to ChSy-1 mRNA expression supporting our earlier data that the 
MEK/ERK pathway is involved in TGF-β-stimulated ChSy-1 mRNA expression. 
Treatment with TGF-β caused a 2.2-fold increase in C4ST-1 mRNA expression 
compared to non-treated controls (Fig. 4.5). The C4ST-1 transcript levels following 
TGF-β exposure were significantly lower in samples pre-treated with PD98059 
(30 μM) and FR180204 (10 μM) showing 1.4 and 1.3-fold, respectively (p<0.01). 
SB431542 (3 μM) completely prevented the TGF-β-stimulated increase in C4ST-1 
mRNA expression (p<0.01). These results strongly suggest that both MEK1 and its 
downstream signalling ERK1/2 participate in the TGF-β-stimulated GAG 
synthesizing enzymes ChSy-1 and C4ST-1 mRNA expression in VSMC. These 
results reinforce the previous finding showing the involvement of the ERK signalling 
pathway in regulating the mRNA expression of GAG synthesizing enzymes.  
  CDK, GSK-3 and PI3K regulate TGF-β-stimulated XT-1, 
ChSy-1 and C4ST-1 mRNA expression in human VSMC 
MAPK ERK and p38 are involved in structural modification of biglycan via 
phosphorylation of Smad2 linker region (232). We have observed in Section 4.3.1 
that ERK and p38 are also mediators for TGF-β-stimulated upregulation of the GAG 
synthesizing enzymes ChSy-1 and C4ST-1. Experiments were then carried out to 
investigate the potential role of other serine/threonine kinases especially those that 
can phosphorylate the Smad2 linker region, in regulating GAG synthesizing enyme 
mRNA expression. 
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Figure 4.5: MEK1 and ERK differentially regulate TGF-β-mediated mRNA 
expression of GAG synthesizing enzyme C4ST-1. 
VSMC were pre-incubated with the following inhibitors: PD98059, FR180204 or 
SB431542 for 30 min before being treated with TGF-β for 6 h. Histogram represents 
the mean ± S.E.M. of three individual experiments which indicate the fold change of 
mRNA expression for C4ST-1 compared to non-treated controls. Experiments were 
analyzed using one-way ANOVA followed by least significant difference post-hoc 
analysis, ##p<0.01 basal versus TGF-β, **p<0.01 inhibitor versus TGF-β.  
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Thus, the effects of three other serine/threonine kinases, namely the CDK, GSK-3 
and PI3K on GAG synthesizing enzyme mRNA expression were examined using 
inhibitors towards the following serine/threonine kinases; CDK 
(flavopiridol), GSK-3 (SB216763) and PI3K (LY294002). To ensure maximal 
inhibitor specificity the concentrations for inhibitors flavopiridol (500 nM), 
SB216763 (10 µM) and LY294002 (20 µM) used in this study were those 
determined in our previous study (236). TGF-β treatment of VSMC for 6 h resulted 
in a 2.2-fold increase in XT-1 mRNA expression (Fig. 4.6). Pre-treatment with the 
CDK inhibitor flavopiridol blocked the TGF-β mediated elevation of the XT-1 
mRNA, and in fact this was reduced by half (0.5-fold) (p<0.01). The GSK-3 
inhibitor (SB216763) did not block XT-1 mRNA expression. LY294002, (PI3K 
inhibitor) prevented TGF-β-stimulated XT-1 mRNA expression to 1.4-fold (p<0.01). 
The positive control SB431542 abolished the TGF-β-mediated increase of XT-1 
mRNA expression (p<0.01). These findings suggest the role of CDK and PI3K as 
mediators of TGF-β-mediated increase in XT-1 mRNA expression. 
 TGF-β treatment of VSMC stimulated ChSy-1 mRNA expression by 2.5-fold 
(p<0.01) (Fig. 4.7). TGF-β-stimulated increase in ChSy-1 mRNA expression was 
inhibited by flavopiridol and LY294002, to 0.1 and 0.7-fold (p<0.01), respectively. 
Meanwhile, presence of SB216763 did not block ChSy-1 mRNA expression 
(2.4-fold). The positive control, SB431542 showed total inhibition of 
TGF-β-stimulated ChSy-1 mRNA expression (p<0.01). These findings suggest that 
CDK and PI3K are intermediates in the TGF-β signalling to ChSy-1 mRNA 
expression.  
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Figure 4.6: CDK, GSK-3 and PI3K differentially regulate TGF-β-mediated 
mRNA expression of GAG synthesizing enzymes XT-1. 
VSMC were pre-incubated with the following inhibitors: flavopiridol, SB216763, 
LY294002 or SB431542 for 30 min before being treated with TGF-β for 6 h. 
Histogram represents the mean ± S.E.M. of three individual experiments which 
indicate the fold change of mRNA expression for XT-1 compared to non-treated 
controls. Experiments were analyzed using one-way ANOVA followed by least 
significant difference post-hoc analysis, ##p<0.01 basal versus TGF-β, **p<0.01 
inhibitor versus TGF-β.  
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Figure 4.7: CDK, GSK-3 and PI3K differentially regulate TGF-β-mediated 
mRNA expression of GAG synthesizing enzyme ChSy-1. 
VSMC were pre-incubated with the following inhibitors: Flavopiridol, SB216763, 
LY294002 or SB431542 for 30 min before being treated with TGF-β (2 ng/ml) for 
6 h. Histogram represents the mean ± S.E.M. of three individual experiments which 
indicate the fold change of mRNA expression for ChSy-1 compared to non-treated 
controls. Experiments were analyzed using one-way ANOVA followed by least 
significant difference post-hoc analysis, ##p<0.01 basal versus TGF-β, **p<0.01 
inhibitor versus TGF-β.  
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 TGF-β stimulation of VSMC for 6 h produced a 2.1-fold increase (p<0.01) in 
the mRNA expression of C4ST-1 (Fig. 4.8). The C4ST-1 transcript levels following 
TGF-β exposure were significantly lower in samples pre-treated with flavopiridol 
and LY294002 showing 0.3 and 1.0-fold (p<0.01), respectively, whereas SB216763 
did not show any inhibition of C4ST-1 mRNA level. SB431542 completely blocked 
the TGF-β induced mRNA expression of C4ST-1 (p<0.01) indicating that the role of 
TGF-β signalling in this process is associated with the actions of CDK and PI3K as 
intermediates. These results suggest that in VSMC, TGF-β-mediated CDK and PI3K 
but not GSK-3 signalling play a role in the upregulation of all three GAG 
synthesizing enzymes mRNA expression being studied including XT-1, ChSy-1 and 
C4ST-1. This shows that PI3K is activated by TGF-β to induce GAG chain synthesis 
whereas its signalling through thrombin and PDGF stimulation of VSMC led to the 
synthesis of proteoglycan core protein (309). The involvement of CDK in events 
related to proteoglycan synthesis could extend the understanding of these kinases 
beyond their known mechansim in cell cycle progression, VSMC proliferation and 
atherosclerosis (242,244). GSK-3 was shown to switch the phosphorylation in the 
Smad linker region from one that favors Smad activation to one that favors Smad 
destruction by creating sites for ubiquitin ligase. Therefore this prevents 
TGF-β-Smad mediated gene expression and could explain the non-involvement of 
GSK-3 in GAG gene expression (336). 
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Figure 4.8: CDK, GSK-3 and PI3K differentially regulate TGF-β-mediated 
mRNA expression of GAG synthesizing enzymes C4ST-1. 
VSMC were pre-incubated with the following inhibitors: flavopiridol, SB216763, 
LY294002 or SB431542 for 30 min before being treated with TGF-β for 6 h. 
Histogram represents the mean ± S.E.M. of three individual experiments which 
indicate the fold change of mRNA expression for C4ST-1 compared to non-treated 
controls. Experiments were analyzed using one-way ANOVA followed by least 
significant difference post-hoc analysis, ##p<0.01 basal versus TGF-β, **p<0.01 
inhibitor versus TGF-β. 
 
 
130 
 
 TGF-β stimulates the phosphorylation of Smad2 linker region 
Thr220, Ser245, Ser250 and Ser255 residues in VSMC 
This study had shown that TGF-β stimulates XT-1, C4ST-1 and ChSy-1 mRNA 
expression and this differentially involves ERK, p38, CDK and PI3K. TGF-β 
regulation of gene expression signals through Smad transcription factors in which 
the linker region can be phosphorylated by serine/threonine kinases to activate 
downstream Smad nuclear translocation and gene transcription. There are at least 
four important phosphorylation sites on the human Smad2 linker region (Smad2L), 
which are positioned at Thr220, Ser245, Ser250 and Ser255 (216). A time course 
experiment (0–4 h) was performed to study the TGF-β-stimulated phosphorylation of 
each of the individual residues on Smad2 linker region (Thr220, Ser245, Ser250 and 
Ser255) in human VSMC. There was a rapid increase in phosphorylation of Thr220 
at 15 min (2.8-fold) (p<0.01) following the addition of TGF-β (Fig. 4.9). 
Phospho-Thr220 level reached a peak at 1 h (3-fold) (p<0.01) after which it fell 
slightly to 2.3-fold at 4 h. SB431542 completely inhibited the TGF-β-mediated 
phosphorylation of Thr220 (p<0.01). 
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The effect of TGF-β on the expression of phospho-Smad2L (Thr220) in VSMC was 
measured 15 min to 4 h post-treatment. Cells treated with TGF-β in the presence of 
TGFβR1 inhibitor SB431542 (10 μM) at 1 h was used as a positive control. Cell 
lysates were collected at time points 15 min to 4 h and proteins were separated by 
SDS-PAGE (10% acrylamide gel) and transferred onto a PVDF membrane. The 
membrane was probed with phospho-Smad2L (Thr220) rabbit polyclonal antibody 
(1:1000) and incubated overnight at 4°C followed by incubation with 
peroxidase-labeled anti-rabbit IgG antibody (1:1000) for 1 h at room temperature. 
The upper band (60 kDa) indicates the Thr220 band of interest. The membrane was 
reprobed with anti-GAPDH antibody (1:4000) for 1 h at room temperature as a 
loading control. The Western blot is a representative of three independent 
experiments. Histogram is a densitometric quantitation of three blots. Histogram 
represents the mean ± S.E.M. Experiments were analyzed using one-way ANOVA 
followed by least significant difference post-hoc analysis, ##p<0.01 basal versus 
TGF-β (1 h), **p<0.01 inhibitor versus TGF-β (1 h). 
Figure 4.9: Western blot of phospho-Smad2L (Thr220) from VSMC treated 
with TGF-β for up to 4 h 
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 In cells treated with TGF-β, a gradual increase in the phosphorylation of 
Ser245 was observed at 15 min, which showed significant increase at 30 min 
(p<0.05) and reaching a peak of 1.8 ± 0.2-fold at 1 h (p<0.01) (Fig. 4.10A). The 
level of phosphorylated Ser245 then fell to 1.5 ± 0.2-fold and remained at this level 
for the next 2 h. SB431542 abolished the TGF-β-mediated increase in 
phosphorylation of Ser245 (p<0.01).  
 Analysis of TGF-β-stimulated Ser250 phosphorylation showed a slight 
elevation in phospho-Ser250 levels at 15 min, after which there was a significant 
increase to 1.7 ± 0.2 and 1.8 ± 0.1-fold at 30 min (p<0.05) and 1 h (p<0.01), 
respectively (Fig. 4.10B). These levels fell 1.2 ± 0.2-fold and 1.1 ± 0.3-fold at 2 and 
4 h, respectively. TGF-β-stimulated phosphorylation of Ser250 was inhibited by 
SB431542 (p<0.05). 
 TGF-β-stimulated phosphorylation of Ser255 resulted in a small increase of 
phospho-Ser255 levels at 15 and 30 min (Fig. 4.10C). At 1 h, these levels had 
increased to 1.9 ± 0.4-fold (p<0.01) before falling to 1.5 ± 0.4-fold at 2 h after it 
remained constant for the next 2 h. As with that seen earlier, the TGFβR1 inhibitor 
SB431542 blocked the TGF-β-mediated phosphorylation of Ser255 (p<0.05). 
 
 
133 
 
 
Figure 4.10: Western blot of phospho-Smad2L (Ser245, Ser250 and Ser255) 
from VSMC treated with TGF-β for up to 4 h 
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Figure 4.10: Western blot of phospho-Smad2L (Ser245, Ser250 and Ser255) 
from VSMC treated with TGF-β for up to 4 h. The effect of TGF-β on the 
expression of phospho-Smad2L (Ser245/250/255) in VSMC was measured 15 min to 
4 h post-treatment. Cells treated with TGF-β (2 ng/ml) in the presence of TGFβR1 
inhibitor SB431542 (10 μM) at 1 h was used as a positive control. Cell lysates were 
collected at time points 15 min to 4 h and proteins were separated by SDS-PAGE 
(10% acrylamide gel) and transferred onto a PVDF membrane. The membrane was 
probed with (A) phospho-Smad2L (Ser245), (B) phospho-Smad2L (Ser250) and (C) 
phospho-Smad2L (Ser255) rabbit polyclonal antibodies (1:1000) and incubated 
overnight at 4°C followed by incubation with peroxidase-labeled anti-rabbit IgG 
antibody (1:1000) for 1 h at room temperature. The membrane was reprobed with 
anti−GAPDH antibody (1:4000) for 1 h at room temperature as a loading control. 
The Western blot is a representative of three independent experiments. Histogram is 
a densitometric quantitation of three Western blots and represents the mean ± S.E.M. 
fold change. Experiments were analyzed using one-way ANOVA followed by least 
significant difference post-hoc analysis, ##p<0.01, #p<0.05 basal versus TGF-β 
(1 h), *p<0.05 inhibitor versus TGF-β (1 h).  
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 These results demonstrate that phosphorylation of the Thr220, Ser245, 
Ser250 and Ser255 on the Smad2 linker region are mediated by the TGF-β-signalling 
pathway. TGF-β phosphorylation of each of the individual residues showed a 
parabolic temporal response with maximum phosphorylation at 1 h. The amount of 
maximal phosphorylation of each residue within 4 h of TGF-β stimulation varied 
between the smallest 1.8-fold for phospho-Ser245 and phospho-Ser250 (Figs. 4.10A 
and 4.10B) to the largest 3-fold for phospho-Thr220 (Fig. 4.9). Ser255 produced 
maximal phosphorylation with 1.9-fold at 1 h (Fig. 4.10C). Thr220 exhibited a more 
rapid response to TGF-β-stimulated phosphorylation compared to Ser245, 250 and 
255 with 2.8-fold (p<0.01) increase in levels after 15 min. The Ser residues undergo 
a more gradual phosphorylation requiring at least 30 min of TGF-β treatment to 
produce phospho-Ser245 and phospho-Ser250 at 1.5-fold (p<0.05) (Fig. 4.10A) and 
1.7-fold (p<0.05) (Fig. 4.10B), respectively. Furthermore TGF-β induced Ser255 
phosphorylation after 1 h (Fig. 4.10C). Thr220 is also rapidly phosphorylated by 
TGF-β in other cells. In primary palatal mesenchymal cells, after 10 min of TGF-β 
treatment, Thr220 phosphorylation showed a 2-fold increase while Ser250 was 
phosphorylated up to a lesser 1.5-fold increase (337). These results suggest that 
among the residues on the Smad2 linker region, Thr220 is required more and most 
probably plays a greater role in TGF–β signalling in VSMC. The 1 h time point for 
TGF-β treatment was used in subsequent experiments to investigate phosphorylation 
of the individual residues of the Smad2 linker region (Section 4.3.5). 
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 The role of ERK, p38, PI3K and CDK in TGF-β-stimulated 
phosphorylation of Smad2 linker region in VSMC 
GAG chain hyperelongation on biglycan involves phosphorylation of the Smad2 
linker region by serine/threonine kinases (216,232). In Section 4.3.1–4.3.3, 
TGF-β-mediated signalling to influence GAG synthesizing enzyme mRNA 
expression involves the intermediates ERK, p38, PI3K and CDK. Here the 
experiments focused on whether TGF-β-mediated phosphorylation of individual 
residues on the Smad2 linker region includes these serine/threonine kinases. In 
Section 4.3.4, TGF-β treated VSMC increased the phosphorylation of the individual 
Smad2 linker region with a peak phosphorylation at 1 h.  
 VSMC were treated with TGF-β for 1 h to allow for the maximal 
phosphorylation of Thr220, Ser245, Ser250 and Ser255. The phospho-Thr220 band 
showed increase in band intensity (3-fold) compared to non-treated controls 
(Fig. 4.11). The presence of MAPK inhibitors (UO126, SB202190 and LY294002) 
did not inhibit this increase in phospho-Thr220 levels. Flavopiridol blocked the 
TGF-β-mediated Thr220 phosphorylation to 1.4-fold (p<0.01) while SB431542 
abolished this increase. These data indicate that Thr220 phosphorylation involves 
TGF-β-mediated CDK and not ERK, p38 and PI3K signalling. 
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Figure 4.11: Effects of MAPK (ERK and p38), CDK and PI3K inhibitors on 
TGF-β-mediated Smad2L (Thr220) phosphorylation in VSMC 
VSMC were treated with TGF-β in the presence and absence of each of the 
following serine/threonine kinase inhibitors: ERK (UO126), p38 (SB202190), PI3K 
(LY294002), CDK (flavopiridol) or TGFβR1 (SB431542) for 1 h. The membrane 
was probed with phospho-Smad2L (Thr220) rabbit polyclonal primary antibody and 
incubated overnight at 4°C followed by incubation with peroxidase-labeled 
anti-rabbit IgG antibody for 1 h at room temperature. The membrane was reprobed 
with anti-GAPDH antibody for 1 h at room temperature as a loading control. The 
Western blot is representative of three independent experiments. Histograms are a 
densitometric quantitation of three blots and represent the mean ± S.E.M. 
fold change. Experiments were analyzed using one-way ANOVA followed by least 
significant difference post-hoc analysis,  ##p<0.01 basal versus TGF-β, **p<0.01 
inhibitor versus TGF-β. 
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 We next analyzed the intermediate kinases involved in the TGF-β-mediated 
signalling pathway to Ser245 phosphorylation. TGF-β treatment of VSMC for 1 h 
caused an increase of phospho-Ser245 up to 2-fold (Fig. 4.12). Inhibition of ERK, 
p38 and PI3K with UO126, SB202190 and LY294002, respectively blocked 
phospho-Ser245 to 1.5-fold (p<0.05), 1.5-fold (p<0.01) and 1.4-fold (p<0.01), 
respectively. Flavopiridol and SB431542 abolished the TGF-β-stimulated 
phosphorylation of Ser245 (p<0.01). Thus, TGF-β stimulates Ser245 
phosphorylation through the activation of ERK, p38, PI3K and CDK. 
 TGF-β-stimulation increased phospho-Ser250 levels 1.9-fold in VSMC after 
1 h. The presence of UO126 showed a total block of phospho-Ser250 (p<0.01) 
(Fig. 4.13). Presence of inhibitors for p38, PI3K and CDK did not block TGF-β 
stimulated phosphorylation of Ser250. SB431542 abolished TGF-β induced Ser250 
phosphorylation (p<0.01) in these cells. These results demonstrate that only ERK 
and not p38, PI3K and CDK are mediators of TGF-β-stimulated phosphorylation of 
Ser250.  
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Figure 4.12: Effects of MAPK (ERK and p38), CDK and PI3K inhibitors on 
TGF-β-mediated Smad2L (Ser245) phosphorylation in VSMC 
VSMC were treated with TGF-β in the presence and absence of each of the 
following serine/threonine kinase inhibitors: ERK (UO126), p38 (SB202190), PI3K 
(LY294002), CDK (flavopiridol) or TGFβR1 (SB431542) for 1 h. The membrane 
was probed with phospho-Smad2L (Ser245) rabbit polyclonal primary antibody and 
incubated overnight at 4°C followed by incubation with peroxidase-labeled 
anti-rabbit IgG antibody for 1 h at room temperature. The membrane was reprobed 
with anti-GAPDH antibody for 1 h at room temperature as a loading control. The 
Western blot is representative of three independent experiments. Histograms are a 
densitometric quantitation of three blots and represent the mean ± S.E.M. 
Experiments were analyzed using one-way ANOVA followed by least significant 
difference post-hoc analysis, ##p<0.01 basal versus TGF-β, **p<0.01, *p<0.05 
inhibitor versus TGF-β. 
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Figure 4.13: Effects of MAPK (ERK and p38), CDK and PI3K inhibitors on 
TGF-β-mediated Smad2L (Ser250) phosphorylation in VSMC 
VSMC were treated with TGF-β in the presence and absence of each of the 
following serine/threonine kinase inhibitors: ERK (UO126), p38 (SB202190), PI3K 
(LY294002), CDK (flavopiridol) or TGFβR1 (SB431542) for 1 h. The membrane 
was probed with phospho-Smad2L (Ser250) rabbit polyclonal primary antibody and 
incubated overnight at 4°C followed by incubation with peroxidase-labeled 
anti-rabbit IgG antibody for 1 h at room temperature. The membrane was reprobed 
with anti-GAPDH antibody for 1 h at room temperature as a loading control. The 
Western blot is representative of three independent experiments. Histograms are a 
densitometric quantitation of three blots and represent the mean ± S.E.M. 
fold change. Experiments were analyzed using one-way ANOVA followed by least 
significant difference post-hoc analysis, ##p<0.01 basal versus TGF-β, **p<0.01 
inhibitor versus TGF-β.
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          Phosphorylation of Ser255 showed a 2.1-fold increase (p<0.01) 1 h 
post-TGF-β treatment (Fig. 4.14). UO126, LY294002 and flavopiridol inhibited the 
phosphorylation of Ser255 to 1.3 (p<0.01), 1.5 (p<0.05) and 1.1-fold (p<0.01), 
respectively. SB431542 also inhibited the TGF-β induced phospho-Ser255 levels in 
these cells. Taken together our earlier findings in Section 4.3.1–4.3.3, this implies 
that TGF-β-mediated phosphorylation of Thr220 occurs via CDK to induce 
expression of GAG synthesizing enzyme mRNA expression XT-1, ChSy-1 and 
C4ST-1 in human VSMC. Meanwhile, Ser245 is phosphorylated by ERK, p38, PI3K 
and CDK. Ser250 phosphorylation occurs through ERK whereas Ser255 
phosphorylation involves ERK, PI3K and CDK. 
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Figure 4.14: Effects of MAPK (ERK and p38), CDK and PI3K inhibitors on 
TGF-β-mediated Smad2L (Ser255) phosphorylation in VSMC 
VSMC were treated with TGF-β in the presence and absence of each of the 
following serine/threonine kinase inhibitors: ERK (UO126), p38 (SB202190), PI3K 
(LY294002), CDK (flavopiridol) or TGFβR1 (SB431542) for 1 h. The membrane 
was probed with phospho-Smad2L (Ser255) rabbit polyclonal primary antibody and 
incubated overnight at 4°C followed by incubation with peroxidase-labeled 
anti-rabbit IgG antibody for 1 h at room temperature. The membrane was reprobed 
with anti-GAPDH antibody for 1 h at room temperature as a loading control. The 
Western blot is representative of three independent experiments. Histograms are a 
densitometric quantitation of three blots and represent the mean ± S.E.M. 
fold change. Experiments were analyzed using one-way ANOVA followed by least 
significant difference post-hoc analysis, ##p<0.01 basal versus TGF-β, **p<0.01, 
*p<0.05 inhibitor versus TGF-β.  
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4.4 Summary of Results 
The results presented in this chapter demonstrate the effects of TGF-β on 
phosphorylation of individual residues on the Smad2 linker region by 
serine/threonine kinase intermediates as well as their signalling to influence GAG 
synthesizing enzyme mRNA expression in VSMC in vitro. The findings from this 
chapter show that: 
 
 The signalling pathways from TGF-β that mediate ChSy-1 and C4ST-1 
mRNA expression involve ERK, p38, PI3K and CDK and not JNK and 
GSK-3.  
 
 The signalling pathways from TGF-β that mediate XT-1 mRNA only involve 
PI3K and CDK serine/threonine kinases and not MAPK and GSK-3. 
 
 TGF-β differentially regulates the phoshorylation of individual Smad2 linker 
region serine/threonine residues. Over 4 h TGF-β stimulation, a parabolic 
temporal response was observed with maximum phosphorylation at 1 h. 
 
 TGF-β-mediated phosphorylation of Thr220 showed a rapid reponse as early 
as 15 min with 2.8-fold increases, which peaked at a maximal 3-fold increase 
at 1 h whilst phosphorylation of Ser245, Ser250 and Ser255 undergo a 
gradual increase from 15 min–2 h. 
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 TGF-β stimulated a larger Thr220 phosphorylation (3-fold) compared to 
phosphorylation of Ser245, Ser250 and Ser255 (approximately 1.8-fold). 
 
 Thr220 phosphorylation can be mediated by CDK and not ERK, p38, JNK, 
GSK-3 and PI3K whereas phosphorylation of Ser245 can be mediated by 
ERK, p38, PI3K and CDK. Ser250 phosphorylation occurs through ERK 
whereas Ser255 phosphorylation involves ERK, PI3K and CDK. 
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Figure 4.15: Schematic diagram illustrating the proposed TGF-β signalling 
pathways involving serine/threonine intermediates and individual Smad2L 
phosphoryation to stimulate XT-1, ChSy-1 and C4ST-1 mRNA expression 
TGF-β-stimulated p38, ERK, PI3K and CDK phosphorylates serine residues leading 
to ChSy-1 and C4ST-1 mRNA expression whereas CDK phosphorylation of Thr220 
results in XT-1 mRNA expression. Stimulation of XT-1 mRNA expression via PI3K 
could be likely through CDK activation. PI3K could also stimulate ERK to 
phosphorylate Ser245 and Ser255 resulting in elevated ChSy-1 and C4ST-1 mRNA 
expression and perhaps GAG chain elongation. 
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4.5 Discussion 
The results from the investigation of the signalling pathways of TGF-β to GAG gene 
expression show that TGF-β can activate ERK and p38 to stimulate the increase in 
ChSy-1 and C4ST-1 mRNA expression. Taking together our previous study that 
TGF-β-stimulated ERK and p38 activation lead to GAG chain hyperelongation 
(232), it is important to realize that apart from the ChSy-1 enzyme that is directly 
involved in addition and elongation of repeated disaccharide units on GAG chain, 
the sulfotransferase enzyme C4ST-1 plays an important role in this TGF-β induced 
signalling events. This further highlights the importance of sulfation by C4ST-1 
which besides contributing to the negatively charged sulfate on GAG chain, sulfation 
is a prerequisite for chain elongation as it provides the docking site for addition of 
disaccharide units described previously (129), ultimately leading to GAG chain 
elongation on biglycan. Among the MAPK involved in TGF-β signalling in VSMC, 
only ERK and p38 but not JNK are mediators in the TGF-β-stimulated gene 
expression of GAG synthesizing enzymes as well as structural modification of GAG 
chain on biglycan. ERK can be either negatively or positively involved in TGF-β 
induced cellular responses. In epithelial cells, overexpression of constitutively active 
ERK cascade blocks nuclear accumulation of Smads to induce gene expression 
(228). Conversely, in kidney mesangial cells overexpression of constitutively active 
members of the ERK cascade promote Smad3-dependent processes (338). In our 
VSMC, ERK is positively implicated in the response to TGF-β via upregulation of 
the downstream target gene ChSy-1 and C4ST-1 involved in proteoglycan synthesis. 
In a recent study investigating the GAG synthesis in nucleous pulposus cells of 
intervertebral discs, ERK is shown to participate in the TGF-β regulation of ChSy-1 
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expression (318). Treatment of nucleous pulposus cells with TGF-β and ERK 
inhibitor PD98059 (30 µM) blocked the TGF-β induced ChSy-1 expression as well 
as reduced secreted GAG revealing that activation of ERK signalling is essential for 
both ChSy-1 expression and GAG synthesis (318). In human cardiac fibroblast cells, 
p38 was reported to participate in the TGF-β-stimulated XT-1 mRNA expression 
that corresponds with an elevated amount of digested GAG content in cardiac tissues 
from patients with myocardial fibrosis (146). XT-1 is used as a measure for the 
proteoglycan biosynthesis rate and is a reliable biochemical serum marker for the 
assessment of fibrotic processes associated with elevated amount of proteoglycan 
synthesis (339). Due to the distinct action of p38 signalling to regulate different 
GAG synthesizing enzymes in various cell types, we postulate that TGF-β activation 
of the same kinase can selectively upregulate individual GAG synthesizing enzymes 
affecting the functional outcome of proteoglycans. Specifically, p38 upregulates 
XT-1 indicative of increased proteoglycan synthesis and fibrosis in fibroblasts, 
whereas in VSMC it increases ChSy-1 and C4ST-1 resulting in structural 
modification of increased GAG chain length on biglycan, relevant to LDL binding 
and atherosclerosis. 
Independent of TGF-β signal transduction, MAPK is also a mediator of the 
C4ST-1 expression via oncogenic signalling of the Harvey rat sarcoma viral 
oncogene homolog (HRAS), involved in Costello syndrome that affects cell growth. 
Interference of the HRAS signalling in fibroblast cells negatively regulates C4ST-1 
causing reduced mRNA and protein expression. Treatment with inhibitors of ERK 
(PD98059), p38 (SB203580) and JNK (SP600125) for 48 h was able to significantly 
elevate the C4ST-1 expression by approximately 2 to 3.5-fold when compared with a 
DMSO-treated control (331). This indicates that in the context of HRAS signalling, 
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ERK, p38 and JNK play a role in mediating a negative regulation of C4ST-1 levels. 
This differs to that seen in the TGF-β signalling pathway, where only ERK and p38 
lead to a positive upregulation of C4ST-1 levels in VSMC whilst JNK is not 
involved entirely. One of the reasons that could affect the differential outcome of 
C4ST-1 expression would be the activation of Smad transcription factor, a key 
downstream mediator of the TGF-β signalling pathway. TGF-β ligand binding 
induces signal transduction through TGF-β receptor complex resulting in receptor 
mediated (R-) Smad2/3 phosphorylation at the Ser465/467 residues on the 
C-terminal allowing a complex with Smad4 (340,341). This complex translocates 
into the nucleus, and regulates target gene expression (342). MAPKs are able to 
phosphorylate the Smad transcription factor outside the C-terminal specifically in the 
linker region (216). Given these points, the regulation of GAG synthesizing enzymes 
are influenced by upstream mediators including Smad and MAPK signalling which 
can result in both upregulation and antagonism and as such is context dependent.  
There are at least four important phosphorylation sites on the Smad2/3L. In 
human Smad2, these sites are at positions Thr220, Ser245, Ser250 and Ser255. 
While in Smad3, phosphorylation can occur at the Thr179 residue, and the Ser 
residues at positions 204, 208 and 213 (216). This study has focussed on the Smad2 
transcription factor because to date we have no evidence to suggest a role and 
involvement of Smad3 in proteoglycan synthesis in VSMC. In addition, the 
TGF-β-stimulated ChSy-1 protein level was inhibited in nucleus pulposus cells of 
intervertebral discs with Smad2 siRNA but not Smad3 siRNA, indicating that the 
former but not the latter was involved in the regulation of ChSy-1 expression (318). 
TGF-β increases the phosphorylation of Thr220, Ser245, Ser250 and Ser255 on the 
Smad2L with a peak phosphorylation at 1 h. Phosphorylation of Smad2C 
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(Ser465/467) in VSMC was reported to be more rapid with significant 
phosphorylation as early as 30 min (232) compared to phosphorylation in the 
Smad2L shown in this study. This could suggest the possibility that Smad2L 
phosphorylation occurs following a rapid nuclear translocation by the 
Smad2C-Smad4 complex. However, this point will require further follow-up 
experiments investigating the subcellular localization of the phosphorylation events 
including use of subcellular fractionation and immunocytochemistry. 
Phosphorylation of Smads in the cytoplasmic or nuclear compartment of the cells 
may have different effects even though the phosphorylation can take place on the 
same serine/threonine residues (204). Interpretation of results could also be 
improved with the use of total Smad2 as Western blot control. The expression of 
total Smad2 allows the identification of the ratio of total/phospho-Smad2 and could 
distinguish between a change in Smad2 expression (change in 
transcription/translation) versus a change in the phosphorylation status of 
Smad2 (225).  
The Smad2L phosphorylation varies between each individual residue. TGF-β 
caused a larger Thr220 phosphorylation (3-fold) compared to phosphorylation of the 
three Ser residues Ser245, Ser250 and Ser255 with 1.8-fold. Significant amount of 
phospho-Thr220 was maintained up to 4 h TGF-β stimulation unlike the Ser residues 
that decreased. The resistance of Thr220 towards dephosphorylation events could 
possibly explain the significant amount of TGF-β phosphorylated Thr220 up to the 
4 h treatment. The existence of small C-terminal domain phosphatase (SCP) 
regulates Smad linker dephosphorylation making Smad phosphorylation a reversible 
and tightly controlled event. SCP1, 2 and 3 were found to specifically 
dephosphorylate certain sites in the Smad2 (Ser245/Ser250/Ser255) and Smad3 
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(Ser204/Ser208/Ser213) linker region, but have no effect on Smad2/3 at Thr220/179. 
In fact, among 40 phosphatases screened, none had phosphatase activity towards 
Smad2/3 at Thr220/179 (343).  
 GAG chain hyperelongation involves Smad2L phosphorylation, which can be 
mediated by serine/threonine kinases MAPK, PI3K, CDK and GSK-3 (216). These 
kinases can differentially phosphorylate individual residues on the Smad2 linker 
region regulating the outcomes of mRNA expression including PAI-1 in endothelial 
cells (236). In this current study, the availability of monoclonal antibodies against 
the individual residues of the Smad2 linker region allowed us to demonstrate the 
specificity of ERK, p38, PI3K and CDK in the phosphorylation of individual 
residues on this linker region. Our findings show that only CDK and not MAPK and 
PI3K were involved in Thr220 phosphorylation, and all the kinases that were 
investigated including MAPK, PI3K and CDK were involved in Ser245 
phosphorylation. ERK was involved in Ser250, and ERK, PI3K and CDK were 
involved in Ser255 phosphorylation. Phosphorylation of Ser250 in palatal 
mesenchymal cells was also shown to be inhibited by UO126 suggesting that Ser250 
is a common residue for ERK signal transduction (337). Smad2 phosphorylation by 
the TGF-β receptor is a rate-limiting step in nuclear translocation and protein 
expression (330). The evidence of multiple kinase intermediates that can be activated 
by TGF-β and most likely by other growth factors including PDGF and thrombin 
(309), illustrates the existence of multiple alternate pathways for Smad linker region 
phosphorylation to occur in diseased arteries which have been shown to release a 
number of growth factors (30). Recently our laboratory had shown that thrombin can 
transactivate the TGF-β receptor to induce regulation of ChSy-1 and C4ST-1 mRNA 
expression involving Smad linker region phosphorylation (344). The involvement of 
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multiple growth factor signalling pathways could possibly contribute to the overall 
increase in GAG synthesizing enzyme mRNA expression and further highlights 
Smad linker region as a central integrating pathway and a potential candidate for a 
therapeutic target during the development of atherosclerosis. 
Phosphorylation of Thr220 shows activation by only CDK and not the 
MAPK nor PI3K. In comparison to the Ser residues investigated in this study, TGF-β 
significantly stimulates up to 2.5-fold (p<0.01) phospho-Thr220 as early as 15 min 
(Fig. 4.9). TGF-β-stimulated CDK family phosphorylation has a greater preference 
over the Thr220 than the Ser residues (238,332,337,345). Thr220 serves as an 
excellent substrate particularly for CDK4 (238,346). Others report that CDK4, 
CDK8 and CDK9 phosphorylation of Smad linker region can occur on nuclear 
phospho-Smad2C and phospho-Smad3C (230,332). Our study used the CDK 
inhibitor flavopiridol, which targets at least six CDK isoforms (CDK1, CDK2, 
CDK4, CDK6, CDK7 and CDK9), which limits the conclusions about specific CDK 
isoforms that can be drawn. Therefore, further investigation is warranted to identify 
specific CDK isoform(s) that are involved. Activated CDKs are largely localized in 
the nucleus and play a major role in cell cycling events (347). In the absence or 
presence of signal, the distributions of Smads are not static, but are constantly 
shuttling between the nucleus and the cytoplasm (348). Thus, Smads are present in 
both the nucleus and cytoplasm by nucleocytoplasmic distribution of events that 
maintain the pool of un-phosphorylated Smads (330). The observation that Thr220 is 
phosphorylated by only CDK coupled with the observation that Thr220 is rapidly 
phosphorylated by TGF-β stimulation at 15 min could suggest that the 
phosphorylation events by CDK takes place in the nucleus involving readily present 
pool of nuclear Smad2 and highly localized nuclear CDK (330). Furthermore, 
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nuclear translocation of receptor-mediated phosphorylation of Smad2 from the 
cytoplasm is reported to occur after approximately 45 min of TGF-β treatment (330). 
Nonetheless, CDK can also phosphorylate translocated phospho-Smad2C in the 
nucleus further enhancing the signalling events. As seen in primary craniofacial 
mesenchymal cells, TGF-β activated kinases served as enhancers of 
phospho-Smad2/3C by Thr220 phosphorylation leading to the increased 
transcriptional regulation of genes related to craniofacial structures (337). It is 
interesting to note that CDK is also able to upregulate XT-1, ChSy-1 and C4ST-1 
mRNA expression as opposed to MAPK that is limited to the increase in only 
ChSy-1 and C4ST-1 mRNA expression. Therefore, CDK phosphorylation of Thr220 
is thought to play a key role in regulating XT-1 mRNA expression.  
 In this current study, PI3K was also shown to regulate XT-1 mRNA 
expression without phosphorylating Thr220 on the Smad linker region (Figs. 4.6 and 
4.11). Other studies had shown that PI3K could act as upstream mediator for CDK 
activation (349). PI3K/PDK1 signalling cascade is reported to activate the 
cyclin-CDK complexes required for FoxM1B-dependent transcription (349). Hence, 
there is a possibility that PI3K could direct its downstream signalling to CDK 
activation eventually phosphorylating the nuclear Smad2 linker region and 
regulating XT-1 expression (Fig. 4.15). Importantly, from the results shown, PI3K 
and CDK regulate the same three GAG synthesizing enzymes XT1, ChSy-1 and 
C4ST-1. We hypothesize that particularly for XT-1 gene regulation, PI3K is able to 
direct its activation through CDK. 
 In VSMC, PI3K participates in thrombin and PDGF stimulated synthesis of 
proteoglycan core protein (309). PDGF and TGF-β also stimulate Akt, a downstream 
mediator of the PI3K signalling pathway to regulate only proteoglycan core and not 
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GAG chain synthesis on proteoglycans (280,350). Because XT-1 is involved in GAG 
chain synthesis, we postulate that in VSMC TGF-β upregulation of XT-1 does not 
involve the PI3K/Akt signalling but instead the PI3K/CDK pathway. There is a study 
in rat lung fibroblasts that supports the involvement of PDGF stimulated PI3K to 
induce biglycan GAG chain synthesis instead of biglycan core protein (351). 
Therefore, knockout studies of CDK would clarify the highly complex signalling 
mediators of the PI3K in regulating XT-1 mRNA expression and ultimately GAG 
chain synthesis in VSMC. 
 ERK and p38 phosphorylate only the three serine residues on the Smad2 
linker region and not the Thr220. A previous study from our laboratory that reported 
the involvement of ERK and p38 in the regulation of proteoglycans via Smad2L, 
used a pan Smad2L antibody that detected all phosphorylated serine residues 
(Ser245/Ser250/Ser255) (232). In this present study, TGF-β-mediated ERK signals 
through phosphorylation of Ser245, Ser250 or Ser255 whereas p38 phosphorylates 
only via the Ser245 (Fig. 4.15). The use of phospho-specific antibodies highlights 
the unique role of each responsible kinase that phosphorylates different individual 
serine/threonine residues despite mediating similar outcomes of increased GAG 
synthesizing enzyme ChSy-1 and C4ST-1 mRNA expression. The exact 
mechanism(s) by which the specificity of individual Smad linker region 
phosphorylation regulates Smad signalling remains to be clearly elucidated. Linker 
region phosphorylation may allosterically regulate intramolecular interactions 
between the MH1 and MH2 domains, and intermolecular interactions between 
Smads and other molecules (e.g. cytoplasmic anchors or cofactors) (348). 
Differential localization of protein kinases that can phosphorylate Smad2/3 whether 
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in the cytoplasm or nucleus also affects multiple signalling responses that determine 
the functional cell outcome (235).  
 Interestingly, both PI3K and ERK can phosphorylate Ser245/Ser255 as well 
as regulate ChSy-1 and C4ST-1 gene expression. In VSMC, cell proliferation in vivo 
and in vitro has been associated with the PI3K/Akt signalling pathway (269,352). 
However, the regulation of GAG chain hyperelongation on proteoglycans in VSMC 
does not involve TGF-β-mediated Akt phosphorylation of Smad2L 
(Ser245/Ser250/Ser255) (280). A previous study had shown that in fibroblasts, 
TGF-β induced replication can be regulated through the PI3K activated ERK 
signalling pathway and leads to the phosphorylation of Smad2L 
(Ser245/Ser250/Ser255) and gene expression (225). Based on these findings, we 
suggest that TGF-β-mediated signal transduction from PI3K to GAG synthesizing 
enzyme ChSy-1 and C4ST-1 mRNA expression takes an alternate pathway not via 
Akt, in this case via the PI3K/ERK signalling pathway (Fig. 4.15). Further 
investigation is warranted to confirm this. 
 Apart from investigations on the upstream signalling events at the protein 
kinase level, it is also essential to elucidate the involvement of co-activators or 
co-repressors that modulate the promoter sequences of each individual GAG enzyme 
genes that ultimately affects the transcriptional gene regulation (235). Smad2/3-
binding regions are eniched with the Smad binding element (SBE) or the CAGA 
box. Due to their relatively low DNA-binding affinity, Smad complexes interact with 
a wide range of DNA-binding proteins and cooperatively regulate a synexpression 
group of target genes (353). Thus Smad2/3-Smad4 complex must interact with other 
DNA-binding cofactors to achieve high affinity and selectivity for specific subsets of 
target genes (208). The activator protein-1 (Ap-1) knockout cells was shown to 
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prevent the TGF-β-mediated ChSy-1 promoter activity indicating that AP-1 is 
required for ChSy-1 promoter activity to occur (318). It remains to be seen whether 
the C4ST-1 promoter is activated by similar combinations of co-activators as that of 
ChSy-1, which could be the reason behind the same serine/threonine kinase 
mediators being involved in ChSy-1 and C4ST-1 regulation in contrast to XT-1 gene 
regulation. Investigations are also warranted to elucidate the role of specific Smad 
linker region phosphorylation have in altering the structural features of the MH1 
domain on the Smad2/3-Smad4 complex that recognizes DNA and determines the 
different DNA-binding partners for transcriptional outcome (208). 
 In summary, we have identified the specificity of mRNA regulation of the 
three GAG synthesizing enzyme XT-1, ChSy-1 and C4ST-1 in VSMC. These 
findings demonstrate that a highly specific signalling pathway from TGF-β to 
Smad2L phosphorylation exists in these cells. We show that XT-1, ChSy-1 and 
C4ST-1 are upregulated by the pro-atherosclerotic growth factor TGF-β. The 
serine/threonine kinases ERK, p38, PI3K and CDK are mediators of this signalling 
pathway. We also show that individual Smad2L is selectively phosphorylated by 
these serine/threonine kinases. Ser245 is phosphorylated only by p38. On the 
contrary, Thr220 is phosphorylated only by CDKs, which in Chapter 5 the specific 
CDK isoforms present in VSMC is investigated. Phosphorylation of the serine 
residues (Ser245/250/255) most likely induced the GAG synthesizing enzymes 
ChSy-1 and C4ST-1 that are closely associated with GAG chain elongation, whereas 
Thr220 phosphorylation is associated with XT-1 enzyme expression that attaches the 
GAG chain to core protein and determines the level of GAG chain synthesis. The 
findings from this chapter provide a better understanding of the complex signalling 
pathways contributing to GAG chain hyperelongation and could facilitate the 
 
 
156 
 
identification of a specific therapeutic target for signalling pathways and biochemical 
events important in the early development of atherosclerosis.  
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5.1 Introduction 
In Chapter 4 the CDKs were demonstrated as one of the serine/threonine kinases 
involved in the TGF-β-mediated regulation of XT-1, ChSy-1 and C4ST-1 mRNA 
expression in human VSMC. Through the TGF-β-mediated signalling pathway, 
CDKs are capable of phosphorylating Thr220, Ser245 and Ser255 on the Smad2 
linker region. CDKs are protein kinases whose activity require association with 
specific cyclin subunits (354). Since their discovery in starfish, Xenopus and yeast 
in the 1970s and 1980s, CDKs especially CDK1, CDK2, CDK4 and CDK6 were 
shown to play critical roles in the cell cycle (355,356). At present, there are at least 
20 different CDKs and cyclins identified in mammalian cells (248). The increased 
number of CDK isoforms in multicellular organisms is thought to fulfil the need 
for a more elaborate control over the proliferation of various cell types during the 
advancement from unicellular to complex multicellular organisms (242). Extensive 
research on these isoforms has revealed that CDKs also play a key role in non-cell 
cycle processes and transcriptional regulation, metabolism and neuronal 
differentiation (242,357,358).  
Overexpression and dysregulation of CDK activity often lead to impairment 
of cell proliferation as seen in cancer progression (359). Indeed, most reports on 
the functional diversity of CDK isoforms and development of therapeutic strategies 
are largely related to cancer studies (360). The progression of atherosclerosis also 
involves excessive cellular proliferation and migration of VSMC and there is 
evidence to suggest is regulated by the CDK driven cell cycle (361,362). VSMC 
within the media of human arteries are normally quiescent, proliferate at low rate 
and exist in the G0 phase of the cell cycle. Elevated stimulatory growth factors and 
cytokines including PDGF, IL-1, IL-6 and TNF-α induces VSMC activation; 
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transforming from a quiescent and contractile phenotype into a synthetic 
phenotype (363). Once activated, the VSMC proliferate in the media and then 
migrate to the intima, where they undergo further cycles of proliferation (363). 
Following entry into the G1 phase, CDKs regulate progression through the cell 
cycle at specific time points. CDK4, CDK6 and CDK2 control the G1 phase, 
CDK2 controls the S phase, and CDK1 the G2 and M phase (364,365). CDK7 acts 
as a CDK-activating kinase (CAK) (366) required for complete activation of CDK 
family proteins. This phosphorylation induces a conformational change that 
enhances the binding capability of CDKs to cyclins (367). Despite all this 
understanding of CDKs, there is a lack of knowledge regarding the functional roles 
of the individual isoforms present in VSMC and their potential role in the early 
development of atherosclerosis particularly in relation to proteoglycan 
modification and GAG chain elongation. We postulate that CDKs in VSMC are 
also involved in GAG chain modification through TGF-β-mediated Smad linker 
region phosphorylation and regulation of GAG synthesizing enzymes.  
In Mv1Lu mink lung epithelial cells, Matsuura et al. (238) showed that 
CDK2 and CDK4 phosphorylated four possible Smad3 linker region 
serine/threonine phosphorylation sites, which limited the proliferative effect of 
TGF-β. This current study is focused on the role of CDK isoforms in regulating 
GAG synthesizing enzymes through TGF-β-mediated Smad linker region 
phosphorylation. Malumbres et al. (242) noted that the functions and distribution 
of the CDK isoforms are cell type specific (242). For instance, the expression of 
CDK2 and CDK4 proteins are lower in the internal mammary SMC compared to 
their expression in coronary artery SMC, contributing to the observed divergent 
proliferative and migratory SMC properties (368). Different CDK isoforms are 
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important as they regulate specific action in cell biology: CDK1, CDK2, CDK4 
and CDK6 are dedicated to cell-division control (249) whilst CDK7, CDK8 and 
CDK9 are primarily implicated in transcription (248). Therefore, the aim of this 
chapter is to first identify the specific CDK isoforms that are found in VSMC. This 
study also investigated whether TGF-β alters CDK protein expression in these cells 
to determine whether TGF-β induced signalling pathways requires the upregulation 
of CDK protein level.  
5.2 Materials and Methods 
 Materials 
Flavopiridol, PD0332991, SB431542 were purchased from Sigma-Aldrich 
(MO, USA). Roscovitine, anti-rabbit immunoglobulin-G (IgG) horseradish 
peroxidase (HRP), anti-mouse IgG HRP, anti-CDK-1 (POH1) (Cat. no 9116), 
anti-CDK2 (78B2) (Cat. no. 2546), anti-CDK4 (D9G3E) (Cat. no. 12790), 
anti-CDK6 (D4S8S) (Cat. no. 13331), anti-CDK7 (MO1) (Cat. no 2916), 
anti-CDK9 (C12F7) (Cat. no 2316), anti-phospho-Rb (Ser807/811) (Cat. no 9308) 
and anti-α-tubulin (Cat. no 2144) were from Cell Signaling Technology 
(MA, USA). HL60 whole cell lysate (Cat. no SC2209) and CVT313 was from Santa 
Cruz Biotechnology (TX, USA). 
 Methods 
The vehicle used for Flavopiridol, PD0332991, SB431542, Roscovitine, and 
CVT313 was DMSO. Tissue culture methods are given in detail in Chapter 2 
(Section 2.2.1). For experiments that utilize CDK inhibitors (Fig. 5.8), 1:1000 
DMSO was added to the DMEM as vehicle control for basal and positive control 
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(cells treated with TGF-β only). Protein expression was analyzed using Western blot 
technique as described in Chapter 2 (Section 2.2.3). Statistical analysis was 
conducted as described in Chapter 2 (Section 2.2.5).  
 
5.3 Results 
 Cyclin-dependent kinase expression in human vascular 
smooth muscle cells 
 Cyclin-dependent kinase 1 (CDK1) 
The presence of CDK1 provides the catalytic unit for the cyclin-A-CDK1 and 
cyclin-B-CDK1 complex to enable progression of cell proliferation, particularly the 
G2-M transition and M phase of the cell cycle, respectively (369). The expression of 
endogenous levels of CDK isoforms in VSMC was undertaken by Western blots. 
Antibodies directed specifically against protein for CDK1, CDK2, CDK4, CDK6, 
CDK7 and CDK9 were used to determine the presence of specific CDK isoforms 
present in VSMC. The promyelocytic cell line HL60 was included as a positive 
control in these blots as all CDK isoforms are highly expressed in these cells (370).  
In VSMC, a low endogenous level of CDK1 expression was detected 
(Fig. 5.1). Treatment of cells with TGF-β (2 ng/ml) for 20 h did not alter the 
expression of CDK1. CDK1 was highly expressed in HL60 cells as seen by the 
presence of a 34 kDa band. These results indicate that in VSMC, CDK1 protein was 
present and treatment with TGF-β did not alter its expression.  
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VSMC were treated with and without TGF-β (2 ng/ml) for 20 h. VSMC lysate and 
HL60 cell lysate were loaded at 30 µg of protein. The blot was probed with 1:1000 
mouse monoclonal CDK1 antibody followed by peroxidase labeled anti-mouse IgG 
secondary antibody (1:2000) and anti-GAPDH HRP-conjugated monoclonal 
antibody (1:4000) was used as the loading control. The molecular weight of CDK1 is 
34 kDa while for GAPDH it is 37 kDa. The Western blot is a representative of three 
independent experiments. 
Figure 5.1: Cyclin-dependent kinase 1 (CDK1) isoform expressed in human 
vascular smooth muscle cells 
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 Cyclin-dependent kinase 2 (CDK2) 
Expression of CDK2 enables activation by cyclin-E leading to passage through the 
restriction point at the boundary of the G1-S phase, and to S phase initiation in the 
cell cycle (369). CDK2 also plays an important role in S phase progression by 
forming a complex with cyclin-A (369). In VSMC, CDK2 expression was detected 
at high levels in the non-treated control cells (Fig. 5.2). When TGF-β was added to 
the cells for 20 h, there was no change in the expression of CDK2. CDK2 
expression in VSMC was confirmed by the positive control 37 kDa band in HL60 
lysates. Only 5 µg of HL60 cell lysate was run on the gel while 30 µg of VSMC 
lysate run on the gel. These amounts are sufficient for the detection of the 33 kDa 
band for CDK2 and prevent overexposure of the band intensity from the HL60 
(as seen in Fig. 5.1 of Section 5.3.1.1) (371). These results confirm the presence of 
CDK2 protein in VSMC and its level of expression is not altered by TGF-β. 
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VSMC were treated with and without TGF-β (2 ng/ml) for 20 h. HL60 shows the 
presence of all CDK isoforms, were loaded less at 5 µg and VSMC lysate were 
loaded at 30 µg. The blot was probed with 1:1000 rabbit monoclonal CDK2 antibody 
followed by peroxidase labeled anti-rabbit IgG secondary antibody (1:2000) and 
anti-GAPDH HRP-conjugated monoclonal antibody (1:4000) for equal loading. The 
molecular weight for CDK2 is 33 kDa while for GAPDH it is at 37 kDa. The 
Western blot is a representative of three independent experiments. 
Figure 5.2: Cyclin-dependent kinase 2 (CDK2) isoform expressed in human 
vascular smooth muscle cells 
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 Cyclin-dependent kinase 4 (CDK4)  
In the non-treated VSMC, low basal levels of CDK4 expression were observed 
(Fig. 5.3). After 20 h of TGF-β treatment, no changes in the level of CDK4 
expression were observed. Lysates from the HL60 expressed the presence of a 
30 kDa band that represents the separated CDK4 protein on a 12% SDS-PAGE gel. 
These results confirm the expression of CDK4 in VSMC and that TGF-β did not 
influence its level of expression. According to the classical model of cell cycle 
control, D-type cyclins can activate CDK4 as a complex that is able to regulate 
events in the early G1 phase of cell proliferation (372).  
 Cyclin-dependent kinase 6 (CDK6) 
The expression of CDK6 protein was investigated in VSMC. An intermediate 
amount of basal CDK6 expression in non-treated cells was observed (Fig. 5.4). After 
20 h treatment of VSMC with TGF-β, no changes in the level of CDK6 expression 
was observed. HL60 cells express the 36 kDa CDK6 protein as seen on a 12% 
SDS-PAGE gel. These findings show that CDK6 is expressed in VSMC and that 
TGF-β did not alter its expression. Presence of CDK6 isoform showed that both 
CDK4 and its functional CDK6 homolog (372) are available for activation in 
VSMC. This suggests that in VSMC, there is more than one CDK isoform for 
CDK-activating kinase (CAK) to induce signal for progression of the G1 phase in the 
cell cycle (373).  
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VSMC were treated with and without TGF-β (2 ng/ml) for 20 h. HL60 shows the 
presence of all CDK isoforms. HL60 lysate were loaded less at 5 µg and VSMC 
lysate were loaded at 30 µg as in Section 5.3.1.2. The blot was probed with 1:1000 
rabbit monoclonal CDK4 antibody followed by peroxidase labeled anti-rabbit IgG 
secondary antibody (1:2000) and anti-GAPDH HRP-conjugated monoclonal 
antibody (1:4000) for equal loading. The molecular weight of the CDK4 isoform is 
30 kDa while for GAPDH it is at 37 kDa. The Western blot is a representative of 
three independent experiments. 
 
 
Figure 5.3: Cyclin-dependent kinase 4 (CDK4) isoform expressed in human 
vascular smooth muscle cells 
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VSMC were treated with and without TGF-β (2 ng/ml) for 20 h. HL60 shows the 
presence of all CDK isoform, were loaded less at 5 µg and VSMC lysate were 
loaded at 30 µg as in Section 5.3.1.2. The blot was probed with 1:1000 rabbit 
monoclonal CDK6 antibody followed by peroxidase labeled anti-rabbit IgG 
secondary antibody (1:2000) and anti-GAPDH HRP-conjugated monoclonal 
antibody (1:4000) for equal loading. The molecular weight of the CDK6 isoform is 
36 kDa while for GAPDH it is at 37 kDa. The Western blot is a representative of 
three independent experiments. 
 
 
Figure 5.4: Cyclin-dependent kinase 6 (CDK6) isoform expressed in human 
vascular smooth muscle cells 
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 Cyclin-dependent kinase 7 (CDK7)  
Control VSMC showed the presence of CDK7 expression at a high level (Fig. 5.5). 
When TGF-β was added to these cells for 20 h, CDK7 expression remained 
unchanged. CDK7 expression in VSMC was confirmed by the presence of a 40 kDa 
band in HL60 cell lysates. These results confirm the expression of CDK7 in VSMC 
and that TGF-β did not affect the CDK7 protein expression. CDK7 is reported as a 
CAK that is responsible for activating phosphorylations of various cell cycle CDKs, 
including CDK4 (374) CDK2 and CDK1 (375). Therefore a relatively high amount 
of CDK7 in VSMC suggests that it plays an essential role in activating cell 
proliferation indirectly via phosphorylation of the cell cycle CDKs.  
 Cyclin-dependent kinase 9 (CDK9)  
In VSMC, CDK9 was shown to be expressed at a high level (Fig. 5.6). TGF-β 
treatment did not alter the expression of CDK9. HL60 cells expressed a 42 kDa 
CDK9 band on the 12% SDS-PAGE gel. These results confirm the presence of 
CDK9 in VSMC and that TGF-β did not influence its expression.  
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VSMC were treated with and without TGF-β (2 ng/ml) for 20 h. HL60 shows the 
presence of all CDK isoform and were loaded less at 5 µg and VSMC lysate were 
loaded at 30 µg as in Section 5.3.1.2. The blot was probed with 1:1000 rabbit 
monoclonal CDK7 antibody followed by peroxidase labeled anti-rabbit IgG 
secondary antibody (1:2000) and anti-GAPDH HRP-conjugated monoclonal 
antibody (1:4000) for equal loading. The molecular weight for CDK7 isoform is 
40 kDa while for GAPDH it is at 37 kDa. The Western blot is a representative of 
three independent experiments.  
 
.
Figure 5.5: Cyclin-dependent kinase 7 (CDK7) isoform expressed in human 
vascular smooth muscle cells 
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VSMC were treated with and without TGF-β (2 ng/ml) for 20 h. HL60 shows the 
presence of all CDK isoform, were loaded less at 5 µg and VSMC lysate were 
loaded at 30 µg as in Section 5.3.1.2. The blot was probed with 1:1000 rabbit 
monoclonal CDK9 antibody followed by peroxidase labeled anti-rabbit IgG 
secondary antibody (1:2000) and anti-GAPDH HRP-conjugated monoclonal 
antibody (1:4000) for equal loading. The molecular weight for CDK9 is 42 kDa 
while for GAPDH it is at 37 kDa. The Western blot is a representative of three 
independent experiments. 
 
Figure 5.6: Cyclin-dependent kinase 9 (CDK9) isoform expressed in human 
vascular smooth muscle cells 
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 Time course of TGF-β-stimulated retinoblastoma (Rb) protein 
phosphorylation in human vascular smooth muscle cells 
To establish whether the CDK signalling pathways in VSMC are activated by 
TGF-β, the phosphorylation of Rb protein was measured. Rb is a CDK-activated 
kinase associated with tumour suppression (252). The Rb protein was initially 
characterized as a regulator of transcription by inhibiting expression of genes under 
the control of E2F transcription factors (254). In the context of cell cycle 
progression, Rb can be phosphorylated by cyclin-D-CDK4 and cyclin-E-CDK2 to 
induce S phase entry (376). Moreover, CDK7 was shown to be an upstream 
regulator of CDK4 and CDK6 further activating Rb phosphorylation (377). The 
effect of TGF-β on Rb phosphorylation over a time period up to 2 h is shown in 
Fig. 5.7. Following treatment with TGF-β there was a statistically significant 
increase in the expression of phospho-Rb (Ser807/811) at 15 min (1.8-fold), which 
peaked at 30 min (1.9-fold) (p<0.05), after which it returned to basal level at 1 h. 
A slight increase in phospho-Rb (1.3-fold) was observed after 2 h TGF-β 
stimulation. The elevated levels of phospho-Rb in TGF-β-treated cells at 30 min 
was completely blocked in the presence of SB431542 (Fig. 5.7, lane 7). These 
results illustrate that in human VSMC, TGF-β mediates a rapid rise in 
phosphorylation of Rb, which reached a peak 30 min post-treatment.  
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Figure 5.7: TGF-β-stimulated phosphorylation of Rb protein in human VSMC 
The effect of TGF-β (2 ng/ml) on the expression of phospho-Rb protein levels in 
VSMC was measured 0–2 h post-treatment. Western blots of whole cell lysates were 
probed with either an anti-phospho-Rb (Ser807/811) (1:1000) or anti-α-tubulin 
monoclonal primary antibody (1:1000) followed by peroxidase-labeled anti-rabbit 
IgG secondary antibody (1:2000). The blot is a representative of three independent 
experiments. The histogram shows the band intensity measured by densitometric 
quantitation of three replicate blots and show the fold change compared to 
non-treated controls. Histogram represents the mean ± S.E.M of these replicates. 
Experiments were analyzed using one-way ANOVA followed by least significant 
difference post-hoc analysis, #p<0.01 basal versus TGF-β (30 min), **p<0.01 
inhibitor versus TGF-β (30 min).  
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 Regulation of TGF-β-mediated CDK activity assessed through 
retinoblastoma (Rb) protein phosphorylation 
The involvement of various CDK isoforms in regulating the TGF-β-mediated Rb 
phosphorylation in VSMC was investigated. As specific individual CDK inhibitors 
are not available, to determine which CDK isoforms are involved in this process, 
this current study used the following inhibitors CVT313 (CDK1 and 
CDK2 inhibitor) (246), roscovitine (CDK2, CDK7, CDK8 and CDK9 inhibitor) 
(243,378), PD0332991 (CDK4 and CDK6 inhibitor) (242) and flavopiridol (CDK1, 
CDK2, CDK4, CDK6, CDK7 and CDK9) to inhibit the action of their respective set 
of CDK targets in the VSMC. VSMC were treated with TGF-β for 30 min to ensure 
maximal phosphorylated Rb levels (as seen in Fig. 5.7) in the cells. TGF-β induced 
a 2.2-fold increase in phospho-Rb levels compared to non-treated controls 
(Fig. 5.8). When these cells were treated with CVT313 (0.1 μM and 1 μM), 
PD0332991 (0.1 μM and 10 μM), roscovitine (10 μM) or flavopiridol (1 μM) there 
was a decrease in TGF-β-stimulated phosphorylation of Rb by 32%, 45%, 77%, 
41% and 45%, respectively (Fig. 5.8). The TGFβR1 inhibitor SB431542 blocked 
phospho-Rb levels by 50% (Fig. 5.8, lane 9). These results demonstrate that Rb 
phosphorylation is mediated by CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9 
activity. This verifies that the pharmacological tools used in this study as all the 
CDK inhibitors blocked Rb protein phosphorylation, a known 
downstream substrate of CDKs (252). 
 
 
174 
 
 
Cells were treated with CVT313 (0.1 μM and 1 μM), PD0332991 (0.1 μM and 
10 μM), roscovitine (10 μM), flavopiridol (1 μM) and SB431542 (3 μM) for 30 min 
then treated with TGF-β (2 ng/ml) for 30 min. Western blots of whole cell lysates 
were probed with anti-phospho-Rb (Ser807/811) (1:1000) or anti-α-tubulin 
monoclonal primary antibody (1:1000) followed by peroxidase labeled anti-rabbit 
IgG secondary antibody (1:2000). The blot is a representative of three independent 
experiments. The histogram shows the band intensity measured by densitometric 
quantitation of three replicate blots and represents the mean ± S.E.M. ##p<0.01 
basal versus TGF-β, **p<0.01 and *p<0.05 inhibitor versus TGF-β, using one-way 
ANOVA followed by least significant difference post-hoc analysis.
Figure 5.8: CDK inhibition of TGF-β-induced phospho-Rb expression 
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5.4 Summary of Results  
The results presented in this chapter demonstrate the expression of multiple CDK 
isoforms and their activity in VSMC in vitro. A summary of the findings from this 
chapter are: 
  
 CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9 expression were 
demonstrated in VSMC and isoforms were confirmed by the positive 
control HL60 cells that express all CDK isoforms. 
 
 High levels of CDK2, CDK7 and CDK9 protein expression were detected 
whilst adequate amount of CDK1, CDK4 and CDK6 were observed.  
 
 Rb phosphorylation is mediated through the TGFβR1 signalling pathway. 
Rb phosphorylation within 2 h time course exhibits a rapid and maximal 
response at 30 min. 
 
 Activation of Rb phosphorylation was inhibited by the CDK inhibitors 
CVT313 (CDK1 and CDK2 inhibitor), roscovitine (CDK2, CDK7, CDK8 
and CDK9 inhibitor), PD0332991 (CDK4 and CDK6 inhibitor) and 
flavopiridol (CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9). 
 
 The pharmacological tools used in this study were validated as all the 
CDK inhibitors were shown to block the Rb protein phosphorylation, a 
known downstream substrate of CDKs. 
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5.5 Discussion 
In this chapter, expression of the CDK isoforms in VSMC was investigated. Six 
CDK isoforms namely CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9 were found 
to be expressed in VSMC but at differing levels. CDK2 and cyclin-E have been 
shown to be expressed in human VSMC found in atherosclerotic and restenotic 
tissue (379). In non-treated VSMC we observed the presence of CDK1, CDK2, 
CDK4, CDK6, CDK7 and CDK9, which were differentially expressed. Based on 
the relatively high amount of CDK2, it can suggest that the proliferation status of 
VSMC during these experiments were expected to be in S/G2 phase in which CDK2 
plays the main regulatory role (355).  
Other than CDK, the levels of cyclins and CDK inhibitors (CKI) are also 
crucial in contributing to the activation of CDK and cell cycle regulation. The levels 
of certain cyclins rise and fall with the specific stages of the cell cycle enabling 
cyclins to bind and activate specific CDKs, which in turn phosphorylate a variety of 
protein substrates that control the cell’s progression through the cell cycle (357). 
Further validation to identify the status of cell cycle phases can be assessed via cell 
proliferative activity assays measuring the relative quantity of 
bromodeoxyuridine (BrdU) incorporated into cells, which is a direct indication of 
cell proliferation (380), as well as using flow cytometric analysis of cell cycle with 
propidium iodide DNA staining (381). 
In basal condition, this current study found that the VSMC possess a high 
level of CDK7 and CDK9 proteins. This might be due to the indispensable role of 
CDK7 and CDK9 in transcriptional control within the cell (382). CDK7 is unique as 
it is involved in both cell cycle, indirectly as a CAK which phosphorylates cell 
cycle CDKs within the activation segment (T-loop), as well as a component of the 
 
 
177 
 
general transcription factor II human (TFIIH), which phosphorylates the 
carboxy-terminal domain (CTD) of the largest subunit of RNA Pol II (383,384). As 
the CTD kinase is associated with TFIIH, CDK7 has been suspected of playing an 
essential role in transcribing most, if not all, class II genes and most probably 
including cell cycle regulatory proteins required throughout the entire stages of cell 
division as well as genes for GAG synthesizing enzyme (384). CDK9 is a 
component of the positive elongation factor b (P-TEFb) that promotes RNA 
synthesis for cell growth, differentiation and apoptosis (385). After transcription 
initiation, Pol II is blocked near the promoter of many genes, a process called 
proximal promoter pausing (386). For productive transcription, P-TEFb comprising 
of CDK9 and cyclin T is then recruited allowing CDK9 to phosphorylate Ser2 in the 
CTD of RNA Pol II, inducing pause release and subsequent transcription elongation 
and RNA maturation (387,388). We can postulate that the presence of CDK9 in 
VSMC could participate in the regulation of GAG synthesizing gene expression 
through RNA Pol II transcriptional regulation.  
In vascular disease, CDK9 has been shown to play a key role in the 
regulation of inflammation (389). This takes place via transcriptional regulation of 
pro-inflammatory factor IL-6 (390). Transcriptional inhibition of monocytes 
through CDK9 was proposed as a novel target in down regulating the inflammatory 
events of atherosclerosis (391). In the context of proteoglycan modification, it 
remains to be elucidated whether this transcriptional control directly involves genes 
for GAG synthesizing enzymes. It would be interesting to explore the specific role 
of CDK7 and CDK9 with regards to their direct transcriptional control via 
activation of RNA Pol II in turn determining the fate of transcriptional elongation 
for GAG gene. In Chapter 7, this current study will discuss the correlation between 
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CDK7 and CDK9 with regards to Smad linker region phosphorylation as a 
transcription factor. 
The expression of CDK1 in VSMC was demonstrated. CDK1 is mostly 
required for successful completion of the M phase in cell cycle (392). Therefore 
these results support the fact that CDK1 is present in VSMC to regulate cell cycle 
specifically M phase, along with CDK2, CDK4 and CDK6 as drivers for interphase.  
CDK4 and CDK6 and its functional homolog are expressed in VSMC (Figs. 
5.3 and 5.4). Results show intermediate level of both isoforms that collectively 
could provide adequate amount of these CDKs required for the process of G1–S 
transition of the cell cycle in VSMC. A study to identify the effects of 
PDGF-mediated salicylate (an anti-inflammatory drug) inhibition of VSMC 
proliferation demonstrated that CDK4 and CDK6 were present in VSMC but their 
expression was not induced by PDGF stimulation (393).  
In this study, TGF-β did not alter the expression of CDK1, CDK2, CDK4, 
CDK6, CDK7 and CDK9 in VSMC. In Chapter 4, flavopiridol inhibited 
TGF-β-mediated XT-1, ChSy-1 and C4ST-1 mRNA expression. This establishes 
that CDK are involved in regulating GAG synthesizing enzyme mRNA expression. 
Therefore, to explain the role of TGF-β-mediated CDK activity in regulating GAG 
chain synthesizing enzyme mRNA expression, TGF-β does not exert its effect 
through altering protein levels of these CDKs. Instead, it can be postulated that 
TGF-β exerts its effect through regulatory protein mediators that contribute to 
increased activation of these CDK. In neonatal VSMC, suppression of proliferative 
activity by 1, 25 dihydroxyvitamin D3 was linked to a reduction in CDK2 activity; 
however this suppression was not associated with a decrease in CDK2 and CDK4 
protein levels (394). The authors observed that endothelin did not stimulate an 
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increase in CDK2 and CDK4 expression compared to non-treated controls (394). 
Therefore, corresponding to our study, the growth factor-mediated CDK activity 
and downstream functional outcomes are not necessarily governed by their protein 
expression levels but by other downstream mediators that influence their activity. 
Followup studies for example the assessment of CDK mRNA level are required to 
further confirm this. 
To establish whether the CDK signalling pathways in VSMC are activated 
by TGF-β, the phosphorylation of Rb was measured. Rb is one of the substrates of 
CDK1 (249,395), CDK2 (396), CDK4 (397), CDK6 (398), CDK7 (377) and CDK9 
(399,400) which plays a central role in controlling cell cycle progression and DNA 
replication (401). Pharmacological inhibitors that target the sets of CDKs expressed 
in VSMC were utilized. Flavopiridol is the first CDK inhibitor used in human 
clinical trials. Phase II trials performed showed high response rates in chronic 
myeloid leukemia (402) and medium responses in pancreatic cancer (403). 
Flavopiridol had been shown to target a wide range of CDK isoforms including 
CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9 (241). CVT-313 is a potent CDK2 
inhibitor identified from a purine analogue library with an IC50 of 0.5 μM in vitro 
(15). Both flavopiridol and CVT313 have been studied as inhibitors of VSMC 
proliferation in vitro and neointimal formation in vivo (244,246). Roscovitine, 
also known by the names of CYC-202 and seliciclib, inhibits CDK2, CDK7 and 
CDK9 (404). Roscovitine had been tested in Phase I clinical trial for patients with 
solid tumors (405) and with hepatocellular carcinoma (406). Roscovitine had been 
suggested as a potential therapeutic tool for the treatment of atherosclerosis by 
blocking angiotensin II induced VSMC proliferation (378). PD0332991, also known 
as palbociclib is a potent and specific oral CDK4/CDK6 inhibitor that has recently 
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been approved for treatment of breast cancer. Phase 2 clinical trials demonstrated 
single-agent activity in mantle-cell lymphoma, breast cancer, liposarcoma and 
teratoma (407). 
Our results showed that flavopiridol (CDK1, CDK2, CDK4, CDK6, CDK7, 
CDK9), roscovitine (CDK2, CDK7, CDK9), PD0332991 (CDK4, CDK6) and 
CVT313 (CDK1, CDK2) exhibited a dose-dependent inhibition of TGF-β-mediated 
Rb phosphorylation (Fig. 5.8). This illustrates that TGF-β signalling was most likely 
involved by regulating the downstream activity of the respective CDKs and 
validated the tools that were used to inhibit downstream CDK activities. Therefore 
these inhibitors were applied in the next chapters to address research questions 
related to CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9 signalling.  
Finally, this current study provides evidence that CDK1, CDK2, CDK4, 
CDK6, CDK7 and CDK9 are present in VSMC. Based on findings from other 
studies, these CDK isoforms are indeed essential regulators of either VSMC 
proliferation through the cell cycle system or transcription via RNA Pol II. One of 
the biggest gaps in the existing literature is on the role of CDK in areas beyond 
regulation of the cell cycle such as proteoglycan synthesis, especially on GAG 
synthesizing enzyme regulation. Hence, from the findings of the CDK isoforms 
present in VSMC, we aim to understand the TGF-β signalling pathways involving 
these CDKs and their relevance to proteoglycan modification, discussed in 
Chapter 6 and Chapter 7. Our initial investigation on the effects of TGF-β treatment 
on VSMC for 20 h did not demonstrate any changes in the level of CDK expression. 
This suggests that increased expression of CDK level is not an essential determinant 
of downstream activities involving TGF-β activation of CDK shown previously in 
Chapter 4. Followup experiments include a comparison of these data with a 
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treatment, which alters the rate of cell growth that does affect CDK levels in 
VSMCs. An example is the use of serum to increase the proliferation rate of 
VSMCs. The next important question to answer in Chapter 6 is to identify the 
involvement of these CDK isoforms in regulating XT-1, ChSy-1 and C4ST-1 
mRNA expression that represents enzymes involved in GAG chain elongation as 
well as biglycan mRNA expression that contributes to biglycan core protein 
synthesis. 
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Chapter 6: TGF-β stimulates 
glycosaminoglycan synthesizing 
enzyme and biglycan mRNA 
expression in vascular smooth 
muscle via multiple CDK isoforms 
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6.1 Introduction 
In Chapter 4, multiple CDKs were shown to modulate the mRNA expression of 
XT-1, ChSy-1 and C4ST-1 GAG synthesizing enzymes. This was demonstrated by 
the outcome that TGF-β-mediated XT-1, ChSy-1 and C4ST-1 mRNA expression 
was blocked by flavopiridol, a pan CDK isoforms inhibitor (245). In Chapter 5, 
CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9 were observed in VSMC. The 
question raised is which CDK isoform(s) is/are directly involved in regulating the 
three GAG synthesizing enzymes? Therefore, in this chapter, selective CDK 
inhibitors were used to elucidate which CDK isoform(s) regulate the mRNA 
expression of GAG synthesizing enzymes XT-1, ChSy-1 and C4ST-1. Inhibitors 
with overlapping specificities CVT313 (CDK1 and CDK2) (246), roscovitine 
(CDK2, CDK7, CDK8 and CDK9) (243,378), PD0332991 (CDK4 and CDK6) (242) 
and flavopiridol (CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9) (242) were used 
because specific individual CDK inhibitors are not available. These CDK inhibitors 
were shown to block the TGF-β-stimulated Rb phosphorylation in VSMC (Fig. 5.8, 
Chap. 5). 
This chapter also explores the relationship between biglycan mRNA 
expression and CDK regulation. TGF-β treatment of VSMC showed increased 
biglycan mRNA expression associated with increased proteoglycan size (232). 
Earlier findings from our laboratory have shown that Akt is a downstream signalling 
component of TGF-β-mediated biglycan core protein synthesis but not of GAG chain 
hyperelongation in VSMC (280). This suggests that different signalling pathways 
exist for a TGF-β in regulating GAG chain and proteoglycan core protein synthesis 
(280). Akt has a central role in cell proliferation and metabolism, and its 
hyperactivation causes many pathophysiological conditions, including cancer (408-
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410). This is due to the interaction between Akt and cyclin-A that mediates cell cycle 
progression through CDKs (410). Therefore, in addition to understanding the role 
that CDK plays in GAG synthesizing enzyme regulation, this chapter also examines 
the association between these isoforms and biglycan synthesis.  
6.2 Materials and Methods 
 Materials 
Primers for biglycan (Forward 5'-CTCAACTACCTGCGCATCTCAG-3', Reverse 
5'-GATGGCCTGGATTTTGTTGTG-3') (232) were derived from publicly 
deposited sequences available in NCBI GenBank and purchased from GeneWorks 
Pty Ltd. Primers for GAG synthesizing enzymes were described in Chapter 3 
(Section 3.2.1). The CDK inhibitors were as described in Chapter 5 (Section 5.2.1). 
 Methods 
Tissue culture methods are given in detail in Chapter 2 (Section 2.2.1). Analysis of 
mRNA expression was performed using Q-RT-PCR analysis as described in 
Chapter 2 (Section 2.2.2). Statistical analysis was conducted as described in 
Chapter 2 (Section 2.2.5). For experiments that utilize CDK inhibitors (Figs. 6.1-6.4, 
6.6), 1:1000 DMSO was added to the DMEM as vehicle control for basal and 
positive control (cells treated with TGF-β only). 
 
 
185 
 
6.3 Results 
 Effect of CDK inhibitor flavopiridol on TGF-β-stimulated 
GAG synthesizing enzyme mRNA expression in VSMC 
This study initially determined the involvement of CDK1, CDK2, CDK4, CDK6, 
CDK7 and CDK9 in regulating TGF-β-stimulated GAG synthesizing enzyme 
mRNA expression in VSMC. Hence, flavopiridol was used which target this set of 
CDKs (242). VSMC were treated with TGF-β (2 ng/ml) for 6 h. TGF-β stimulation 
caused a 1.5-fold increase in XT-1 mRNA expression (p<0.01) in these cells 
(Fig.  6.1A). Flavopiridol (25–500 nM) had a dose-dependent inhibitory effect on 
XT-1 mRNA expression (p<0.01) (Fig 6.1A). The TGFβR1 inhibitor, SB431542 
(232) was used as a positive control in this study and it abolished TGF-β stimulated 
expression of XT-1 mRNA.  
TGF-β treatment increased ChSy-1 mRNA expression 3-fold compared to 
non-treated control cells (p<0.01) (Fig. 6.1 B). Flavopiridol (50 nM) caused a 40% 
decrease in the level of ChSy-1 mRNA, compared to those cells treated with TGF-β 
alone (p<0.01). At 100 nM flavopiridol abolished the TGF-β stimulation of ChSy-1 
mRNA expression in these cells (p<0.01). At higher doses flavopiridol 
(250-500 nM) blocked TGF-β stimulated ChSy-1 mRNA expression up to 90% 
compared to cells with TGF-β treatment alone (p<0.01). SB431542 also abolished 
the TGF-β stimulation of ChSy-1 mRNA expression in these cells (p<0.01). 
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Figure 6.1: Effect of flavopiridol on TGF-β-stimulated mRNA expression of 
GAG synthesizing enzymes XT-1, ChSy-1 and C4ST-1 
VSMC were pre-incubated with either flavopiridol (5–500 nM) or SB431542 
(3 μM) for 30 min before being treated with TGF-β (2 ng/ml) for 6 h. Histograms 
represents the mean ± S.E.M. of three individual experiments measured in duplicate 
which indicate the fold change of (A) XT-1, (B) ChSy-1 and (C) C4ST-1 mRNA 
expression compared to non-treated controls. Experiments were analyzed using 
one-way ANOVA followed by least significant difference post-hoc analysis, 
##p<0.01 basal versus TGF-β, **p<0.01 inhibitor versus TGF-β.  
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TGF-β-stimulated mRNA expression of C4ST-1 was upregulated 2-fold 
(p<0.01) (Fig. 6.1C) compared to non-treated control cells. At low doses 
flavopiridol (5–25 nM) caused a slight inhibition of C4ST-1 mRNA expression. At 
50 nM, flavopiridol caused more than 50% inhibition (p<0.01). At higher doses 
(100–500 nM) flavopiridol caused a concentration-dependent decrease in 
TGF-β-mediated C4ST-1 mRNA expression (p<0.01). SB431542 totally blocked 
the TGF-β-stimulated C4ST-1 mRNA expression in the VSMC (p<0.01). These 
results suggest that one or more of the CDK isoforms (CDK1, CDK2, CDK4 
CDK6, CDK7 or CDK9) modulate the mRNA expression of XT-1, ChSy-1 and 
C4ST-1 GAG synthesizing enzymes in VSMC.  
 Effect of CDK inhibitor CVT313 on TGF-β-stimulated mRNA 
expression of GAG synthesizing enzymes XT-1, ChSy-1 and 
C4ST-1 
To further investigate whether CDK1 and CDK2 modulates the mRNA expression of 
the GAG synthesizing enzymes, the CDK1 and CDK2 inhibitor CVT313 was used 
(246). VSMC were treated with TGF-β (2 ng/ml) for 6 h. This resulted in a 2.0-fold 
increase in the mRNA expression of the enzyme XT-1 (p<0.01) (Fig. 6.2A). Low 
doses of CVT313 (0.1 and 0.3 μM) did not inhibit XT-1 mRNA expression. At 
higher doses (1 and 3 μM), there was a dose-dependent inhibition elicited by 
CVT313 (p<0.01). SB431542 completely inhibited TGF-β enhanced expression of 
XT-1 mRNA (p<0.01).  
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Figure 6.2: Effect of CDK inhibitor CVT313 on TGF-β-stimulated mRNA 
expression of GAG synthesizing enzymes XT-1, ChSy-1 and C4ST-1 
VSMC were pre-incubated with either CVT313 (0.1–3 μM) or SB431542 for 
30 min before being treated with TGF-β (2 ng/ml) for 6 h. Histograms represents 
the mean ± S.E.M. of three individual experiments which indicate the fold change 
of (A) XT-1, (B) ChSy-1 and (C) C4ST-1 mRNA expression compared to 
non-treated controls. Experiments were analyzed using one-way ANOVA followed 
by least significant difference post-hoc analysis, ##p<0.01 basal versus TGF-β, 
**p<0.01 inhibitor versus TGF-β. 
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Treatment of VSMC with TGF-β caused a 4-fold increase in the mRNA 
expression of ChSy-1 enzyme (p<0.01) (Fig. 6.2B). CVT313 (0.1 μM) caused a 50% 
inhibition of ChSy-1 mRNA expression compared to TGF-β treatment alone 
(p<0.01). Higher doses of CVT313 (0.3–3 μM) further inhibited TGF-β stimulated 
ChSy-1 mRNA expression to at least 1.3 fold (p<0.01). SB431542 completely 
inhibited TGF-β enhanced expression of ChSy-1 mRNA expression (p<0.01). 
TGF-β (2 ng/ml) stimulated 2.1-fold increase (p<0.01) in C4ST-1 mRNA 
expression (Fig. 6.2C). Treatment with CVT313 (0.1–3 μM) caused a 
concentration-dependent decrease in TGF-β-stimulated C4ST-1 mRNA expression 
in these cells (p<0.01). The TGF-β-stimulated mRNA expression of C4ST-1 was 
also abolished by SB431542 (p<0.01). These findings further support the notion 
that CDK1 and CDK2 are involved in modulating the mRNA expression of XT-1, 
ChSy-1 and C4ST-1 GAG synthesizing enzymes. 
 Effect of CDK inhibitor PD0332991 on TGF-β-stimulated 
mRNA expression of XT-1, ChSy-1 and C4ST-1 
The role CDK4 and CDK6 play in modulating the mRNA expression of the GAG 
synthesizing enzymes was determined using the inhibitor PD0332991 (242). VSMC 
were treated with TGF-β for 6 h, which caused a 2-fold increase in XT-1 mRNA 
expression (p<0.01) (Fig. 6.3A). PD0332991 (1 μM) caused an 80% inhibition 
(p<0.05) of the TGF-β induced stimulation of XT-1 mRNA expression. Higher 
doses of PD0332991 (3 and 10 μM) did not cause any further reduction in XT-1 
mRNA expression levels. The positive control, SB431542 abolished the TGF-β 
induced expression of XT-1 mRNA (p<0.01) in these cells.  
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Figure 6.3: Effect of CDK inhibitor PD0332991 on TGF-β-stimulated mRNA 
expression of GAG synthesizing enzymes XT-1, ChSy-1 and C4ST-1 
VSMC were pre-incubated with either PD0332991 (0.1–10 μM) or SB431542 
(3 μM) for 30 min before being treated with TGF-β (2 ng/ml) for 6 h. Histograms 
represents the mean ± S.E.M. of three individual experiments which indicate the 
fold change of (A) XT-1, (B) ChSy-1 and (C) C4ST-1 mRNA expression compared 
to non-treated controls. Experiments were analyzed using one-way ANOVA 
followed by least significant difference post-hoc analysis, ##p<0.01 basal versus 
TGF-β, **p<0.01, *p<0.05 inhibitor versus TGF-β. 
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 TGF-β treatment of VSMC for 6 h caused a 4-fold increase in ChSy-1 
mRNA expression (p<0.01) (Fig. 6.3B). Low concentration of the CDK4 and 
CDK6 inhibitor PD0332991 (0.1–0.3 μM) did not inhibit ChSy-1 mRNA 
expression. At 1 μM, the mRNA expression of ChSy-1 was prevented to 2.9-fold 
compared to non-treated control (p<0.01).  
Analysis of C4ST-1 mRNA expression showed that TGF-β treatment caused 
a 1.7-fold rise in the amount of mRNA expression compared to non-treated controls 
(p<0.01) (Fig. 6.3C). Treatment with PD0332991 (1–10 μM) caused a 
dose-dependent decrease of TGF-β-mediated C4ST-1 mRNA expression (p<0.05). 
Higher PD0332991 concentrations (3–10 μM) did not further inhibit 
TGF-β-induced mRNA expression of C4ST-1 synthesizing enzymes. SB431542 
abolished the TGF-β-induced C4ST-1 mRNA expression (p<0.01). 
These results suggest the involvement of CDK4 and CDK6 in regulating the 
mRNA expression of XT-1, ChSy-1 and C4ST-1 GAG synthesizing enzymes in 
VSMC treated with TGF-β. Nevertheless, the partial inhibition of TGF-β-stimulated 
XT-1 and ChSy-1 mRNA expression even after higher doses of PD0332991 
suggests that CDK4 and CDK6 could have less involvement in XT-1 and ChSy-1 
regulation compared to other CDK isoforms. 
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 Effect of CDK inhibitor roscovitine on TGF-β-stimulated 
mRNA expression of GAG synthesizing enzymes XT-1, 
ChSy-1 and C4ST-1 
Roscovitine inhibits the activity of CDK2, CDK7, CDK8 and CDK9 (242). The 
addition of TGF-β to VSMC resulted in a 2.0 ± 0.2-fold increase in the expression 
of XT-1 mRNA (Fig. 6.4A). Roscovitine only at 30 μM was shown to inhibit the 
TGF-β-induced expression of XT-1 mRNA in these cells (p<0.01). Similarly, 
SB431542 (3 μM) also inhibited the TGF-β stimulation of XT-1 mRNA expression 
(p<0.01).  
TGF-β treatment on VSMC induced 4.9 ± 0.5-fold upregulation of ChSy-1 
mRNA expression (p<0.01) (Fig. 6.4B). Roscovitine at 1 and 3 μM caused 25% 
inhibition of ChSy-1 mRNA expression compared to cells treated with TGF-β alone 
(p<0.05). Further increase in concentration of roscovitine caused a dose-dependent 
inhibition of ChSy-1 mRNA expression (p<0.01). SB431542 totally abolished the 
TGF-β induced mRNA expression of ChSy-1 (1.0 ± 0.01-fold) (p<0.01).  
TGF-β stimulation caused a 3.0 ± 0.2-fold elevation of C4ST-1 mRNA 
expression compared to non-treated control (p<0.01) (Fig. 6.4C). The presence of 
roscovitine (3-10 μM) resulted in a dose-dependent inhibition of C4ST-1 mRNA 
expression (p<0.05). Inhibition of the TGFβR1 by SB431542 blocked the 
TGF-β-stimulation of C4ST-1 mRNA expression (p<0.01). These results further 
suggest that CDK2, CDK7 and CDK9 are involved in the TGFβR1 mediated XT-1, 
ChSy-1 and C4ST-1 mRNA expression. 
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Figure 6.4: Effect of CDK inhibitor roscovitine on TGF-β-stimulated mRNA 
expression of GAG synthesizing enzymes XT-1, ChSy-1 and C4ST-1 
VSMC were pre-incubated with either Roscovitine (1–100 μM) or SB431542 
(3 μM) for 30 min before being treated with TGF-β (2 ng/ml) for 6 h. Histograms 
represents the mean ± S.E.M. of three individual experiments which indicate the 
fold change of (A) XT-1, (B) ChSy-1 and (C) C4ST-1 mRNA expression compared 
to non-treated controls. Experiments were analyzed using one-way ANOVA 
followed by least significant difference post-hoc analysis, ##p<0.01 basal versus 
TGF-β, **p<0.01, *p<0.05 inhibitor versus TGF-β.  
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 TGF-β-mediated time course of biglycan mRNA expression in 
VSMC  
Proteoglycans consist of a core protein to which is attached GAG chains. Both the 
core protein and GAG chains can be regulated by growth factors including TGF-β 
(156,280,411). In addition to measuring the expression of genes for GAG enzymes, 
the effects of CDK inhibition on the synthesis of biglycan mRNA expression were 
also explored to specifically elucidate the effects TGF-β has on core protein 
synthesis. TGF-β has been reported to increase biglycan mRNA expression in 
VSMC (232). Therefore, a time course experiment for TGF-β-mediated biglycan 
core protein mRNA expression was performed. VSMC were treated with TGF-β 
from 2–24 h (Fig. 6.5) and a biphasic response was observed during this period. 
Maximal biglycan mRNA expression (4.1-fold) was observed at 4 h post-TGF-β 
treatment. At 20 h a second peak in mRNA expression was observed which dropped 
to 1.2-fold at 24 h. This result indicates that biglycan mRNA expression is 
modulated by TGF-β, resulting in a biphasic pattern of expression that was seen 
throughout the 24 h time course. 
For this particular study, only one experiment was carried out to determine 
the optimum time for TGF-β-stimulated biglycan mRNA expression to perform 
subsequent studies using CDK inhibitors. 
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Figure 6.5: Time course of TGF-β-stimulated biglycan mRNA expression 
VSMC were treated with TGF-β (2 ng/ml) for different periods of time, 2–24 h as 
indicated and the biglycan core protein mRNA expression was measured. 
Histogram shows the mean fold change ± range of a single individual 
experiment measured in duplicate. 
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 Effects of CDK inhibitors flavopiridol, CVT313, PD0332991 
and roscovitine on TGF-β-stimulated biglycan mRNA 
expression in VSMC 
To analyze the effect of CDK inhibition on the biglycan core protein synthesis, the 
expression of biglycan mRNA was measured in VSMC treated with TGF-β for up 
to 4 h in the presence or absence of CDK inhibitors (156). All four CDK inhibitors 
used to analyze the involvement of CDK and GAG synthesizing enzyme mRNA 
expression (Section 6.3.1–6.3.4) were utilised. The 4 h TGF-β treatment increased 
biglycan mRNA expression up to 1.4-fold (p<0.01) (Fig. 6.6). This elevated 
biglycan mRNA expression level is lower compared to the 4 h time point in the time 
course experiment (Fig. 6.5, Section 6.3.5), which was a single experiment, 
performed using early passage of VSMC that produced larger response of mRNA 
expression. The variable responsiveness depending on the passage of VSMC could 
be caused by increased amount of intracellular signalling modulators such as 
ERK1/2 MAPK (412). Previous study from our laboratory (232) and unpublished 
data showed similar amount of biglycan mRNA expression from three experiments 
that were pooled together, indicating that the average response from VSMC would 
be within the range observed in this current experiment (Fig. 6.6). Nevertheless, the 
TGF-β-stimulated biglycan mRNA expression (p<0.01) in this experiment was 
sufficient for pharmacological analysis.  
All inhibitors were tested at 1 and 10 μM, except for flavopiridol, which was 
only used at 1 μM. All of the CDK inhibitors (CVT313, PD0332991, roscovitine 
and flavopiridol) were able to inhibit (p<0.01 or p<0.05) the TGF-β-stimulated 
biglycan mRNA expression (Fig. 6.6). SB431542 completely blocked 
TGF-β-stimulated biglycan mRNA expression (p<0.05). 
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Figure 6.6: Effects of CDK inhibitors flavopiridol, CVT313, PD0332991 and 
roscovitine on TGF-β-stimulated biglycan mRNA expression 
VSMC were pre-incubated with the following CDK inhibitors: CVT313 (1 and 
10 μM), PD0332991 (1 and 10 μM), roscovitine (1 and 10 μM), flavopiridol (1 μM) 
and SB431542 (3 μM) for 30 min followed by TGF-β (2 ng/ml) for 4 h. The 
histogram shows the mean fold change ± S.E.M. from three individual experiments 
compared to non-treated controls. Experiments were analyzed using one-way 
ANOVA followed by least significant difference post-hoc analysis, ##p<0.01 basal 
versus TGF-β, **p<0.01 and *p<0.05 inhibitor versus TGF-β. 
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These results suggest that CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9 
regulate not only GAG synthesizing enzymes but also biglycan 
core protein expression in VSMC. 
 
6.4 Summary of Results  
The results presented in this chapter demonstrate the effects of CDK inhibitors on 
TGF-β-mediated regulation of GAG synthesizing enzymes XT-1, ChSy-1 and 
C4ST-1 and proteoglycan biglycan mRNA expression produced by VSMC in vitro. 
A summary of the findings from this chapter are: 
 
 Flavopiridol, CVT313, roscovitine and PD0332991 elicit a dose inhibitory 
effect on the TGF-β-stimulated mRNA expression of GAG synthesizing 
enzymes XT-1, ChSy-1 and C4ST-1. 
 
 A biphasic pattern of mRNA expression was seen for biglycan through the 
24 h TGF-β time course experiment. An early response of TGF-β-mediated 
mRNA expression was seen at 2 h which peaked at 4 h followed by a later 
stimulation that peaked at 20 h.  
 
 Flavopiridol, CVT313, roscovitine and PD0332991 elicit a dose inhibitory 
effect on the TGF-β-stimulated mRNA expression of biglycan.  
 
 PD0332991 shows less inhibitory effects on TGF-β-stimulated XT-1, ChSy-1 
and C4ST-1 mRNA expression compared to flavopiridol, CVT313 and 
roscovitine. 
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6.5  Discussion 
The mRNA expression of GAG synthesizing enzymes XT-1, ChSy-1 and C4ST-1 
was regulated by TGF-β stimulation in VSMC (Chapter 3). This study also reported 
that TGF-β-stimulated increase in ChSy-1 and C4ST-1 mRNA expression was 
sufficient to elevate the level of these proteins in the cell. In Chapter 4, TGF-β was 
shown to regulate mRNA expression through the ERK and p38 signalling pathways. 
This links to a previous finding from our laboratory that showed TGF-β-mediated 
GAG chain hyperelongation on biglycan produced by human VSMC in vitro 
requires both ERK and p38 intermediate kinases (232). Therefore, this highly 
suggests that an increase in GAG synthesizing mRNA expression has an imperative 
effect on the increase in GAG chain hyperelongation on biglycan, which 
serine/threonine kinases are intermediates of these processes.  
In this chapter, the relationship between CDK isoforms in human VSMC with 
the regulation of the mRNA of the GAG synthesizing enzymes was investigated. 
Data from the dose-dependent inhibitory studies of the CDK inhibitors towards 
GAG synthesizing enzyme mRNA expression (Figs. 6.1-6.4) were used to provide 
the suitable inhibitor concentration for the experiment in Section 5.3.3: Regulation 
of TGF-β-mediated CDK activity assessed through Rb protein phosphorylation In 
addition to focusing on GAG chain elongation pathways, the relationship between 
CDK and the signalling pathways related to biglycan mRNA expression was also 
investigated. CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9 are expressed in 
human VSMC (Chap. 5). Flavopiridol, CVT313, roscovitine and PD0332991 
elicited a dose inhibitory effect on the TGF-β-stimulated mRNA expression of GAG 
synthesizing enzymes XT-1, ChSy-1 and C4ST-1 as well as biglycan. CDK1, 
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CDK2, CDK4, CDK6, CDK7 and CDK9 are targets of the CDK inhibitors 
flavopiridol, CVT313, roscovitine and PD0332991. Hence, these results suggest the 
involvement of these CDKs in regulating the mRNA expression of GAG 
synthesizing enzymes as well as biglycan core protein. Therefore, it is possible that 
via TGF-β-stimulated CDK activation, biglycan core protein synthesis and GAG 
chain elongation can occur jointly contributing to increased biglycan core protein 
with higher levels of modified GAG chains.  
In human VSMC, biglycan mRNA expression was increased by TGF-β 
stimulation and pharmacological experiments suggest that CDKs are involved as 
mediators of this signalling pathway. Biglycan expression in the blood vessel wall 
has been shown to be increased in human atherosclerotic lesions (54). A study 
investigating the effects of biglycan overexpression on vascular proliferation found 
that an increase in biglycan expression contributed to the upregulation of vascular 
smooth muscle growth and migration through the stimulation of the cell cycle 
pathway (308). This involved an increase in CDK2 expression and reduction of CDK 
inhibitor p27 levels (308). Another study showed that the effect of induced vascular 
proliferation in airway SMC by proteoglycans was unique to biglycan and not 
decorin (413). This finding supports the notion that CDKs can activate biglycan core 
protein expression as seen in our current study. The stimulation of GAG chain can be 
further enhanced by additional activation of CDK signalling by biglycan 
overexpression, in turn contributing to the overall TGF-β-mediated core protein and 
GAG chain elongation. This reinforces a role for CDKs in atherosclerosis 
progression. 
The wide diversity of CDK isoforms has made drug development 
challenging as these CDK isoforms are both context specific and cell type 
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dependent. As an example, CDK4 is involved in Ras- or Her2-gland tumour 
development but not involved in Myc-induced tumorigenesis (241). Hence, 
inhibition of CDK4 alone can only protect mammary gland cells from Ras- or 
Her2-, but not Myc-induced breast carcinoma (241). In the context of this current 
study, we provide evidence of the role of subsets of CDKs (as determined through 
the use of CDK inhibitors) towards regulating GAG synthesizing enzyme mRNA 
expression in VSMC. This extends the importance of CDKs in the development of 
cardiovascular disease in VSMC through proteoglycan modification. One of the 
currently known processes of atherosclerosis relating to CDK is accelerated cell 
proliferation and migration of VSMC. The resulting focal accumulation of VSMC 
within the intima exacerbates the development of atherosclerotic lesion in humans 
(361,362). In aortas of cholesterol-fed rabbits, elevated expression and activity 
of CDK1, CDK2 and CDK4 was reported after eight weeks of modest plaque 
development, and 16 weeks of severe plaque progression (414). Therefore, findings 
from our study support the involvement of CDK1, CDK2 and CDK4 in the 
development of atherosclerosis and further highlighting that the mechanism behind 
this includes a novel role of CDKs, which causes increase in GAG chain elongation. 
It is essential to understand other mechanisms involving CDKs 
particularly non-proliferative functions that may contribute to atherosclerosis 
progression. This includes participation of CDK in the “response to retention” 
events via proteoglycan modification leading to retention of atherosclerotic 
lipoprotein. Understanding the multiple roles of CDK helps widen the beneficial 
mechanisms of these inhibitors in the context of identifying therapeutic targets 
for atherosclerosis (82). Studies on the effects of CDK inhibitors had been 
mainly focused on its role to target cell proliferation and growth mechanisms 
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that lead to the development of atherosclerosis (244). Local administration of the 
CDK1 and CDK2 inhibitors, CVT313 (1.25 mg/kg) for 15 min under pressure at the 
site of balloon angioplasty lead to an 80% reduction of neointima formation in rats 
(246). On the other hand, oral administration of flavopiridol at 5 mg/kg for 5 days 
starting on the day of balloon angioplasty was shown to reduce neointima formation 
by 35% and by 39% at day 7 and 14, respectively (245). In this current study, we 
have shown that flavopiridol (inhibitor of CDK1, CDK2, CDK4, CDK6, CDK7 and 
CDK9 activity) inhibited GAG synthesizing enzyme mRNA expression at very low 
concentrations. The inhibitory concentration at 50% (IC50) was between the range of 
50–100 nM for XT-1, ChSy-1 and C4ST-1 mRNA expression. Flavopiridol inhibits 
CDK activity by competing with ATP for the active site of each kinase (415). In 
human breast carcinoma and HeLa cells, the activities of CDK1, CDK2, CDK4, 
CDK6 and CDK7 were also inhibited by flavopiridol at low IC50 values ranging 
from 20–300 nM (415). The results of both the flavopiridol and CVT313 inhibition 
studies strongly support the involvement of CDK1 and CDK2 in GAG synthesizing 
enzyme mRNA expression in VSMC. 
Data from this study showed that CVT313 inhibited GAG chain elongation 
and this is linked to inhibition of GAG synthesizing enzyme mRNA expression. 
Thus we can postulate that CVT313 could prevent atherosclerosis development by 
blocking CDK1 and CDK2 as intermediates of TGF-β-stimulated XT-1, ChSy-1 
and C4ST-1 mRNA expression in VSMC. A natural extension of this experiment 
could be to use apoE-knockout mice fed with high-fat diet that develops 
hypercholesterolemia and treat with CVT313 to demonstrate the effects of CDK1 
and CDK2 inhibition in preventing atherosclerotic plaque development through 
retention of lipoproteins by proteoglycan modification.  
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Inhibition of TGF-β-stimulated GAG synthesizing enzymes XT-1, ChSy-1 
and C4ST-1 by PD0332991 showed that CDK4 and CDK6 play a role in this 
process. Our results showed that the inhibitory effects of PD0332991 on two 
enzymes XT-1 and ChSy-1 mRNA expression remained at a plateau at high 
inhibitor concentrations (Fig. 6.3). This could imply that the targets of this inhibitor 
i.e. CDK4 and CDK6 have less regulatory role on XT-1 and ChSy-1 mRNA 
expression compared to other CDK isoforms. Despite that, inhibition of CDK1, 
CDK2, CDK7 and CDK9 by CVT313 (CDK1 and CDK2 inhibitor) and roscovitine 
(CDK2, CDK7 and CDK9 inhibitor) caused a dose-dependent inhibition of the three 
GAG synthesizing enzyme XT-1, ChSy-1 and C4ST-1. Flavopiridol that targeted all 
the CDKs isoform studied (CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9) totally 
abolished the TGF-β-stimulated XT-1, ChSy-1 and C4ST-1 mRNA at 
concentrations as low as 50 nM, 100 nM and 50 nM, respectively (Fig. 6.1). Further 
investigation using different CDK siRNA is warranted to allow deeper 
understanding on the involvement of each CDK isoform with regards to XT-1 
ChSy-1 and C4ST-1 mRNA expression. 
Roscovitine is a 2,6,9-trisubstituted purine currently in phase II clinical trials 
as an anticancer drug, and inhibits CDK2, CDK7 and CDK9 activity (405,416). 
This current study showed that in VSMC, roscovitine inhibits GAG synthesizing 
enzymes XT-1, ChSy-1 and C4ST-1 mRNA expression. Both flavopiridol and 
roscovitine inhibit CDK7 and CDK9 activity. Hence, these data suggest that CDK7 
and CDK9 are regulators of XT-1, ChSy-1 and C4ST-1 enzyme gene expression. 
One of the possible mechanisms could be transcriptional regulation via RNA Pol II. 
CDK7 and CDK9 have been reported to engage in cross-talk, sequentially 
phosphorylating CTD of RNA Pol II that provides a docking site for various 
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proteins, bridging nuclear factors for both transcriptional initiation and elongation 
processes to transcription (417,418). In human fibroblasts, roscovitine suppressed 
cell growth caused by blocking phosphorylation of the CTD of RNA Pol II and 
inhibiting mRNA synthesis (419). The CTD/DNA complex is recognized by CDK7 
allowing subsequent phosphorylation at the Ser5 residue. Phosphorylated Ser5 of 
CTD RNA Pol II is competent for the initiation of transcription but not for 
elongation or to transcribe the entire mRNA (388,420). Concurrently, 
phosphorylation by CDK7 makes it available for CDK9 phosphorylation of the Ser2 
residue that modifies RNA Pol II, becoming recognizable by elongation factors such 
as Elongator allowing assembly of the elongation-competent RNA Pol II (421). 
Based on these data, it is tempting to speculate that TGF-β-stimulated CDK7 and 
CDK9 could induce transcriptional initiation and elongation of the XT-1, ChSy-1 
and C4ST-1 genes. In Chapter 5, high levels of CDK7 and CDK9 protein 
expression was observed in VSMC suggesting an essential role of these proteins 
which at least in part via transcriptional regulation of GAG synthesizing enzymes. 
To verify this interpretation of the data, experiments on gene mechanism 
specifically chromatin immunoprecipitation (ChIP) assay are warranted to delineate 
the RNA Pol II–GAG gene interactions with absence or presence of CDK7 and 
CDK9 inhibitors (422,423). 
In Chapter 5, the inhibition of TGF-β-mediated Rb phosphorylation by 
roscovitine, flavopiridol, CVT313 and PD033291 was demonstrated. This suggests 
that CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9 downstream effects are 
mediated by TGF-β signalling pathways. With regards to TGF-β signalling and its 
relation to CDKs, this mechanism would involve Smad transcription factors. In 
tumour cells, TGF-β potently inhibits cell proliferation by causing cell cycle arrest 
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at the G1 phase (174,256). The potent growth-inhibitory effects are due to the 
ultimate downregulation of c-myc promoter expression and the upregulation of the 
CDK inhibitors p15 and p21 (257,258). Smad3 acts as a key mediator in this 
anti-proliferative effect of TGF-β and provides a target for inhibitory 
phosphorylation by CDK2 and CDK4 (238). The CDKs can directly phosphorylate 
9 out of 14 residues on Smad3 that can be phosphorylated (four residues are on the 
linker region; Thr179, Ser204, Ser208 and Ser213) (238). All of the four residues in 
the linker region were phosphorylated by CDK2 and CDK4 in vitro while in vivo 
only Thr179 and Ser213 were phosphorylated (238). The CDK phosphorylation of 
Smad3 to inhibit Smad3 anti-proliferative function also describes a negative 
feedback control of CDK activities (259). 
Alarcon et al. (230) observed that CDK8 and CDK9 phosphorylated the 
Smad3 linker region at Thr179, Ser208 and Ser213 in human keratinocyte cells 
(HaCaT cells). These phosphorylated residues on the linker region would then act as 
a binding site for the E3 ubiquitin ligases, smurf1 and Nedd4L (230). This complex 
then accumulates in the nucleus and regulates the transcription of target genes that 
include cell cycle regulators such as the CDK inhibitors p15 and p21 and the 
proto-oncogene c-myc (247). All of these findings indicate that the Smad linker 
regions are substrates of phosphorylation by CDK2, CDK4, CDK8 and CDK9. Still, 
the involvement of Smads and CDKs in VSMC associated with biglycan synthesis 
and GAG chain elongation is poorly understood. Therefore, in the next chapter, this 
study explores Smad linker region phosphorylation involving CDKs and TGF-β. 
In summary, in this chapter we have shown that CDK1, CDK2, CDK4, 
CDK6, CDK7 and CDK9 are potential regulators of elevated XT-1, ChSy-1, C4ST-1 
and biglycan mRNA expression. These effects are mediated at least in part by TGF-β 
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stimulation. The results reinforce the concept that CDKs possess multiple roles in 
biological processes, which extend far beyond cell cycle control. This may have 
important implications on our understanding of CDKs in the process of 
atherosclerosis development. In particular, the dual role of CDK as an essential 
regulator of proteoglycan modification via GAG synthesizing enzymes and biglycan 
mRNA expression, as well as its role as an established regulator of accelerated 
VSMC proliferation. 
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7.1 Introduction 
TGF-β signalling involves gene regulation by Smad transcription factors (208). In 
Chapter 3, the data shows that XT-1, ChSy-1 and C4ST-1 mRNA expression in 
VSMC in vitro is upregulated by TGF-β. This likely contributes towards the 
increase in GAG chain hyperelongation observed in vivo by Anggraeni et al. (145) 
which showed a correlation between increased mRNA expression of ChSy-1 and 
C4ST-1 with GAG chain elongation in the development of atherosclerosis in vivo. 
In this chapter, the aim is to investigate the relationship between 
TGF-β-induced GAG synthesizing enzyme gene expression and the ultimate effects 
on biglycan size as assessed by SDS-PAGE. Early stages of atherosclerotic lesion 
development are caused by the accumulation of proteoglycans including biglycan in 
the ECM of atherosclerotic-prone artery walls (424). In Chapter 6, the data also 
demonstrates that TGF-β-stimulated GAG synthesizing enzymes XT-1, ChSy-1 and 
C4ST-1 mRNA expression involves CDKs. Therefore, in this chapter, the role of 
CDK in regulating biglycan size is also examined. In particular, analysis of biglycan 
GAG chain hyperelongation was investigated to determine whether CDKs are 
mediators of the TGF-β induced GAG chain hyperelongation on biglycan in human 
VSMC.  
The involvement of CDKs with Smad2L phosphorylation in the TGF-β 
signalling pathway has been identified (Chap. 4). The CDK complex is known to 
phosphorylate substrates that are involved in transcriptional process, for example the 
Rb protein which is a transcriptional repressor for E2F (425), p220NPAT (426), 
CREB-binding protein (427) and RNA Pol II (387). Rb was the only demonstrated 
substrate of CDK4 until Matsuura et al. (238) showed that Smad3 was 
phosphorylated by both CDK2 and CDK4 in vivo and in vitro (238). CDK2 and 
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CDK4 phosphorylated four possible Smad3 linker region sites (Thr179, Ser204, 
Ser208 and Ser213), which limited the proliferative effect of TGF-β in Mv1Lu mink 
lung epithelial cells (238). Another aim in this chapter is to identify which CDK(s) 
can phosphorylate Smad linker region in VSMC as this key phosphorylation event is 
associated with biglycan GAG chain hyperelongation (232).  
7.2 Materials and Methods 
 Materials 
Carrier-free [35S]-SO4 was from MP Biomedicals (Irvine, USA), Cetylpyridinium 
chloride (CPC) from Uni-lab Chemicals and Pharmaceuticals (Mumbai, India), 
inhibitors for CDKs were described in Chapter 5 (Section 5.2.1) and the antibodies 
for Western blotting were described in Chapter 4 (Section 4.2.1). 
 Methods 
Tissue culture methods are given in detail in Chapter 2 (Section 2.2.1). For 
experiments that utilize CDK inhibitors (Figs. 7.1-7.4 and 7.6-7.7), 1:1000 DMSO 
was added to the DMEM as vehicle control for basal and positive control (cells 
treated with TGF-β only). Protein expression was analyzed using Western blot 
technique as described in Chapter 2 (Section 2.2.3). Proteoglycan synthesis was 
measured using quantification of radiolabel incorporation into proteoglycans while 
determination of proteoglycan size was determined using SDS-PAGE. Methods for 
proteoglycan study are given in detail in Chapter 2 (Section 2.2.4). Statistical 
analysis was conducted as described in Chapter 2 (Section 2.2.5).  
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7.3 Results 
 Effects of CDK inhibitors flavopiridol, PD0332991, roscovitine 
and CVT313 on TGF-β-stimulated proteoglycan synthesis and 
GAG chain elongation in VSMC 
Proatherogenic growth factors including thrombin, PDGF and TGF-β stimulate 
VSMC resulting in an increase in the size of the GAG chains on secreted 
proteoglycans (161,232,428). Longer GAG chains are associated with increased 
binding in vitro to LDL (429,430). To measure proteoglycan synthesis from VSMC, 
the incorporation of radioactive [35S]-SO4 into secreted proteoglycans was 
performed (308,309). [35S]-SO4 is metabolically incorporated into the proteoglycan 
GAG chains and core protein. More core protein synthesis allows more sites for the 
initiation and polymerization of GAG chains (124). SDS-PAGE is utilized to 
measure the size of proteoglycans.  
The role of TGF-β-mediated CDK signalling in proteoglycan synthesis was 
investigated using CDK inhibitors flavopiridol, PD0332991, roscovitine and 
CVT313. Effects of Flavopiridol on endogenous proteoglycan synthesis were 
determined in lane 2, Fig. 7.1. In VSMC treated with TGF-β there was at least a 
2-fold increase in [35S]-SO4 incorporation into secreted proteoglycans compared to 
non-treated controls (p<0.01) (Fig. 7.1, lane 3 vs lane 1). When VSMC were treated 
with CDK inhibitors at 1 μM for 24 h, there was a complete inhibition of TGF-β 
stimulated [35S]-SO4 incorporation into proteoglycans by flavopiridol and CVT313. 
PD0332991 inhibited [35S]-SO4 incorporation by 30% (p<0.01) while roscovitine 
did not inhibit [35S]-SO4 incorporation (Fig. 7.1, lane 4–7). 
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Figure 7.1: Effects of CDK inhibitors flavopiridol, PD0332991, roscovitine and 
CVT313 on TGF-β-stimulated [35S]-SO4 incorporation into proteoglycans 
VSMC were treated with or without flavopiridol, PD0332991, roscovitine, 
CVT313, or SB431542 for 24 h with presence of TGF-β (2 ng/ml) and [35S]-SO4 
(50 μCi/ml). Medium containing secreted proteoglycans was harvested and spotted 
onto 3MM paper and were quantitated by Cetylpyridinium chloride (CPC) 
precipitation to measure radiolabel incorporation. The histogram shows the amount 
of [35S]-SO4 incorporated into proteoglycans. Results shown are the mean ± S.E.M 
of data normalized to control from two independent experiments performed in 
triplicate. Experiments were analyzed using one-way ANOVA followed by least 
significant difference post-hoc analysis, ##p<0.01 basal versus TGF-β, **p<0.01 
inhibitor versus TGF-β.  
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At higher concentrations, flavopiridol and CVT313 (10 μM) completely 
inhibited [35S]-SO4 incorporation into the proteoglycans while PD0332991 (10 μM) 
and roscovitine (10 μM) inhibited by 50% and 35%, respectively (p<0.01) (Fig. 7.2, 
lane 4–7). The TGFβR1 inhibitor, SB431542 (3 μM) was used as a positive control 
and it totally blocked TGF-β-stimulated [35S]-SO4 incorporation into the 
proteoglycans (Figs. 7.1 and 7.2, lane 8). These results show dose-dependent 
inhibitory effects of TGF-β-mediated [35S]-SO4 incorporation into proteoglycans by 
the respective CDK inhibitors flavopiridol (CDK1, CDK2, CDK4, CDK6, CDK7 
and CDK9), CVT313 (CDK1 and CDK2), PD0332991 (CDK4 and CDK6) and 
roscovitine (CDK2, CDK7 and CDK9). From the findings that these inhibitors 
block the set of CDKs in TGF-β-mediated [35S]-SO4 incorporation into 
proteoglycans, we can postulate that CDK1, CDK2, CDK4, CDK6, CDK7 and 
CDK9 are regulators of biglycan core proteins and GAG chain synthesis which is 
part of the TGF-β signalling pathway. 
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Figure 7.2: Effects of CDK inhibitors flavopiridol, PD0332991, roscovitine and 
CVT313 on TGF-β-stimulated [35S]-SO4 incorporation into proteoglycans 
VSMC were treated with or without flavopiridol, PD0332991, roscovitine, 
CVT313, or SB431542 for 24 h with presence of TGF-β (2 ng/ml) and [35S]-SO4 
(50 μCi/ml). Medium containing secreted proteoglycans was harvested and spotted 
onto 3MM paper and were quantitated by CPC precipitation to measure radiolabel 
incorporation. The histogram shows the amount of [35S]-SO4 incorporated into 
proteoglycans. Results shown are the mean ± S.E.M. of data normalized to control 
from two independent experiments performed in triplicate. Experiments were 
analyzed using one-way ANOVA followed by least significant difference post-hoc 
analysis, ##p<0.01 basal versus TGF-β, **p<0.01 inhibitor versus TGF-β.  
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 To determine the effect of CDKs on GAG chain synthesis, the size of the 
proteoglycans was assessed by SDS-PAGE. Unlike protein bands on Western blot, 
proteoglycans do not appear as sharp bands but instead as broad bands (smears) on 
SDS-PAGE technique due to the spectrum of the different sizes of GAG chains on 
proteoglycans (Figs. 7.3 and 7.4). The relative electrophoretic mobility of the bands 
indicates their relative size, which can be compared to a protein standard run 
simultaneously. Proteoglycans that are larger in size do not migrate as far down the 
gel as the smaller porosity of the gel impedes the movement of the larger molecules. 
Smaller proteoglycans are able to migrate further away from the origin of the gel, as 
they are not subjected to the same degree of the physical constraints as larger 
proteoglycans. The band which has a molecular mass of approximately 220 kDa has 
been identified as biglycan (431) (Fig. 7.3). Previously, to confirm the identification 
of a 200–300 kDa band as biglycan, Kinsella et al. (431) concentrated the 
proteoglycans from the culture media, and the 200–300 kDa band was purified by 
SDS-PAGE. Upon radioiodination and chondroitin ABC lyase digestion, this band 
yielded a 50 kDa core protein, which was recognized on a Western blot by a bovine 
biglycan specific antibody (LF-96). As the proteoglycan core protein size is fixed, 
any increase in size observed represents an increase in CS/DS GAG chain size 
(309).  
Effects of Flavopiridol on endogenous proteoglycan synthesis were 
determined in lane 2, Fig. 7.3. SDS-PAGE analysis showed a decrease in 
electrophoretic mobility of biglycan in the presence of TGF-β compared to 
non-treated controls (Fig. 7.3, lane 3 vs lane 1) indicating an increase in the overall 
size of biglycan.  
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VSMC were treated with or without flavopiridol (1 μM), PD0332991 (1 μM), 
roscovitine (1 μM), CVT313 (1 μM), or SB431542 (3 μM) for 24 h with presence of 
TGF-β (2 ng/ml) and [35S]-SO4 (50 μCi/ml). Medium containing secreted 
proteoglycans was harvested and spotted onto 3MM paper and were quantitated by 
CPC precipitation to measure radiolabel incorporation. Secreted proteoglycans were 
isolated using ion-exchange chromatography (DEAE-Sephacel) and concentrated by 
ethanol/potassium acetate precipitation and electrophoresed on a 4–13% 
SDS-PAGE. This gel is a representative from two experiments. 
Figure 7.3: Effects of CDK inhibitors flavopiridol, PD0332991, roscovitine and 
CVT313 on TGF-β-stimulated increase in biglycan size 
 1       2       3      4       5       6      7       8    
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There was no effect on biglycan electrophoretic mobility in the presence of 
1 μM inhibitors (PD0332991, roscovitine and CVT313) relative to TGF-β treatment 
alone (Fig. 7.3 lane 5–7 vs lane 3) indicating that at low concentration, these 
inhibitors did not block the TGF-β induced biglycan size. Electrophoretic mobility 
of biglycan in TGF-β treated cells was increased in the presence of flavopiridol 
(1 μM) and SB431542 (3 μM) (Fig. 7.3 lane 4 and lane 8).  
When the TGF-β treated cells were exposed to 10 μM flavopiridol, 
PD0332991 and CVT313 there was an increase in biglycan electrophoretic mobility 
(Fig. 7.4, lane 4–7 vs lane 3). However, roscovitine (10 μM) did not alter the 
electrophoretic mobility of the TGF-β-stimulated biglycan. In the presence of 
SB431542 the biglycan size in the TGF-β treated cells was the same size as seen in 
the non-treated controls (Fig. 7.4, lane 8).  
These results demonstrate that the increase in the size of biglycan in the 
TGF-β-stimulated VSMC is dose-dependently blocked by the CDK inhibitors 
flavopiridol (CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9), CVT313 (CDK1 
and CDK2) and PD0332991 (CDK4 and CDK6). From the findings that these 
inhibitors block the set of CDKs in TGF-β-mediated increase in the size of biglycan, 
it can be postulated that one or more of CDK1, CDK2, CDK4, CDK6, CDK7 and 
CDK9 may play a role in TGF-β-stimulated GAG chain hyperelongation in 
biglycan secreted by VSMC. 
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Figure 7.4: Effects of CDK inhibitors flavopiridol, PD0332991, roscovitine and 
CVT313 on TGF-β-stimulated increase in biglycan size 
VSMC were treated with or without flavopiridol (1 μM), PD0332991 (10 μM), 
roscovitine (10 μM), CVT313 (10 μM) and SB431542 (3 μM) for 24 h with presence 
of TGF-β (2 ng/ml) and [35S]-SO4 (50 μCi/ml). Medium containing secreted 
proteoglycans was harvested and spotted onto 3MM paper and were quantitated by 
CPC precipitation to measure radiolabel incorporation. Secreted proteoglycans were 
isolated using ion-exchange chromatography (DEAE-Sephacel) and concentrated by 
ethanol/potassium acetate precipitation and electrophoresed on a 4–13% 
SDS-PAGE. This gel is a representative from two experiments. 
 1       2       3       4     5       6      7       8    
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 Effects of CDK inhibitors flavopiridol, PD0332991, roscovitine 
and CVT313 on TGF-β-mediated Smad2 linker region 
phosphorylation in VSMC 
In the previous section, multiple CDKs are shown to participate in the 
TGF-β-induced biglycan size. In VSMC, TGF-β-stimulated increase in biglycan 
size involves Smad2L phosphorylation (232). CDK2 and CDK4 have been shown to 
mediate Smad3L phosphorylation in Mv1Lu mink lung epithelial cells (238). Here, 
the relationship between CDKs and Smad2L phosphorylation in VSMC was 
investigated. The pan-antibody directed against the phospho-serine residues 
Ser245/250/255 on Smad2L was used in this experiment. A time course of 
TGF-β-stimulated Smad2L (Ser245/250/255) phosphorylation in human VSMC was 
determined using Western blots. Phospho-Smad2L levels reached a peak at 60 min 
post-TGF-β treatment (Fig. 7.5). It has been reported that phospho-Smad2L levels 
can remain elevated for up to 6 h (232).  
VSMC were treated with TGF-β in the presence and absence of CDK 
inhibitors. In the cells treated with TGF-β for 60 min, phospho-Smad2L 
(Ser245/250/255) levels increased 2.7-fold above non-treated controls (Fig. 7.6). 
CVT313 (1 μM) blocked the TGF-β-mediated increase in phospho-Smad2L level by 
53% (Fig. 7.6) while PD0332991 at either 0.1 or 10 μM had no effect. Roscovitine 
(10 μM) and flavopiridol (1 μM) reduced (p<0.01) TGF-β-mediated stimulation of 
phospho-Smad2L levels by 71% and 88%, respectively. 
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Figure 7.5: Time course (0–2 h) of TGF-β-stimulated phospho-Smad2L 
(Ser245/250/255) levels in VSMC 
Western blot of cell lysates was probed with either phospho-Smad2L 
(Ser245/250/255) rabbit polyclonal or α-tubulin rabbit polyclonal antibody followed 
by peroxidase-labeled anti-Rabbit IgG secondary antibody. The Western blot is a 
representative of three independent experiments. The histogram represents the 
densitometric quantitation of the three replicates and indicates the mean ± S.E.M. 
fold change. ##p<0.01 and #p<0.05 basal versus TGF-β (1 h), **p<0.01 inhibitor 
versus TGF-β (1 h), using one-way ANOVA followed by least significant difference 
post-hoc analysis. 
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Figure 7.6: The effects of CDK inhibitors on TGF-β-stimulated 
phospho-Smad2L (Ser245/250/255) levels in VSMC 
Cells were treated with TGF-β (2 ng/ml) for 60 min in the presence or absence of 
each of the following CDK inhibitors: CVT313, PD0332991, roscovitine, 
flavopiridol or the TGFβR1 inhibitor SB431542. The membrane was probed with 
phospho-Smad2L (Ser245/250/255) rabbit polyclonal primary antibody followed by 
peroxidase labeled anti-Rabbit IgG secondary antibody. Anti-GAPDH 
HRP-conjugated monoclonal antibody was used for loading control. The Western 
blot is a representative of three independent experiments. The histogram represents 
the densitometric quantitation of the three replicates and the mean ± S.E.M. 
fold change. ## p<0.01 basal versus TGF-β, **p<0.01 and *p<0.05 inhibitor versus 
TGF-β, using one-way ANOVA followed by least significant difference post-hoc 
analysis.
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 Positive control SB431542 (3 μM) abolished the TGF-β-stimulated Smad2L 
phosphorylation (Fig. 7.6). PD0332991 did not inhibit the phosphorylation of 
Smad2L at Ser245/250/255, and suggests that both CDK4 and CDK6 do not 
modulate phosphorylation of these residues. From these results, it can be postulated 
that the CDKs involved in Smad2L (Ser245/250/255) phosphorylation in VSMC 
include CDK1, CDK2, CDK7 and CDK9. 
 
 PD0332991 selectively inhibits TGF-β-mediated Smad2 linker 
region Thr220 phosphorylation.  
The Smad2 linker region contains four major potential phosphorylation sites 
(Thr220/Ser245/Ser250/Ser255) (216). To investigate the potential involvement of 
CDK phosphorylation of the Thr220 residue on the linker region, a site-specific 
antibody for phospho-Thr220 (236,332) was used. Following the addition of 
TGF-β (2 ng/ml) there was an increase in phospho-Thr220 levels between 15 min to 
4 h post-exposure with a peak seen at 1 h (p<0.01) (Section 4.3.4). TGF-β 
stimulation of VSMC for 60 min resulted in a 2.3-fold increase in phospho-Thr220 
levels compared to non-treated controls (Fig. 7.7). PD0332991 (0.1 μM and 10 μM) 
treatment showed a dose-dependent inhibition of phospho-Thr220 levels. In 
contrast, roscovitine treatment had no effect. CVT313 (1 μM) and flavopiridol 
(1 μM) reduced TGF-β-induced phospho-Thr220 levels by 62% and 100%, 
respectively. These results suggest that CDK4 and CDK6 phosphorylation of 
Smad2L is specific to the Thr220 residue while CDK1, CDK2, CDK7 and CDK9 
phosphorylates one or more of the serine residues (Ser245/250/255) in the Smad2 
linker region. 
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Figure 7.7: The effects of CDK inhibitors on TGF-β-stimulated 
phospho-Smad2L (Thr220) levels in VSMC 
VSMC were pre-incubated for 30 min in the absence or presence of the CDK 
inhibitors: CVT313 (0.1 μM and 1 μM), PD0332991 (0.1 μM and 10 μM), 
roscovitine (10 μM), flavopiridol (1 μM) or the TGFβR1 inhibitor SB431542 
(3 μM) before being stimulated with TGF-β (2 ng/ml) for 60 min. The membrane 
was probed with phospho-Thr220/179 rabbit polyclonal antibody followed by 
peroxidase labeled anti-Rabbit IgG secondary antibody. The upper band (60 kDa) 
indicates the Thr220 band of interest. Anti-GAPDH HRP-conjugated monoclonal 
antibody was used for loading control. The Western blot is a representative of three 
independent experiments. Histograms are a densitometric quantitation of three 
replicates and represent the mean ± S.E.M. for the fold change of expression. ## 
p<0.01 basal versus TGF-β, **p<0.01 and *p<0.05 inhibitor versus TGF-β, using 
one-way ANOVA. 
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7.4 Summary of Results  
The results presented in this chapter demonstrate the effect of a range of CDK 
inhibitors on proteoglycan synthesis/size and Smad2 linker region suggesting a role 
for CDKs in proteoglycan synthesis/size in VSMC. The major findings in this 
chapter can be summarized as:  
 
 CVT313, PD0332991, roscovitine and flavopiridol elicit a dose inhibitory 
effect on the TGF-β-stimulated proteoglycan synthesis and biglycan GAG 
chain hyperelongation in VSMC. 
 
 CVT313, PD0332991, roscovitine and flavopiridol inhibited the 
TGF-β-stimulated Smad2L (Ser245/250/255) phosphorylation in VSMC.  
 
 PD0332991 inhibited the TGF-β-stimulated Smad2L (Thr220) 
phosphorylation in VSMC.  
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7.5 Discussion 
The synthesis of proteoglycans in VSMC is important because the binding of lipids 
to modified proteoglycans initiates the development of atherosclerosis (43,50). 
Various vasoactive growth factors mediate the synthesis and structure of 
proteoglycans and their cellular signalling pathways are of interest as potential 
therapeutic targets (82,280,432). TGF-β is involved in the development of 
atherosclerosis by stimulating proteoglycan synthesis (190,232). Synthesis of 
proteoglycans occurs through the regulatory actions of multiple GAG synthesizing 
enzymes (127,433). In Chapter 3, TGF-β stimulates GAG synthesizing enzyme 
XT-1, ChSy-1 and C4ST-1 mRNA expression. Data from this chapter indicates that 
the elevated GAG synthesizing enzyme expression contributes to the increased 
proteoglycan size particularly via GAG chain hyperelongation. Thus it is suggested 
that TGF-β stimulation elevates GAG expression that results in GAG chain 
hyperelongation. TGF-β mainly signals its effects through the canonical Smad 
transcription factor pathway (219) and recent findings have shown a potentially 
important role for serine/threonine kinases in determining the response to TGF-β via 
the Smad linker region (216,236). Data from this chapter suggests the involvement 
of multiple CDKs in proteoglycan size via TGF-β stimulated Smad linker region 
phosphorylation (Fig. 7.8). Flavopiridol, CVT313, roscovitine and PD0332991 
elicit a dose inhibitory effect on the TGF-β-stimulated proteoglycan synthesis and 
biglycan GAG chain hyperelongation in VSMC. These suggest that the CDK targets 
of these inhibitors (CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9) are involved 
in the TGF-β-stimulated biglycan core protein synthesis and GAG chain 
hyperelongation in VSMC.  
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Figure 7.8 : Involvement of CDK in Smad linker region phosphorylation and 
GAG chain hyperelongation in human VSMC 
Schematic diagram illustrating the proposed TGF-β signalling pathways involving 
serine/threonine intermediates and individual Smad linker region to stimulate XT-1, 
ChSy-1 and C4ST-1 mRNA expression. TGF-β-stimulated p38, ERK, PI3K and 
CDK directly or indirectly phosphorylates serine residues to enhance ChSy-1 and 
C4ST-1 mRNA expression whereas CDK phosphorylation of Thr220 stimulates 
XT-1 mRNA expression. Stimulation of XT-1 mRNA expression via PI3K could be 
likely through CDK activation. PI3K could also stimulate ERK to phosphorylate 
Ser245 and Ser255 resulting in elevated ChSy-1 and C4ST-1 mRNA expression also 
resulting in GAG chain hyperelongation.  
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Flavopiridol, CVT313 and roscovitine but not PD0332991 inhibited the 
TGF-β-stimulated Smad2L (Ser245/250/255) phosphorylation in VSMC (Fig. 7.6). 
This suggests that CDK1, CDK2, CDK7 and CDK9 mediate TGF-β-stimulated 
Smad2L (Ser245/250/255) phosphorylation in these cells. Nevertheless, PD0332991 
inhibited the TGF-β-stimulated Smad2L (Thr220) phosphorylation in VSMC 
further suggesting that CDK4 and CDK6 mediate TGF-β-stimulated Smad2L 
(Thr220) phosphorylation in VSMC (Fig. 7.8).  
 In this study the role of CDKs in proteoglycan synthesis was investigated. 
CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9 are potential mediators of the 
TGF-β-stimulated proteoglycan synthesis and GAG chain elongation. This pathway 
also involves the specific phosphorylation of Smad2L and CDK4 and CDK6 have 
unique preference for phosphorylation of Thr220. Other CDKs are able to signal 
through both the Smad2L Thr220 and serine residues, Ser245 and Ser255 (Fig 7.8). 
Biglycan is present in the intima of normal human blood vessels, including coronary 
and other major arteries (97,98,434). Biglycan and decorin are the main 
proteoglycans synthesized by human arterial SMC and both have been shown to 
bind apoB-containing lipoproteins in vitro (54). Of all the vascular proteoglycans, 
biglycan was shown to colocalize with apoB in experimental mouse models and 
atherosclerotic tissue (50). Thus biglycan overexpression in transgenic mice 
maintained on an atherogenic diet was correlated with increased lipid retention and 
severity of atherosclerotic lesions (158). In this current study, TGF-β caused an 
increase in size of biglycan in human VSMC. CDK1, CDK2, CDK4, CDK6, CDK7 
and CDK9 are most likely involved in this process, as seen by their ability to 
upregulate XT-1, ChSy-1 and C4ST-1 mRNA expression (Chap. 6).  
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TGF-β-stimulated biglycan synthesis via CDK causes an increase in 
[35S]-SO4 incorporation (Fig. 7.2) in both the core proteins as well as GAG chains. 
An important finding from this study is that it provides good evidence that suggests 
apart from the established role of CDKs in cell proliferation, they also may play a 
role in the development of atherosclerosis via proteoglycan modification. 
Nevertheless, the relevance of the findings from this current study to events 
occurring in vivo awaits further experiments using animal model of atherosclerosis. 
To examine the role of CDK isoforms in regulating the progression of atherosclerotic 
plaque development, an experiment on apoE knockout mice fed with high-fat 
western diet and treated with CDK inhibitors is warranted. 
Previous studies have focused on the response of TGFβR1 direct 
phosphorylation and activation of Smad transcription factors (Smad2/3) in the 
carboxy terminus (208). Recently, it has been shown that the additional 
phosphorylation of serine and threonine residues within the linker region of Smads 
can integrate and regulate a wide range of cellular events (216,337). Smad linker 
region can be phosphorylated by multiple serine/threonine kinases including MAPK, 
PI3K, CDK, ROCK and GSK3 (216). MAPK and CDK show a preference for 
specific residues on the linker region. Three serine residues are phosphorylation sites 
for cytoplasmic MAPKs (ERK, p38 and JNK) induced by growth factors and 
pro-inflammatory cytokines while Thr220 in Smad2L and Thr179 in Smad3L are 
preferred sites for the CDK family in response to TGF-β stimulation (235). These 
specific phosphorylations are essential for the regulation, stability, activity and 
nuclear transport of Smad2/3 (332). ERK and p38 are known to participate in the 
TGF-β-mediated proteoglycan synthesis in VSMC via Smad2L 
phosphorylation (232).  
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In Chapter 4 the data shows that pan-CDK inhibitor flavopiridol blocked the 
TGF-β-stimulated phosphorylation of Thr220, Ser245 and Ser255 (Fig. 4.13, 4.14 
and 4.16) indicating that CDKs play a role in this process (Fig. 7.8). In this chapter, 
the findings were extended to identify specific CDK isoforms that phosphorylate the 
linker region and regulate biglycan synthesis. The Smad3 linker region is a target for 
CDK2 and CDK4 phosphorylation in Mv1Lu mink lung epithelial cells (238).  
Based on the inhibition of CDK7 and CDK9 by flavopiridol seen in this 
current study, it can be postulated that these kinases are associated with Smad2L 
phosphorylation in VSMC. The direct phosphorylation of Smad2L by CDK7 and 
CDK9 has not been investigated in this study, but it has been shown that CDK9 can 
phosphorylate the Smad3 linker region (230). It is a likely occurrence as Smad2 and 
Smad3 are very similar in structure, reflected by the 91% shared identity in amino 
acid sequence (220). Alarcon et al. (230) reported that CDK9 phosphorylates 
Thr179, Ser208 and Ser213 in the Smad3 linker region residues. These sites then act 
as a binding site for E3 ubiquitin ligases, smurf1 and Nedd4L (230). These 
complexes then accumulate in the nucleus and upregulate the transcription of target 
genes that include cell cycle regulators including the CDK inhibitors p15 and p21 
and the proto-oncogene c-myc (247). Experiments to further assess whether CDK 
directly phosphorylate the Smad linker region can be performed using in vitro kinase 
assays. Endogenous CDKs immunoprecipitated from VSMC by an affinity-purified 
CDK-specific antibody, and full-length Smad proteins fused to glutathione 
S-transferase (GST) could be used as substrates (238). Moreover, further mutational 
studies of the Thr220, Ser245 and Ser255 on the Smad linker region would identify 
the exact phosphorylation sites in Smad2 targeted by each CDK. 
CDK7 and CDK9 are involved in gene transcription (248) however their 
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specific relationship with downstream gene transcription in VSMC needs 
clarification. As discussed in Chapter 5, both CDK7 and CDK9 can directly 
phosphorylate RNA Pol II in transcriptional control events in cardiac muscle cells 
(382). CDK7 is a component of the general transcription factor II human (TFIIH), 
which phosphorylates the C-terminal domain (CTD) of the largest subunit of RNA 
Pol II (383,384) whilst CDK9 can phosphorylate Ser2 in the C-terminal domain 
(CTD) of RNA Pol II, inducing pause release and subsequent transcription 
elongation (387). From the findings in Chapter 6 that CDK7 and CDK9 are potential 
regulators of increased GAG synthesizing enzymes mRNA expression, this current 
study suggests the role for these kinases in controlling the transcription of GAG 
synthesizing enzyme genes XT-1, ChSy-1 and C4ST-1 via RNA Pol II. Therefore, 
this adds to the potential alternative roles of CDK7 and CDK9 in transcriptional 
control events either via Smad2 linker region phosphorylation or RNA Pol II. 
Further investigation is required to elucidate the mechansims behind these events.  
In epithelial cells, TGFβR1 and Ras-associated kinases, including ERK, 
JNK and CDK4 (238) differentially phosphorylate Smad2 and Smad3 either in the 
carboxy-terminus, linker region or both (332). These CDK-mediated 
phosphorylation events create variable Smad2/3 phosphoisoforms that can 
differentially interact with Smad4 and then either translocate or blocked from 
entering the nucleus to initiate the transcription of target genes (211). The temporal 
and kinase specific regulation of Smad2/3 phosphoisoforms creates a complex 
signalling cascade that determines the switching of TGF-β mediated tumour 
suppressive effects in early stages of cancer to advanced carcinomas (435). In 
VSMC, the specificity of these signalling pathways is not well understood at 
present. A study of these pathways will facilitate a better understanding in the 
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identification of new therapeutic targets for preventing and/or treating 
atherosclerosis (156). In endothelial cells, individual residues in the Smad2L are 
phosphorylated by different kinases that alter mRNA expression of PAI-1 (236). In 
this current study, two antibodies were used, a pan antibody detecting serine 
residues Ser245/250/255 while the other detected phosphorylated threonine residue 
Thr220. In Chapter 4, flavopiridol was shown to block the TGF-β-stimulated 
phosphorylation of Ser245 and Ser255 only (Figs. 4.14 and 4.16) suggesting that 
CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9 do not phosphorylate Ser250 
(Fig. 7.8).  
In this chapter, the CDK4 and CDK6 inhibitor PD0332991 inhibited the 
phosphorylation of Smad2L Thr220 but not Smad2L Ser245/255. On the contrary, 
the inhibition of CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9 reduced the 
phosphorylation of both serine and threonine residues on Smad2L. The Thr220 
residue on the Smad linker region was reported as an excellent substrate for CDK4 
activity (238,346). Other studies also demonstrate that TGF-β-mediated CDK 
family phosphorylation of the Smad linker region has a greater preference for 
threonine than serine residues (238,332,337). These results demonstrate clearly that 
in VSMC TGF-β-mediated phosphorylation of Smad2L Thr220 is mediated by 
CDK4 and CDK6 although CDK1, CDK2, CDK7 and CDK9 can phosphorylate 
Ser245 or Ser255.  
From the results of both Chapter 4 and this current chapter, 
TGF-β-stimulated p38, ERK, PI3K, CDK1, CDK2, CDK7 and CDK9 
phosphorylates Ser245/Ser250/Ser255 leading to increased ChSy-1 and C4ST-1 
mRNA expression whereas CDK4 and CDK6 phosphorylation of Thr220 results in 
enhanced XT-1 mRNA expression (Fig. 7.8). Stimulation of XT-1 mRNA 
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expression via PI3K is most likely through CDK4 and CDK6 activation of Thr220. 
PI3K can also stimulate ERK to phosphorylate Ser245 and Ser255 resulting in 
elevated ChSy-1 and C4ST-1 mRNA expression contributing to GAG chain 
elongation in biglycan (Fig. 7.8). 
The data in this chapter provides evidence of a signalling pathway involving 
CDKs. Various CDKs have been shown to have specific signalling pathways 
through Smad2L which affects proteoglycan synthesis and has the potential to affect 
LDL binding affinity in early atherosclerosis (79,158). Despite that, the specific 
mechanism of TGF-β stimulation of CDK is unknown. Further investigations are 
needed to address how TGF-β activates and upregulates CDK activity as well as 
confirmatory experiments using individual CDK knockout studies to verify the 
involvement of specific CDKs in this signalling pathway (Fig. 7.8). The main 
regulatory components of CDKs are cyclins (354) and their overexpression can be 
stimulated by growth factors including TGF-β (436). Thus, it is possible that the 
regulation of cyclin levels by TGF-β determines the CDK activation in VSMC. A 
single cyclin can activate multiple CDKs, hence could contribute to the involvement 
of a range of CDK isoforms in the TGF-β signalling pathway (248).  
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  CVD is the leading cause of mortality globally and atherosclerosis is the 
major underlying cause (437). The development of atherosclerosis is triggered 
primarily by retention of lipid in the vessel wall via interaction with modified 
proteoglycans that exhibit high binding affinity for lipoproteins (23,57). Mechanical 
strain and cytokines exacerbate retention of modified proteoglycans facilitating the 
oxidative modification and promoting inflammatory response eventually resulting in 
plaque formation (58). An essential component of the interaction between lipid and 
proteoglycan is the negatively charged residues on the sulfated GAG chain (56,57). 
The sulfate groups on the GAG chain of proteoglycans interact with basic amino 
acids in the apoB100 of atherogenic lipoproteins (149). As a proof of concept, after 
20 weeks of high-fat high-cholesterol Western diet, transgenic mice with mutations 
of the apoB100 gene develop less atherosclerosis due to the reduced ability of 
apoB100-modified lipoprotein to bind with arterial wall proteoglycans (79). 
Moreover, when apoE knockout mice fed a high-fat high-cholesterol diet were given 
anti-CS GAG monoclonal antibodies, both lipid retention and oxidation levels were 
lower. As a result, the extent of atherosclerotic lesion were reduced which indicates 
the crucial role of GAG chains in lipid retention as well as atherosclerotic 
progression (438). Variation in the structure of proteoglycans by an increase in chain 
length and/or a greater degree of sulfation is the main contributor that influences the 
binding capacity towards lipids (57,158). Therefore, preventing the alteration in 
proteoglycan synthesis and structure is proposed to be a reliable therapeutic target 
for the prevention of atherosclerosis (156). The studies presented in this thesis have 
focused on the mechanisms of GAG chain hyperelongation in particular the 
signalling pathways that increase GAG synthesizing enzyme expression (Fig. 8.1).  
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Figure 8.1: Cell signalling schema for TGF-β-mediated GAG synthesizing 
enzyme expression and GAG chain hyperelongation 
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Figure 8.1: Schematic diagram illustrating the proposed TGF-β signalling pathways 
involving serine/threonine intermediates and individual phosphorylated Smad linker 
region residues that stimulate XT-1, ChSy-1 and C4ST-1 mRNA expression. 
Through TGF-β-stimulated intermediates that warrants further investigation and 
identification, p38, ERK, PI3K and CDK is activated to phosphorylate serine 
residues leading to ChSy-1 and C4ST-1 mRNA expression whereas CDK 
phosphorylation of Thr220 results in XT-1 mRNA expression. Stimulation of XT-1 
mRNA expression via PI3K is most likely through CDK activation. PI3K can also 
stimulate ERK to phosphorylate Ser245 and Ser255 resulting in elevated ChSy-1 and 
C4ST-1 mRNA expression and GAG chain hyperelongation with higher affinity for 
LDL binding. Increased LDL retention initiates the development of atherosclerosis. 
Atherosclerotic plaque figure reproduced from Ross et al. (32). 
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 Previously it was shown that increased GAG chain elongation contributes to 
increased lipid binding (439). GAG chain synthesis occurs via post-translational 
modification of the proteoglycan core protein driven by the concerted action of a 
wide range of GAG synthesizing enzymes (127). An in vivo study showed that 
elevated GAG synthesizing enzyme gene expression contributes to the development 
of atherosclerosis (145). Although this study did not explore the regulation of GAG 
synthesizing enzyme and its relation to lipid binding, our laboratory had shown 
previously that hyperelongation of GAG chain on biglycan contributes to greater 
lipid binding (158,439). Findings from this current study revealed that increased 
GAG synthesizing enzyme expression led to GAG chain hyperelongation on 
biglycan (see Discussion, Chap. 7). Therefore, it is postulated that elevated GAG 
synthesizing enzyme expression is associated with an increased capacity of lipid 
binding by biglycan ultimately contributing to the development of atherosclerosis. 
For that reason, identifying the specific enzymes and the signalling pathways that 
control this process is of utmost importance to prevent the development of 
atherosclerosis.  
8.1 Cell signalling pathways of TGF-β-stimulated 
glycosaminoglycan synthesizing enzyme mRNA 
expression 
The first aim of this study was to identify which GAG synthesizing enzyme is 
involved in the signalling pathways relevant to GAG chain hyperelongation and is 
addressed in Chapter 3. VSMC in the neointimal space produce altered 
proteoglycans that have high affinity to lipids thus they play a major role in the early 
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development of atherosclerosis (424). Previously, we have shown that TGF-β, a 
pleiotropic growth factor associated with atherogenesis stimulates GAG chain 
hyperelongation in human VSMC (232). Findings from this current study showed 
that in human VSMC, TGF-β stimulates a time-dependent increase in XT-1, ChSy-1, 
ChPF and C4ST-1 mRNA expression (Figs. 3.1, 3.2, 3.3 and 3.5 in Section 3.3.1, 
3.3.2 and 3.3.3). Susarla et al. (224) also observed TGF-β-stimulated XT-1, ChSy-1 
and C4ST-1 mRNA expression in neural cells which was associated with increased 
CS proteoglycan expression suggesting that TGF-β stimulation of these GAG 
synthesizing enzymes can also occur in other cell types. Findings from this current 
study also showed that TGF-β treatment of VSMC did not increase ChGn-2 or 
C4ST-2 mRNA expression (Figs. 3.4 and 3.6 in Section 3.3.2 and 3.3.3). As 
discussed in Chapter 3, the enzymes stimulated by TGF-β are those crucial for GAG 
chain elongation in VSMC. Clearly not all GAG synthesizing enzymes are 
upregulated by TGF-β. Notwithstanding, there is a possibility that other growth 
factors such as PDGF (440) and thrombin (441), which are highly expressed during 
atherogenesis in vivo could elevate the expression of other GAG synthesizing 
enzymes that are not stimulated by TGF-β. In vitro studies have shown that the 
G-protein coupled receptor agonist thrombin (232) as well as PDGF (350) can 
elongate the GAG chain on proteoglycans in human VSMC. As a result, both are 
potential regulators of GAG synthesizing enzymes. Further investigation to identify 
these potential regulators is needed. 
TGF-β-regulated mRNA expression of two sulfotransferase homologs, 
C4ST-1 and C4ST-2 was determined to be different. TGF-β only stimulated C4ST-1 
but not C4ST-2 mRNA expression. The mRNA expression profiles of these two 
enzymes over 24 h post-TGF-β treatments were the opposite of each other (Figs. 3.5 
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and 3.6 in Section 3.3.3). This indicates that despite the high structural similarity 
between the homologs, individual GAG synthesizing enzymes possess unique 
functions that determine their role in the development of atherosclerosis. The 
evidence of unique regulation between the sulfotransferases supports the 
non-redundant function of each homolog in the sulfation of monosaccharides on the 
GAG chains (136), which directly contributed to differential impact on 
atherosclerotic progression (see Discussion, Chap. 3). In particular, only C4ST-1 but 
not C4ST-2 is involved through TGF-β signalling and GAG chain hyperelongation 
on proteoglycans in VSMC.  
An extension of the findings that TGF-β induced XT-1, ChSy-1 and C4ST-1 
GAG enzyme expression is to identify whether any single enzyme is sufficient or a 
combined action of the multiple GAG enzymes is compulsory for TGF-β-stimulated 
hyperelongation to manifest (Fig. 8.1). The observation that XT-1, ChSy-1 
and C4ST-1 expression in 24 h TGF-β stimulation occurs in a biphasic pattern, 
maximal at 6 h and 24 h (Figs. 3.1, 3.2 and 3.5 in Section 3.3.1, 3.3.2 and 3.3.3) 
allows speculation that overexpression of these enzymes should occur at a common 
time point or interval to enable a grouped enzymatic action to happen simultaneously 
within the Golgi (102). Independently targeting these individual genes by siRNA and 
studying the effects of TGF-β stimulation on GAG chain length would answer this 
question and form the basis of further research. 
 It is postulated that induced mRNA expression of these enzymes leads to 
overexpression of GAG synthesizing enzyme proteins that regulates the assembly of 
monosaccharides necessary for the elongation of CS GAG chain in the Golgi (102). 
The observation that TGF-β stimulates increased ChSy-1 and C4ST-1 protein 
expression (Figs. 3.7 and 3.8 in Section 3.3.4 and 3.3.5) supports the hypothesis that 
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elevated GAG synthesizing enzyme mRNA expression is sufficient to induce protein 
overexpression in vivo. The increased numbers of GAG synthesizing enzymes in the 
Golgi would enhance GAG chain polymerization and most likely cause the GAG 
chain hyperelongation on proteoglycans (Fig. 8.1). Therefore, it is suggested that 
even within a physiological transit time of proteoglycan synthesis in the Golgi, GAG 
chain elongation can increase and escalate to a pathological state i.e. production of 
GAG chain with higher affinity for lipid binding (158). Even though only a 24 h 
time course of TGF-β stimulation was examined in this study, it was shown that 
prolonged TGF-β stimulation for 3 days on astrocytes led to increased proteoglycans 
in neural cells compared to non-treated cells (224). Prolonged treatment with TGF-β 
caused the deposition of CS proteoglycan that were inhibitory to axonal regeneration 
(224). Therefore, it is postulated that sufficient stimulation of TGF-β in human 
VSMC may lead to overexpression of GAG synthesizing enzymes in the Golgi, 
resulting in the production of hyperelongated GAG chains on proteoglycans that 
have a higher affinity towards lipid binding, consequently accelerating the 
development of atherosclerosis (Fig. 8.1).  
The aim in this current study was not to knock out GAG synthesizing enzyme 
genes as a therapeutic target. Applying siRNA as a therapeutic target could be less 
effective as it could result in widespread loss of GAG synthesizing enzymes in a 
human causing diseases for example chondrodysplasia (326). Physiological levels of 
GAG synthesizing enzymes are required to maintain normal structural functions of 
ECM in the body. ChSy-1 knockout mice are viable but exhibit chondrodysplasia, 
progression of the bifurcation of digits, delayed endochondral ossification and 
reduced bone density (326). In humans, loss of function mutations at the ChSy-1 
locus have resulted in shortened or absent middle phalanges, a characteristic of 
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human syndromic recessive preaxial brachydactyly (442,443). A missense mutation 
in XT-1 gene of a mouse, where Tryptophan932 is replaced by Arginine resulted in 
early ossification which led to a shorter body length than that of a wild type embryo 
(444). Furthermore, C4ST-1 mutant mice exhibit abnormalities in the cartilage 
growth plate and chondrocyte columns, severe dwarfism and died only within 6 h of 
birth due to respiratory failure (445).  
In contrast, targeting the growth factor signalling pathway that upregulates 
these GAG synthesizing enzymes using antagonists, would be more successful since 
these pathways are activated in a pro-atherosclerotic vessel wall (32). The role of 
pharmacological agents in regulating proteoglycan metabolism especially GAG 
synthesizing enzyme regulation as well as its impact of altered proteoglycan 
structures on binding to atherogenic lipoproteins is less understood (156). It is 
expected that blocking the induced elevation of these enzymes could delay 
atherosclerotic development. It is important to note that we are focused on 
preventing GAG chain hyperelongation thus a more suitable target is inhibiting the 
signalling pathways that cause this overproduction of the elongation process. Thus, 
in this study, we identified that TGF-β signalling can result in the overexpression of 
GAG synthesizing enzymes XT-1, ChSy-1 and C4ST-1 that consequently induce 
GAG chain hyperelongation.  
The second aim of this study was to investigate the involvement of 
serine/threonine kinases in the TGF-β-mediated regulation of XT-1, ChSy-1 and 
C4ST-1 mRNA expression. Several kinases that were linked to the development of 
atherosclerosis were investigated in this current study and found to participate in the 
TGF-β-mediated GAG synthesizing enzyme expression (Fig. 8.1). The signalling 
pathways of TGF-β-mediated upregulation of ChSy-1 and C4ST-1 mRNA 
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expression involves ERK, p38, PI3K and CDK but not JNK and GSK3 (Figs. 4.2, 
4.3, 4.7 and 4.8 in Section 4.3.1 and 4.3.3). Furthermore, the signalling pathways 
from TGF-β that induce XT-1 mRNA involve PI3K and CDK but not MAPK and 
CDK (Figs. 4.1 and 4.6 in Section 4.3.1 and 4.3.3). These kinases are important 
regulators of atherosclerosis (30,446-448). The expression and activity of p38 is 
relatively low in healthy vasculature yet markedly elevated in macrophages of 
atherosclerotic lesions and is reported to participate in the initiation of the 
inflammatory response (446,447). In human coronary artery samples from explanted 
hearts, the p38 expression was upregulated in advanced plaques and strongly 
expressed by lesional macrophage foam cells (449). Overexpression and activation 
of ERK is seen in atherosclerotic lesions of cholesterol-fed rabbits (448) while PI3K 
is involved in inflammatory events in all stages of atherosclerosis as it can be 
activated by several chemokines (IL-8 and MCP-1) and vasoactive stimuli including 
angiotensin II (450). There is also evidence of induced CDK activity which promotes 
cell proliferation of VSMC, contributing to the development of atherosclerosis (30). 
The findings from this current study support the involvement of these kinases in 
mediating the progression of atherosclerosis with emphasis on their role in 
proteoglycan GAG chain hyperelongation. Our previous results demonstrating the 
involvement of ERK and p38 but not JNK in GAG chain hyperelongation on 
biglycan (232) is strengthened by the observation that this process is associated with 
induced GAG synthesizing enzyme expression via ERK, p38, PI3K and CDK 
(see Discussion, Chap. 4).  
The third aim of this study was to look at the involvement of Smad 
transcription factors in GAG synthesizing enzyme gene expression as they are the 
main downstream regulators of the TGF-β signalling pathway (201). They are also 
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important as a central integrating point allowing cross-talk between various receptor 
signalling pathways via the Smad linker region that can be phosphorylated by several 
intermediary serine/threonine kinases (216). Because of this central role, this makes 
Smad linker region a suitable target for therapeutic intervention of atherosclerosis. 
This is true especially when the development of atherosclerosis involves many 
growth factors, which can activate these kinases throughout atherogenesis. The 
evidence of multiple kinase intermediates that are activated by TGF-β, and most 
likely by other growth factors including PDGF and thrombin (309), suggests the 
existence of multiple alternate pathways for Smad linker region phosphorylation to 
occur in diseased arteries where many growth factors are secreted (30). Recently our 
laboratory had reported that thrombin can transactivate the TGFβR1 to induce 
ChSy-1 and C4ST-1 mRNA expression through Smad linker region phosphorylation 
(344). The involvement of multiple growth factor signalling pathways could 
contribute to the overall increase in GAG synthesizing enzyme mRNA expression 
and further highlights Smad linker region as a central integrating pathway and a 
potential candidate for a therapeutic target during atherogenesis. Blocking the Smad 
linker region as a therapeutic strategy to prevent development of atherosclerosis 
would also control off-target effects commonly demonstrated by other drugs that 
deliver receptor pleiotropic actions such as the plethora of drugs that are often 
termed anti-inflammatory (451). In addition, the intervention is most likely to be 
most effective when initiated in early stage of atherosclerosis when proteoglycan 
modification is TGF-β driven (50,190).  
TGF-β-stimulated GAG synthesizing enzymes involves ERK, p38, PI3K and 
CDK phosphorylation of the Smad linker region (see Discussion, Chap. 4). Our 
previous findings reported that the Smad linker region is involved in biglycan GAG 
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chain hyperelongation (232). Further investigation on the phosphorylation of 
individual Smad2 linker region residues points out that each residue is selectively 
phosphorylated by these serine/threonine kinases. Ser245 was phosphorylated only 
by p38 (Fig. 4.12 in Section 4.3.5) while Thr220 was only phosphorylated by CDKs 
(Fig. 4.11 in Section 4.3.5). As discussed in Chapter 4, phosphorylation of the serine 
residues (Ser245/250/255) most likely induced GAG synthesizing enzymes ChSy-1 
and C4ST-1 that are closely associated with GAG chain elongation whereas Thr220 
phosphorylation was associated with XT-1 which determines the addition of GAG 
chains to core protein (Fig. 8.1). It is specifically unclear as to how more than one 
linker residue could impact downstream events particularly the expression of GAG 
synthesizing enzymes. Further investigations are warranted to identify the 
relationship between individual linker region phosphorylation events whether these 
phosphorylations are additive, mutually exclusive or temporally reinforcing. In 
mouse embryo-derived fibroblasts, Smad2 phosphorylation at Thr220, Ser245 and 
Ser255 collectively blocked the growth-inhibitory effect of TGF-β while Smad2 
mutants lacking individual phosphorylation sites in the linker region showed weaker 
suppression of growth, indicating additive effects of these phosphorylation events 
(235). 
The C-terminal phosphorylation and activation of Smads in human VSMC is 
strong and rapid, occurring in minutes after receptor stimulation (232). On the other 
hand, the temporal aspects and the strength of Smad linker region phosphorylation 
via TGF-β stimulated serine/threonine kinases varies with the Thr220 showing rapid 
response, but Ser phosphorylation more delayed, possibly suggesting that both 
responses (C-terminal and linker region phosphorylation) co-exist to induce 
downstream effects. Hence, the use of SB431542 in this study blocks both TGF-β 
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signalling directly via Smad2 at the C-terminal as well as indirectly at the linker 
region via serine/threonine kinases. Smad3 linker region phosphorylation was shown 
to be dependent on the Smad3 phosphorylation at the C-terminal. TGF-β induced 
Smad3 linker region phosphorylation was abolished in cells with C-tail mutant of 
Smad3 (226). In fact, phosphorylation of the linker region was also found to be 
important from the observation that prior to the deletion of the Smad3 linker region, 
TGF-β-stimulated gene transcription activity was affected despite its ability to 
become phosphorylated at the C-terminal and form a complex with Smad4 (227).  
In VSMC, cell proliferation in vivo and in vitro has been associated with the 
PI3K/Akt signalling pathway (269,352). However, the regulation of GAG chain 
hyperelongation on proteoglycans in VSMC does not involve TGF-β-mediated Akt 
phosphorylation of Smad2 linker region (Ser245/250/255) (280). Thus, it is possible 
that TGF-β-mediated signal transduction from PI3K resulting in GAG enzyme 
ChSy-1 and C4ST-1 mRNA expression does not pass through Akt, but through ERK 
(Fig. 8.1). Hough et al. (225) reported that in fibroblasts, TGF-β-induced replication 
can be regulated through PI3K activated ERK signalling via Smad linker region 
(Ser245/250/255) phosphorylation which was similar to that seen in VSMC. The 
findings that only CDK and PI3K regulate XT-1 mRNA expression suggests that the 
stimulation of XT-1 expression via PI3K is most likely through CDK4 and CDK6 
activation of Thr220 (Fig. 8.1).  
Major et al. (349) reported that the PI3K/PDK1 signalling cascade can activate 
the CDK-cyclin complexes required for FoxM1B-dependent transcription in bone 
marrow derived epithelial cells. If this can apply in VSMC with GAG synthesizing 
enzyme mRNA expression, there is a possibility that PI3K directs its downstream 
signalling to CDK activation eventually phosphorylating the nuclear Smad2 linker 
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region and regulating XT-1 expression (Fig. 8.1). Further investigation is needed to 
confirm if this signalling pathway activates XT-1 expression.  
 Of the three Smad2 linker region serine residues, Ser245 is a target for 
TGF-β-stimulated ERK, p38, PI3K, CDK1, CDK2, CDK7 and CDK9 signalling that 
promotes ChSy-1 and C4ST-1 mRNA expression, and suggests that this residue is a 
common target for GAG chain hyperelongation. Follow-up experiments would be 
done to mutate Ser245 on the Smad2 linker region and confirm its impact on 
TGF-β-stimulated ChSy-1 and C4ST-1 expression as well as biglycan 
hyperelongation. To inactivate Ser245 phosphorylation, VSMC could be transfected 
by retroviral vector carrying Smad2 mutants with Ser245 replaced by alanine residue 
(452). It can be hypothesized that if Ser245 is blocked, ChSy-1 and C4ST-1 mRNA 
expression would be reduced and block GAG chain hyperlongation. 
Important future studies on Smad linker region would be to investigate the 
involvement of Pin1, a member of the peptidyl-prolyl isomerase parvulins, that can 
catalyse the isomerisation of cis/trans peptidyl-prolyl bonds on phosphorylated 
serine or threonine such as those found on phosphorylated Smad linker region 
residues (453). The cis/trans isomerisation by Pin1 on the bound protein results in 
post-phosphorylation regulation that produces distinct effects in different target 
proteins controlling diverse cellular responses including cell cycle progression, gene 
expression, signal transduction pathways and cell proliferation (454-457). 
Kim et al. (458) reported that Pin1 is mainly expressed in the intima and media of 
damaged arteries suggesting it plays a role in neointima formation. From this current 
study Smad linker region plays a primary role in GAG synthesizing enzyme 
expression (Chap. 3 and 4) as well as proteoglycan hyperelongation (Chap. 6), and 
we can postulate that Pin1 may share a role in elevating GAG synthesizing enzyme 
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gene expression. To date there is no information on the role of Pin1 in regulating 
GAG synthesizing enzyme expression. Matsuura et al. (176) reported that Pin1 binds 
to phosphorylated Smad2/3 when human HaCaT keratinocytes cells are treated with 
TGF-β, but not EGF, suggesting a specific involvement of Pin1 in the TGF-β and 
Smad signalling pathway. We hypothesize that if Pin1 promotes GAG gene 
expression via up regulating phospho-Ser245 activity, inhibition of Pin1 could then 
block signal by phospho-Ser245 and prevents TGF-β-stimulated ERK, p38, PI3K 
and CDK signalling. Further investigation on the functionality and potential 
therapeutic targets of Pin1 in the development of atherosclerosis will be very 
enlightening (217). 
8.2 The role of CDK in biglycan synthesis and cell 
signalling mechanisms involving TGF-β 
The fourth aim of this study was to systematically determine the presence of CDK 
isoforms in VSMC and study their involvement in regulating GAG synthesizing 
enzymes XT-1, ChSy-1 and C4ST-1. CDK1, CDK2, CDK4, CDK6, CDK7 and 
CDK9 present in VSMC (Figs. 5.1-5.6 in Section 5.3.1) are determined to regulate 
the elevated XT-1, ChSy-1, C4ST-1 and biglycan mRNA expression (Figs. 6.1-6.4 
in Section 6.3.1-6.3.4). This regulation is mediated in part by TGF-β stimulation. 
Further experiments to study the association of CDK isoforms with biglycan 
synthesis as well as the signalling pathways involved (fifth aim) showed that 
TGF-β-induced GAG synthesizing gene expression involving CDKs affects the 
actual increase in size of biglycan particulary GAG chain hyperelongation as 
assessed by SDS-PAGE (Fig. 7.4 in Section 7.3.1). 
 
 
247 
 
The signalling pathways of CDK-mediated GAG synthesizing enzyme 
regulation is also shown to regulate via Smad2 linker region phosphorylation 
(Figs. 7.6 and 7.7 in Section 7.3.2). This study did not investigate the direct 
phosphorylation of Smad linker regions by CDK, yet Matsuura et al. (238) had 
shown that apart from Rb as a substrate of CDK, Smad3 can also be phosphorylated 
by CDK2 and CDK4. Therefore, it is possible that CDK directly phosphorylates the 
Smad2 linker region in the TGF-β-stimulated signalling pathway of GAG 
synthesizing enzymes. As seen in Fig. 8.1, TGF-β-mediated CDK1, CDK2, CDK7 
and CDK9 phosphorylates Smad2 linker serine residues (Ser245/255) and lead to 
increased ChSy-1 and C4ST-1 mRNA expression whereas CDK4 and CDK6 
phosphorylation of Thr220 results in enhanced XT-1 mRNA expression. Further 
experiments are required to investigate whether CDKs can directly phosphorylate 
Smad2 linker region in VSMC.  
This current study proposes the focus on CDK2 signalling as supported by 
evidence that dysregulation of the activity of this CDK is associated with 
progression of CVD (246,459). In rat carotid arteries, CDK2 promotes neointimal 
proliferation of VSMC, which is one of the stages in the pre-inflammatory phase of 
atherosclerotic development (246,459). Future experiments could be focused on the 
role of CDK2 as a mediator of GAG synthesizing enzyme ChSy-1 and C4ST-1 
expression, GAG chain hyperelongation and atherosclerotic development via Smad2 
linker region Ser245/255 phosphorylation (Fig. 8.1). To confirm whether CDK2 can 
directly phosphorylate Smads, in vitro kinase assays using endogenous CDK2 
immunoprecipitated from VSMC by an affinity-purified CDK2-specific antibody 
would be very informative. Full-length GST fusion proteins of Smad2 and Rb could 
be included as substrates (238) and positive controls, respectively. To identify the 
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exact Smad2 linker residue that is phosphorylated by the endogenous CDK2, 
mutational studies of the Ser245 and Ser255 would be beneficial. A decrease in 
phosphorylation by CDK2 after mutation of the Smad2 linker region residues would 
indicate that this occurs within the potential phosphorylation site(s). To analyze the 
downstream activity of CDK phosphorylation of Smad2, the effect of mutation of the 
Smad2-CDK2 as mentioned above on GAG synthesizing enzyme gene expression 
could then be investigated. Co-transfection of VSMC with CDK2 siRNA will allow 
validation of the involvement of this kinase in TGF-β-induced GAG synthesising 
enzyme expression.  
A useful follow-up study would be to use an atherosclerotic mouse model, 
apoE knockout mice fed with high-fat western diet and treating them with CDK 
inhibitors, such as CVT313, to examine the role of CDK1 and CDK2 in regulating 
the progression of atherosclerotic plaque development. The data from this current 
study presents evidence that in human VSMC, CDK1 and CDK2 are involved in 
GAG synthesizing enyme XT-1, ChSy-1 and C4ST-1 mRNA expression as well as 
GAG chain hyperelongation. Therefore, by inhibiting CDK1 and CDK2 activity 
would it confirm the role of these kinases in an in vivo setting of atherosclerotic 
development. Brooks et al. (246) used the CVT313 to prevent neointimal 
proliferation in a rat restenosis model. Experiments using CVT313 in an apoE 
knockout mice fed with high-fat western diet would emphasize the role of CDK1 and 
CDK2 in GAG chain hyperlongation and contribution to atherosclerotic plaque 
development. As neointimal proliferation also plays a part during the early 
development of atherosclerosis, these data would strengthen the evidence on the role 
of CDKs in CVD especially atherosclerosis. The main challenge that needs to be 
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properly addressed in such a model would be to separate between the CDK 
proliferative effects versus the GAG chain hyperelongation effects. 
Other than studies on CDK2, there is a strong need to elucidate the role of 
CDK7 and CDK9 as transcriptional regulators of GAG synthesizing enzyme gene. 
Apart from the role in activating Smad2 linker region phosphorylation (Figs. 7.6 
and 7.7 in Section 7.3.2), there exists alternative roles of CDK7 and CDK9 linked to 
the action of RNA polymerase in transcriptional regulation of GAG synthesizing 
enzyme mRNA expression. It can be speculated that TGF-β-stimulated CDK7 and 
CDK9 could induce transcriptional initiation and elongation of the XT-1, ChSy-1 
and C4ST-1 genes. Experiments using the ChIP assays would allow the 
determination of the interaction between RNA Pol II and these particular genes. 
Through the use of specific CDK7 or CDK9 inhibitors, this would confirm which of 
these CDKs are involved in GAG synthesizing mRNA expression via direct 
regulation of RNA Pol II activity (422,423).  
This thesis has investigated the role of CDK phosphorylation in proteoglycan 
synthesis which has not been looked at previously in other studies on CDK and 
cardiovascular diseases. Findings from this study provide early exciting data 
showing previously unknown roles for CDKs and emphasizes the idea that CDKs 
possess multiple roles in biological processes extending far beyond cell cycle 
control. For instance, Smad transcription factor phosphorylation involved in 
promoting GAG chain hyperelongation on biglycan occurs beyond cell cycle 
dependent action of CDKs. Data from this current study propose a potential role for 
CDKs in promoting the regulation of XT-1, ChSy-1 and C4ST-1 enzyme expression 
that are involved in the development of atherosclerosis. Thus, it is postulated that 
during atherogenesis CDKs can undertake a dual role both as a regulator of 
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proteoglycan GAG chain hyperelongation via GAG synthesizing enzyme and 
biglycan mRNA expression as well as accelerating VSMC proliferation (361,362). In 
the aortas of cholesterol-fed rabbits, elevated expression and activity of CDK1, 
CDK2 and CDK4 was seen after 8 weeks of modest plaque development, and 16 
weeks of severe plaque progression (414). This suggests that elevated CDK activity 
contributes to plaque progression by promoting VSMC proliferation and 
eventually increasing the production of proteoglycans (30,43). Similarly, elevated 
CDK activity could also influence the production of modified proteoglycans with 
hyperelongated GAG chain due to increased GAG synthesizing enzyme mRNA 
expression (414). Elevated lipid retention would be the direct consequence of 
lipid binding to hyperelongated proteoglycan GAG chain (158,424) and this might 
explain the acceleration of atherosclerotic lesions in humans due to the focal 
accumulation of VSMC within the intima (361,362) (Fig. 8.1).  
Given these points, understanding the multiple roles of CDK will broaden 
the beneficial mechanisms of specific inhibitors which should include as 
therapeutic strategies in preventing the development of atherosclerosis (82). 
Whilst the implication of CDK inhibitors on proteoglycan modification and 
atherosclerotic plaque development in vivo awaits further study, work shown in this 
thesis demonstrates that these inhibitors have the ability to inhibit GAG chain 
elongation on biglycan secreted by VSMC in vitro (Fig. 7.4 in Section 7.3.1). 
Studies with CDK inhibitors have mainly focused on their role in targeting cell 
proliferation and growth mechanisms (244). CDK inhibitors in clinical practice are 
associated with a range of unwanted effects which include secretory diarrhoea and a 
pro-inflammatory syndrome associated with hypotension (460). It needs to be 
appreciated that the role of the cyclins/CDKs and endogenous CDK inhibitors 
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system is expanding beyond their role in regulating cell cycle (238,332). Thus, the 
potential exists for CDK inhibitors to have a variety of effects beyond the identified 
therapeutic target which in this case is the role of hyperelongated GAG chains in the 
aetiology of the early stages of atherosclerosis.  
Although the hypothesized effect of the CDK inhibitors is to prevent GAG 
chain hyperelongation in smooth muscle cells of the vessel wall, among the 
challenges that needs to be considered is whether or not a CDK inhibitor affects the 
normal physiology of cell cycle. The cell cycle is regulated by cyclins/CDKs and 
endogenous CDK inhibitors such as p27, thus improper administration of exogenous 
CDK inhibitors could produce unwanted effects on normal proliferating cells (461). 
Nevertheless, most cells in the body are differentiated and not cycling and as such 
these cells will not be affected by a CDK inhibitor(s). Some cells, such as those in 
the gastrointestinal tract will be cycling in a controlled manner and it is possible that 
they may be affected by the interaction with exogenous CDK inhibitors. In some 
specialized cell types, CDKs have unexpected roles hence the toxicity of a specific 
CDK isoform might be restricted to a few cell types, for instance germ cells for 
CDK2 inhibitors and pituitary or pancreatic β cells for CDK4 inhibitors (241,462). 
Endothelial cells are quiescent in normal blood vessels but undergo burst of 
proliferation after vascular injury and during angiogenesis due to activated CDK2 
activity and downregulation of the endogenous CDK inhibitor p27 (463). As 
endothelial cell dysfunction induced by atherogenic stimuli is among the earliest 
alterations at sites predisposed to atherosclerosis, thus effects of CDK inhibitors on 
endothelial cells in the vessel wall would most likely provide beneficial outcome in 
preventing development of atherosclerosis (379).  
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In a model of restenosis, local therapeutic application of the pan CDK 
inhibitor flavopiridol via coated stents implanted in rat carotid arteries had been 
reported to prevent neointima formation following stent placement (464). Despite the 
association of flavopiridol with the induction of apoptosis in tumour cell lines (35), it 
is found that both coronary artery SMC as well as endothelial cells neither exhibited 
any evidence of accelerated apoptosis following treatment with this inhibitor (464). 
The need will be for studies in animal models and later in translational studies to 
establish a specific CDK inhibitor that can successfully target proteoglycan changes 
in the vessel wall associated with the early stages of atherosclerosis. Gene knockout 
and knockin models provide an ideal platform to identify drug specificity and target 
selection under highly controlled conditions. 
Future outcomes of this work will be the identification of a specific CDK 
inhibitor as a therapeutic agent that reduces atherosclerotic lesions and thereby 
prevent cardiovascular disease. This specific CDK inhibitor would benefit through 
both prevention of elevated CDK activity resulting in overexpression of cell 
proliferation as well as reducing proteoglycan modification and lipid retention. Such 
an agent could work effectively in combination with a HMG-CoA reductase 
inhibitor such as a statin, where the latter would reduce blood cholesterol levels 
(465) while the former, acting as a proteoglycan inhibitor would block the 
hyperelongation of GAG chains on biglycan in the vessel wall thereby rendering it 
less sticky for atherogenic lipoproteins (430). The proposed use of combined therapy 
with statins also allows for the possibility of the use of low doses of a specific CDK 
inhibitor. This would only target the upregulation of specific CDK isoforms that 
directly contribute to GAG chain hyperelongation, hence avoiding impact on other 
CDK activity and preventing unwanted side effects in a chronic disease setting. The 
 
 
253 
 
question for optimal drug release remains open and may be dependent on the mode 
of drug action and pharmacogenetics, as well as the characteristics of lesion 
development.  
In conclusion, the current study has identified the mRNA regulation of three 
GAG synthesizing enzymes XT-1, ChSy-1 and C4ST-1 in VSMC. A highly specific 
signalling pathway from TGF-β to Smad2 linker region phosphorylation exists in 
these cells. Three GAG synthesizing enzymes were shown to be upregulated by the 
pro-atherosclerotic growth factor TGF-β. The serine/threonine kinases ERK, p38, 
PI3K and CDK were found to be key mediators in this pathway. Individual Smad2 
linker region sites are selectively phosphorylated. For example Ser245 by p38 and 
Thr220 by CDKs. Phosphorylation of three serine residues (Ser245/250/255) induces 
mRNA expression of the GAG synthesizing enzymes ChSy-1 and C4ST-1. Smad2 
linker region (Thr220) phosphorylation is linked with XT-1 and determines the level 
of GAG chain synthesis. Further analysis of multiple CDKs that are involved in this 
overall process provides exciting new findings showing previously unknown roles of 
these kinase in the development of atherosclerosis. Together, these findings provide 
a better understanding of the complex signalling pathways that contribute to GAG 
chain hyperelongation and may facilitate the identification of a specific therapeutic 
target(s) for events important in the early development of atherosclerosis. 
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8.3 Limitations of this study  
There are a few limitations in the present study. Firstly, in Chapters 4 and 7, Western 
blot analysis of the individual phospho-Smad linker region residues was compared to 
GAPDH as the gel loading control. In Chapter 5, the analysis of phospho-Rb also 
utilized GAPDH. Whilst the use of GAPDH ensured consistent amount of each 
loaded samples for the basal control and treated cells, the use of a total Smad2 and 
total Rb antibody is required to validate the data fully. The utilization of such 
antibodies allows a comparison between phosphorylated Smad2 and total Smad2, as 
well as the comparison between phosphoryated Rb and total Rb. This allows precise 
measurement of the effects of TGF-β treatment and inhibitors towards the 
phosphorylation of Smad2 and Rb proteins present in the loaded samples. Analysis 
of the phosphorylation rate could also be achieved using such antibodies. 
Secondly, all the experiments in this study were carried out using smooth 
muscle cells obtained from saphenous veins. Although VSMC from surgically 
relocated saphenous veins are known to undergo atherosclerotic changes and can be 
used to investigate atherosclerosis-related biology, it would have been more 
interesting to know whether any of these pathways were also active in coronary 
artery smooth muscle cells.  
Thirdly, in this study, only pharmacological inhibitors were employed to 
evaluate the functions of serine/threonine kinases. Some of the inhibitors used in this 
study may exhibit off target effects. Roscovitine was shown to be selective for CDK, 
in fact most kinases are not affected, yet there is evidence showing it binds to an 
unexpected non-protein kinase target, the pyridoxal kinase (466). On the other hand, 
Flavopiridol can exhibit off target effects on Epidermal Growth Factor Receptor and 
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on Protein Kinase C (415). The use of only pharmacological inhibitors may limit the 
conclusion of the hypothesis made to correlative rather than showing causation. 
Therefore, alternate approaches including the use of molecular tools are necessary. 
For example, the use of siRNA to the kinases targeted by the inhibitors allows 
validation whether or not the same results obtained from this study could be 
reproduced. The use of several knockouts of the serine/threonine kinases could 
distinguish whether there is synergy between the different signalling pathways, given 
they target different phosphorylation events. This study could also be strengthened 
by knockouts of individual CDK, providing more specific answers. Meanwhile, in 
order to demonstrate the role of the different phosphorylation site in the Smad linker 
region, these sites must be mutated.  
Finally, all of the results for GAG synthesizing enzyme mRNA expression 
are shown as fold change. Experiments on the relative basal levels of expression 
between each of these enzymes could provide information on the physiological level 
of the individual GAG synthesizing enzymes in VSMC. Studies had shown that 
variation of these enzymes are seen in different tissues. C4ST-1 is strongly expressed 
in the heart, brain, placenta and lung whilst ChSy-1 is strongly expressed in the 
placenta and heart, in addition to moderate expression in the brain, skeletal muscle, 
kidney and liver (121,141). 
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8.4 Recommendation for future work  
Although this thesis has demonstrated the TGF-β signalling pathways controlling 
glycosaminoglycan chain synthesizing enzyme gene expression as a therapeutic 
target for atherosclerosis, further studies are required to elucidate the mechanism 
involved. This section presents some of these studies. 
 The role of CDK2 in atherosclerotic plaque development  
In this study, we have provided evidence of CDK2 involvement in TGF-β-mediated 
GAG synthesizing enzyme expression and GAG chain hyperelongation using 
in vitro model of human VSMC. Verification of the role of CDK2 in this process 
would be obtained by using CDK2 siRNA interference to observe its effects on GAG 
chain hyperelongation and its impact on TGF-β-stimulated lipid binding. 
Furthermore, exploring the use of apoE knockout mice fed with high-fat western diet 
and treatment with CDK2 inhibitor CVT313 will establish a correlation with 
mechanisms occurring in vivo. 
 Pin1 involvement in Smad linker region phosphorylation and 
GAG synthesizing enzyme expression 
Smad linker region phosphorylation is involved in GAG synthesizing enzyme 
expression and GAG chain hyperelogation. Pin1 is known for its ability to modify 
downstream signalling through isomerisation of cis/trans peptidyl-prolyl bonds on 
phosphorylated serine/threonine. Such bonds are found on the phosphorylated Smad 
linker region, thus the potential role of Pin1 in isomerisation of phospho-Smad linker 
region and its effects on GAG synthesizing enzyme expression should be explored. 
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 Mechanism of Ser245 phosphorylation on TGF-β-stimulated 
ChSy-1 and C4ST-1 expression as well as GAG chain 
hyperelongation  
Among the four Smad2 linker region residue being studied, Ser245 was mostly 
phosphorylated by ERK, p38, PI3K and CDK. This led to increased mRNA 
expression of ChSy-1 and C4ST-1. By inactivating Ser245 phosphorylation via 
amino acid replacement, VSMC expressing Ser245 mutants are reliable models to 
investigate the relationship between one or more phosphorylated Smad liker region 
residue and GAG synthesizing enzyme expression. The specific mechanism of 
Ser245 phosphorylation such as structural modification to the Smad complex could 
also be investigated. 
 Differential impact of cell cycle CDK isoforms on GAG chain 
hyperelongation 
As the cell cycle CDKs are shown to affect GAG chain hyperelongation, 
experiments to identify the differential impact of individual CDK isoforms on GAG 
chain elongation can be studied. CDK1, CDK2, CDK4 and CDK6 expression varies 
during each phase of the cell cycle. By synchronizing the phases of cell cycle, the 
investigation on differential impact of each CDK isoform on GAG chain elongation 
can be performed. This could be possible with the use of the flow cytometric 
analysis of cell cycle and propidium iodide DNA staining.  
 
 
 
258 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 9: References 
 
 
 
259 
 
1. Deaton, C., Froelicher, E. S., Wu, L. H., Ho, C., Shishani, K., and Jaarsma, T. 
(2011) The Global Burden of Cardiovascular Disease. Eur. J. Cardiovasc. 
Nurs. 10, S5-S13 
2. World Health Organization (2011) Global Atlas on Cardiovascular Disease 
Prevention and Control [Report]. Retrieved from: 
http://www.who.int/cardiovascular_diseases/publications/atlas_cvd/en, 
20/9/2015 
3. The National Heart Foundation of Australia (2014) Australian heart disease 
statistics 2014 [Report]. Retrieved from: 
https://heartfoundation.org.au/images/uploads/publications/HeartStats_2014_w
eb.pdf, 30/4/2015 
4. Thom, T., Haase, N., Rosamond, W., Howard, V. J., Rumsfeld, J., Manolio, T., 
Zheng, Z.-J., Flegal, K., O’Donnell, C., Kittner, S., Lloyd-Jones, D., Goff, D. 
C., Hong, Y., Adams, R., Friday, G., Furie, K., Gorelick, P., Kissela, B., 
Marler, J., Meigs, J., Roger, V., Sidney, S., Sorlie, P., Steinberger, J., 
Wasserthiel-Smoller, S., Wilson, M., and Wolf, P. (2006) Heart Disease and 
Stroke Statistics—2006 Update: A Report From the American Heart 
Association Statistics Committee and Stroke Statistics Subcommittee. 
Circulation 113, e85-e151 
5. Australian Institute of Health and Welfare (2011) Cardiovascular disease: 
Australian facts 2011 [Fact sheet]. Retrieved 
from:http://www.aihw.gov.au/publication-detail/?id=10737418510, 2/5/2015 
6. Reiner, Z., and Tedeschi-Reiner, E. (2006) Atherosclerosis - A paradox of 
Eastern European countries. Atherosclerosis 7, Supp J, 461-461 
7. Beaglehole, R., and Bonita, R. (2008) Global public health: a scorecard. The 
Lancet 372, 1988-1996 
8. Gersh, B. J., Sliwa, K., Mayosi, B. M., and Yusuf, S. (2010) Novel therapeutic 
concepts: The epidemic of cardiovascular disease in the developing world: 
Global implications. Eur. Heart J. 31, 642-648 
9. Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M. R., 
Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., Erdine, 
S., Halcox, J., Hobbs, R., Kjekshus, J., Filardi, P. P., Riccardi, G., Storey, R. 
F., and Wood, D. (2011) ESC/EAS Guidelines for the management of 
dyslipidaemias. Eur. Heart J. 32, 1769-1818 
10. Frostegard, J. (2013) Immunity, atherosclerosis and cardiovascular disease. 
BMC Med. 11, 117 
 
 
260 
 
11. Weber, C., and Noels, H. (2011) Atherosclerosis: current pathogenesis and 
therapeutic options. Nat. Med. 17, 1410-1422 
12. Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey 
Smith, G., Ward, K., and Ebrahim, S. (2013) Statins for the primary prevention 
of cardiovascular disease. Cochrane Database Syst. Rev. 1, CD004816 
13. Maron, D. J., Fazio, S., and Linton, M. F. (2000) Current Perspectives on 
Statins. Circulation 101, 207-213 
14. Jones, P. H., Nair, R., and Thakker, K. M. (2012) Prevalence of Dyslipidemia 
and Lipid Goal Attainment in Statin-Treated Subjects From 3 Data Sources: A 
Retrospective Analysis. J. Am. Heart Assoc. 1, e001800 
15. Gasser, T. C., Ogden, R. W., and Holzapfel, G. A. (2006) Hyperelastic 
modelling of arterial layers with distributed collagen fibre orientations. J. R. 
Soc. Interface 3, 15-35 
16. Glagov, S., Zarins, C. K., Masawa, N., Xu, C. P., Bassiouny, H., and Giddens, 
D. P. (1993) Mechanical functional role of non-atherosclerotic intimal 
thickening. Front. Med. Biol. Eng. 5, 37-43 
17. Rajendran, P., Rengarajan, T., Thangavel, J., Nishigaki, Y., Sakthisekaran, D., 
Sethi, G., and Nishigaki, I. (2013) The Vascular Endothelium and Human 
Diseases. Int. J. Biol. Sci. 9, 1057-1069 
18. Allahverdian, S., Chehroudi, A. C., McManus, B. M., Abraham, T., and 
Francis, G. A. (2014) Contribution of Intimal Smooth Muscle Cells to 
Cholesterol Accumulation and Macrophage-Like Cells in Human 
Atherosclerosis. Circulation 129, 1551-1559 
19. Wagenseil, J. E., and Mecham, R. P. (2009) Vascular Extracellular Matrix and 
Arterial Mechanics. Physiol. Rev. 89, 957-989 
20. Hu, Y., and Xu, Q. (2011) Adventitial Biology: Differentiation and Function. 
Arterioscler. Thromb. Vasc. Biol. 31, 1523-1529 
21. Holzapfel, G., Gasser, T., and Ogden, R. (2000) A New Constitutive 
Framework for Arterial Wall Mechanics and a Comparative Study of Material 
Models. J. Elasticity 61, 1-48 
22. Singh, R. B., Mengi, S. A., Xu, Y.-J., Arneja, A. S., and Dhalla, N. S. (2002) 
Pathogenesis of atherosclerosis: A multifactorial process. Exp. Clin. Cardiol. 
7, 40-53 
 
 
261 
 
23. Tabas, I., Williams, K. J., and Borén, J. (2007) Subendothelial lipoprotein 
retention as the initiating process in atherosclerosis. Circulation 116, 1832-
1844 
24. Libby, P., Ridker, P. M., and Hansson, G. K. (2011) Progress and challenges in 
translating the biology of atherosclerosis. Nature 473, 317-325 
25. Gu, L., Okada, Y., Clinton, S. K., Gerard, C., Sukhova, G. K., Libby, P., and 
Rollins, B. J. (1998) Absence of Monocyte Chemoattractant Protein-1 Reduces 
Atherosclerosis in Low Density Lipoprotein Receptor–Deficient Mice. Mol. 
Cell 2, 275-281 
26. Nigro, J., Osman, N., Dart, A. M., and Little, P. J. (2006) Insulin Resistance 
and Atherosclerosis. Endocr. Rev. 27, 242-259 
27. Smith, J. D., Trogan, E., Ginsberg, M., Grigaux, C., Tian, J., and Miyata, M. 
(1995) Decreased atherosclerosis in mice deficient in both macrophage colony-
stimulating factor (op) and apolipoprotein E. Proc. Natl. Acad. Sci. U. S. A. 92, 
8264-8268 
28. Qiao, J. H., Tripathi, J., Mishra, N. K., Cai, Y., Tripathi, S., Wang, X. P., Imes, 
S., Fishbein, M. C., Clinton, S. K., Libby, P., Lusis, A. J., and Rajavashisth, T. 
B. (1997) Role of macrophage colony-stimulating factor in atherosclerosis: 
studies of osteopetrotic mice. Am. J. Pathol. 150, 1687-1699 
29. Bouhlel, M. A., Derudas, B., Rigamonti, E., Dièvart, R., Brozek, J., Haulon, 
S., Zawadzki, C., Jude, B., Torpier, G., Marx, N., Staels, B., and Chinetti-
Gbaguidi, G. (2007) PPARγ Activation Primes Human Monocytes into 
Alternative M2 Macrophages with Anti-inflammatory Properties. Cell Metab. 
6, 137-143 
30. Rivard, A., and Andres, V. (2000) Vascular smooth muscle cell proliferation in 
the pathogenesis of atherosclerotic cardiovascular diseases. Histol. 
Histopathol. 15, 557-571 
31. Crowther, M. A. (2005) Pathogenesis of Atherosclerosis. ASH Education 
Program Book 2005, 436-441 
32. Ross, R. (1999) Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 
340, 115 - 126 
33. Tabas, I. (2010) Macrophage death and defective inflammation resolution in 
atherosclerosis. Nat. Rev. Immunol. 10, 36-46 
34. Kolodgie, F. D., Burke, A. P., Nakazawa, G., and Virmani, R. (2007) Is 
Pathologic Intimal Thickening the Key to Understanding Early Plaque 
 
 
262 
 
Progression in Human Atherosclerotic Disease? Arterioscler. Thromb. Vasc. 
Biol. 27, 986-989 
35. Dalager, S., Paaske, W. P., Bayer Kristensen, I., Marsvin Laurberg, J., and 
Falk, E. (2007) Artery-Related Differences in Atherosclerosis Expression: 
Implications for Atherogenesis and Dynamics in Intima-Media Thickness. 
Stroke 38, 2698-2705 
36. Stary, H. C. (2001) The development of calcium deposits in atherosclerotic 
lesions and their persistence after lipid regression. Am. J. Cardiol. 88, 16-19 
37. Kolodgie, F. D., Gold, H. K., Burke, A. P., Fowler, D. R., Kruth, H. S., Weber, 
D. K., Farb, A., Guerrero, L. J., Hayase, M., Kutys, R., Narula, J., Finn, A. V., 
and Virmani, R. (2003) Intraplaque Hemorrhage and Progression of Coronary 
Atheroma. N. Engl. J. Med. 349, 2316-2325 
38. Davies, M. J. (1990) A macro and micro view of coronary vascular insult in 
ischemic heart disease. Circulation 82, II38-46 
39. Libby, P. (2009) Molecular and cellular mechanisms of the thrombotic 
complications of atherosclerosis. J. Lipid Res. 50, S352-S357 
40. Ross, R., and Glomset, J. A. (1976) The pathogenesis of atherosclerosis 
(second of two parts). N. Engl. J. Med. 295, 420-425 
41. Berliner, J. A., Navab, M., Fogelman, A. M., Frank, J. S., Demer, L. L., 
Edwards, P. A., Watson, A. D., and Lusis, A. J. (1995) Atherosclerosis: basic 
mechanisms. Oxidation, inflammation, and genetics. Circulation 91, 2488-
2496 
42. Williams, K. J., and Tabas, I. (1995) The Response-to-Retention Hypothesis of 
Early Atherogenesis. Arterioscler. Thromb. Vasc. Biol. 15, 551-561 
43. Little, P. J., Osman, N., and O'Brien, K. D. (2008) Hyperelongated biglycan: 
the surreptitious initiator of atherosclerosis. Curr. Opin. Lipidol. 19, 448-454  
44. Jonasson, L., Holm, J., Skalli, O., Bondjers, G., and Hansson, G. K. (1986) 
Regional accumulations of T cells, macrophages, and smooth muscle cells in 
the human atherosclerotic plaque. Arterioscler. Thromb. Vasc. Biol. 6, 131-138 
45. Van der Wal, A. C., Das, P. K., Bentz van de Berg, D., van der Loos, C. M., 
and Becker, A. E. (1989) Atherosclerotic lesions in humans. In situ 
immunophenotypic analysis suggesting an immune mediated response. Lab. 
Invest. 61, 166-170 
46. Goldstein, J. L., Ho, Y. K., Basu, S. K., and Brown, M. S. (1979) Binding site 
on macrophages that mediates uptake and degradation of acetylated low 
 
 
263 
 
density lipoprotein, producing massive cholesterol deposition. Proc. Natl. 
Acad. Sci. U. S. A. 76, 333-337 
47. Haberland, M. E., Olch, C. L., and Folgelman, A. M. (1984) Role of lysines in 
mediating interaction of modified low density lipoproteins with the scavenger 
receptor of human monocyte macrophages. J. Biol. Chem. 259, 11305-11311 
48. Camejo, G., Fager, G., Rosengren, B., Hurt-Camejo, E., and Bondjers, G. 
(1993) Binding of low density lipoproteins by proteoglycans synthesized by 
proliferating and quiescent human arterial smooth muscle cells. J. Biol. Chem. 
268, 14131-14137 
49. Ylä-Herttuala, S., Solakivi, T., Hirvonen, J., Laaksonen, H., Möttönen, M., 
Pesonen, E., Raekallio, J., Akerblom, H. K., and Nikkari, T. (1987) 
Glycosaminoglycans and apolipoproteins B and A-I in human aortas. Chemical 
and immunological analysis of lesion-free aortas from children and adults. 
Arterioscler. Thromb. Vasc. Biol. 7, 333-340 
50. Nakashima, Y., Fujii, H., Sumiyoshi, S., Wight, T. N., and Sueishi, K. (2007) 
Early human atherosclerosis: accumulation of lipid and proteoglycans in 
intimal thickenings followed by macrophage infiltration. Arterioscler. Thromb. 
Vasc. Biol. 27, 1159-1165 
51. Nakashima, Y., Chen, Y. X., Kinukawa, N., and Sueishi, K. (2002) 
Distributions of diffuse intimal thickening in human arteries: preferential 
expression in atherosclerosis-prone arteries from an early age. Virchows Arch. 
441, 279-288 
52. Fukuchi, M., Watanabe, J., Kumagai, K., Baba, S., Shinozaki, T., Miura, M., 
Kagaya, Y., and Shirato, K. (2002) Normal and oxidized low density 
lipoproteins accumulate deep in physiologically thickened intima of human 
coronary arteries. Lab. Invest. 82, 1437-1447 
53. Wyler von Ballmoos, M., Dubler, D., Mirlacher, M., Cathomas, G., Muser, J., 
and Biedermann, B. C. (2006) Increased apolipoprotein deposits in early 
atherosclerotic lesions distinguish symptomatic from asymptomatic patients. 
Arterioscler. Thromb. Vasc. Biol. 26, 359-364 
54. O’Brien, K. D., Olin, K. L., Alpers, C. E., Chiu, W., Ferguson, M., Hudkins, 
K., Wight, T. N., and Chait, A. (1998) Comparison of Apolipoprotein and 
Proteoglycan Deposits in Human Coronary Atherosclerotic Plaques: 
Colocalization of Biglycan With Apolipoproteins. Circulation 98, 519-527 
55. Proctor, S. D., Vine, D. F., and Mamo, J. C. L. (2002) Arterial retention of 
apolipoprotein B48- and B100-containing lipoproteins in atherogenesis. Curr. 
Opin. Lipidol. 13, 461-470 
 
 
264 
 
56. Camejo, G., Hurt-Camejo, E., Wiklund, O., and Bondjers, G. (1998) 
Association of apo B lipoproteins with arterial proteoglycans: Pathological 
significance and molecular basis. Atherosclerosis 139, 205-222 
57. Chait, A., and Wight, T. N. (2000) Interaction of native and modified low-
density lipoproteins with extracellular matrix. Curr. Opin. Lipidol. 11, 457-463 
58. Lee, R. T., Yamamoto, C., Feng, Y., Potter-Perigo, S., Briggs, W. H., 
Landschulz, K. T., Turi, T. G., Thompson, J. F., Libby, P., and Wight, T. N. 
(2001) Mechanical strain induces specific changes in the synthesis and 
organization of proteoglycans by vascular smooth muscle cells. J. Biol. Chem. 
276, 13847-13851 
59. Selvin, E., Coresh, J., Golden, S. H., Boland, L. L., Brancati, F. L., and Steffes, 
M. W. (2005) Glycemic Control, Atherosclerosis, and Risk Factors for 
Cardiovascular Disease in Individuals With Diabetes: The Atherosclerosis 
Risk in Communities study. Diabetes Care 28, 1965-1973 
60. Fruchart, J.-C., Nierman, M. C., Stroes, E. S. G., Kastelein, J. J. P., and Duriez, 
P. (2004) New Risk Factors for Atherosclerosis and Patient Risk Assessment. 
Circulation 109, III-15-III-19 
61. Berry, C., Noble, S., Gregoire, J. C., Ibrahim, R., Levesquie, S., Lavoie, M. A., 
L'Allier, P. L., and Tardif, J. C. (2010) Glycaemic status influences the nature 
and severity of coronary artery disease. Diabetologia 53, 652-658 
62. Dzau, V. J. (1998) Mechanism of protective effects of ACE inhibition on 
coronary artery disease. Eur. Heart J. 19, Supp J, J2-6 
63. Rosenson, R. S. (2003) Modulating atherosclerosis through inhibition or 
blockade of angiotensin. Clin. Cardiol. 26, 305-311 
64. Gelosa, P., Cimino, M., Pignieri, A., Tremoli, E., Guerrini, U., and Sironi, L. 
(2007) The role of HMG-CoA reductase inhibition in endothelial dysfunction 
and inflammation. Vasc. Health Risk Manag. 3, 567-577 
65. Libby, P. (2005) The Forgotten Majority: Unfinished Business in 
Cardiovascular Risk Reduction. J. Am. Coll. Cardiol. 46, 1225-1228 
66. Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., 
Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., and Skene, A. M. (2004) 
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary 
Syndromes. N. Engl. J. Med. 350, 1495-1504 
67. Peterson, A. S., Fong, L. G., and Young, S. G. (2008) PCSK9 function and 
physiology. J. Lipid Res. 49, 1152-1156 
 
 
265 
 
68. Everett, B. M., Smith, R. J., and Hiatt, W. R. (2015) Reducing LDL with 
PCSK9 Inhibitors — The Clinical Benefit of Lipid Drugs. N. Engl. J. Med. 
373, 1588-1591 
69. Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., 
McQueen, M., Budaj, A., Pais, P., Varigos, J., and Lisheng, L. Effect of 
potentially modifiable risk factors associated with myocardial infarction in 52 
countries (the INTERHEART study): case-control study. The Lancet 364, 937-
952 
70. Buttar, H. S., Li, T., and Ravi, N. (2005) Prevention of cardiovascular 
diseases: Role of exercise, dietary interventions, obesity and smoking 
cessation. Exp. Clin. Cardiol. 10, 229-249 
71. Domanski, M. J., Borkowf, C. B., Campeau, L., Knatterud, G. L., White, C., 
Hoogwerf, B., Rosenberg, Y., and Geller, N. L. (2000) Prognostic factors for 
atherosclerosis progression in saphenous vein graftsThe postcoronary artery 
bypass graft (post-CABG) trial. J. Am. Coll. Cardiol. 36, 1877-1883 
72. Yusuf, S., Zucker, D., Passamani, E., Peduzzi, P., Takaro, T., Fisher, L. D., 
Kennedy, J. W., Davis, K., Killip, T., Norris, R., Morris, C., Mathur, V., 
Varnauskas, E., and Chalmers, T. C. Effect of coronary artery bypass graft 
surgery on survival: overview of 10-year results from randomised trials by the 
Coronary Artery Bypass Graft Surgery Trialists Collaboration. The Lancet 
344, 563-570 
73. Michaels, A. D., and Chatterjee, K. (2002) Angioplasty Versus Bypass Surgery 
for Coronary Artery Disease. Circulation 106, e187-e190 
74. Stefanini, G. G., and Holmes, D. R. (2013) Drug-Eluting Coronary-Artery 
Stents. N. Engl. J. Med. 368, 254-265 
75. Davignon, J., and Ganz, P. (2004) Role of Endothelial Dysfunction in 
Atherosclerosis. Circulation 109, III-27-III-32 
76. Witztum, J. L. (1994) The oxidation hypothesis of atherosclerosis. The Lancet 
344, 793-795 
77. Libby, P. (2002) Inflammation in atherosclerosis. Nature 420, 868-874 
78. Libby, P., Ridker, P. M., and Maseri, A. (2002) Inflammation and 
atherosclerosis. Circulation 105, 1135-1143 
79. Skalen, K., Gustafsson, M., Rydberg, E. K., Hulten, L. M., Wiklund, O., 
Innerarity, T. L., and Boren, J. (2002) Subendothelial retention of atherogenic 
lipoproteins in early atherosclerosis. Nature 417, 750-754 
 
 
266 
 
80. Staels, B. (2002) Cardiovascular biology - A cholesterol tether. Nature 417, 
699-701 
81. Dadlani, H., Ballinger, M. L., Osman, N., Getachew, R., and Little, P. J. 
(2008) Smad and p38 MAP kinase-mediated signaling of proteoglycan 
synthesis in vascular smooth muscle. J. Biol. Chem. 283, 7844-7852 
82. Little, P. J., Ballinger, M. L., and Osman, N. (2007) Vascular wall 
proteoglycan synthesis and structure as a target for the prevention of 
atherosclerosis. Vasc. Health Risk Manag. 3, 117-124  
83. Wight, T. N. (1989) Cell biology of arterial proteoglycans. Arterioscler. 
Thromb. Vasc. Biol. 9, 1-20 
84. Grande-Allen, K. J., Osman, N., Ballinger, M. L., Dadlani, H., Marasco, S., 
and Little, P. J. (2007) Glycosaminoglycan synthesis and structure as targets 
for the prevention of calcific aortic valve disease. Cardiovasc. Res. 76, 19-28 
85. Mettouchi, A. (2012) The role of extracellular matrix in vascular branching 
morphogenesis. Cell Adh. Migr. 6, 528-534 
86. Wu, Y. J., Pierre, D. P. L. A., Wu, J., Yee, A. J., and Yang, B. B. (2005) The 
interaction of versican with its binding partners. Cell Res. 15, 483-494 
87. Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., and Walter, P. 
(2002) Molecular Biology of the Cell, New York: Garland Science 
88. Järveläinen, H., Sainio, A., Koulu, M., Wight, T. N., and Penttinen, R. (2009) 
Extracellular Matrix Molecules: Potential Targets in Pharmacotherapy. 
Pharmacol. Rev. 61, 198-223 
89. Schaefer, L., and Schaefer, R. (2010) Proteoglycans: from structural 
compounds to signaling molecules. Cell Tissue Res. 339, 237-246 
90. Hultgårdh-Nilsson, A., and Durbeej, M. (2007) Role of the extracellular matrix 
and its receptors in smooth muscle cell function: implications in vascular 
development and disease. Curr. Opin. Lipidol. 18, 540-545 
91. Goldoni, S., and Iozzo, R. V. (2008) Tumor microenvironment: Modulation by 
decorin and related molecules harboring leucine-rich tandem motifs. Int. J. 
Cancer 123, 2473-2479 
92. Iozzo, R., Zoeller, J., and Nyström, A. (2009) Basement membrane 
proteoglycans: Modulators Par Excellence of cancer growth and angiogenesis. 
Mol. Cells 27, 503-513 
 
 
267 
 
93. Chang, M. Y., Potter-Perigo, S., Tsoi, C., Chait, A., and Wight, T. N. (2000) 
Oxidized Low Density Lipoproteins Regulate Synthesis of Monkey Aortic 
Smooth Muscle Cell Proteoglycans That Have Enhanced Native Low Density 
Lipoprotein Binding Properties. J. Biol. Chem. 275, 4766-4773 
94. Camejo, G. (1982) The interaction of lipids and lipoproteins with the 
intercellular matrix of arterial tissue: its possible role in atherogenesis. Adv. 
Lipid Res. 19, 1-53 
95. Olin-Lewis, K., Krauss, R. M., La Belle, M., Blanche, P. J., Barrett, P. H., 
Wight, T. N., and Chait, A. (2002) ApoC-III content of apoB-containing 
lipoproteins is associated with binding to the vascular proteoglycan biglycan. 
J. Lipid Res. 43, 1969-1977 
96. O'Brien, K. D., Lewis, K., Fischer, J. W., Johnson, P., Hwang, J. Y., Knopp, E. 
A., Kinsella, M. G., Barrett, P. H., Chait, A., and Wight, T. N. (2004) Smooth 
muscle cell biglycan overexpression results in increased lipoprotein retention 
on extracellular matrix: implications for the retention of lipoproteins in 
atherosclerosis. Atherosclerosis 177, 29-35 
97. Merrilees, M. J., Beaumont, B., and Scott, L. J. (2001) Comparison of deposits 
of versican, biglycan and decorin in saphenous vein and internal thoracic, 
radial and coronary arteries: correlation to patency. Coron. Artery Dis. 12, 7-16 
98. Gutierrez, P., OBrien, K. D., Ferguson, M., Nikkari, S. T., Alpers, C. E., and 
Wight, T. N. (1997) Differences in the distribution of versican, decorin, and 
biglycan in atherosclerotic human coronary arteries. Cardiovasc. Pathol. 6, 
271-278 
99. Kunjathoor, V. V., Chiu, D. S., O'Brien, K. D., and LeBoeuf, R. C. (2002) 
Accumulation of biglycan and perlecan, but not versican, in lesions of murine 
models of atherosclerosis. Arterioscl. Throm. Vas. 22, 462-468 
100. Olin, K. L., Potter-Perigo, S., Barrett, P. H., Wight, T. N., and Chait, A. (2001) 
Biglycan, a vascular proteoglycan, binds differently to HDL2 and HDL3: role 
of apoE. Arterioscler. Thromb. Vasc. Biol. 21, 129-135 
101. Prydz, K., and Dalen, K. T. (2000) Synthesis and sorting of proteoglycans. J. 
Cell Sci. 113, 193-205 
102. Silbert, J. E., and Sugumaran, G. (2002) Biosynthesis of chondroitin/dermatan 
sulfate. IUBMB life 54, 177-186 
103. Hardingham, T. E., and Fosang, A. J. (1992) Proteoglycans: many forms and 
many functions. FASEB J. 6, 861-870 
 
 
268 
 
104. Caterson, B. (2012) Fell-Muir Lecture: Chondroitin sulphate 
glycosaminoglycans: fun for some and confusion for others. Int. J. Exp. 
Pathol. 93, 1-10 
105. Sugahara, K., and Kitagawa, H. (2000) Recent advances in the study of the 
biosynthesis and functions of sulfated glycosaminoglycans. Curr. Opin. Struct. 
Biol. 10, 518-527 
106. Fraser, J. R. E., Laurent, T. C., and Laurent, U. B. G. (1997) Hyaluronan: its 
nature, distribution, functions and turnover. J. Intern. Med. 242, 27-33 
107. Spicer, A. P., and Tien, J. Y. L. (2004) Hyaluronan and morphogenesis. Birth 
Defects Res. C Embryo Today 72, 89-108 
108. Evanko, S. P., Angello, J. C., and Wight, T. N. (1999) Formation of 
Hyaluronan- and Versican-Rich Pericellular Matrix Is Required for 
Proliferation and Migration of Vascular Smooth Muscle Cells. Arterioscler. 
Thromb. Vasc. Biol. 19, 1004-1013 
109. Riessen, R., Wight, T. N., Pastore, C., Henley, C., and Isner, J. M. (1996) 
Distribution of Hyaluronan During Extracellular Matrix Remodeling in Human 
Restenotic Arteries and Balloon-Injured Rat Carotid Arteries. Circulation 93, 
1141-1147 
110. Jain, M., He, Q., Lee, W. S., Kashiki, S., Foster, L. C., Tsai, J. C., Lee, M. E., 
and Haber, E. (1996) Role of CD44 in the reaction of vascular smooth muscle 
cells to arterial wall injury. J. Clin. Invest. 97, 596-603 
111. Funderburgh, J. L. (2002) Keratan sulfate biosynthesis. IUBMB life 54, 187-
194 
112. Uchimura, K. (2015) Keratan sulfate: biosynthesis, structures, and biological 
functions. Methods Mol. Biol. 1229, 389-400 
113. Sugahara, K., and Kitagawa, H. (2002) Heparin and Heparan Sulfate 
Biosynthesis. IUBMB life 54, 163-175 
114. Sugahara, K., Yamada, S., Yoshida, K., de Waard, P., and Vliegenthart, J. F. 
(1992) A novel sulfated structure in the carbohydrate-protein linkage region 
isolated from porcine intestinal heparin. J. Biol. Chem. 267, 1528-1533 
115. Kamhi, E., Joo, E. J., Dordick, J. S., and Linhardt, R. J. (2013) 
Glycosaminoglycans in infectious disease. Biol. Rev. 88, 928-943 
116. Vynios, D. H. (2014) Metabolism of Cartilage Proteoglycans in Health and 
Disease. BioMed Res. Int. 2014, 9 
 
 
269 
 
117. Bishop, J., Schuksz, M., and Esko, J. (2007) Heparan sulphate proteoglycans 
fine-tune mammalian physiology. Nature 446, 1030-1037 
118. Sarrazin, S., Lamanna, W. C., and Esko, J. D. (2011) Heparan Sulfate 
Proteoglycans. Cold Spring Harbor Perspectives in Biology 3,  a004952 
119. Stringer, S. E. (2006) The role of heparan sulphate proteoglycans in 
angiogenesis. Biochem. Soc. Trans. 34, 451-453 
120. Theocharis, A. D., and Theocharis, D. A. (2002) High-performance capillary 
electrophoretic analysis of hyaluronan and galactosaminoglycan-disaccharides 
in gastrointestinal carcinomas. Differential disaccharide composition as a 
possible tool-indicator for malignancies. Biomed. Chromatogr. 16, 157 - 161 
121. Kitagawa, H., Izumikawa, T., Uyama, T., and Sugahara, K. (2003) Molecular 
cloning of a chondroitin polymerizing factor that cooperates with chondroitin 
synthase for chondroitin polymerization. J. Biol. Chem. 278, 23666-23671 
122. Maeda, N., Ishii, M., Nishimura, K., and Kamimura, K. (2011) Functions of 
Chondroitin Sulfate and Heparan Sulfate in the Developing Brain. Neurochem. 
Res. 36, 1228-1240 
123. Uebelhart, D. (2008) Clinical review of chondroitin sulfate in osteoarthritis. 
Osteoarthr. Cartil. 16, Supp J, S19-S21 
124. Little, P. J., Ballinger, M. L., Burch, M. L., and Osman, N. (2008) 
Biosynthesis of natural and hyperelongated chondroitin sulfate 
glycosaminoglycans: new insights into an elusive process. Open Biochem. J. 2, 
135 
125. Kalathas, D., Theocharis, D., Bounias, D., Kyriakopoulou, D., 
Papageorgakopoulou, N., Stavropoulos, M., and Vynios, D. (2009) Alterations 
of glycosaminoglycan disaccharide content and composition in colorectal 
cancer: Structural and expressional studies. Oncol. Rep. 22, 369 - 375 
126. Saigoh, K., Izumikawa, T., Koike, T., Shimizu, J., Kitagawa, H., and 
Kusunoki, S. (2011) Chondroitin beta-1,4-N-acetylgalactosaminyltransferase-1 
missense mutations are associated with neuropathies. J. Hum. Genet. 56, 143-
146 
127. Mikami, T., and Kitagawa, H. (2013) Biosynthesis and function of chondroitin 
sulfate. Biochim. Biophys. Acta 1830, 4719-4733 
128. Koike, T., Izumikawa, T., Sato, B., and Kitagawa, H. (2014) Identification of 
phosphatase that dephosphorylates xylose in the glycosaminoglycan-protein 
linkage region of proteoglycans. J. Biol. Chem. 289, 6695-6708 
 
 
270 
 
129. Izumikawa, T., Okuura, Y., Koike, T., Sakoda, N., and Kitagawa, H. (2011) 
Chondroitin 4-O-sulfotransferase-1 regulates the chain length of chondroitin 
sulfate in co-operation with chondroitin N-acetylgalactosaminyltransferase-2. 
Biochem. J 434, 321-331 
130. Kjellen, L., and Lindahl, U. (1991) Proteoglycans - Structures and Interactions. 
Annu. Rev. Biochem. 60, 443-475 
131. Götting, C., Kuhn, J., and Kleesiek, K. (2007) Human xylosyltransferases in 
health and disease. Cell. Mol. Life Sci. 64, 1498-1517 
132. Kusche-Gullberg, M., and Kjellen, L. (2003) Sulfotransferases in 
glycosaminoglycan biosynthesis. Curr. Opin. Struct. Biol. 13, 605-611 
133. Almeida, R., Levery, S. B., Mandel, U., Kresse, H., Schwientek, T., Bennett, 
E. P., and Clausen, H. (1999) Cloning and Expression of a Proteoglycan UDP-
Galactose: -Xylose  1,4-Galactosyltransferase I: A seventh member of the 
human  4-galactosyltransferase gene family. J. Biol. Chem. 274, 26165-26171 
134. Bai, X., Zhou, D., Brown, J. R., Crawford, B. E., Hennet, T., and Esko, J. D. 
(2001) Biosynthesis of the linkage region of glycosaminoglycans: cloning and 
activity of galactosyltransferase II, the sixth member of the beta 1,3-
galactosyltransferase family (beta 3GalT6). J. Biol. Chem. 276, 48189-48195 
135. Kitagawa, H., Tone, Y., Tamura, J., Neumann, K. W., Ogawa, T., Oka, S., 
Kawasaki, T., and Sugahara, K. (1998) Molecular cloning and expression of 
glucuronyltransferase I involved in the biosynthesis of the glycosaminoglycan-
protein linkage region of proteoglycans. J. Biol. Chem. 273, 6615-6618 
136. Izumikawa, T., Uyama, T., Okuura, Y., Sugahara, K., and Kitagawa, H. (2007) 
Involvement of chondroitin sulfate synthase-3 (chondroitin synthase-2) in 
chondroitin polymerization through its interaction with chondroitin synthase-1 
or chondroitin-polymerizing factor. Biochem. J. 403, 545-552 
137. Izumikawa, T., Koike, T., Shiozawa, S., Sugahara, K., Tamura, J. I., and 
Kitagawa, H. (2008) Identification of chondroitin sulfate glucuronyltransferase 
as chondroitin synthase-3 involved in chondroitin polymerization - 
Chondroitin polymerization is achieved by multiple enzyme complexes 
consisting of chondroitin synthase family members. J. Biol. Chem. 283, 11396-
11406 
138. Maccarana, M., Olander, B., Malmstrom, J., Tiedemann, K., Aebersold, R., 
Lindahl, U., Li, J. P., and Malmstrom, A. (2006) Biosynthesis of dermatan 
sulfate - Chondroitin-glucuronate C5-epimerase is identical to SART2. J. Biol. 
Chem. 281, 11560-11568 
 
 
271 
 
139. Pacheco, B., Maccarana, M., and Malmstrom, A. (2009) Dermatan 4-O-
sulfotransferase 1 is pivotal in the formation of iduronic acid blocks in 
dermatan sulfate. Glycobiology 19, 1197 - 1203 
140. Sugahara, K., Mikami, T., Uyama, T., Mizuguchi, S., Nomura, K., and 
Kitagawa, H. (2003) Recent advances in the structural biology of chondroitin 
sulfate and dermatan sulfate. Curr. Opin. Struct. Biol. 13, 612-620 
141. Okuda, T., Mita, S., Yamauchi, S., Matsubara, T., Yagi, F., Yamamori, D., 
Fukuta, M., Kuroiwa, A., Matsuda, Y., and Habuchi, O. (2000) Molecular 
Cloning, Expression, and Chromosomal Mapping of Human, Chondroitin 4-
Sulfotransferase, Whose Expression Pattern in Human Tissues Is Different 
from That of Chondroitin 6-Sulfotransferase. J. Biochem. 128, 763 - 770 
142. Yada, T., Gotoh, M., Sato, T., Shionyu, M., Go, M., Kaseyama, H., Iwasaki, 
H., Kikuchi, N., Kwon, Y. D., Togayachi, A., Kudo, T., Watanabe, H., 
Narimatsu, H., and Kimata, K. (2003) Chondroitin Sulfate Synthase-
2:Molecular cloning and characterization of a novel human glycosyltransferase 
homologous to chondroitin sulfate glucuronyltransferase, which has dual 
enzymatic activities. J. Biol. Chem. 278, 30235 - 30247 
143. Gulberti, S., Jacquinet, J. C., Chabel, M., Ramalanjaona, N., Magdalou, J., 
Netter, P., Coughtrie, M. W. H., Ouzzine, M., and Fournel-Gigleux, S. (2012) 
Chondroitin sulfate N-acetylgalactosaminyltransferase-1 (CSGalNAcT-1) 
involved in chondroitin sulfate initiation: Impact of sulfation on activity and 
specificity. Glycobiology 22, 561-571 
144. Sato, T., Gotoh, M., Kiyohara, K., Akashima, T., Iwasaki, H., Kameyama, A., 
Mochizuki, H., Yada, T., Inaba, N., Togayachi, A., Kudo, T., Asada, M., 
Watanabe, H., Imamura, T., Kimata, K., and Narimatsu, H. (2003) Differential 
roles of two N-acetylgalactosaminyltransferases, CSGalNAcT-1, and a novel 
enzyme, CSGalNAcT-2 - Initiation and elongation in synthesis of chondroitin 
sulfate. J. Biol. Chem. 278, 3063-3071 
145. Anggraeni, V. Y., Emoto, N., Yagi, K., Mayasari, D. S., Nakayama, K., 
Izumikawa, T., Kitagawa, H., and Hirata, K. (2011) Correlation of C4ST-1 and 
ChGn-2 expression with chondroitin sulfate chain elongation in 
atherosclerosis. Biochem. Biophys. Res. Commun. 406:36-41 
146. Prante, C., Milting, H., Kassner, A., Farr, M., Ambrosius, M., Schön, S., 
Seidler, D. G., Banayosy, A. E., Körfer, R., Kuhn, J., Kleesiek, K., and 
Götting, C. (2007) Transforming Growth Factor β1-regulated 
Xylosyltransferase I Activity in Human Cardiac Fibroblasts and Its Impact for 
Myocardial Remodeling. J. Biol. Chem. 282, 26441-26449 
147. German, J. B., Smilowitz, J. T., and Zivkovic, A. M. (2006) Lipoproteins: 
When size really matters. Curr. Opin. Colloid Interface Sci. 11, 171-183 
 
 
272 
 
148. Segrest, J. P., Jones, M. K., De Loof, H., and Dashti, N. (2001) Structure of 
apolipoprotein B-100 in low density lipoproteins. J. Lipid Res. 42, 1346-1367 
149. Boren, J., Olin, K., Lee, I., Chait, A., Wight, T. N., and Innerarity, T. L. (1998) 
Identification of the principal proteoglycan-binding site in LDL. A single-point 
mutation in apo-B100 severely affects proteoglycan interaction without 
affecting LDL receptor binding. J. Clin. Invest. 101, 2658-2664 
150. Stein, Y., and Stein, O. (2003) Lipoprotein lipase and atherosclerosis. 
Atherosclerosis 170, 1-9 
151. Pentikäinen, M. O., Oksjoki, R., Öörni, K., and Kovanen, P. T. (2002) 
Lipoprotein Lipase in the Arterial Wall: Linking LDL to the Arterial 
Extracellular Matrix and Much More. Arterioscler. Thromb. Vasc. Biol. 22, 
211-217 
152. Kaplan, M., and Aviram, M. (2001) Retention of oxidized LDL by 
extracellular matrix proteoglycans leads to its uptake by macrophages - An 
alternative approach to study lipoproteins cellular uptake. Arterioscl. Throm. 
Vas. 21, 386-393 
153. Tabas, I. (1999) Nonoxidative modifications of lipoproteins in atherogenesis. 
Annu. Rev. Nutr. 19, 123-139 
154. Stemme, S., Faber, B., Holm, J., Wiklund, O., Witztum, J. L., and Hansson, G. 
K. (1995) T lymphocytes from human atherosclerotic plaques recognize 
oxidized low density lipoprotein. Proc. Natl. Acad. Sci.U.S.A. 92, 3893-3897 
155. Hurt-Camejo, E., Olsson, U., Wiklund, O., Bondjers, G., and Camejo, G. 
(1997) Cellular consequences of the association of apoB lipoproteins with 
proteoglycans. Potential contribution to atherogenesis. Arterioscler. Thromb. 
Vasc. Biol. 17, 1011-1017 
156. Ballinger, M. L., Nigro, J., Frontanilla, K. V., Dart, A. M., and Little, P. J. 
(2004) Regulation of glycosaminoglycan structure and atherogenesis. Cell. 
Mol. Life Sci. 61, 1296-1306 
157. Schonherr, E., Jarvelainen, H. T., Kinsella, M. G., Sandell, L. J., and Wight, T. 
N. (1993) Platelet-derived growth factor and transforming growth factor-beta 1 
differentially affect the synthesis of biglycan and decorin by monkey arterial 
smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 13, 1026-1036 
158. Little, P. J., Tannock, L., Olin, K. L., Chait, A., and Wight, T. N. (2002) 
Proteoglycans Synthesized by Arterial Smooth Muscle Cells in the Presence of 
Transforming Growth Factor-β1 Exhibit Increased Binding to LDLs. 
Arterioscler. Thromb. Vasc. Biol. 22, 55-60 
 
 
273 
 
159. Figueroa, J. E., and Vijayagopal, P. (2002) Angiotensin II stimulates 
synthesis of vascular smooth muscle cell proteoglycans with enhanced low 
density lipoprotein binding properties. Atherosclerosis 162, 261-268 
160. Olsson, U., Bondjers, G., and Camejo, G. (1999) Fatty acids modulate the 
composition of extracellular matrix in cultured human arterial smooth muscle 
cells by altering the expression of genes for proteoglycan core proteins. 
Diabetes 48, 616-622 
161. Cardoso, L. E. M., Little, P. J., Ballinger, M. L., Chan, C. K., Braun, K. R., 
Potter-Perigo, S., Bornfeldt, K. E., Kinsella, M. G., and Wight, T. N. (2010) 
Platelet-derived Growth Factor Differentially Regulates the Expression and 
Post-translational Modification of Versican by Arterial Smooth Muscle Cells 
through Distinct Protein Kinase C and Extracellular Signal-regulated Kinase 
Pathways. J. Biol. Chem. 285, 6987-6995 
162. Srinivasan, S. R., Xu, J. H., Vijayagopal, P., Radhakrishnamurthy, B., and 
Berenson, G. S. (1993) Injury to the arterial wall of rabbits produces 
proteoglycan variants with enhanced low-density lipoprotein-binding property. 
Biochim. Biophys. Acta 1168, 158-166 
163. Yang, S. N. Y., Burch, M. L., Getachew, R., Ballinger, M. L., Osman, N., and 
Little, P. J. (2009) Growth factor-mediated hyper-elongation of 
glycosaminoglycan chains on biglycan requires transcription and translation. 
Arch. Physiol. Biochem. 115, 147-154 
164. Vijayagopal, P., Ciolino, H. P., and Berenson, G. S. (1992) Endothelial cell-
conditioned medium modulates the synthesis and structure of proteoglycans in 
vascular smooth muscle cells. Biochim. Biophys. Acta 1135, 129-140 
165. Toma, L., Pinhal, M. A. S., Dietrich, C. P., Nader, H. B., and Hirschberg, C. B. 
(1996) Transport of UDP-Galactose into the Golgi Lumen Regulates the 
Biosynthesis of Proteoglycans. J. Biol. Chem. 271, 3897-3901 
166. Westergren-Thorsson, G., Schmidtchen, A., Sarnstrand, B., Fransson, L. A., 
and Malmstrom, A. (1992) Transforming growth factor-beta induces selective 
increase of proteoglycan production and changes in the copolymeric structure 
of dermatan sulphate in human skin fibroblasts. Eur. J. Biochem. 205, 277-286 
167. Edwards, I. J., and Wagner, W. D. (1988) Distinct synthetic and structural 
characteristics of proteoglycans produced by cultured artery smooth muscle 
cells of atherosclerosis-susceptible pigeons. J. Biol. Chem. 263, 9612-9620 
168. Curwen, K. D., and Smith, S. C. (1977) Aortic glycosaminoglycans in 
atherosclerosis-susceptible and -resistant pigeons. Exp. Mol. Pathol. 27, 121-
133 
 
 
274 
 
169. Mizumoto, S., Yamada, S., and Sugahara, K. (2014) Human Genetic Disorders 
and Knockout Mice Deficient in Glycosaminoglycan. BioMed Res. Int. 2014, 
24 
170. Ihling, C., Technau, K., Gross, V., Schulte-Monting, J., Zeiher, A. M., and 
Schaefer, H. E. (1999) Concordant upregulation of type II-TGF-beta-receptor, 
the cyclin-dependent kinases inhibitor P27Kip1 and cyclin E in human 
atherosclerotic tissue: implications for lesion cellularity. Atherosclerosis 144, 
7-14 
171. Massague, J. (1998) TGF-beta signal transduction. Annu. Rev. Biochem. 67, 
753-791 
172. McCartney-Francis, N. L., Frazier-Jessen, M., and Wahl, S. M. (1998) TGF-
beta: a balancing act. Int. Rev. Immunol. 16, 553-580 
173. Grainger, D. J. (2007) TGF-β and atherosclerosis in man. Cardiovasc. Res. 74, 
213-222 
174. Derynck, R., Akhurst, R. J., and Balmain, A. (2001) TGF-β signaling in tumor 
suppression and cancer progression. Nat. Genet. 29, 117-129 
175. Massagué, J., and Wotton, D. (2000) New embo member’s review: 
Transcriptional control by the TGF-β/Smad signaling system. EMBO J. 19, 
1745 
176. Matsuura, I., Chiang, K.-N., Lai, C.-Y., He, D., Wang, G., Ramkumar, R., 
Uchida, T., Ryo, A., Lu, K., and Liu, F. (2010) Pin1 Promotes Transforming 
Growth Factor-β-induced Migration and Invasion. J. Biol. Chem. 285, 1754-
1764 
177. Burch, M., Zheng, W., and Little, P. (2011) Smad linker region 
phosphorylation in the regulation of extracellular matrix synthesis. Cell. Mol. 
Life Sci. 68, 97-107 
178. Wicks, S. J., Grocott, T., Haros, K., Maillard, M., Dijke, P. t., and Chantry, A. 
(2006) Reversible ubiquitination regulates the Smad/TGF-β signalling 
pathway. Biochem. Soc. Trans. 34, 761-763 
179. Zhang, L., Zhou, F., and ten Dijke, P. (2013) Signaling interplay between 
transforming growth factor-β receptor and PI3K/AKT pathways in cancer. 
Trends Biochem. Sci. 38, 612-620 
180. Grainger, D. J. (2004) Transforming Growth Factor β and Atherosclerosis: So 
Far, So Good for the Protective Cytokine Hypothesis. Arterioscler. Thromb. 
Vasc. Biol. 24, 399-404 
 
 
275 
 
181. Feng, X.-H., and Derynck, R. (2005) Specificity And Versatility In TGF-β 
Signaling Through Smads. Annu. Rev. Cell Dev. Biol. 21, 659-693 
182. Bjorkerud, S. (1991) Effects of transforming growth factor-beta 1 on human 
arterial smooth muscle cells in vitro. Arterioscler. Thromb. 11, 892-902 
183. Grainger, D. J., Metcalfe, J. C., Grace, A. A., and Mosedale, D. E. (1998) 
Transforming growth factor-beta dynamically regulates vascular smooth 
muscle differentiation in vivo. J. Cell Sci. 111, 2977-2988 
184. Fujita, M., and Sasayama, S. (2010) Coronary Collateral Growth and Its 
Therapeutic Application to Coronary Artery Disease. Circ. J. 74, 1283-1289 
185. Muto, A., Model, L., Ziegler, K., Eghbalieh, S. D. D., and Dardik, A. (2010) 
Mechanisms of Vein Graft Adaptation to the Arterial Circulation - Insights 
Into the Neointimal Algorithm and Management Strategies. Circ. J. 74, 1501-
1512 
186. Shimada, K. (2009) Immune System and Atherosclerotic Disease - 
Heterogeneity of Leukocyte Subsets Participating in the Pathogenesis of 
Atherosclerosis. Circ. J. 73, 994-1001 
187. Battegay, E. J., Raines, E. W., Seifert, R. A., Bowen-Pope, D. F., and Ross, R. 
TGF-β induces bimodal proliferation of connective tissue cells via complex 
control of an autocrine PDGF loop. Cell 63, 515-524 
188. Stouffer, G. A., and Owens, G. K. (1992) Angiotensin II-induced mitogenesis 
of spontaneously hypertensive rat-derived cultured smooth muscle cells is 
dependent on autocrine production of transforming growth factor-beta. Circ. 
Res. 70, 820-828 
189. Grainger, D. J., and Metcalfe, J. C. (1995) A Pivotal role for TGF-β in 
atherogenesis? Biol. Rev. 70, 571-596 
190. Bobik, A., Agrotis, A., Kanellakis, P., Dilley, R., Krushinsky, A., Smirnov, V., 
Tararak, E., Condron, M., and Kostolias, G. (1999) Distinct Patterns of 
Transforming Growth Factor-β Isoform and Receptor Expression in Human 
Atherosclerotic Lesions: Colocalization Implicates TGF-β in Fibrofatty Lesion 
Development. Circulation 99, 2883-2891 
191. McCaffrey, T. A., Du, B., Consigli, S., Szabo, P., Bray, P. J., Hartner, L., 
Weksler, B. B., Sanborn, T. A., Bergman, G., and Bush, H. L., Jr. (1997) 
Genomic instability in the type II TGF-beta1 receptor gene in atherosclerotic 
and restenotic vascular cells. J. Clin. Invest. 100, 2182-2188 
192. McCaffrey, T. A., Du, B. H., Fu, C. H., Pray, D. J., Sanborn, T. A., Deutsch, 
E., Tarazona, N., Shaknovitch, A., Newman, G., Patterson, C., and Bush, H. L. 
 
 
276 
 
(1999) The expression of TGF-beta receptors in human atherosclerosis: 
Evidence for acquired resistance to apoptosis due to receptor imbalance. J. 
Mol. Cell. Cardiol. 31, 1627-1642 
193. Oklu, R., Hesketh, R., Wicky, S., and Metcalfe, J. C. (2011) Localization of 
Latent Transforming Growth Factor-beta Binding Protein-1 in Human 
Coronary Atherosclerotic Plaques. Circ. J. 75, 196-200 
194. Merrilees, M. J., and Beaumont, B. (1993) Structural heterogeneity of the 
diffuse intimal thickening and correlation with distribution of TGF-beta 1. J. 
Vasc. Res. 30, 293-302 
195. Schönherr, E., Järveläinen, H. T., Sandell, L. J., and Wight, T. N. (1991) 
Effects of platelet-derived growth factor and transforming growth factor-beta 1 
on the synthesis of a large versican-like chondroitin sulfate proteoglycan by 
arterial smooth muscle cells. J. Biol. Chem. 266, 17640-17647 
196. Lin, H., Ignatescu, M., Wilson, J. E., Roberts, C. R., Horley, K. J., Winters, G. 
L., Costanzo, M. R., and McManus, B. M. (1996) Prominence of 
apolipoproteins B, (a), and E in the intimae of coronary arteries in transplanted 
human hearts: geographic relationship to vessel wall proteoglycans. J. Heart 
Lung Transplant. 15, 1223-1232 
197. Riessen, R., Isner, J. M., Blessing, E., Loushin, C., Nikol, S., and Wight, T. N. 
(1994) Regional differences in the distribution of the proteoglycans biglycan 
and decorin in the extracellular matrix of atherosclerotic and restenotic human 
coronary arteries. Am. J. Pathol. 144, 962-974 
198. Evanko, S. P., Raines, E. W., Ross, R., Gold, L. I., and Wight, T. N. (1998) 
Proteoglycan distribution in lesions of atherosclerosis depends on lesion 
severity, structural characteristics, and the proximity of platelet-derived growth 
factor and transforming growth factor-beta. Am. J. Pathol. 152, 533-546 
199. Sun, P. D., and Davies, D. R. (1995) The Cystine-Knot Growth-Factor 
Superfamily. Annu. Rev. Biophys. Biomol. Struct. 24, 269-292 
200. Nickel, J., Sebald, W., Groppe, J. C., and Mueller, T. D. (2009) Intricacies of 
BMP receptor assembly. Cytokine Growth Factor Rev. 20, 367-377 
201. Shi, Y., and Massague, J. (2003) Mechanisms of TGF-beta signaling from cell 
membrane to the nucleus. Cell 113, 685-700 
202. Huse, M., Muir, T. W., Xu, L., Chen, Y.-G., Kuriyan, J., and Massagué, J. 
(2001) The TGFβ Receptor Activation Process: An Inhibitor- to Substrate-
Binding Switch. Mol. Cell 8, 671-682 
 
 
277 
 
203. Verrecchia, F., Mauviel, A., and Farge, D. (2006) Transforming growth factor-
β signaling through the Smad proteins: Role in systemic sclerosis. 
Autoimmunity Reviews 5, 563-569 
204. Wrighton, K. H., Lin, X., and Feng, X.-H. (2009) Phospho-control of TGF-β 
superfamily signaling. Cell Res. 19, 8-20 
205. DaCosta Byfield, S., Major, C., Laping, N. J., and Roberts, A. B. (2004) SB-
505124 Is a Selective Inhibitor of Transforming Growth Factor-β Type I 
Receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 65, 744-752 
206. Inman, G. J., Nicolás, F. J., Callahan, J. F., Harling, J. D., Gaster, L. M., Reith, 
A. D., Laping, N. J., and Hill, C. S. (2002) SB-431542 Is a Potent and Specific 
Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin 
Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7. Mol. 
Pharmacol. 62, 65-74 
207. Moustakas, A., Souchelnytskyi, S., and Heldin, C.-H. (2001) Smad regulation 
in TGF-β signal transduction. J. Cell Sci. 114, 4359-4369 
208. Massagué, J., Seoane, J., and Wotton, D. (2005) Smad transcription factors. 
Genes Dev. 19, 2783-2810 
209. Shi, Y., Hata, A., Lo, R. S., Massague, J., and Pavletich, N. P. (1997) A 
structural basis for mutational inactivation of the tumour suppressor Smad4. 
Nature 388, 87-93 
210. Itoh, F., Asao, H., Sugamura, K., Heldin, C. H., ten Dijke, P., and Itoh, S. 
(2001) Promoting bone morphogenetic protein signaling through negative 
regulation of inhibitory Smads. EMBO J. 20, 4132-4142 
211. Derynck, R., and Zhang, Y. E. (2003) Smad-dependent and Smad-independent 
pathways in TGF-β family signalling. Nature 425, 577-584 
212. Zawel, L., Le Dai, J., Buckhaults, P., Zhou, S., Kinzler, K. W., Vogelstein, B., 
and Kern, S. E. (1998) Human Smad3 and Smad4 are sequence-specific 
transcription activators. Mol. Cell 1, 611-617 
213. Shi, Y., Wang, Y.-F., Jayaraman, L., Yang, H., Massagué, J., and Pavletich, N. 
P. (1998) Crystal Structure of a Smad MH1 Domain Bound to DNA: Insights 
on DNA Binding in TGF-β Signaling. Cell 94, 585-594 
214. Moustakas, A., and Heldin, C.-H. (2009) The regulation of TGFβ signal 
transduction. Development 136, 3699-3714 
 
 
278 
 
215. Ten Dijke, P., Miyazono, K., and Heldin, C.-H (2000) Signaling inputs 
converge on nuclear effectors in TGF-β signaling. Trends Biochem. Sci. 25, 
64-70 
216. Kamato, D., Burch, M. L., Piva, T. J., Rezaei, H. B., Rostam, M. A., Xu, S., 
Zheng, W., Little, P. J., and Osman, N. (2013) Transforming growth factor-β 
signalling: Role and consequences of Smad linker region phosphorylation. 
Cell. Signal. 25, 2017-2024 
217. Rostam, M. A., Piva, T. J., Rezaei, H. B., Kamato, D., Little, P. J., Zheng, W., 
and Osman, N. (2015) Peptidyl-prolyl isomerases: Functionality and potential 
therapeutic targets in cardiovascular disease. Clin. Exp. Pharmacol. Physiol. 
42, 117-124 
218. Abdollah, S., Macı́as-Silva, M., Tsukazaki, T., Hayashi, H., Attisano, L., and 
Wrana, J. L. (1997) TβRI Phosphorylation of Smad2 on Ser465 and Ser467 Is 
Required for Smad2-Smad4 Complex Formation and Signaling. J. Biol. Chem. 
272, 27678-27685 
219. Correia, J. J., Chacko, B. M., Lam, S. S., and Lin, K. (2001) Sedimentation 
studies reveal a direct role of phosphorylation in Smad3:Smad4 homo- and 
hetero-trimerization. Biochemistry 40, 1473-1482 
220. Heldin, C. H., Miyazono, K., and Ten Dijke, P. (1997) TGF-β signalling from 
cell membrane to nucleus through SMAD proteins. Nature 390, 465-471 
221. Piek, E., Heldin, C. H., and Dijke, P. T. (1999) Specificity, diversity, and 
regulation in TGF-β superfamily signaling. FASEB J. 13, 2105-2124 
222. Brown, K. A., Pietenpol, J. A., and Moses, H. L. (2007) A tale of two proteins: 
Differential roles and regulation of Smad2 and Smad3 in TGF-β signaling. J. 
Cell. Biochem. 101, 9-33 
223. Dennler, S., Huet, S., and Gauthier, J. M. (1999) A short amino-acid sequence 
in MH1 domain is responsible for functional differences between Smad2 and 
Smad3. Oncogene 18, 1643-1648 
224. Susarla, B. T., Laing, E. D., Yu, P., Katagiri, Y., Geller, H. M., and Symes, A. 
J. (2011) Smad proteins differentially regulate transforming growth factor-
beta-mediated induction of chondroitin sulfate proteoglycans. J. Neurochem. 
119, 868-878 
225. Hough, C., Radu, M., and Doré, J. J. E. (2012) TGF-Beta Induced Erk 
Phosphorylation of Smad Linker Region Regulates Smad Signaling. PLoS One 
7, e42513 
 
 
279 
 
226. Wang, G., Matsuura, I., He, D., and Liu, F. (2009) Transforming Growth 
Factor-β-inducible Phosphorylation of Smad3. J. Biol. Chem. 284, 9663-9673 
227. Inman, G. J. (2005) Linking Smads and transcriptional activation. Biochem. J. 
386, e1-e3 
228. Kretzschmar, M., Doody, J., Timokhina, I., and Massague, J. (1999) A 
mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. 
Genes Dev. 13, 804-816 
229. Cushing, M. C., Mariner, P. D., Liao, J.-T., Sims, E. A., and Anseth, K. S. 
(2008) Fibroblast growth factor represses Smad-mediated myofibroblast 
activation in aortic valvular interstitial cells. FASEB J. 22, 1769-1777 
230. Alarcón, C., Zaromytidou, A.-I., Xi, Q., Gao, S., Yu, J., Fujisawa, S., Barlas, 
A., Miller, A. N., Manova-Todorova, K., Macias, M. J., Sapkota, G., Pan, D., 
and Massagué, J. (2009) CDK8/9 drive Smad transcriptional action, turnover 
and YAP interactions in BMP and TGFβ pathways. Cell 139, 757-769 
231. Blanchette, F., Rivard, N., Rudd, P., Grondin, F., Attisano, L., and Dubois, C. 
M. (2001) Cross-talk between the p42/p44 MAP Kinase and Smad Pathways in 
Transforming Growth Factor β1-induced Furin Gene Transactivation. J. Biol. 
Chem. 276, 33986-33994 
232. Burch, M. L., Yang, S. N., Ballinger, M. L., Getachew, R., Osman, N., and 
Little, P. J. (2010) TGF-beta stimulates biglycan synthesis via p38 and ERK 
phosphorylation of the linker region of Smad2. Cell. Mol. Life Sci. 67, 2077-
2090 
233. Bruce, D. L., and Sapkota, G. P. (2012) Phosphatases in SMAD regulation. 
FEBS Lett. 586, 1897-1905 
234. Yoshida, K., Murata, M., Yamaguchi, T., and Matsuzaki, K. (2014) TGF-
beta/Smad signaling during hepatic fibro-carcinogenesis. Int. J. Oncol. 45, 
1363-1371 
235. Matsuzaki, K. (2013) Smad phospho-isoforms direct context-dependent TGF-β 
signaling. Cytokine Growth Factor Rev. 24, 385-399 
236. Kamato, D., Rostam, M. A., Piva, T. J., Babaahmadi Rezaei, H., Getachew, R., 
Thach, L., Bernard, R., Zheng, W., Little, P. J., and Osman, N. (2014) 
Transforming growth factor β-mediated site-specific Smad linker region 
phosphorylation in vascular endothelial cells. J. Pharm. Pharmacol. 66, 1722-
1733 
237. Vaughan, D. E. (2005) PAI-1 and atherothrombosis. J. Thromb. Haemost. 3, 
1879-1883 
 
 
280 
 
238. Matsuura, I., Denissova, N. G., Wang, G., He, D., Long, J., and Liu, F. (2004) 
Cyclin-dependent kinases regulate the antiproliferative function of Smads. 
Nature 430, 226-231 
239. Malumbres, M., and Barbacid, M. (2001) Milestones in cell division : To cycle 
or not to cycle: a critical decision in cancer. Nat. Rev. Cancer 1, 222-231 
240. Massague, J. (2004) G1 cell-cycle control and cancer. Nature 432, 298-306 
241. Malumbres, M., Pevarello, P., Barbacid, M., and Bischoff, J. R. (2008) CDK 
inhibitors in cancer therapy: what is next? Trends Pharmacol. Sci. 29, 16-21 
242. Malumbres, M., and Barbacid, M. (2009) Cell cycle, CDKs and cancer: a 
changing paradigm. Nat. Rev. Cancer 9, 153-166 
243. Knockaert, M., Greengard, P., and Meijer, L. (2002) Pharmacological 
inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 23, 417-425 
244. Sriram, V., and Patterson, C. (2001) Cell Cycle in Vasculoproliferative 
Diseases: Potential Interventions and Routes of Delivery. Circulation 103, 
2414-2419 
245. Ruef, J., Meshel, A. S., Hu, Z., Horaist, C., Ballinger, C. A., Thompson, L. J., 
Subbarao, V. D., Dumont, J. A., and Patterson, C. (1999) Flavopiridol Inhibits 
Smooth Muscle Cell Proliferation In Vitro and Neointimal Formation In Vivo 
After Carotid Injury in the Rat. Circulation 100, 659-665 
246. Brooks, E. E., Gray, N. S., Joly, A., Kerwar, S. S., Lum, R., Mackman, R. L., 
Norman, T. C., Rosete, J., Rowe, M., Schow, S. R., Schultz, P. G., Wang, X., 
Wick, M. M., and Shiffman, D. (1997) CVT-313, a Specific and Potent 
Inhibitor of CDK2 That Prevents Neointimal Proliferation. J. Biol. Chem. 272, 
29207-29211 
247. Feng, X. H., Liang, Y. Y., Liang, M., Zhai, W., and Lin, X. (2002) Direct 
interaction of c-Myc with Smad2 and Smad3 to inhibit TGF-beta-mediated 
induction of the CDK inhibitor p15(Ink4B). Mol. Cell 9, 133-143 
248. Malumbres, M., and Barbacid, M. (2005) Mammalian cyclin-dependent 
kinases. Trends Biochem. Sci. 30, 630-641 
249. Blewett, A. (2007) Cell division: CDK1 in the driving seat. Nat. Rev. Mol. Cell 
Biol. 8, 755-755 
250. Sherr, C. J., and Roberts, J. M. (1999) CDK inhibitors: positive and negative 
regulators of G1-phase progression. Genes Dev. 13, 1501-1512 
 
 
281 
 
251. Landis, M. W., Pawlyk, B. S., Li, T., Sicinski, P., and Hinds, P. W. (2006) 
Cyclin D1-dependent kinase activity in murine development and mammary 
tumorigenesis. Cancer Cell 9, 13-22 
252. Sherr, C. J. (2004) Principles of Tumor Suppression. Cell 116, 235-246 
253. Stevaux, O., and Dyson, N. J. (2002) A revised picture of the E2F 
transcriptional network and RB function. Curr. Opin. Cell Biol. 14, 684-691 
254. Weinberg, R. A. (1995) The retinoblastoma protein and cell cycle control. Cell 
81, 323-330 
255. Lapenna, S., and Giordano, A. (2009) Cell cycle kinases as therapeutic targets 
for cancer. Nat. Rev. Drug Disc. 8, 547-566 
256. Massagué, J., Blain, S. W., and Lo, R. S. (2000) TGFβ Signaling in Growth 
Control, Cancer, and Heritable Disorders. Cell 103, 295-309 
257. Chen, C.-R., Kang, Y., and Massagué, J. (2001) Defective repression of c-myc 
in breast cancer cells: A loss at the core of the transforming growth factor β 
growth arrest program. Proc. Natl. Acad. Sci. U. S. A. 98, 992-999 
258. Yagi, K., Furuhashi, M., Aoki, H., Goto, D., Kuwano, H., Sugamura, K., 
Miyazono, K., and Kato, M. (2002) c-myc Is a Downstream Target of the 
Smad Pathway. J. Biol. Chem. 277, 854-861 
259. Liu, F., and Matsuura, I. (2004) Inhibition of Smad Antiproliferative Function 
by CDK Phosphorylation. Cell Cycle 4, 63-66 
260. Yue, J., and Mulder, K. M. (2001) Transforming growth factor-β signal 
transduction in epithelial cells. Pharmacol. Ther. 91, 1-34 
261. Johnson, G. L., and Lapadat, R. (2002) Mitogen-activated protein kinase 
pathways mediated by ERK, JNK, and p38 protein kinases. Science 298, 1911-
1912 
262. Kamimura, M., Bea, F., Akizawa, T., Katus, H. A., Kreuzer, J., and Viedt, C. 
(2004) Platelet-derived growth factor induces tissue factor expression in 
vascular smooth muscle cells via activation of Egr-1. Hypertension 44, 944-
951 
263. Zhou, L., Opalinska, J., and Verma, A. (2007) p38 MAP Kinase Regulates 
Stem Cell Apoptosis in Human Hematopoietic Failure. Cell Cycle 6, 534-537 
 
 
282 
 
264. Yogi, A., Callera, G. E., Tostes, R. C., and Touyz, R. (2006) c-Src mediates 
angiotensin II but not endothelin-1-induced activation of MAP kinases in 
vascular smooth muscle cells. Hypertension 48, E83-E84 
265. Yoshida, K., Matsuzaki, K., Mori, S., Tahashi, Y., Yamagata, H., Furukawa, 
F., Seki, T., Nishizawa, M., Fujisawa, J., and Okazaki, K. (2005) Transforming 
Growth Factor-β and Platelet-Derived Growth Factor Signal via c-Jun N-
Terminal Kinase-Dependent Smad2/3 Phosphorylation in Rat Hepatic Stellate 
Cells after Acute Liver Injury. Am J Pathol. 166, 1029–1039 
266. Teramoto, H., and Gutkind, J. S. (2013) Mitogen-Activated Protein Kinase 
Family in Encyclopedia of Biological Chemistry, Waltham: Academic Press 
267. Kretzschmar, M., Doody, J., and Massagu, J. (1997) Opposing BMP and EGF 
signalling pathways converge on the TGF-[beta] family mediator Smad1. 
Nature 389, 618-622 
268. Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J., and Waterfield, 
M. D. (2001) Cellular Function Of Phosphoinositide 3-Kinases: Implications 
for Development, Immunity, Homeostasis, and Cancer. Annu. Rev. Cell Dev. 
Biol. 17, 615-675 
269. Morello, F., Perino, A., and Hirsch, E. (2009) Phosphoinositide 3-kinase 
signalling in the vascular system. Cardiovasc. Res. 82:261-271 
270. Fougerat, A., Gayral, S., Gourdy, P., Schambourg, A., Rückle, T., Schwarz, M. 
K., Rommel, C., Hirsch, E., Arnal, J.-F., Salles, J.-P., Perret, B., Breton-
Douillon, M., Wymann, M. P., and Laffargue, M. (2008) Genetic and 
Pharmacological Targeting of Phosphoinositide 3-Kinase-γ Reduces 
Atherosclerosis and Favors Plaque Stability by Modulating Inflammatory 
Processes. Circulation 117, 1310-1317 
271. Puri, K. D., Doggett, T. A., Huang, C.-Y., Douangpanya, J., Hayflick, J. S., 
Turner, M., Penninger, J., and Diacovo, T. G. (2005) The role of endothelial 
PI3Kγ activity in neutrophil trafficking. Blood 106, 150-157 
272. Vecchione, C., Patrucco, E., Marino, G., Barberis, L., Poulet, R., Aretini, A., 
Maffei, A., Gentile, M. T., Storto, M., Azzolino, O., Brancaccio, M., Colussi, 
G. L., Bettarini, U., Altruda, F., Silengo, L., Tarone, G., Wymann, M. P., 
Hirsch, E., and Lembo, G. (2005) Protection from angiotensin II–mediated 
vasculotoxic and hypertensive response in mice lacking PI3Kγ. J. Exp. Med. 
201, 1217-1228 
273. Pincheira, R., Castro, A. F., Ozes, O. N., Idumalla, P. S., and Donner, D. B. 
(2008) Type 1 TNF Receptor Forms a Complex with and Uses Jak2 and c-Src 
to Selectively Engage Signaling Pathways That Regulate Transcription Factor 
Activity. J. Immunol. 181, 1288-1298 
 
 
283 
 
274. Assinder, S. J., Dong, Q., Kovacevic, Z., and Richardson, D. R. (2009) The 
TGF-beta, PI3K/Akt and PTEN pathways: established and proposed 
biochemical integration in prostate cancer. Biochem. J. 417, 411-421 
275. Yi, J. Y., Shin, I., and Arteaga, C. L. (2005) Type I Transforming Growth 
Factor β Receptor Binds to and Activates Phosphatidylinositol 3-Kinase. J. 
Biol. Chem. 280, 10870-10876 
276. Jahan, N., and Hannila, S. S. (2015) Transforming growth factor β-induced 
expression of chondroitin sulfate proteoglycans is mediated through non-Smad 
signaling pathways. Exp. Neurol. 263, 372-384 
277. Sansal, I., and Sellers, W. R. (2004) The biology and clinical relevance of the 
PTEN tumor suppressor pathway. J. Clin. Oncol. 22, 2954-2963 
278. Cantley, L. C., and Neel, B. G. (1999) New insights into tumor suppression: 
PTEN suppresses tumor formation by restraining the phosphoinositide 3-
kinase/AKT pathway. Proc. Natl. Acad. Sci. U. S. A. 96, 4240-4245 
279. Suwanabol, P. A., Seedial, S. M., Zhang, F., Shi, X., Si, Y., Liu, B., and Kent, 
K. C. (2012) TGF-β and Smad3 modulate PI3K/Akt signaling pathway in 
vascular smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 302, 
H2211-2219. 
280. Osman, N., Getachew, R., Burch, M., Lancaster, G., Wang, R., Wang, H., 
Zheng, W., and Little, P. J. (2011) TGF-β stimulates biglycan core protein 
synthesis but not glycosaminoglycan chain elongation via Akt phosphorylation 
in vascular smooth muscle. Growth Factors 29, 203-210 
281. Woodgett, J. R. (1994) Regulation and functions of the glycogen synthase 
kinase-3 subfamily. Semin. Cancer Biol. 5, 269-275 
282. Kerkela, R., Kockeritz, L., MacAulay, K., Zhou, J., Doble, B. W., Beahm, C., 
Greytak, S., Woulfe, K., Trivedi, C. M., Woodgett, J. R., Epstein, J. A., Force, 
T., and Huggins, G. S. (2008) Deletion of GSK-3β in mice leads to 
hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. 
J. Clin. Invest. 118, 3609-3618 
283. Matsuda, T., Zhai, P., Maejima, Y., Hong, C., Gao, S., Tian, B., Goto, K., 
Takagi, H., Tamamori-Adachi, M., Kitajima, S., and Sadoshima, J. (2008) 
Distinct roles of GSK-3α and GSK-3β phosphorylation in the heart under 
pressure overload. Proc. Natl. Acad. Sci. U.S.A 105, 20900-20905 
284. Ahmad, F., Lal, H., Zhou, J., Vagnozzi, R. J., Yu, J. E., Shang, X., Woodgett, 
J. R., Gao, E., and Force, T. (2014) Cardiomyocyte-specific deletion of GSK3 
alpha mitigates post-myocardial infarction remodeling, contractile dysfunction, 
and heart failure. J. Am. Coll. Cardiol. 64, 696-706 
 
 
284 
 
285. Lal, H., Ahmad, F., Zhou, J., Yu, J. E., Vagnozzi, R. J., Guo, Y., Yu, D., Tsai, 
E. J., Woodgett, J., Gao, E., and Force, T. (2014) Cardiac Fibroblast Glycogen 
Synthase Kinase-3β Regulates Ventricular Remodeling and Dysfunction in 
Ischemic Heart. Circulation 130, 419-430 
286. Millet, C., Yamashita, M., Heller, M., Yu, L. R., Veenstra, T. D., and Zhang, 
Y. E. (2009) A negative feedback control of transforming growth factor-β 
signaling by glycogen synthase kinase 3-mediated Smad3 linker 
phosphorylation at Ser-204. J. Biol. Chem. 284, 19808-19816 
287. Guo, X., Ramirez, A., Waddell, D. S., Li, Z., Liu, X., and Wang, X. F. (2008) 
Axin and GSK3-β control Smad3 protein stability and modulate TGF-β 
signaling. Genes Dev. 22, 106-120 
288. Means, A. R. (2000) Regulatory Cascades Involving Calmodulin-Dependent 
Protein Kinases. Mol. Endocrinol. 14, 4-13 
289. Hook, S. S., and Means, A. R. (2001) Ca2+/CaM-dependent kinases: From 
Activation to Function. Annu. Rev. Pharmacol. Toxicol. 41, 471-505 
290. Wicks, S. J., Stephen, L., Abdel-Wahab, N., Mason, R. M., and Chantry, A. 
(2000) Inactivation of Smad-transforming growth factor β signaling by Ca2+-
calmodulin-dependent protein kinase II. Mol. Cell. Biol. 20, 8103-8111 
291. Kobayashi, Y., Fukuda, T., Tanaka, M., and Matsui, T. (2012) The anti-
atherosclerotic di-peptide, Trp-His, inhibits the phosphorylation of voltage-
dependent L-type Ca(2+) channels in rat vascular smooth muscle cells. FEBS 
Open Bio. 2, 83-88 
292. He, B. J., and Anderson, M. E. (2013) Aldosterone and cardiovascular disease: 
the heart of the matter. Trends Endocrinol. Metab. 24, 21-30 
293. Swaminathan, P. D., Purohit, A., Hund, T. J., and Anderson, M. E. (2012) 
Calmodulin-Dependent Protein Kinase II: Linking Heart Failure and 
Arrhythmias. Circ. Res. 110, 1661-1677 
294. Kushnir, A., Shan, J., Betzenhauser, M. J., Reiken, S., and Marks, A. R. (2010) 
Role of CaMKIIδ phosphorylation of the cardiac ryanodine receptor in the 
force frequency relationship and heart failure. Proc. Natl. Acad. Sci. U. S. A. 
107, 10274-10279 
295. Wu, Y., Gao, Z., Chen, B., Koval, O. M., Singh, M. V., Guan, X., Hund, T. J., 
Kutschke, W., Sarma, S., Grumbach, I. M., Wehrens, X. H. T., Mohler, P. J., 
Song, L.-S., and Anderson, M. E. (2009) Calmodulin kinase II is required for 
fight or flight sinoatrial node physiology. Proc. Natl. Acad. Sci. U. S. A. 106, 
5972-5977 
 
 
285 
 
296. Hahmann, C., and Schroeter, T. (2010) Rho-kinase inhibitors as therapeutics: 
from pan inhibition to isoform selectivity. Cell. Mol. Life Sci. 67, 171-177 
297. Chen, K., Rund, L. A., Beever, J. E., and Schook, L. B. (2006) Isolation and 
molecular characterization of the porcine transforming growth factor beta type 
I receptor (TGFBR1) gene. Gene 384, 62-72 
298. Kamaraju, A. K., and Roberts, A. B. (2005) Role of Rho/ROCK and p38 MAP 
kinase pathways in transforming growth factor-beta-mediated Smad-dependent 
growth inhibition of human breast carcinoma cells in vivo. J. Biol. Chem. 280, 
1024-1036 
299. Chen, S., Crawford, M., Day, R. M., Briones, V. R., Leader, J. E., Jose, P. A., 
and Lechleider, R. J. (2006) RhoA modulates Smad signaling during 
transforming growth factor-beta-induced smooth muscle differentiation. J. 
Biol. Chem. 281, 1765-1770 
300. Bhowmick, N. A., Ghiassi, M., Aakre, M., Brown, K., Singh, V., and Moses, 
H. L. (2003) TGF-β-induced RhoA and p160ROCK activation is involved in 
the inhibition of Cdc25A with resultant cell-cycle arrest. Proc. Natl. Acad. Sci. 
U. S. A. 100, 15548-15553 
301. Lee, S., and Helfman, D. M. (2004) Cytoplasmic p21Cip1 Is Involved in Ras-
induced Inhibition of the ROCK/LIMK/Cofilin Pathway. J. Biol. Chem. 279, 
1885-1891 
302. Adlam, D., Antoniades, C., Lee, R., Diesch, J., Shirodaria, C., Taggart, D., 
Leeson, P., and Channon, K. M. (2011) OCT Characteristics of Saphenous 
Vein Graft Atherosclerosis. JACC Cardiovasc. Imaging 4, 807-809 
 
303. Campeau , L., Enjalbert , M., Lespérance , J., Bourassa , M. G., Kwiterovich , 
P. J., Wacholder , S., and Sniderman , A. (1984) The Relation of Risk Factors 
to the Development of Atherosclerosis in Saphenous-Vein Bypass Grafts and 
the Progression of Disease in the Native Circulation. N. Engl. J. Med. 311, 
1329-1332 
304. Bourassa, M. G. (1991) Fate of venous grafts: The past, the present and the 
future. J. Am. Coll. Cardiol. 17, 1081-1083 
 
305. Fitzgibbon, G. M., Kafka, H. P., Leach, A. J., Keon, W. J., Hooper, G. D., and 
Burton, J. R. (1996) Coronary bypass graft fate and patient outcome: 
Angiographic follow-up of 5,065 grafts related to survival and reoperation in 
1,388 patients during 25 years. J. Am. Coll. Cardiol. 28, 616-626 
306. Chamley-Campbell, J., Campbell, G. R., and Ross, R. (1979) The smooth 
muscle cell in culture. Physiol. Rev. 59, 1-61 
 
 
286 
 
307. Schmittgen, T. D., and Livak, K. J. (2008) Analyzing real-time PCR data by 
the comparative CT method. Nat. Protocols 3, 1101-1108 
 
308. Shimizu-Hirota, R., Sasamura, H., Kuroda, M., Kobayashi, E., Hayashi, M., 
and Saruta, T. (2004) Extracellular Matrix Glycoprotein Biglycan Enhances 
Vascular Smooth Muscle Cell Proliferation and Migration. Circ. Res. 94, 
1067-1074 
309. Getachew, R., Ballinger, M. L., Burch, M. L., Reid, J. J., Khachigian, L. M., 
Wight, T. N., Little, P. J., and Osman, N. (2010) PDGF β-Receptor Kinase 
Activity and ERK1/2 Mediate Glycosaminoglycan Elongation on Biglycan and 
Increases Binding to LDL. Endocrinology 151, 4356-4367 
310. Nigro, J., Dilley, R. J., and Little, P. J. (2002) Differential effects of 
gemfibrozil on migration, proliferation and proteoglycan production in human 
vascular smooth muscle cells. Atherosclerosis 162, 119-129 
311. Laemmli, U. K. (1970) Cleavage of Structural Proteins during the Assembly of 
the Head of Bacteriophage T4. Nature 227, 680-685 
312. Götting, C., Kuhn, J., Zahn, R., Brinkmann, T., and Kleesiek, K. (2000) 
Molecular Cloning and Expression of Human UDP-d-Xylose:Proteoglycan 
Core Protein β-d-Xylosyltransferase and its First Isoform XT-II. J. Mol. Biol. 
304, 517-528 
313. Kitagawa, H., Uyama, T., and Sugahara, K. (2001) Molecular Cloning and 
Expression of a Human Chondroitin Synthase. J. Biol. Chem. 276, 38721-
38726 
314. Uyama, T., Kitagawa, H., Tanaka, J., Tamura, J.-i., Ogawa, T., and Sugahara, 
K. (2003) Molecular Cloning and Expression of a Second Chondroitin N-
Acetylgalactosaminyltransferase Involved in the Initiation and Elongation of 
Chondroitin/Dermatan Sulfate. J. Biol. Chem. 278, 3072-3078 
315. Hiraoka, N., Nakagawa, H., Ong, E., Akama, T. O., Fukuda, M. N., and 
Fukuda, M. (2000) Molecular Cloning and Expression of Two Distinct Human 
Chondroitin 4-O-Sulfotransferases That Belong to the HNK-1 Sulfotransferase 
Gene Family. J. Biol. Chem. 275, 20188-20196 
316. Karumbaiah, L., Anand, S., Thazhath, R., Zhong, Y., McKeon, R. J., and 
Bellamkonda, R. V. (2011) Targeted downregulation of N-acetylgalactosamine 
4-sulfate 6-O-sulfotransferase (GalNAc4S6ST) significantly mitigates 
chondroitin sulfate proteoglycan (CSPG) mediated inhibition. Glia 59, 981-
996 
 
 
287 
 
317. Schiller, M., Javelaud, D., and Mauviel, A. (2004) TGF-β-induced SMAD 
signaling and gene regulation: consequences for extracellular matrix 
remodeling and wound healing. J. Dermatol. Sci. 35, 83-92 
318. Hu, B., Shi, C., Tian, Y., Zhang, Y., Xu, C., Chen, H., Cao, P., and Yuan, W. 
(2015) TGF-β Induces Up-Regulation of Chondroitin Sulfate Synthase 1 
(CHSY1) in Nucleus Pulposus Cells Through MAPK Signaling. Cell. Physiol. 
Biochem. 37, 793-804 
319. Vollberg Sr, T. M., George, M. D., and Jetten, A. M. (1991) Induction of 
extracellular matrix gene expression in normal human keratinocytes by 
transforming growth factor β is altered by cellular differentiation. Exp. Cell 
Res. 193, 93-100 
320. Grande, J., Melder, D., Zinsmeister, A., and Killen, P. (1993) Transforming 
growth factor-beta 1 induces collagen IV gene expression in NIH-3T3 cells. 
Lab. Invest. 69, 387-395 
321. Kolm, V., Sauer, U., Olgemoller, B., and Schleicher, E. D. (1996) High 
glucose-induced TGF-beta 1 regulates mesangial production of heparan sulfate 
proteoglycan. Am. J. Physiol. 270, F812-821 
322. Yan, J., Stringer, S. E., Hamilton, A., Charlton-Menys, V., Götting, C., Müller, 
B., Aeschlimann, D., and Alexander, M. Y. (2011) Decorin GAG Synthesis 
and TGF-β Signaling Mediate Ox-LDL–Induced Mineralization of Human 
Vascular Smooth Muscle Cells. Arterioscler. Thromb. Vasc. Biol. 31, 608-615 
323. Lyon, M., Rushton, G., and Gallagher, J. T. (1997) The Interaction of the 
Transforming Growth Factor-βs with Heparin/Heparan Sulfate Is Isoform-
specific. J. Biol. Chem. 272, 18000-18006 
324. Horiguchi, M., Ota, M., and Rifkin, D. B. (2012) Matrix control of 
transforming growth factor-β function. J. Biochem. 152, 321-329 
325. Chen, Q., Sivakumar, P., Barley, C., Peters, D. M., Gomes, R. R., Farach-
Carson, M. C., and Dallas, S. L. (2007) Potential Role for Heparan Sulfate 
Proteoglycans in Regulation of Transforming Growth Factor-β (TGF-β) by 
Modulating Assembly of Latent TGF-β-binding Protein-1. J. Biol. Chem. 282, 
26418-26430 
326. Wilson, D. G., Phamluong, K., Lin, W. Y., Barck, K., Carano, R. A. D., Diehl, 
L., Peterson, A. S., Martin, F., and Solloway, M. J. (2012) Chondroitin sulfate 
synthase 1 (Chsy1) is required for bone development and digit patterning. Dev. 
Biol. 363, 413-425 
327. Ogawa, H., Hatano, S., Sugiura, N., Nagai, N., Sato, T., Shimizu, K., Kimata, 
K., Narimatsu, H., and Watanabe, H. (2012) Chondroitin Sulfate Synthase-2 Is 
 
 
288 
 
Necessary for Chain Extension of Chondroitin Sulfate but Not Critical for 
Skeletal Development. PLoS One 7, e43806 
328. Gollan, P. J., and Bhave, M. (2010) A thylakoid-localised FK506-binding 
protein in wheat may be linked to chloroplast biogenesis. Plant Physiol. 
Biochem. 48, 655-662 
329. Gotoh, M., Yada, T., Sato, T., Akashima, T., Iwasaki, H., Mochizuki, H., 
Inaba, N., Togayachi, A., Kudo, T., Watanabe, H., Kimata, K., and Narimatsu, 
H. (2002) Molecular Cloning and Characterization of a Novel Chondroitin 
Sulfate Glucuronyltransferase That Transfers Glucuronic Acid to N-
Acetylgalactosamine. J. Biol. Chem. 277, 38179 - 38188 
330. Grimm, O. H., and Gurdon, J. B. (2002) Nuclear exclusion of Smad2 is a 
mechanism leading to loss of competence. Nat. Cell Biol. 4, 519-522 
331. Kluppel, M., Samavarchi-Tehrani, P., Liu, K., Wrana, J. L., and Hinek, A. 
(2012) C4ST-1/CHST11-controlled chondroitin sulfation interferes with 
oncogenic HRAS signaling in Costello syndrome. Eur. J. Hum. Genet. 20, 
870-877 
332. Matsuzaki, K., Kitano, C., Murata, M., Sekimoto, G., Yoshida, K., Uemura, 
Y., Seki, T., Taketani, S., Fujisawa, J., and Okazaki, K. (2009) Smad2 and 
Smad3 phosphorylated at both linker and COOH-terminal regions transmit 
malignant TGF-beta signal in later stages of human colorectal cancer. Cancer 
Res. 69, 5321-5330 
333. 333. Burch, M. L., Ballinger, M. L., Yang, S. N. Y., Getachew, R., Itman, 
C., Loveland, K., Osman, N., and Little, P. J. (2010) Thrombin stimulation of 
proteoglycan synthesis in vascular smooth muscle is mediated by protease-
activated receptor-1 transactivation of the transforming growth factor βtype I 
receptor. J. Biol. Chem. 285, 26798-26805 
334. Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., and Saltiel, A. R. (1995) 
PD 098059 is a specific inhibitor of the activation of mitogen-activated protein 
kinase kinase in vitro and in vivo. J. Biol. Chem. 270, 27489-27494 
335. Ohori, M., Kinoshita, T., Okubo, M., Sato, K., Yamazaki, A., Arakawa, H., 
Nishimura, S., Inamura, N., Nakajima, H., Neya, M., Miyake, H., and Fujii, T. 
(2005) Identification of a selective ERK inhibitor and structural determination 
of the inhibitor–ERK2 complex. Biochem. Biophys. Res. Commun. 336, 357-
363 
336. Aragón, E., Goerner, N., Zaromytidou, A.-I., Xi, Q., Escobedo, A., Massagué, 
J., and Macias, M. J. (2011) A Smad action turnover switch operated by WW 
domain readers of a phosphoserine code. Genes Dev. 25, 1275-1288 
 
 
289 
 
337. Yumoto, K., Thomas, P. S., Lane, J., Matsuzaki, K., Inagaki, M., Ninomiya-
Tsuji, J., Scott, G. J., Ray, M. K., Ishii, M., Maxson, R., Mishina, Y., and 
Kaartinen, V. (2013) TGF-β-activated Kinase 1 (Tak1) Mediates Agonist-
induced Smad Activation and Linker Region Phosphorylation in Embryonic 
Craniofacial Neural Crest-derived Cells. J. Biol. Chem. 288, 13467-13480 
338. Hayashida, T., deCaestecker, M., and Schnaper, H. W. (2003) Cross-talk 
between ERK MAP kinase and Smad-signaling pathways enhances TGF-β 
dependent responses in human mesangial cells. FASEB J. 17, 1576-1578 
339. Gotting, C., Sollberg, S., Kuhn, J., Weilke, C., Huerkamp, C., Brinkmann, T., 
Krieg, T., and Kleesiek, K. (1999) Serum xylosyltransferase: A new 
biochemical marker of the sclerotic process in systemic sclerosis. J. Invest. 
Dermatol. 112, 919-924 
340. Zhang, Y., Feng, X.-H., Wu, R.-Y., and Derynck, R. (1996) Receptor-
associated Mad homologues synergize as effectors of the TGF-[beta] response. 
Nature 383, 168-172 
341. Zhang, Y., Musci, T., and Derynck, R. (1997) The tumor suppressor 
Smad4/DPC 4 as a central mediator of Smad function. Curr. Biol. 7, 270-276 
342. Macías-Silva, M., Abdollah, S., Hoodless, P. A., Pirone, R., Attisano, L., and 
Wrana, J. L. (1996) MADR2 Is a Substrate of the TGF-β Receptor and Its 
Phosphorylation Is Required for Nuclear Accumulation and Signaling. Cell 87, 
1215-1224 
343. Wrighton, K. H., Willis, D., Long, J., Liu, F., Lin, X., and Feng, X.-H. (2006) 
Small C-terminal Domain Phosphatases Dephosphorylate the Regulatory 
Linker Regions of Smad2 and Smad3 to Enhance Transforming Growth 
Factor-β Signaling. J. Biol. Chem. 281, 38365-38375 
344. Kamato, D., Thach, L., Getachew, R., Burch, M., Hollenberg, M. D., Zheng, 
W., Little, P. J., and Osman, N. (2016) Protease activated receptor-1 mediated 
dual kinase receptor transactivation stimulates the expression of 
glycosaminoglycan synthesizing genes. Cell. Signal. 28, 110-119 
345. Gao, S., Alarcón, C., Sapkota, G., Rahman, S., Chen, P. Y., Goerner, N., 
Macias, M. J., Erdjument-Bromage, H., Tempst, P., and Massagué, J. (2009) 
Ubiquitin Ligase Nedd4L Targets Activated Smad2/3 to Limit TGF-β 
Signaling. Mol. Cell 36, 457-468 
346. Zelivianski, S., Cooley, A., Kall, R., and Jeruss, J. S. (2010) Cyclin-Dependent 
Kinase 4–Mediated Phosphorylation Inhibits Smad3 Activity in Cyclin D–
Overexpressing Breast Cancer Cells. Mol. Cancer Res. 8, 1375-1387 
 
 
290 
 
347. Hiromura, K., Pippin, J. W., Blonski, M. J., Roberts, J. M., and Shankland, S. 
J. (2002) The subcellular localization of cyclin dependent kinase 2 determines 
the fate of mesangial cells: role in apoptosis and proliferation. Oncogene 21, 
1750-1758 
348. Ross, S., and Hill, C. S. (2008) How the Smads regulate transcription. Int. J. 
Biochem. Cell Biol. 40, 383-408 
349. Major, M. L., Lepe, R., and Costa, R. H. (2004) Forkhead box M1B 
transcriptional activity requires binding of Cdk-cyclin complexes for 
phosphorylation-dependent recruitment of p300/CBP coactivators. Mol. Cell. 
Biol. 24, 2649-2661 
350. Osman, N., Getachew, R., Thach, L., Wang, H., Su, X., Zheng, W., and Little, 
P. J. (2014) Platelet-derived growth factor-stimulated versican synthesis but 
not glycosaminoglycan elongation in vascular smooth muscle is mediated via 
Akt phosphorylation. Cell. Signal. 26, 912-916 
351. Liu, J., Fitzli, D., Liu, M., Tseu, I., Caniggia, I., Rotin, D., and Post, M. (1998) 
PDGF-induced glycosaminoglycan synthesis is mediated via 
phosphatidylinositol 3-kinase. Am. J. Physiol. Lung Cell Mol. Physiol. 274, 
L702-L713 
352. Stabile, E., Zhou, Y. F., Saji, M., Castagna, M., Shou, M., Kinnaird, T. D., 
Baffour, R., Ringel, M. D., Epstein, S. E., and Fuchs, S. (2003) Akt controls 
vascular smooth muscle cell proliferation in vitro and in vivo by delaying G1/S 
exit. Circ. Res. 93, 1059-1065 
353. Morikawa, M., Koinuma, D., Miyazono, K., and Heldin, C. H. (2013) 
Genome-wide mechanisms of Smad binding. Oncogene 32, 1609-1615 
354. Morgan, D. O. (1995) Principles of CDK regulation. Nature 374, 131-134 
355. Hochegger, H., Takeda, S., and Hunt, T. (2008) Cyclin-dependent kinases and 
cell-cycle transitions: does one fit all? Nat. Rev. Mol. Cell Biol. 9, 910-916 
356. Lew, D. J., and Kornbluth, S. (1996) Regulatory roles of cyclin dependent 
kinase phosphorylation in cell cycle control. Curr. Opin. Cell Biol. 8, 795-804 
357. Lim, S., and Kaldis, P. (2013) Cdks, cyclins and CKIs: roles beyond cell cycle 
regulation. Development 140, 3079-3093 
358. Malumbres, M. (2011) Physiological Relevance of Cell Cycle Kinases. 
Physiol. Rev. 91, 973-1007 
359. Deshpande, A., Sicinski, P., and Hinds, P. W. (2005) Cyclins and cdks in 
development and cancer: a perspective. Oncogene 24, 2909-2915 
 
 
291 
 
360. Asghar, U., Witkiewicz, A. K., Turner, N. C., and Knudsen, E. S. (2015) The 
history and future of targeting cyclin-dependent kinases in cancer therapy. Nat. 
Rev. Drug Discov. 14, 130-146 
361. Wessely, R. (2010) Atherosclerosis and cell cycle: put the brakes on! Critical 
role for cyclin-dependent kinase inhibitors. J. Am. Coll. Cardiol. 55, 2269-
2271 
362. Ross, J. S., Stagliano, N. E., Donovan, M. J., Breitbart, R. E., and Ginsburg, G. 
S. (2001) Atherosclerosis and Cancer. Ann. N. Y. Acad. Sci. 947, 271-293 
363. Charron, T., Nili, N., and Strauss, B. H. (2006) The cell cycle: A critical 
therapeutic target to prevent vascular proliferative disease. Can. J. Cardiol. 22, 
41B-55B 
364. Zhang, Y., Jiang, Z., Li, L., Zhou, Y., Song, Z., and Shu, M. (2014) Geminin 
Interference Facilitates Vascular Smooth Muscle Cell Proliferation by 
Upregulation of CDK-1. Cardiovasc. Drugs Ther. 28, 407-414 
365. Mathew, O. P., Ranganna, K., and Yatsu, F. M. (2010) Butyrate, an HDAC 
inhibitor, stimulates interplay between different posttranslational modifications 
of histone H3 and differently alters G1-specific cell cycle proteins in vascular 
smooth muscle cells. Biomed. Pharmacother. 64, 733-740 
366. Fisher, R. P., and Morgan, D. O. A novel cyclin associates with M015/CDK7 
to form the CDK-activating kinase. Cell 78, 713-724 
367. Paulovich, A. G., and Hartwell, L. H. A checkpoint regulates the rate of 
progression through S phase in S. cerevisiae in Response to DNA damage. Cell 
82, 841-847 
368. Lange, M., Fujikawa, T., Koulova, A., Kang, S., Griffin, M. J., Lassaletta, A. 
D., Erat, A., Tobiasch, E., Bianchi, C., Elmadhun, N., Sellke, F. W., and 
Usheva, A. (2014) Arterial territory-specific phosphorylated retinoblastoma 
protein species and CDK2 promote differences in the vascular smooth muscle 
cell response to mitogens. Cell Cycle 13, 315-323 
369. Sherr, C. J., and Roberts, J. M. (2004) Living with or without cyclins and 
cyclin-dependent kinases. Genes Dev. 18 
370. Wang, K., Hampson, P., Hazeldine, J., Krystof, V., Strnad, M., Pechan, P., and 
M, J. (2012) Cyclin-Dependent Kinase 9 Activity Regulates Neutrophil 
Spontaneous Apoptosis. PLoS One 7, e30128 
371. Lee, K.-W., Kim, H. J., Lee, Y. S., Park, H.-J., Choi, J.-W., Ha, J., and Lee, 
K.-T. (2007) Acteoside inhibits human promyelocytic HL-60 leukemia cell 
 
 
292 
 
proliferation via inducing cell cycle arrest at G0/G1 phase and differentiation 
into monocyte. Carcinogenesis 28, 1928-1936 
372. Braden, W. A., McClendon, A. K., and Knudsen, E. S. (2008) Cyclin-
dependent kinase 4/6 activity is a critical determinant of pre-replication 
complex assembly. Oncogene 27, 7083-7093 
373. Bockstaele, L., Coulonval, K., Kooken, H., Paternot, S., and Roger, P. P. 
(2006) Regulation of CDK4. Cell Div. 1, 25-25 
374. Kato, J. Y., Matsuoka, M., Strom, D. K., and Sherr, C. J. (1994) Regulation of 
cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase. Mol. Cell. Biol. 
14, 2713-2721 
375. Larochelle, S., Merrick, K. A., Terret, M.-E., Wohlbold, L., Barboza, N. M., 
Zhang, C., Shokat, K. M., Jallepalli, P. V., and Fisher, R. P. (2007) 
Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of 
Cdk2 revealed by chemical genetics in human cells. Mol. Cell 25, 839-850 
376. Giacinti, C., and Giordano, A. (2006) RB and cell cycle progression. 
Oncogene 25, 5220-5227 
377. Schachter, M. M., Merrick, K. A., Larochelle, S., Hirschi, A., Zhang, C., 
Shokat, K. M., Rubin, S. M., and Fisher, R. P. (2013) A Cdk7-Cdk4 T-Loop 
Phosphorylation Cascade Promotes G1 Progression. Mol. Cell 50, 250-260 
378. Li, A.-Y., Han, M., Zheng, B., and Wen, J.-K. (2008) Roscovitine inhibits 
ERK1/2 activation induced by angiotensin II in vascular smooth muscle cells. 
FEBS Lett. 582, 243-248 
379. Andrés, V. (2004) Control of vascular cell proliferation and migration by 
cyclin-dependent kinase signalling: new perspectives and therapeutic potential. 
Cardiovasc. Res. 63, 11-21 
 
380. Ii, M., Hoshiga, M., Fukui, R., Negoro, N., Nakakoji, T., Nishiguchi, F., 
Kohbayashi, E., Ishihara, T., and Hanafusa, T. (2001) Beraprost sodium 
regulates cell cycle in vascular smooth muscle cells through cAMP signaling 
by preventing down-regulation of p27Kip1. Cardiovasc. Res. 52, 500-508 
381. Traganos, F., Juan, G., and Darzynkiewicz, Z. (2001) Cell-Cycle Analysis of 
Drug-Treated Cells in DNA Topoisomerase Protocols, Humana Press, Totowa 
(NJ) 
382. Sano, M., and Schneider, M. D. (2003) Cyclins that don't cycle-cyclin 
T/cyclin-dependent kinase-9 determines cardiac muscle cell size. Cell Cycle 2, 
99-104 
 
 
293 
 
383. Harper, J. W., and Elledge, S. J. (1998) The role of Cdk7 in CAK function, 
a retro-retrospective. Genes Dev. 12, 285-289 
384. Fisher, R. P. (2005) Secrets of a double agent: CDK7 in cell-cycle control and 
transcription. J. Cell Sci. 118, 5171-5180 
385. Peng, J., Zhu, Y., Milton, J. T., and Price, D. H. (1998) Identification of 
multiple cyclin subunits of human P-TEFb. Genes Dev. 12, 755-762 
386. Kwak, H., and Lis, J. T. (2013) Control of Transcriptional Elongation. Annu. 
Rev. Genet. 47, 483-508 
387. Eick, D., and Geyer, M. (2013) The RNA Polymerase II Carboxy-Terminal 
Domain (CTD) Code. Chem. Rev. 113, 8456-8490 
388. Kobor, M. S., and Greenblatt, J. (2002) Regulation of transcription elongation 
by phosphorylation. Biochim. Biophys. Acta 1577, 261-275 
389. Schmerwitz, U. K., Sass, G., Khandoga, A. G., Joore, J., Mayer, B. A., 
Berberich, N., Totzke, F., Krombach, F., Tiegs, G., Zahler, S., Vollmar, A. M., 
and Furst, R. (2011) Flavopiridol protects against inflammation by attenuating 
leukocyte-endothelial interaction via inhibition of cyclin-dependent kinase 9. 
Arterioscler. Thromb. Vasc. Biol. 31, 280-288 
390. Hou, T., Ray, S., and Brasier, A. R. (2007) The functional role of an 
interleukin 6-inducible CDK9.STAT3 complex in human gamma-fibrinogen 
gene expression. J. Biol. Chem. 282, 37091-37102 
391. Han, Y., Zhan, Y., Hou, G., and Li, L. I. (2014) Cyclin-dependent kinase 9 
may as a novel target in downregulating the atherosclerosis inflammation 
(Review). Biomed. Rep. 2, 775-779 
392. Gavet, O., and Pines, J. (2010) Progressive activation of CyclinB1-Cdk1 
coordinates entry to mitosis. Dev. Cell 18, 533-543 
 
393. Marra, D. E., Simoncini, T., and Liao, J. K. (2000) Inhibition of Vascular 
Smooth Muscle Cell Proliferation by Sodium Salicylate Mediated by 
Upregulation of p21Waf1 and p27Kip1. Circulation 102, 2124-2130 
394. Chen, S., Law, C. S., and Gardner, D. G. (2010) Vitamin D-dependent 
suppression of endothelin-induced vascular smooth muscle cell proliferation 
through inhibition of CDK2 activity. J. Steroid Biochem. Mol. Biol. 118, 135-
141 
 
 
294 
 
395. Santamaria, D., Barriere, C., Cerqueira, A., Hunt, S., Tardy, C., Newton, K., 
Caceres, J. F., Dubus, P., Malumbres, M., and Barbacid, M. (2007) Cdk1 is 
sufficient to drive the mammalian cell cycle. Nature 448, 811-815 
396. Akiyama, T., Ohuchi, T., Sumida, S., Matsumoto, K., and Toyoshima, K. 
(1992) Phosphorylation of the retinoblastoma protein by cdk2. Proc. Natl. 
Acad. Sci. U. S. A. 89, 7900-7904 
397. Berthet, C., and Kaldis, P. (2006) Cdk2 and Cdk4 cooperatively control the 
expression of Cdc2. Cell Div. 1, 10 
398. Takaki, T., Fukasawa, K., Suzuki-Takahashi, I., Semba, K., Kitagawa, M., 
Taya, Y., and Hirai, H. (2005) Preferences for Phosphorylation Sites in the 
Retinoblastoma Protein of D-Type Cyclin–Dependent Kinases, Cdk4 and 
Cdk6, In Vitro. J. Biochem. 137, 381-386 
399. Simone, C., Bagella, L., Bellan, C., and Giordano, A. (2002) Physical 
interaction between pRb and cdk9/cyclinT2 complex. Oncogene 21, 4158-
4165 
400. Graña, X., De Luca, A., Sang, N., Fu, Y., Claudio, P. P., Rosenblatt, J., 
Morgan, D. O., and Giordano, A. (1994) PITALRE, a nuclear CDC2-related 
protein kinase that phosphorylates the retinoblastoma protein in vitro. Proc. 
Natl. Acad. Sci. U. S. A. 91, 3834-3838 
401. Macaluso, M., Montanari, M., Cinti, C., and Giordano, A. (2005) Modulation 
of Cell Cycle Components by Epigenetic and Genetic Events. Semin. Oncol. 
32, 452-457 
402. Lin, T. S., Ruppert, A. S., Johnson, A. J., Fischer, B., Heerema, N. A., 
Andritsos, L. A., Blum, K. A., Flynn, J. M., Jones, J. A., Hu, W., Moran, M. 
E., Mitchell, S. M., Smith, L. L., Wagner, A. J., Raymond, C. A., Schaaf, L. J., 
Phelps, M. A., Villalona-Calero, M. A., Grever, M. R., and Byrd, J. C. (2009) 
Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia 
Demonstrating High Response Rates in Genetically High-Risk Disease. J. 
Clin. Oncol. 27, 6012-6018 
403. Carvajal, R. D., Tse, A., Shah, M. A., Lefkowitz, R. A., Gonen, M., Gilman-
Rosen, L., Kortmansky, J., Kelsen, D. P., Schwartz, G. K., and O'Reilly, E. M. 
(2009) A Phase 2 Study of Flavopiridol (Alvocidib) in Combination with 
Docetaxel in Refractory, Metastatic Pancreatic Cancer. Pancreatology 9, 404-
409 
404. Cicenas, J., and Valius, M. (2011) The CDK inhibitors in cancer research and 
therapy. J. Cancer Res. Clin. Oncol. 137, 1409-1418 
 
 
295 
 
405. Benson, C., White, J., Bono, J. D., O'Donnell, A., Raynaud, F., Cruickshank, 
C., McGrath, H., Walton, M., Workman, P., Kaye, S., Cassidy, J., Gianella-
Borradori, A., Judson, I., and Twelves, C. (2007) A phase I trial of the 
selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-
Roscovitine), administered twice daily for 7 days every 21 days. Br. J. Cancer 
96, 29-37 
406. Whitlock, J. A., Krailo, M., Reid, J. M., Ruben, S. L., Ames, M. M., Owen, 
W., and Reaman, G. (2005) Phase I Clinical and Pharmacokinetic Study of 
Flavopiridol in Children With Refractory Solid Tumors: A Children's 
Oncology Group Study. J. Clin. Oncol. 23, 9179-9186 
407. Clark, A. S., Karasic, T. B., DeMichele, A., and et al. (2015) Palbociclib 
(PD0332991)—A selective and potent cyclin-dependent kinase inhibitor: A 
review of pharmacodynamics and clinical development. JAMA Oncology, 1-8 
408. Toker, A. (2008) Akt signaling: a damaging interaction makes good. Trends 
Biochem. Sci. 33, 356-359 
409. Luo, J., Manning, B. D., and Cantley, L. C. (2003) Targeting the PI3K-Akt 
pathway in human cancer: Rationale and promise. Cancer Cell 4, 257-262 
410. Liu, P., Begley, M., Michowski, W., Inuzuka, H., Ginzberg, M., Gao, D., 
Tsou, P., Gan, W., Papa, A., Kim, B. M., Wan, L., Singh, A., Zhai, B., Yuan, 
M., Wang, Z., Gygi, S. P., Lee, T. H., Lu, K.-P., Toker, A., Pandolfi, P. P., 
Asara, J. M., Kirschner, M. W., Sicinski, P., Cantley, L., and Wei, W. (2014) 
Cell-cycle-regulated activation of Akt kinase by phosphorylation at its 
carboxyl terminus. Nature 508, 541-545 
411. Osman, N., Grande-Allen, K. J., Ballinger, M. L., Getachew, R., Marasco, S., 
O'Brien, K. D., and Little, P. J. (2013) Smad2-dependent glycosaminoglycan 
elongation in aortic valve interstitial cells enhances binding of LDL to 
proteoglycans. Cardiovasc. Pathol. 22, 146-155 
412. Gennaro, G., Ménard, C., Giasson, E., Michaud, S.-É., Palasis, M., Meloche, 
S., and Rivard, A. (2003) Role of p44/p42 MAP Kinase in the Age-Dependent 
Increase in Vascular Smooth Muscle Cell Proliferation and Neointimal 
Formation. Arterioscler. Thromb. Vasc. Biol. 23, 204 
 
413. D'Antoni, M. L., Torregiani, C., Ferraro, P., Michoud, M.-C., Mazer, B., 
Martin, J. G., and Ludwig, M. S. (2008) Effects of decorin and biglycan on 
human airway smooth muscle cell proliferation and apoptosis, Am. J. Physiol. 
Lung Cell. Mol Physiol. 294, L764-771 
 
 
296 
 
414. Zettler, M. E., Merchant, M. A., and Pierce, G. N. (2010) Augmented cell 
cycle protein expression and kinase activity in atherosclerotic rabbit vessels. 
Exp. Clin. Cardiol. 15, e139-e144 
415. Sedlacek, H. H. (2001) Mechanisms of action of flavopiridol. Crit. Rev. Oncol. 
Hematol. 38, 139-170 
416. Le Tourneau, C., Faivre, S., Laurence, V., Delbaldo, C., Vera, K., Girre, V., 
Chiao, J., Armour, S., Frame, S., Green, S. R., Gianella-Borradori, A., Diéras, 
V., and Raymond, E. (2010) Phase I evaluation of seliciclib (R-roscovitine), a 
novel oral cyclin-dependent kinase inhibitor, in patients with advanced 
malignancies. Eur. J. Cancer 46, 3243-3250 
417. Devaiah, B. N., and Singer, D. S. (2012) Cross-talk Among RNA Polymerase 
II Kinases Modulates C-terminal Domain Phosphorylation. The Journal of 
Biological Chemistry 287, 38755-38766 
418. Sims, R. J., Belotserkovskaya, R., and Reinberg, D. (2004) Elongation by 
RNA polymerase II: the short and long of it. Genes Dev. 18, 2437-2468 
419. Ljungman, M., and Paulsen, M. T. (2001) The cyclin-dependent kinase 
inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation 
of p53 that is unmodified at Ser15 and Lys382. Mol. Pharmacol. 60, 785-789 
420. Oelgeschläger, T. (2002) Regulation of RNA polymerase II activity by CTD 
phosphorylation and cell cycle control. J. Cell. Physiol. 190, 160-169 
421. Otero, G., Fellows, J., Li, Y., de Bizemont, T., Dirac, A. M. G., Gustafsson, C. 
M., Erdjument-Bromage, H., Tempst, P., and Svejstrup, J. Q. Elongator, a 
Multisubunit Component of a Novel RNA Polymerase II Holoenzyme for 
Transcriptional Elongation. Mol. Cell 3, 109-118 
422. Nelson, J., Denisenko, O., and Bomsztyk, K. (2011) Profiling RNA 
Polymerase II Using the Fast Chromatin Immunoprecipitation Method. in RNA 
(Nielsen, H. ed.), Humana Press. pp 219-234 
423. Gade, P., and Kalvakolanu, D. V. (2012) Chromatin Immunoprecipitation 
Assay as a Tool for Analyzing Transcription Factor Activity. Methods Mol. 
Biol. 809, 85-104 
424. Nakashima, Y., Wight, T. N., and Sueishi, K. (2008) Early atherosclerosis in 
humans: role of diffuse intimal thickening and extracellular matrix 
proteoglycans. Cardiovasc. Res. 79, 14-23 
425. Errico, A., Deshmukh, K., Tanaka, Y., Pozniakovsky, A., and Hunt, T. (2010) 
Identification of substrates for cyclin dependent kinases. Adv. Enzyme Regul. 
50, 375-399 
 
 
297 
 
426. Ma, T., Van Tine, B. A., Wei, Y., Garrett, M. D., Nelson, D., Adams, P. D., 
Wang, J., Qin, J., Chow, L. T., and Harper, J. W. (2000) Cell cycle–regulated 
phosphorylation of p220(NPAT) by cyclin E/Cdk2 in Cajal bodies promotes 
histone gene transcription. Genes Dev. 14, 2298-2313 
427. Ait-Si-Ali, S., Ramirez, S., Barre, F. X., Dkhissi, F., Magnaghi-Jaulin, L., 
Girault, J. A., Robin, P., Knibiehler, M., Pritchard, L. L., Ducommun, B., 
Trouche, D., and Harel-Bellan, A. (1998) Histone acetyltransferase activity of 
CBP is controlled by cycle-dependent kinases and oncoprotein E1A. Nature 
396, 184-186 
428. Ivey, M. E., and Little, P. J. (2008) Thrombin regulates vascular smooth 
muscle cell proteoglycan synthesis via PAR-1 and multiple downstream 
signalling pathways. Thromb. Res. 123, 288-297 
429. Gustafsson, M., Levin, M., Skålén, K., Perman, J., Fridén, V., Jirholt, P., 
Olofsson, S. O., Fazio, S., Linton, M. F., Semenkovich, C. F., Olivecrona, G., 
and Borén, J. (2007) Retention of low-density lipoprotein in atherosclerotic 
lesions of the mouse: Evidence for a role of lipoprotein lipase. Circ. Res. 101, 
777-783 
430. Ballinger, M. L., Osman, N., Hashimura, K., Haan, J. B. D., Jandeleit-Dahm, 
K., Allen, T., Tannock, L. R., Rutledge, J. C., and Little, P. J. (2010) Imatinib 
inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL 
binding in vitro and aortic lipid deposition in vivo. J. Cell. Mol. Med. 14, 
1408-1418 
431. Kinsella, M. G., Tsoi, C. K., Järveläinen, H. T., and Wight, T. N. (1997) 
Selective Expression and Processing of Biglycan during Migration of Bovine 
Aortic Endothelial Cells: The Role Of Endogenous Basic Fibroblast Growth 
Factor. J. Biol. Chem. 272, 318-325 
432. Little, P. J., Getachew, R., Rezaei, H. B., Sanchez-Guerrero, E., Khachigian, L. 
M., Wang, H., Liao, S., Zheng, W., Ballinger, M. L., and Osman, N. (2012) 
Genistein inhibits PDGF-stimulated proteoglycan synthesis in vascular smooth 
muscle without blocking PDGFβ receptor phosphorylation. Arch. Biochem. 
Biophys. 525, 25-31 
433. Uyama, T., Kitagawa, H., Izumikawa, T., and Sugahara, K. (2004) Chondroitin 
polymerization is achieved by multiple enzyme complexes consisting of 
chondroitin synthase family members. Glycobiology 14, 1054-1055 
434. Sardo, M. A., Mandraffino, G., Campo, S., Saitta, C., Bitto, A., Alibrandi, A., 
Riggio, S., Imbalzano, E., and Saitta, A. (2009) Biglycan expression in 
hypertensive subjects with normal or increased carotid intima-media wall 
thickness. Clin. Chim. Acta 406, 89-93 
 
 
298 
 
435. Matsuzaki, K. (2011) Smad phosphoisoform signaling specificity: the right 
place at the right time. Carcinogenesis 32, 1578-1588 
436. Dai, M., Al-Odaini, A. A., Fils-Aime, N., Villatoro, M. A., Guo, J., Arakelian, 
A., Rabbani, S. A., Ali, S., and Lebrun, J. (2013) Cyclin D1 cooperates with 
p21 to regulate TGFbeta-mediated breast cancer cell migration and tumor local 
invasion. Breast Cancer Res. 15, R49 
437. Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., 
Cushman, M., de Ferranti, S., Després, J.-P., Fullerton, H. J., Howard, V. J., 
Huffman, M. D., Judd, S. E., Kissela, B. M., Lackland, D. T., Lichtman, J. H., 
Lisabeth, L. D., Liu, S., Mackey, R. H., Matchar, D. B., McGuire, D. K., 
Mohler, E. R., Moy, C. S., Muntner, P., Mussolino, M. E., Nasir, K., Neumar, 
R. W., Nichol, G., Palaniappan, L., Pandey, D. K., Reeves, M. J., Rodriguez, 
C. J., Sorlie, P. D., Stein, J., Towfighi, A., Turan, T. N., Virani, S. S., Willey, 
J. Z., Woo, D., Yeh, R. W., and Turner, M. B. (2014) Heart Disease and Stroke 
Statistics—2015 Update: A Report From the American Heart Association. 
Circulation 131, e29-e322 
438. Delgado-Roche, L., Brito, V., Acosta, E., Pérez, A., Fernández, J. R., 
Hernández-Matos, Y., Griñán, T., Soto, Y., León, O. S., Marleau, S., and 
Vázquez, A. M. (2015) Arresting progressive atherosclerosis by immunization 
with an anti-glycosaminoglycan monoclonal antibody in apolipoprotein E-
deficient mice. Free Radic. Biol. Med. 89, 557-566 
439. Yang, S. N. Y., Burch, M. L., Tannock, L. R., Evanko, S., Osman, N., and 
Little, P. J. (2010) Transforming growth factor-β regulation of proteoglycan 
synthesis in vascular smooth muscle: Contribution to lipid binding and 
accelerated atherosclerosis in diabetes. J. Diabetes 2, 233-242 
440. Tennant, M., and McGeachie, J. K. (1991) Platelet-Derived Growth Factor 
And Its Role In Atherogenesis: A Brief Review. Aust. N. Z. J. Surg. 61, 482-
488 
441. Kalz, J., Cate, H., and Spronk, H. M. H. (2013) Thrombin generation and 
atherosclerosis. J. Thromb. Thrombolysis 37, 45-55 
442. Li, Y., Laue, K., Temtamy, S., Aglan, M., Kotan, L. D., Yigit, G., Canan, H., 
Pawlik, B., Nürnberg, G., Wakeling, E. L., Quarrell, O. W., Baessmann, I., 
Lanktree, M. B., Yilmaz, M., Hegele, R. A., Amr, K., May, K. W., Nürnberg, 
P., Topaloglu, A. K., Hammerschmidt, M., and Wollnik, B. (2010) Temtamy 
Preaxial Brachydactyly Syndrome Is Caused by Loss-of-Function Mutations in 
Chondroitin Synthase 1, a Potential Target of BMP Signaling. Am. J. Hum. 
Genet. 87, 757-767 
443. Tian, J., Ling, L., Shboul, M., Lee, H., O'Connor, B., Merriman, B., Nelson, S. 
F., Cool, S., Ababneh, O. H., Al-Hadidy, A., Masri, A., Hamamy, H., and 
Reversade, B. (2010) Loss of CHSY1, a Secreted FRINGE Enzyme, Causes 
 
 
299 
 
Syndromic Brachydactyly in Humans via Increased NOTCH Signaling. Am. J. 
Hum. Genet. 87, 768-778 
444. Mis, E. K., Liem Jr, K. F., Kong, Y., Schwartz, N. B., Domowicz, M., and 
Weatherbee, S. D. (2014) Forward genetics defines Xylt1 as a key, conserved 
regulator of early chondrocyte maturation and skeletal length. Dev. Biol. 385, 
67-82 
445. Klüppel, M., Wight, T. N., Chan, C., Hinek, A., and Wrana, J. L. (2005) 
Maintenance of chondroitin sulfation balance by chondroitin-4-sulfotransferase 
1 is required for chondrocyte development and growth factor signaling during 
cartilage morphogenesis. Development 132, 3989-4003 
446. Senokuchi, T., Matsumura, T., Sakai, M., Matsuo, T., Yano, M., Kiritoshi, S., 
Sonoda, K., Kukidome, D., Nishikawa, T., and Araki, E. (2004) Extracellular 
signal-regulated kinase and p38 mitogen-activated protein kinase mediate 
macrophage proliferation induced by oxidized low-density lipoprotein. 
Atherosclerosis 176, 233-245 
447. Elkhawad, M., Rudd, J. H. F., Sarov-Blat, L., Cai, G., Wells, R., Davies, L. C., 
Collier, D. J., Marber, M. S., Choudhury, R. P., Fayad, Z. A., Tawakol, A., 
Gleeson, F. V., Lepore, J. J., Davis, B., Willette, R. N., Wilkinson, I. B., 
Sprecher, D. L., and Cheriyan, J. (2012) Effects of p38 Mitogen-Activated 
Protein Kinase Inhibition on Vascular and Systemic Inflammation in Patients 
With Atherosclerosis. JACC Cardiovasc. Imaging 5, 911-922 
448. Hu, Y., Dietrich, H., Metzler, B., Wick, G., and Xu, Q. (2000) 
Hyperexpression and Activation of Extracellular Signal–Regulated Kinases 
(ERK1/2) in Atherosclerotic Lesions of Cholesterol-Fed Rabbits. Arterioscler. 
Thromb. Vasc. Biol. 20, 18-26 
449. Rajamaki, K., Mayranpaa, M. I., Risco, A., Tuimala, J., Nurmi, K., Cuenda, 
A., Eklund, K. K., Oorni, K., and Kovanen, P. T. (2016) p38delta MAPK: A 
Novel Regulator of NLRP3 Inflammasome Activation With Increased 
Expression in Coronary Atherogenesis. Arterioscler. Thromb. Vasc. Biol. 36, 
1937-1946 
 
450. Fougerat, A., Gayral, S., Malet, N., Briand-Mesange, F., Breton-Douillon, M., 
and Laffargue, M. (2009) Phosphoinositide 3-kinases and their role in 
inflammation: potential clinical targets in atherosclerosis? Clin. Sci. 116, 791-
804 
451. Jain, M. K., and Ridker, P. M. (2005) Anti-inflammatory effects of statins: 
clinical evidence and basic mechanisms. Nat Rev Drug Discov 4, 977-987 
 
 
300 
 
452. Sekimoto, G., Matsuzaki, K., Yoshida, K., Mori, S., Murata, M., Seki, T., 
Matsui, H., Fujisawa, J. I., and Okazaki, K. (2007) Reversible Smad-dependent 
signaling between tumor suppression and oncogenesis. Cancer Res. 67, 5090-
5096 
453. Nakano, A., Koinuma, D., Miyazawa, K., Uchida, T., Saitoh, M., Kawabata, 
M., Hanai, J., Akiyama, H., Abe, M., and Miyazono, K. (2009) Pin1 down-
regulates transforming growth factor-β (TGF-β) signaling by inducing 
degradation of Smad proteins. J. Biol. Chem. 284, 6109 
454. Yaffe, M. B., Schutkowski, M., Shen, M., Zhou, X. Z., Stukenberg, P. T., 
Rahfeld, J.-U., Xu, J., Kuang, J., Kirschner, M. W., Fischer, G., Cantley, L. C., 
and Lu, K. P. (1997) Sequence-Specific and Phosphorylation-Dependent 
Proline Isomerization: A Potential Mitotic Regulatory Mechanism. Science 
278, 1957-1960 
455. Davis, T. L., Walker, J. R., Campagna-Slater, V., Finerty, P. J., Paramanathan, 
R., Bernstein, G., MacKenzie, F., Tempel, W., Hui, O. Y., Lee, W. H., 
Eisenmesser, E. Z., and Dhe-Paganon, S. (2010) Structural and Biochemical 
Characterization of the Human Cyclophilin Family of Peptidyl-Prolyl 
Isomerases. PLOS Biol. 8, e1000439 
456. Ryo, A., Liou, Y. C., Lu, K. P., and Wulf, G. (2003) Prolyl isomerase Pin1: a 
catalyst for oncogenesis and a potential therapeutic target in cancer. J. Cell Sci. 
116, 773-783 
457. Lu, K. P., Finn, G., Lee, T. H., and Nicholson, L. K. (2007) Prolyl cis-trans 
isomerization as a molecular timer. Nat. Chem. Biol. 3, 619-629 
458. Kim, S. E., Lee, M. Y., Lim, S. C., Hien, T. T., Kim, J. W., Ahn, S. G., Yoon, 
J. H., Kim, S. K., Choi, H. S., and Kang, K. W. (2010) Role of Pin1 in 
neointima formation: down-regulation of Nrf2-dependent heme oxygenase-1 
expression by Pin1. Free Radic. Biol. Med 48, 1644-1653 
459. Chen, D., Krasinski, K., Sylvester, A., Chen, J., Nisen, P. D., and Andrés, V. 
(1997) Downregulation of cyclin-dependent kinase 2 activity and cyclin A 
promoter activity in vascular smooth muscle cells by p27(KIP1), an inhibitor 
of neointima formation in the rat carotid artery. J. Clin. Invest. 99, 2334-2341 
460. Senderowicz, A. M., and Sausville, E. A. (2000) Preclinical and Clinical 
Development of Cyclin-Dependent Kinase Modulators. J. Natl. Cancer Inst. 
92, 376-387 
461. Malumbres, M., and Barbacid, M. (2007) Cell cycle kinases in cancer. Curr. 
Opin. Genet. Dev. 17, 60-65 
 
 
301 
 
462. Malumbres, M., and Barbacid, M. (2006) Is Cyclin D1-CDK4 kinase a bona 
fide cancer target? Cancer Cell 9, 2-4 
463. Chen, D., Walsh, K., and Wang, J. (2000) Regulation of cdk2 Activity in 
Endothelial Cells That Are Inhibited From Growth by Cell Contact. 
Arterioscler. Thromb. Vasc. Biol. 20, 629-635 
464. Jaschke, B., Milz, S., Vogeser, M., Michaelis, C., Vorpahl, M., Schömig, A., 
Kastrati, A., and Wessely, R. (2004) Local cyclin-dependent kinase inhibition 
by flavopiridol inhibits coronary artery smooth muscle cell proliferation and 
migration: Implications for the applicability on drug-eluting stents to prevent 
neointima formation following vascular injury. FASEB J. 18, 1285-1287 
465. Gotto, A. M. (2002) Statins: Powerful Drugs for Lowering Cholesterol: Advice 
for Patients. Circulation 105, 1514-1516 
 
466. Bach, S., Knockaert, M., Reinhardt, J., Lozach, O., Schmitt, S., Baratte, B., 
Koken, M., Coburn, S. P., Tang, L., Jiang, T., Liang, D.-c., Galons, H., 
Dierick, J.-F., Pinna, L. A., Meggio, F., Totzke, F., Schächtele, C., Lerman, 
A. S., Carnero, A., Wan, Y., Gray, N., and Meijer, L. (2005) Roscovitine 
Targets, Protein Kinases and Pyridoxal Kinase. J. Biol. Chem. 280, 31208-
31219 
 
 
 
